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Abstract 
The Prevalence of Neurological Disorders in the 70 years and older Population of the Hai 
District in Northern Tanzania 
 
Aim 
To determine the prevalence of neurological disorders in the 70 and over population of 
the Hai district in northern Tanzania through the production and utilisation of  a screening 
questionnaire, and to describe the subtypes, the level of diagnosis, treatment and 
associated disability.  
 
Introduction  
There are limited data on neurological disorder and disability prevalence from developing 
countries despite a highlighted need from the World Health Organisation (WHO). This is 
partly due to the lack of a feasible and valid screening tool.   
 
Methods  
A screening questionnaire was created and validated for use in the elderly population of a 
developing country.  A cross-sectional two phased epidemiological survey was then 
performed in the Hai district demographic surveillance site (DSS) (n=161,119). 2232 
participants (1/4 of the DSS 70+ population) were screened.  Positive responders 
underwent neurological assessment and were questioned regarding health seeking 
behaviour. Disability assessment was performed using the Barthel Index. 
 
Results  
The screening questionnaire was validated in one randomly selected village (n=277). 
Further substantiation was performed in a larger population (n=1955). The sensitivity and 
specificity were 87.8-97.0% and 90.4-94.9% respectively. In 2232 participants, there were 
384 neurological diagnoses amongst 349 people. The age adjusted prevalence of 
ii 
 
neurological diagnoses (95% confidence intervals (CI)) was 168.94/1000 (153.39 to 
184.48). 58.6% had sought help for their symptoms, 14.6% had been correctly diagnosed 
and 10.6% were on appropriate treatment. The age adjusted prevalence of severe and 
moderate disability was 3.7% and 6.2% respectively. Those with neurological disorders 
had significantly greater odds of  disablement. 
 
Conclusions  
This is the first screening instrument to measure the prevalence of neurological disorders 
specifically in an elderly population in Sub-Saharan Africa (SSA).  It is feasible and valid 
with a high sensitivity and specificity. This is the first community-based neurological 
disorder prevalence study specifically in the elderly in SSA. It reveals high neurological 
morbidity and associated disability and low diagnosis and treatment levels.  
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I spent 9 months, from November 2009 to July 2010 living and working in Tanzania. 
Preceding this I made a preliminary visit for 1 week for pilot work and to meet the 
research team. I performed all training of local staff required for the project and to 
ensure capacity building in the district. I devised the Neurology screening 
questionnaire, performed the literature review and created the information sheets 
and proforma. I performed all interviews and examined all patients. I was responsible 
for the follow up of patients and for the distribution of paperwork to ensure patient’s 
diagnosis and future treatment was known about and could continue locally. Professor 
Richard Walker organised the initial census. The project was performed in association 
with my colleague Dr Matthew Dewhurst who studied the same population and 
therefore was also involved with collecting the demographic data and in performing 
blood pressure (BP) and electrocardiogram (ECG) recordings. 
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Aims 
The primary aim of this study was to determine the prevalence of Neurological 
Disorders and Consequent Disability in the 70 and over population of the Hai District 
Demographic Surveillance Site (DSS) in Northern Tanzania.  This is the first community-
based prevalence study specifically for Neurological Disorders in this age group in sub-
Saharan Africa (SSA). 
 
The subsidiary aims of this study were: 
 To produce a validated and improved screening tool for the detection of 
Neurological Disease specific to the 70 years and older population. 
 To describe the subtypes and nature of Neurological disorders in the Hai district 
of northern Tanzania, with respect to age, gender, disability, health seeking 
behaviour and prior treatment. 
 To describe the disability level within the 70 and over population in the Hai 
district of Northern Tanzania and the proportion that is directly attributable to 
Neurological Disease. 
 
At the completion of the study, I have identified the extent of all-cause 
neurological morbidity in the 70 years and older age group of a SSA population. 
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Chapter 1. Introduction 
1.1  Introduction 
1.1.1 The Importance of Ageing 
Populations worldwide, but particularly in developing countries, are ageing rapidly. By 
2050 an estimated 2 billion people will be aged 60 and over and 80% will reside in 
resource poor settings [1]. This epidemiological transition will generate an increase in 
non-communicable disease including neurological disorders. Collectively this provides 
a public health dilemma which low income countries are ill equipped to deal with [2]. 
In addition there is potential for these diseases to result in increased disability and 
dependence at a time when the Human Immunodeficiency Virus (HIV)/ Acquired 
Immunodeficiency Syndrome (AIDS) epidemic threatens traditional family networks. 
 
The importance of studying the elderly is highlighted by data that estimates the 
population of over 50s in Africa will increase from 83 million in 1990 to 186 million in 
2015 [2]. According to the WHO the 60 years and older age group is the fastest 
growing age group worldwide, with 650 million people aged 60 years and older in 
2007, predicted to increase to 2 billion by 2050. It is important to study the cause of 
morbidity and mortality in this age group as 80% of deaths will be in this age group by 
2050 [1]. 
 
1.1.2 Neurological Disorders 
Neurological Disorders are known to cause significant morbidity and mortality in high-
income countries. Little is known about the true prevalence of neurological disorders 
in SSA. There are no up-to-date community based epidemiological studies on this 
topic. There have only been three population-based assessments of the prevalence of 
adult neurological disease in Africa; Nigeria in 1982-85 [3], Tunisia in 1985 [4], and 
Ethiopia in 1986-88 [5], all predated the HIV epidemic, all used limited screening 
instruments [6] and none focused on the growing elderly population.  
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Anecdotal and projected prevalence figures indicate that Neurological Disorders also 
have significant public health consequences in SSA but are contradictory regarding the 
level of burden. The Global Burden of Disease Study estimated that neurological 
disorders account for 4.5% of morbidity in low income countries [7]. However, recent 
African hospital studies suggest that neurological disorders account for 20-30% of 
admissions [8, 9]. There is a general presumption that prevalence increases with age 
but there are no published community-based studies on the prevalence of 
Neurological Disorders specifically in the African elderly.  
 
The World Health Organisation (WHO) highlight the public health importance of Non 
Communicable Diseases (NCD) stating they accounted for 59% of deaths globally in 
2002 and predict this group of diseases will account for 69% of deaths in 2030. Of 
these neurological disorders cerebrovascular disease is an important contributor as it 
accounts for 8.6-11.0% of deaths[10]. 
 
1.1.2.1 Justification of the measurement of neurological disorder prevalence as the 
primary aim.  
There is an urgent need to document the true prevalence of neurological disorders in 
the African community, to expose an expected high level of under diagnosis and 
treatment and to create an infrastructure to continue measurement and identification 
of patients for which cost effective treatment is available.. Accurate data on level of 
burden are paramount for  health care planning especially in resource poor settings, a 
assessment of the contribution that neurological morbidity makes to the ageing 
population’s NCD epidemic is essential. 
 
Many Neurological disorders can be treated readily and inexpensively. Aspirin and 
Phenobarbital are two examples of inexpensive treatments available for the 
neurological conditions of stroke and epilepsy. It has recently been reported that 
African nations have between none and four neurologists per country [11] and very 
few neurosurgeons [12]. As a result the care of African patients with neurological 
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disorders is poor. Without accurate  data to support the case for funding this poverty 
of care will remain. In particular funds are needed for the neurological education of 
primary care givers and the recruitment of specialists. 
 
There are neurological disorders for which "active treatment" is not available; this may 
be because it is: unavailable only in sub-Saharan Africa, unavailable in low-income 
countries or unavailable worldwide. Identification of patients with such disorders is 
still beneficial. A diagnosis and explanation can have a positive impact on a patient's 
life, it can reduce stigma caused by ignorance and improve acceptance into society. In 
addition supportive, palliative care and rehabilitation techniques may still be used to 
improve quality of life [13]. 
 
It is important to document disease prevalence worldwide in order to identify 
variations. Neurological disorders are no exception to this general rule. Patterns of 
disease prevalence can vary widely across countries and regions worldwide. Variations 
in prevalence between developed and developing countries may expose aetiological 
differences (if data is ensured to be comparable)that in turn could generate 
hypotheses on disease causation to the benefit of the entire world. An example of such 
a situation is the increased incidence and prevalence of Coronary Heart Disease (CHD) 
and its risk factors in the South Asian Immigrant population of the UK compared with 
the white UK population or their counterparts in their native countries. Hypotheses 
created as a result of these observations examine the way that social and biological 
factors interact to cause variation in disease rates. This is an area of research that 
holds much promise for scientific advance. When differences in prevalence are found 
between regions and populations they should be viewed as an opportunity [14].  
 
Another possible way to identify neurological morbidity would be to measure disability 
and then quantify what proportion is due to neurological disorders. "Measuring the 
disability level within the 70 and over population in the Hai district of Northern 
Tanzania and the proportion that is directly attributable to Neurological Disease " was 
one of our subsidiary aims and therefore I recognise the merit of recording disability in 
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the community. However, the use of disability to subsequently record neurological 
morbidity has a number of important limitations; 
 
1. Difficulty in making comparisons 
As described in our recent paper, entitled "The prevalence of disability in older people 
in Hai, Tanzania" [15] disability prevalence rates around the world vary significantly 
because of different definitions, study designs and the lack of a universal assessment 
instrument. Thus inter-study comparisons can be difficult. For example, review of the 
Tanzanian Disability Survey from 2008 [16] reveals that subjective questioning was 
used to produce a report of ‘some’ difficulty with seeing, hearing, walking, self-care or 
communicating and this defined disability. They report disability levels of 41.3% for the 
70–74 age group, rising to 55.6%for those aged 80 years and older. In our experience, 
the majority of these people will still be fully independent and therefore it is difficult to 
contextualise these results and fully assess their significance.  The importance of easy 
comparison for hypothesis generation on causation and effect needs to be highlighted.  
 
2. Different definitions of disability 
The WHO defines disability as an umbrella term covering impairments, activity 
limitations and participation restrictions, many disability scales only focus on one area 
of disability, for example, physical disability (as measured by the BI) [17-19]. 
 
3. Disability rates may underestimate morbidity caused by neurological disease in low 
income countries 
Studies from both high- and low-income countries indicate that disability rates are 
higher in the developed world; however, the different measures used complicate 
interpretation [20-23].These differences may reflect increased risk factors for disability 
such as greater age, obesity, physical inactivity and higher prevalence of NCD in high-
income countries and may also reflect increased mortality from disabling disease in 
low-income countries. Detection of e disorders before they become disabling and 
cause death is necessary to  truly represent the burden they place on society. 
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4. By the time disability is established less may be possible to improve quality of life 
Clearly models of rehabilitation from high-income countries may have limitations in 
SSA where there is limited resources and transportation, a community-based 
rehabilitation strategy maybe more appropriate but still the resources to provide such 
a programme may not be present. Prevention and early detection to prevent 
progression is therefore fundamental. To only measure disability would miss important 
cases that would be likely to progress. 
 
1.1.3 Epidemiological Studies 
There is an urgent need to document the true prevalence of neurological disorders in 
the African community and then to create an infrastructure to continue measurement 
and identification of patients who would benefit from the available cost effective 
treatment.. A feasible and valid screening tool for the detection of neurological 
disorders could be utilised for this dual purpose, it would enable evidence-based 
health care planning (a concept of paramount importance in resource poor settings) 
and it has the potential to rectify the large level of under diagnosis and treatment in 
the community. 
 
Two phased community prevalence studies have long been established as the gold 
standard to document disease prevalence in low income countries [24, 25].  
Hospital based studies of all neurological diseases suggest that neurological morbidity 
is the cause of 18-30% of medical admissions in SSA [11, 26-29], these contradict the 
Global Burden of Disease Study that suggests neurological disease accounts for only 
3.9% of the total disease burden [7, 30]. These discrepancies in morbidity rates require 
investigation. However it is difficult to obtain accurate prevalence data in resource 
poor countries for many reasons which generally are a reflection of the lack of 
epidemiological infrastructure; 
 
1. People do not present to hospital for geographical and financial reasons and 
therefore community based studies are likely to provide a better representation of 
true prevalence. 
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2. Demographic data on hospital diagnoses and deaths are limited and often non-
existent. 
 
3. Medical records are often hand held in exercise books or contained within rural 
clinics. They are often incomplete and are not computerised. 
 
These epidemiological shortcomings have long been recognised, first described in 1982 
by Schoenberg et al who developed the two phased approach to developing accurate 
prevalence data in a resource poor setting[25]. 
 
An initial screening phase utilising a screening tool that is feasible (acceptable, brief 
and easily administered by Non Medical Investigators (NMI), recruited from the local 
community and valid (sensitive- to detect all neurological cases and specific-to reduce 
second phase costs) precedes a second phase of physicians confirming disease in 
positive responders. NMI are ideal screeners as they are cheap to employ, readily 
available, know the geography of the community, and are more likely to be accepted 
by the population so as to increase participation rate.  
 
1.1.3.1  Screening questionnaires for neurological disorders 
Established instruments for identification of Neurological Disorders are unsatisfactory 
for the purpose of this thesis. The rationale for this is justified below [6, 31-36]. 
 
In 1981 the Neurosciences Program of the WHO developed a screening protocol 
consisting of 15 questions and 7 examination points. It was designed to pick up 
cerebrovascular disease, epilepsy, extrapyramidal disorders, peripheral neuropathy, 
intracranial neoplasms, and migraine headache. It was the standard tool for 
neuroepidemiological studies for many years[25, 26]. A literature review was 
performed to collect data on the deficiencies identified in the 1981 WHO protocol by 
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investigators, these were multiple and are presented below, the screening tool itself is 
initially presented to facilitate discussion: 
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  Figure 1.1: The 1981 Original World Health Organisation Screening Tool 
Q1. Have you ever lost consciousness? 
Q2 Have you ever had episodes where you lost contact with your surroundings? 
Q3 Have you ever had episodes of shaking of your arms or legs which you could not 
control? 
Q4 Is your speech normal? 
Q5 Have you had episodes of pain in the face? 
Q6 Has your face or part of your face ever been paralyzed for more than 24 hours? 
Q7 Have you ever had weakness in your arms or legs for more than 24 hours? 
Q8 Have you been unable to walk properly? 
Q9 Have you ever had loss of sensation or abnormal sensation affecting your arms 
and legs, lasting more than 24 hours? 
Q10 Have you ever suffered from headache? 
Q11 Do you suffer from severe headaches, chiefly on one side of the head, which 
come on from time to time? 
Q12 In association with these headaches, do you suffer from visual disturbances: 
e.g. black spots or zigzag lines in front of your eyes? 
Q13 In association with these headaches, do you suffer from nausea or vomiting? 
Q14 In association with these headaches, do you suffer from weakness or 
numbness in the limbs that lasts less than a few days? 
Q15 Do these headaches occur only when you have a febrile illness? 
E1 Hold both arms above head for 30 s. 
E2 Pick up matchstick from ground. 
E3 Close your eyes. Feel cloth sample. Is it smooth or rough? 
E4 Put your hands out in front of you. Close your eyes. Touch your nose with the 
right index. Repeat it using your left. 
E5 Walk heel to toe along the white line (2 meter cloth). 
E6 Stand with both feet together. 
E7 Close your eyes and stand still for 15 s (only if able to perform E6). 
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1. Limitations of neurological disease ascertainment; 
The WHO protocol was designed to assess the prevalence of 6 predefined diseases or 
groups of diseases. This is not a complete list of neurological disorders and therefore 
"all-cause" neurological disorder prevalence cannot be recorded (WHO ICD 10). This 
was highlighted by Gourie-Devi et al [37] who made their "symptom check list" or 
questions more comprehensive.  
 
The WHO protocol does not focus on diseases of public health significance as data 
indicating disease burden was not available at time of production and will 
subsequently have changed, therefore, some neurological diseases of public health 
significance are not designed to be screened for and sensitivity for others is low 
(WHO). This is highlighted by Kapoor et al [32] who, when screening for neurological 
disorders in rural India, utilised the WHO screening protocol but added questions on 
head trauma as they felt this was of public health significance in their population.  
 
2. The examination section of seven points complicates interpretation of the results 
and therefore the screening protocols use by NMI; 
The examination points are an excellent and efficient test for multiple neurological 
signs however interpretation of results by NMI is problematic, this is supported by 
Morgante et al [38] who found the need to modify the WHO screening protocol, more 
specifically they had to qualify the possible different responses to the examination 
section making it more complex to read but easier to interpret. 
 
3. The examination section reduces acceptability for participants;  
Gourie Devi et al [37] found that it was not feasible to perform the examination 
section of the WHO screening protocol as they described that "people in semi-urban 
and rural (Indian) villages were reluctant to perform the clinical tests under instruction 
by field assistants and were insistent that a doctor carry out the tests". They therefore 
omitted the examination section from their tool.  
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4. The examination section fails to add anything to sensitivity and specificity; 
Bower et al [39] recently reported that an examination section reduces specificity and 
feasibility but does not increase sensitivity. Sensitivity and specificity are arguably the 
most important statistics on which to judge the quality of a screening tool.  
 
5. Low specificity increasing the cost and anxiety of false positives; 
Original data on the unmodified WHO screening protocol from the 1980s and 1990s 
quote specificities of 80-85% [3, 4, 40]. More recent evaluation from Bower et al [26] 
revealed a specificity of 29.2%, the authors highlighted that Q1, Q2, and Q7 required 
modification with subsections to increase specificity. This low specificity is highlighted 
by Kapoor et al, when screening for neurological disorders in rural India they used the 
WHO screening tool but had to delete questions on headache as they felt they would 
reduce specificity [32]. They also highlighted that that two questions (Q8, Q9) had a 
very low specificity and these required modification before data collection began. 
Despite these modifications they still found specificity to be only 80%.Cruz et al 
highlighted Q2 and Q9 as poorly specific questions and rephrased them, subsequently 
they found specificity to be 78% [31]. Morgante et al also modified questions and 
provided clarifications for responses and found the specificity to be 85% [38].  
 
6. Sensitivity to identify neurological morbidity; 
Reports of sensitivity are high but variable. The original data from the unmodified 
WHO screening protocol from the 1980s and 1990s quote sensitivities of 91-95% [3-5]. 
More recent sensitivities of the unmodified protocol have been quoted as 98.4% [26]. 
Modified versions of the protocol have been reported to have sensitivities between 
93-100% [31, 32]. 
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7. Not widely applicable; 
Kapoor et al criticise the WHO protocol in saying that it cannot be applied to different 
populations without completely retesting it in all respects (comprehension, sensitivity 
and specificity) [32]. 
 
Finally, Meneghini et al [41, 42] for numerous reasons describe the need to 
significantly modify the WHO protocol to develop their screening instrument for the 
Sicilian Neuroepidemiological Study (SNES) "questions and physical tests pertaining to 
some disorders were dropped. Other questions and brief tests were added or made 
suitable for the local situation". This modified protocol has been used in multiple 
regions since. 
 
Other screening instruments have been piloted and used since [26, 41, 43-48]. A 
literature review was performed to collect data on published neurological screening 
tools or protocols. The full details of the search are included in the methods section of 
this thesis. Papers were included in the review if they detailed information on a 
neurological screening tool that screened for more than two neurological disorders. 
Some studies used numerous screening tools that only detected one or two 
neurological disorders to detect more than two neurological disorders, the features of 
the individual screenings tools were presented but not their combined sensitivity and 
specificity so these were not included [47]. Screening questionnaires from both 
developed and developing countries were included. As a result 12 different screening 
tools were reviewed from 21 articles, of these 3 articles described the 1981 WHO 
screening protocol as described above. Eight screening tools have been produced 
through modification of the WHO screening protocol and 3 screening tools have been 
produced without direct reference/modification of the WHO screening protocol. Only 
one screening tool was produced for and validated in an elderly population. However 
this tool only screened for parkinsonism and essential tremor and was therefore 
excluded from analysis [47].  
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Bower et al [26, 39] have recently published 2 papers on their screening instrument to 
measure the prevalence of neurological disability in resource poor settings. The 
screening instrument is a modified version of the 1981 WHO protocol. The authors 
researched the literature to identify deficiencies in the original tool. The modifications 
were mainly to: highlight diseases of public health significance, identify those people 
with neurological impairment secondary to non neurological or unclear diagnoses, 
ensure the tool was suitable to be used by non-medically trained staff, ensure the tool 
was acceptable to the population, sensitive enough to detect neurological morbidity in 
Africa and specific enough to minimise the cost and anxiety of false positives. The final 
screening instrument comprised a history and examination section. There were 24 
history questions, 10 of which had between 1 and 6 subsections one of which needed 
to be positive for the question response to be positive overall. There are 16 
examination points, these require a NMI to interpret: a pronator drift, complex tests of 
sensation, tests of coordination, bradykinesia, visual fields, cranial nerves, speech, 
hearing and gait.  Their screening tool was very relevant to my research questions, it 
was also conducted in northern Tanzania, however they validated their screening 
questionnaire in a general adult population and did not focus on the elderly 
population.  
 
The first paper published in 2009 uses a neurologist's diagnosis as the gold standard in 
determining the presence or absence of a neurological condition [26]. The exact details 
as to how this diagnosis was made are not expanded upon, it is not known if 
investigation or just clinical assessment was used. The study was performed in a 
hospital population in a tertiary referral hospital in northern Tanzania. This is a biased 
sub-population in a developing country as it comprises those who have the financial 
ability to be seen in an expensive hospital and are likely to  be well educated. Many 
patients had a neurological condition which had been explained to them, as a result 
they were more likely to answer positively when questioned. This does not reflect the 
general population of a developing country, the proposed audience for the screening 
tool used in this thesis. The final screening instrument was only tested on 37 cases and 
41 controls; the spectrum of subjects was therefore limited. There is no mention as to 
whether the interviewers were blinded to the presence of a neurological diagnoses, 
the supervising neurologist was not blinded in fact they appeared to provide a gold 
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standard diagnosis before screening occurred. Observer bias was therefore not 
avoided. There were discrepancies with results produced by different observers, in 
over 20% of cases there was disagreement between the neurologist screening and the 
NMI. 
 
Sensitivity was found to be excellent at 100%. Specificity was however only 61% 
indicating that high cost and anxiety may still result from false positives. The authors 
did however improve on the specificity of the WHO screening protocol with which they 
made a direct comparison It scored 29.2% in their population. The authors report that 
their tool was extremely feasible and no participants were distressed by the 
completion of the tool but, of course this is a biased population who expected to be 
questioned and examined in hospital.  A sample of the community may not be as 
amenable to such an intervention.  
 
In summary the positive aspects of the screening instrument and the study were that it 
identifies most neurological diseases of public health significance and has a high 
sensitivity. The negative aspects were its poor specificity, small size, the hospital 
population studied, its lengthy and complicated questions with a complex examination 
section that reduces inter observer reliability.  
 
It was acknowledged by the authors that this screening instrument must be piloted in 
its proposed area of use; a community setting and this is covered by their second 
paper, published in 2012 and set in the same community as my study population, with 
a second community population in Ethiopia [39]. Subjects were not randomly selected, 
for convenience households were seen in clusters. The abstract indicates 669 subjects 
were involved in the study across 2 sites, however only 25 known cases (in one site) 
were used to test sensitivity and these were of limited diagnoses (Parkinson's disease, 
stroke and epilepsy). All of these 25 cases knew of their disease and had been 
educated regarding it and were likely to answer positively. The gold standard for 
sensitivity was diagnoses from previous prevalence studies, the details of how these 
diagnoses were made were not obvious in the paper. Only 42 subjects (in the same 
site) were used to test specificity, the gold standard against which this was checked 
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was a neurologist’s review, although the extent of this was not detailed. The authors 
state they reported the results of the same tool that they piloted in the hospital 
population but now state that the tool has only 22 questions (and 16 examination 
points as previously documented) there is no explanation provided for this 
discrepancy. The importance of using non medically trained staff as screeners was 
highlighted throughout both papers but despite this the authors used village health 
workers to screen. The health workers were blinded to diagnoses and so was the 
neurologist with regard to reviewing participants to test specificity. However, when 
reviewing cases to test sensitivity the presence of one of three neurological disorders 
was already known about. Inter observer variability was not tested.  
 
The authors report a sensitivity of 100% for detecting a limited number of neurological 
diseases and a specificity of 82.4%. The authors go on to analyse the history section  of 
the questionnaire in isolation, they reported a sensitivity of 100% and a specificity of 
91.2%. They concluded that the examination section adds nothing, complicates the 
screen and is potentially prohibitive to NMIs. 
 
Two papers by Meneghini et al [41, 49]reported the validation and utilisation of the 
1987 Sicilian Neuro Epidemiologic Study (SNES) screening instrument. The initial paper  
provided an overview of how a two phased neurological prevalence survey in the 
Sicilian community was conducted [49]. It described the neurological screening 
instrument used: The screening instrument was a revised and adapted version of the 
WHO protocol. The authors describe how "their experience and other methodological 
considerations prompted significant modifications of the original screening instrument. 
Questions and physical tests pertaining to some disorders were dropped. Other 
questions and brief tests were added or made suitable to the local situation. For 
example a brief test of elbow tone was inserted for screening for parkinsonism." 
 
The questionnaire was only translated into Italian and was not translated into the 
Sicilian dialect. This has the potential to cause problems for the elderly population who 
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may not have understood. Questions focussed on impairment of consciousness, 
uncontrolled limb movements, speech changes, facial paralysis, mouth drooping, limb 
weakness or paralysis, limb sensory abnormalities, rigidity, bradykinesia and tremor. 
Physical examination assessed arm strength, hand sensations, coordination, gait, 
standing with eyes open, standing with eyes closed, and elbow tone. Questions on self 
reported diagnoses of Parkinson's disease, epilepsy, stroke and peripheral neuropathy 
were also asked. A positive response was reported as one positive question, one 
positive examination section OR one, self reported diagnosis. 
 
The authors report it took five to ten minutes to administer the screening instrument 
and it was easy to use. 
 
The second paper describes the validation of screening instrument in more detail. The 
instrument only screens for 4 neurological disorders, parkinsonism, peripheral 
neuropathies, stroke and epilepsy, which although of great public health significance 
are far from a complete list and therefore cannot enable the documentation of the 
prevalence of all cause neurological disease [41]. The screening instrument was 
compared with a true and appropriate gold standard, clinical evaluation (history and 
examination not investigation) based on specified criteria.  
 
Unfortunately the validation study did not include a large spectrum of subjects. The 
authors highlight the importance of a community survey and yet validate in a hospital 
population which is potentially biased; the patients are aware of their diagnosis (and 
although the direct question part of the questionnaire was removed for analysis) they 
are likely to  be more aware of their symptoms and their relevance than an 
undiagnosed community population. No attempt was made to further validate in the 
community e.g. sample negatives. The authors do point out that their limitations are 
that the neurological diseases studied had resulted in inpatient admission and 
therefore the diseases are more likely to be advanced. They also acknowledge that the 
use of visitors to a neurology ward as controls has limitations as they may also have 
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increased awareness of diseases given a relative or friend may have one of the 
conditions. The authors state "biases may be encountered regarding hospital 
ambience, disease severity and non-representativeness of syndrome subtypes" 
 
Only 108 subjects were studied and this included 21 controls. Conclusions drawn from 
such a small study may be considered tentative.. ‘Screeners’ were neurologists, 
therefore this study uses (and this instrument is only validated for) expert screeners. 
This makes it very difficult and expensive to recreate, potentially prohibitively so in 
developing countries. To the authors benefit the screeners were blinded to the 
patients’ diagnoses which avoided observer bias. Inter-observer bias was not 
examined. 
 
The features of the test demonstrated a favourable sensitivity, 100% for parkinsonism 
(n=21), 96% for peripheral neuropathies (n=22), 96% for stroke (n=22) and 96% for 
epilepsy (n=22). The specificity was 86% (n=21 hospital visitors free of any of the study 
diseases) this was relatively low and indicated that in a large community prevalence 
study a high number of false positives may make phase two difficult. Confidence 
intervals were not presented limiting conclusions.  
  
In summary the SNES screening instrument was limited by only screening for four 
neurological diseases, a low specificity, expensive specialist screeners and poor 
validation in a hospital population. 
 
Nicoletti et al [33] also utilised the SNES protocol to document the prevalence of 
neurological disorders in rural Bolivia. They report that they translated the 
questionnaire into Spanish and pre-tested it. They briefly state how they piloted the 
newly translated SNES screening tool in October 1994 in two small communities of 291 
inhabitants which do not appear to be randomly selected. Pilot investigations and 
screening were carried out by varied health professionals including neurologists. The 
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authors report that revision of the questionnaire occurred and minor changes were 
made, however they do not report what those changes were or the revised 
sensitivities and specificities. 
 
Vita and Morgante et al [38, 46] presented the findings of the validation of a screening 
tool (consisting of 9 questions and 7 examination points) in Sicily in 1989 for which 
field work was performed in 1984 [38, 46]. Their screening tool aimed to screen for 
some of the major neurological disorders, namely cerebrovascular diseases, epilepsy, 
extrapyramidal syndromes, peripheral neuropathies, migraine and intracranial 
neoplasms. The reasons for selecting these conditions were justified, as these 
disorders were of medical and social importance, but it is important to point out that 
this is far from a complete list of neurological diseases. The screening tool was 
produced through modification of the original WHO protocol. The screening tool was 
compared with the standard gold standard of full neurological history and examination 
by a person with neurological training with reference to diagnostic criteria. No 
laboratory tests were used. Diseases were coded using WHO classification 1975 
edition. The validation study included a broad spectrum of subjects, a whole 
community (a small town) of 1638 were screened (eliminating sampling error). Only 37 
subjects refused to take part, giving a final sample of 1601. All neurological disorders 
screened for were present in this population. Work up bias was avoided by avoiding 
sampling and by visiting patients, who were unable or refused to come to the clinic, in 
their own home. The screeners were medically trained and one of each team was a 
neurology specialist, which would limit the reproducibility of this procedure in 
resource poor settings with few neurologists. Inter observer reliability of the screening 
tool was not reported and observer bias was not avoided. The features of the test 
were an excellent sensitivity of 100%, however the specificity was only 85% and the 
positive predictive value was only 44%. The authors admit "this value is low and has to 
be enhanced by modifying the questionnaire before a much larger population is 
examined". The high number of false positives produced would make the second 
phase of a study performed with this tool expensive and unwieldy. Confidence 
intervals for the features of the test were not presented. The study also appeared to 
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identify a large number of neurological diseases not included in the questionnaire and 
it is not clear how this occurred [38, 46].  
 
In summary these papers present the features of a screening tool validated for use in 
Italy. It identifies a limited number of neurological diseases and its validation using 
neurologists as screeners and its low positive predictive value indicate that its use in a 
developing country would be limited. 
 
Gutierrez-del-Olmo et al [31] present the findings of the validation of a screening tool 
to detect neurological disorders in Madrid, Spain. The screening tool was described as 
"an extensive questionnaire and a brief screening neurological examination" designed 
to identify ,migraine, epilepsy, peripheral neuropathies, completed stroke, transient 
ischaemic attack (TIA) and Parkinson's disease (a far from complete list of neurological 
disorders). It was not however described in more detail or presented in an appendix so 
it is not known how it was produced and whether it was a modification of an already 
validated tool, however other literature indicates it was a modification of the WHO 
protocol. The gold standard for comparison was stated to be "examination by a 
neurologist". The validation study included a large number of subjects, 961. The choice 
of area was in close proximity to the specialist neurology hospital (for convenience for 
the neurologists and the subjects in the study), this however may introduce some bias 
as those geographically close to such a hospital may be more likely to have already 
received a neurological diagnosis than those living in rural areas or urban areas with 
less facilities. However the authors report that the age, occupation and economic 
distribution of the population closely matches the general Spanish population. Random 
sampling was used to identify 375 households for the study, however 32 were 
eliminated because no-one was home and 94 households refused to take part. This 
represents 27% of the population, a large percentage with the potential to introduce 
bias as the reasons for their refusals were not explored. This is a community study 
which is therefore more representative of the general Spanish population than a 
hospital population, however only households were included in sampling and 
institutions such as nursing homes which may contain large numbers of people with 
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neurological disorders were not included. Interviewers were medical students, 
therefore they had some medical training and would be more expensive to employ 
than NMI but would be cheaper and more available than trained doctors or 
neurologists. Inter observer bias was not examined. 
 
The sensitivities of the screening tool were between 93-98%. The specificity was poor 
at 78% which is represented by the fact that of 961 people screened, 509 (52%) 
screened positive making the second phase very large and expensive. In addition to 
that, of the 509, 108 (21%) declined further examination.  The screening results and 
medical records were used to classify refusers into probable presence or absence of 
neurological disease. It is not clear how these extrapolations were used in the results 
of the features of the screening questionnaire or the prevalence figures. It is 
acknowledged by the authors that seeing patients in their own home in the second 
phase would have increased the participation rate but this was not attempted due to 
time limitations. Positive predictive values and confidence intervals were not 
presented. The authors identify problem questions for false positives as being; "have 
you had episodes of loss of awareness or contact with your surroundings?" and "have 
you had tingling or pins and needles in your arms or legs that you could not explain?” 
The latter question was improved by defining that the symptoms had to last more than 
24 hours. The authors also identified some problem examination sections. One 
sections asked participants to "get up and sit down from a chair 3 times without using 
your hands" with another asking participants to "walk 2 metres on your toes and two 
metres on your heels". They state elderly individuals with arthritis but with no 
neurological disorders had particular difficulty in performing these tasks. 
 
This study highlights the increased number of false positives that can result from 
screening an elderly population and the problems this represents to previously 
published screening questionnaires.  
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Anderson et al [45] report the validation of a screening tool for the detection of 5 
neurological disorders; epilepsy, parkinsonism, stroke, febrile seizures and TIAs in an 
urban community in Buenos Aires, Argentina. The instrument was based on that used 
in the Copiah County Study in 1982 [50]. A precise questionnaire was used to ask one 
member of the household about all other members of that household (no examination 
section was included). This method is cheaper, quicker and easier than direct 
questioning of individuals but has increased likelihood of error, particularly false 
negatives (for reasons of ignorance and stigma). The gold standard for comparison was 
full neurological history and examination. Interviewers were trained personnel with 
academic backgrounds as teachers or social workers, a protocol that would be 
relatively easy to recreate in other developing countries.  
 
The validation procedure was complex and had 3 main sections; 
1. Evolution of the screening questionnaire through drafts given to relatives and 
acquaintances of the authors and interviewers. This was to avoid embarrassing or 
confusing sections and to alter wording accordingly. 
 
2. Sensitivity and Specificity were tested in a hospital environment. 10-15 individuals 
with the conditions and 10-15 controls were assessed by the authors and interviewers. 
They were not blinded to patient’s conditions and the results of this phase are not 
presented in the paper. 
 
3. A pilot site in a rural community (not representative of the final urban study site and 
not randomly selected) was used. The sample included 912 individuals from 281 
households. All conditions were represented. The sensitivities presented were epilepsy 
19/20 (95%), febrile seizures, 9/10 (90%), stroke 19/20 (95%), TIAs 8/10 (80%), 
Parkinsonism 24/24 (100%). The specificity estimate was 16/20 (80%); however it is 
not clear where this estimate comes from as all negatives were not examined. 
Confidence intervals and predictive values were not presented. Observer bias was 
reduced by the fact that interviewers did not have prior knowledge of participants’ 
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neurological conditions. Questions about drooling were deemed embarrassing and so 
removed, questions with regard to speed of eating were removed for poor sensitivity 
and questions with reference to accurate timescales were removed as participants 
found them difficult to understand. It is not clear whether these modifications 
occurred before or after pilot testing. Inter observer reliability was not tested for. 
 
In summary, Anderson et al present the validation of a screening tool which has a low 
specificity and only tests for 5 neurological conditions. Validation of the tool was a 
complex process that appears to have some discrepancies. The utilisation of NMI and 
the lack of an examination section would make it easy to use in a developing country 
[45]. 
 
Two papers from the late 1980s report the screening protocol from Gourie-Devi et al 
[37, 51] used in the neuroepidemiological study in Gowribidanur, India. They used a 
symptom check-list for 16 primary symptoms and 5 secondary symptoms. They state 
that they screened for more neurological disorders than the WHO protocol but they do 
not state what these were or how they were decided upon. The screening 
questionnaire was produced through modification of the WHO protocol questions. 
They did not utilise an examination section as they stated it would not be acceptable 
to the local community to be examined by trained screeners who were not doctors and 
were non-professional workers with schooling of 12 years, living in the study area. This 
improved the reproducibility of the study in other developing countries and the 
acceptability of the study within the local community. The symptom checklist was 
asked to the head of the household, this may improve case ascertainment (as each 
member of the household does not need to be seen) but it may also increase the 
number of false negatives (due to ignorance of the head of the household to another's 
symptoms or fear of stigma). The screening questionnaire was compared with the gold 
standard of history and examination by a neurologist. The validation study occurred in 
a large population representative of the main study population. A sample of 10% of 
the main study population was selected but it is not clear whether this selection was 
random. Unfortunately there were only 21 true cases of neurological disorders in the 
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sample and it was not detailed which disorders these were; it is therefore difficult to 
assess whether the pilot study results are representative of the screening 
questionnaires performance in the main study. The sensitivity and specificity were high 
at 95% and 98% respectively. However the positive predicative value was only 36%. 
This screening tool appears to be highly feasible in a developing country however its 
validation is unsatisfactory.  
 
Gourie-Devi et al [44, 52]reports on the use of their screening questionnaire again in 
1996 and 2004, where they pilot it in a large urban population. The questionnaire has 
been modified from its original form and now consists of only 12 questions. The pilot 
population was randomly selected and was therefore representative of a standard 
Bangalore population where the main prevalence study was to take place. To their 
credit they continue to use NMIs which are cheap and easy to employ. They report 
high sensitivity and specificity of 95% and 98% respectively but a positive predicative 
value of 68% indicating that a high number of false positives may be identified The 
details of their validation are again unclear. The large pilot study identifies a wide 
range of neurological disorders and so tests the questionnaires ability to successfully 
identify these.  
 
Kapoor et al [32]report the performance of a modified version of the WHO protocol in 
rural India. They modified the screening tool by deleting questions on headache and 
adding questions on head trauma. The main validation of their screening tool occurred 
in a biased population of a health clinic where participants had known neurological 
disorders and their relatives acted as controls. As these groups will have more 
knowledge of the symptoms and signs of neurological disorders that the general rural 
population this may not be representative of the tools performance in the wider 
community. The size of this initial pilot was not specified. The tool was compared with 
the gold standard of full history and examination and it was partially validated in a 
wider population.  A village (n=729) was selected, although not randomly, to be a pilot 
site for further evaluation of the screening tool and the preliminary report of 
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prevalence data. All the positive responders were examined by a neurologist; however 
the negative responders were not. 
 
Reported sensitivities and specificities of the screening tool for the initial pilot were 
found to be 100% and 80% respectively. The positive predictive value was reported for 
the second village based pilot study as 62.1%.The question that produced the highest 
number of false positives were found to be "have you ever been unable to walk 
properly?" The low specificity and positive predictive value found in this study indicate 
that the second phase of a larger study may be unfeasible due to a high number of 
false positives. 
 
Das et al [43] report the validation of a screening tool for the detection of the "major 
neurological disorders" such as epilepsy, stroke and Parkinsonism in the city of Kolkata. 
Their tool was based on national Institute of Mental Health and Neuro Sciences 
(NIMHANS) protocol but this is not referenced or expanded upon. The screening 
instrument was piloted against a gold standard of history and examination by a 
neurologist. Standard diagnostic criteria were used to define diseases. The screening 
tool was validated in a large pilot study of 3041 subjects although it is not clear how 
these subjects were identified and if randomisation was used.  
 
Authors report that the sensitivity and specificity of the screening tool was 84% and 
99.9% respectively. The low sensitivity indicates that a number of cases would be 
missed in future studies that use this tool. Positive and negative predictive values were 
98.5% and 99.5% respectively. The authors report good inter-observer reliability but 
they do not present the data to support this. “Field workers” performed the screening, 
they were a minimum graduate in social science with experience of carrying out 
epidemiological surveys. Field workers required an intensive 3 months training which 
may be expensive and difficult to reproduce.  
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Das et al [53] go on to report the prevalence of neurological disorders specifically in a 
geriatric population. They use the same screening methodology as presented in the 
afore-mentioned study. No modification is made to the screening tool to 
accommodate this different population.  
 
The Copiah County Study from the 1980s utilised a screening questionnaire to detect 
the disorders of cerebral palsy, epilepsy, stroke, Parkinson's disease, essential tremor 
and severe dementia[50]. The authors report the importance of designing the 
screening questionnaire with the population to be screened in mind; this is with 
particular reference to wording of the questions. Questions were directed to the head 
of the household about all other members in the house, this has the advantage of 
improved ascertainment whilst potentially increasing false negatives due to ignorance 
of the responder about others symptoms or for fear of stigma. The gold standard was 
neurological history and examination, no laboratory tests were used. The pilot study 
was conducted throughout the region of Hinds County this area was deemed to be 
representative of the population proposed for the larger prevalence study. The 
questionnaire was tested on known cases or known controls, which may introduce 
bias. No attempts for blinding were described. The size of the pilot study and the 
results were not described in more detail. 
 
Quet et al [54] evaluated the performance of a modification of the WHO standard 
protocol in a rural community of central Mexico. This modification consisted of 12 
standardised questions and 4 simple tasks for a quick evaluation of motor or sensory 
deficit, tremor and ataxia. Four more questions were added to improve sensitivity 
regarding epilepsy, psychomotor delay, diplopia and memory failure. Not only was the 
questionnaire evaluated against a gold standard of clinical examination (with reference 
to standard diagnostic criteria) performed by or under the observation of a 
neurologist, the performance of a questionnaire for individuals (IQ) was compared 
with a questionnaire for the household leader about everyone in the household (HQ). 
The HQ was the same as the IQ except for the examination section was removed. To 
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compare the questionnaires, the IQ and HQ were simultaneously and independently 
applied to each household during the screening phase. 
 
As the study was performed in a large rural community an appropriate spectrum of 
subjects were included.  Interviewers were semi-specialised medical, nursing or 
veterinary students, more expensive to employ than NMI. They were trained for 3 days 
before the study in order to minimize inter and intra observer variations, however 
these were not tested for. A whole region was screened so there was no possibility of 
sampling errors, however 15.5% of families refused to participate or could not be 
contacted in the study, and this has the potential to introduce bias. The authors found 
that the IQ detected significantly more patients (127/143, 88.8%) than the HQ (73/143, 
51.0%). This difference was mainly due to the inability of the HQ to detect headaches: 
the IQ detected 74 of the 81 patients with headache (91.4%), while the HQ detected 
only 28 (34.6%). This therefore reduces the possibility that the lack of an examination 
section is the main contributing factor to the poor performance of the HQ. However, 
the usefulness of questionnaires remained significantly different when all ND excluding 
headaches were considered. In this case, the IQ detected 60 of the 70 neurological 
disorders (85.7%) while the HQ detected 47 of the 70 neurological disorders (67.1%). 
HQ does however detect the most severe neurological disorders and the authors 
therefore conclude that given its improved ease of use over the IQ, it could be used 
with this purpose in mind. 
 
The major problem with this study was that negative responders to the screening 
questionnaires were not evaluated; therefore one can only calculate positive 
predictive value and not sensitivity, specificity, or negative predictive value. 
 
1.1.3.1.1 Screening questionnaires for neurological disorders in the elderly 
None of the screening tools already in existence for screening for multiple neurological 
disorders focussed on the elderly, a population likely to reduce a tool’s specificity. The 
elderly are a unique population who require their own screening tool for neurological 
disorders for the following reasons; 
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1. Screening tools should be focussed on diseases of public health significance [39].This 
is different for the elderly population who have an increased prevalence of stroke, 
Parkinson’s disease, essential tremor and epilepsy [53]. 
 
2. Elderly people have more co morbidities and this can often lead to decreased 
specificity through an increased number of false positives [55]. 
 
3, The elderly population is less likely to accept to be participants in a study with an 
examination section and more specifically for a medical examination to be performed 
by non-medical personnel [35, 56]. Therefore it is important that a screening tool 
designed specifically for the elderly omits an examination section so as to optimise 
participations rates.  
 
1.1.3.1.2 Examination sections of screening questionnaires for neurological 
disorders 
Flaws of the inclusion of an examination section in screening tools have been detailed 
above specifically with reference to the WHO protocol. After reviewing problems 
highlighted in the literature I reviewed how applicable these issues were to our local 
population, the following conclusions were made: 
 
1. The elderly in our population did not want to be examined (however superficially, by 
a non medical personnel) - this was discovered during preliminary fieldwork where the 
population to be researched were informed of how brief the examination would be  
but they remained concerned. 
 
2. The examination sections utilised in published tools vary in length from 7 to 16 
examination points. The Non-Medical Investigators did not want to  perform an 
examination nor interpret the results. The latter in particular was anticipated to be 
problematic.  This is evidenced by the work from Bower et al [39]who state that 
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examination sections reduce specificity without making any improvement to sensitivity 
and Morgante et al [38] who highlight the need for clarification of examination 
responses complicates training. NMI did report that when questioning patients on 
symptoms they would feel happy to provide simple demonstrations of what they 
meant by certain symptoms to help participants understand. 
 
The use of NMIs is important, as there are few medically trained people available to 
act as interviewers and NMIs can be relatively inexpensive to employ. Furthermore 
NMIs often have extensive local knowledge of people and geography. This can make 
them more acceptable to participants and so increase participation rates. 
 
Gourie-Devi et al [52] report that "it was found that people in semi urban and rural 
villages in India were reluctant to perform clinical tests under instruction by field 
assistants and were insistent that a doctor carry out the tests" for that reason they 
omitted an examination section from their screening tool. 
 
1.1.3.1.3 Cultural specificity of screening questionnaires 
If a screening tool is proposed for use either in all developing countries or worldwide, 
efforts should be made to make its content  culturally non specific, however, its 
wording should remain culturally specific through translation and back-translation to 
ensure ease of use. Sarangmath et al [57] looked at potential cultural issues when they 
designed a screening questionnaire for PD, they reported that if a questionnaire was 
not culturally non-specific NMI’s responses had lower specificity when compared to 
Medical Interviewer’s (MI) responses. Particularly important is the exclusion of 
questions regarding reading or writing to ensure screening questionnaires can be used 
in all literacy levels. The aim or the screening tool I used was for it to detect 
neurological disorders in the elderly in low income countries and therefore it was 
important to make its content culturally non specific but its wording correctly 
culturally specific. 
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1.1.3.1.4 The sensitivity of screening questionnaires 
A screening questionnaire must have a high sensitivity (to ensure all neurological 
disorders are identified).The sensitivity of published screening tools varies from 84.0% 
to 100.0% (Those piloted in SSA 91.0%-100.0%) [3, 6, 26, 40], (Those piloted elsewhere 
84.0% to 100.0%) [31, 33, 37, 41, 43-48, 53, 58].  
 
1.1.3.1.5 The specificity of screening questionnaires 
A screening questionnaire should have a high specificity (to reduce the number of false 
positives picked up which if numerous have the potential to make the study unfeasible 
due to the high financial cost of the second phase). The specificity of published 
screening tools used in SSA ranges from 29.2% to 85% [3, 6, 26, 40] and the specificity 
of those piloted in non SSA countries varies from 80% to 99.9% [31, 33, 37, 41, 43-48, 
53, 58]. These screening tools were used in the whole of the adult population, not just 
the elderly (a population group known to reduce the specificity of the screening tool 
further due to multiple co morbidities). Previous investigators have commented that 
when screening mass populations it is important to accept poor specificity to achieve a 
high sensitivity [59]; however this should not be the case especially when screening an 
elderly population with an increased likelihood of  false positives due to their co 
morbidities this increases the need to have a high specificity. The cases missed are 
often not disabled by their symptoms and a low specificity would make screening 
unwieldy and financially impractical. 
 
It has been demonstrated that the WHO screening tool can be more sensitive and 
specific when neurologists are used as screeners, however this is generally financially 
and logistically unfeasible in resource poor countries with few neurologists [60, 61].  
 
1.1.3.1.6 Screening questionnaires for neurological disorders in SSA 
The majority of published screening tools have not been validated for use in SSA [31, 
33, 37, 41, 43-48, 53, 58], which is not a criticism given they were never developed for 
this population but it does limit their use in this population without further validation. 
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1.1.4 Disability 
Current data estimate 10% of the world’s population are disabled [18], however there 
are few data on true prevalence of disability in developing countries, particularly 
amongst the elderly [62] despite the association between disability, increasing age and 
poverty (both cause and effect) [63],[64],[65], supportive data from the African 
community is required. In 2006, the United Nations (UN) highlighted the importance of 
disability to governments and international development agencies [18].The availability 
of high quality, internationally comparable up to date data on disability is integral for 
the planning, implementation, monitoring, and evaluation of inclusive policies. 
 
Many disabling conditions can be prevented or treated readily and inexpensively. 
There are cost-effective measures for rehabilitation and disability improvement. 
Identification of those with disability and diseases that result in disability is clearly an 
important component in the reduction of the morbidity burden [66].  
 
Reported disability prevalence rates around the world vary significantly because of 
different definitions, study designs, and lack of a universal assessment tool. This leads 
to comparison difficulties.  In view of its simplicity, high validity, reliability, sensitivity 
and utility, the Barthel Index (BI) has been proposed as the standard measure of 
disability and the gold standard to which new measures should be compared [67, 68]. 
 
There is clearly a need to address health issues in the African Elderly and to accurately 
document levels of Neurological morbidity and disability. 
 
1.2 Neurological Disorders 
Neurological disorders are diseases of the central nervous system (CNS) (the brain and 
spinal cord), the peripheral nervous system (PNS) (the cranial nerves, peripheral 
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nerves, nerve roots, nerve plexus, neuromuscular junction and muscles) and the 
autonomic nervous system (ANS). 
 
Psychiatric disorders are diseases in which the primary abnormality is one of thought, 
feeling or behaviour, producing either distress or impairment of function. These 
disorders include dementia which, although included in the neurological section of the 
World Health Organization (WHO) – International Classification of Neurological Disease 
(ICD) 10th edition (WHO-ICD 10) will not be elaborated on in this thesis. Further 
rationale for this decision is detailed later. 
 
Hundreds of millions of people worldwide are affected by neurological disorders: For 
example, 50 million people have epilepsy; 62 million are affected by cerebrovascular 
disease; 326 million people suffer from migraine [69]. 
 
1.2.1 Classification - WHO ICD 10 
ICD-10 was endorsed by the Forty-third World Health Assembly in May 1990 and came 
into use from 1994. The World Health Assembly adopted the WHO Nomenclature 
Regulations in 1967 that stipulate use of ICD in its most current revision for mortality 
and morbidity statistics by all Member States.  
 
The ICD is the international standard diagnostic classification for all general 
epidemiology, many health management purposes and clinical uses. These include;  
 The analysis of the general health situation of population groups  
 Monitoring of the incidence and prevalence of diseases  
 Assessing health problems in relation to variables such as the characteristics 
and circumstances of the individuals affected.  
 Assessing requirements for resource allocation.  
 Ensuring adequate quality control and up-to-date guidelines. 
 Enabling accurate records of health and death to facilitate the storage and 
retrieval of diagnostic information for clinical, epidemiological and quality 
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purposes. These records also provide the basis for the compilation of national 
mortality and morbidity statistics by WHO Member States[70]. 
 
The latest updates for ICD-10 were performed in 2007. A summary of the “Diseases of 
the Nervous System” section is detailed in appendix 1.1 [71]. 
 
The National Institute of Neurological Disorders and Stroke (NINDS) present the same 
disorders in an A to Z format [72]. 
 
Additional sub-classifications and diagnostic criteria from different health 
organizations are available and were utilised in this project with respect to different 
sub-types of neurological diseases. These are described within the relevant sections. 
 
1.2.2 Epidemiological and Clinical Diagnostic Divisions 
It is important to recognise the WHO ICD 10 for epidemiological studies especially 
when devising a screening tool as this allows full inclusion and consideration of all 
neurological diagnoses. Therefore, all patients diagnosed with a neurological condition 
have been allocated a WHO ICD 10 diagnosis. However, for practical reasons 
description of all the patients and the prevalence rates is often best performed with a 
more clinically relevant method to divide up the cases. This is done using a 
combination of the clinical and anatomical picture that the individual conditions 
produce. I used a practical combination of clinical classification and the ICD10 criteria 
to describe the prevalence rates (figure 1.1). 
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Figure 1.2: Epidemiological and Clinical Divisions of Burdensome Neurological 
Disorders. (WHO ICD 10 categories are presented in brackets) [71] 
 
  
Central Nervous System Disorders 
1. Movement Disorders (G20-G26) 
a. Tremor – all causes including cerebellar disease and Parkinsonism (G11.2-G46.4) 
b. Parkinsonism (G20-G23.1) 
c. Cerebellar Disorders (G11.2-G46.4) 
d. Other Dyskinesias (G25.5-G25.8) 
2. Episodic and Paroxysmal Disorders (G40-G47) 
a. Headache Disorders (G44.1-G50.0) 
b. Stroke (G46.0-G46.7) 
c. Epilepsy (G40.6) 
3. Systemic Atrophies/Degenerative Diseases affecting the Central Nervous System (G10-G13/G30-G32) 
a. Motor Neuron Disease (G12.2) 
4. Injury resulting in CNS dysfunction 
a. Spinal Cord Injury (G95.2-95.9/S14.1) 
5. Spinal cord dysfunction - other 
6. Infection resulting in CNS dysfunction 
Peripheral Nervous System Disorders 
1. Polyneuropathies (G60-G64)/(G62.9) 
2. Nerve, nerve root and plexus disorders (G50-G59) 
a. Cranial Nerves (G51.0-G52.8/S04.1) 
b. Upper Limb mononeuropathies (G56.0-G56.2)/(S54.0-S54.7) 
c. Lower Limb mononeuropathies (S74.0-S84.1) 
d. Plexus pathology (S14.3-S34.4) 
e. Root pathology (G54.2-G54.9) 
3. Inflammatory/infectious diseases of the peripheral nervous system (A00-B99) 
a. Polio (A80.3) 
b. Leprosy (A30.9) 
4. Diseases of the myoneural junction and muscle (G70-G73) 
a. Myaesthenia Gravis (G70.0) 
b. Muscle wasting and atrophy (M65.2) 
 
 
35 
 
 
It is important to justify why the ICD 10 was used and why the diagnoses detailed 
above were the inclusive list. Systematic use of the WHO International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) criteria 
ensured that the study was fully inclusive [20]. Cases with visual problems, hearing 
problems, dementia, and mild cognitive impairment, but no other signs or symptoms, 
were not considered to have a neurological disorder for the purposes of this study. A 
large proportion (46.9 %) of people in the study population responded positively when 
asked if they had problems with their vision. Likewise, large numbers of elderly people 
report problems with their hearing, mainly due to the high prevalence of presbyacusis. 
Inclusion of these diagnoses would substantially reduce a screening instrument’s 
specificity. Questions about subjective deterioration in memory are notoriously 
unreliable for accurate detection of cognitive decline [21]. If detection of memory 
problems is desirable, I would recommend using an additional, appropriately validated, 
cognitive screening instrument. Overall, I feel the criteria set out above would be 
unlikely to miss a significant number of cases since very few neurological disorders are 
present with these excluded symptoms in isolation. Although the ICD 10 may have 
some flaws when used in low- and middle income countries, and some diagnoses may 
be difficult, it is a recognized international standard and allows direct comparison 
between studies carried out in different settings. Thus, I feel it was the most 
appropriate diagnostic criteria to use. 
 
The disorders of Stroke and Dementia are included in several sections of the ICD 10, 
justification of their inclusion and exclusion respectively is therefore provided in more 
detail below: 
 
Stroke is part of the "Diseases of the Nervous System" section of the ICD10 (section 
G00-G99). Specifically, it is part of episodic and paroxysmal disorders G40-G47 and 
comprises; G45 Transient cerebral ischaemic attacks and related syndromes and G46 
Vascular syndromes of brain in cerebrovascular diseases. It is  also mentioned under 
diseases of the circulatory system but this does not justify exclusion from neurological 
disorders. 
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Dementia is included in the "Diseases of the Nervous System" section of the ICD10  
(section G00-G99), however only in part. A more complete description of dementia is 
included in the "Mental and Behavioural disorders" section more specifically "Organic, 
including symptomatic, mental disorders" (F00-F09), I The use of subjective memory 
questions for the diagnosis of dementia is fraught with difficulty and requires a 
specialised screening tool and prevalence study [73]. For these reasons dementia is 
excluded from this study. 
 
Acceptance of  the aforementioned definition of a neurological disorder means that 
stroke is and dementia is not a neurological disorder. 
 
1.3 Diagnosis of Neurological Disorders – History, Examination and Investigation 
The Neurological history and the physical examination are fundamental for an 
appropriate management plan (investigation and treatment) to be instigated [74]. 
 
1.3.1 Neurological History 
A neurological history is composed of; 
 Neurological symptoms recognition, namely; 
Seizures [75] 
Dyskinesias/Abnormal Movements [76, 77] 
Weakness - graded using the Medical Research Council (MRC) muscle 
power scale [75, 78] 
Sensory abnormalities [75] 
Ataxia/Coordination problems [75, 76] 
Dysphasias/ Speech abnormalities [72, 74-76, 79] 
 Characterizing the pattern of the neurological disease over time 
 Establishing precipitating factors and preceding and subsequent events 
 Collateral history if required 
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 Interpretation of a neurological history based on knowledge of the hierarchal 
organization of the nervous system and the principles of functional localisation 
and pathological processes.[79]. 
 
1.3.2 The Neurological Examination 
The detailed neurological examination consists of  assessment of speech and language 
and  gait and  examination of the motor system, sensory system, cranial nerves and 
coordination [76]. Pathology in different areas of the nervous system produces 
different clinical signs [72, 74-76, 79, 80]. 
 
1.3.3 Neurological Investigation 
A thorough history and examination remains the primary way to establish a differential 
diagnosis. Only when these have been satisfactorily performed should these be used 
to focus neurological investigation. Some investigations carry risks and all come at an 
expense, additionally within developing countries such as SSA they are often not 
available and clinical skills remain the only way to arrive at a diagnosis and instigate 
potential treatment [75].  
 
Neurological Investigations available within the research area included, basic blood 
tests, simple x-rays, computerised tomography (CT) and electroencephalograms (EEG). 
Neurological Investigations not available within the research area were magnetic 
resonance imaging (MRI), angiography, nerve conduction studies (NCS)[75, 81, 82].  
 
1.4 Prevalence and Incidence [83] 
1.4.1 Prevalence 
The prevalence of a disorder is “the number of live cases suffering from that disorder, 
usually expressed per 100,000 of the population (or per 1000 of the population if the 
disease is more common), at a defined time.”  The prevalence of a disorder is affected 
by length of survival of those with the disease. For diseases with long survival times 
this is not an issue, but for diseases where patients may die soon after diagnosis, a 
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prevalence figure may be misleadingly low. In this case the incidence of the disease is a 
better marker of how common it is. 
 
1.4.1.1 Point Prevalence  
Point prevalence is a measure of the proportion of people in a population who have a 
disease or condition at a particular time, such as a particular date. This measure is best 
used for chronic conditions and was the measure used in this prevalence study. 
 
1.4.1.2 Period Prevalence 
Period prevalence is a measure of the proportion of people in a population who have a 
disease or condition over a specific period of time, say a season, or a year, this 
measure is better used for acute conditions. 
 
1.4.2 Incidence 
Incidence is “The number of instances of illnesses commencing or of people falling ill, 
during a given period in a specified population. More generally, the number of new 
health-related events in a defined population within a specified period of time. It may 
be measured as a frequency count, a rate, or a proportion.” [84] In developing 
countries many patients may not receive medication for their illness. It is therefore 
possible that survival will be affected, meaning that patients may die earlier and thus 
lower prevalence. This would indicate that incidence is a better measure in these 
populations. However incidence studies are reliant upon patients seeking medical help 
quickly after symptom onset, something that often does not happen in developing 
countries due to financial restrictions and low availability of local healthcare resources.  
 
1.4.3 The appropriate measurement of neurological disease morbidity burden 
In the majority of Neurological disorders the disease has a chronic trajectory and 
therefore prevalence is a more accurate reflection of disease burden. The exception to 
this rule is Stroke and Neurological deficit caused by accidental injury; in these cases 
the rural setting, the age of the patient and their financial situation often prevent them 
from seeking help further complicating a successful incidence study. It was felt that an 
incidence study in rural Tanzania of all Neurological Disorders and their consequent 
disability, in this age group, would be difficult to undertake and prevalence was a more 
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accurate representation of morbidity. Chan et al [85] state that although incidence is a 
better measure of disease occurrence, it is difficult to obtain in chronic diseases[83].  
 
1.5 Detailed description of Neurological Disorders 
This prevalence study aimed to identify a complete list of neurological disorders as 
defined by the WHO ICD 10 (see figure 1.1); 
 
The diagnostic criteria and epidemiology of the most common and public health 
relevant conditions namely, tremor, parkinsonism, cerebellar disorders, headache, 
stroke and epilepsy, have been described in full. The prevalence study also aimed to 
identify, dyskinesias, motor neuron disease, spinal cord dysfunction including injury, 
infection resulting in CNS dysfunction, polyneuropathies, nerve, nerve root and plexus 
disorders and inflammatory/infectious diseases of the PNS e.g. polio and leprosy.  A 
more superficial review of the diagnostic criteria and epidemiology of these conditions 
has been included in appendix 1.2 and 1.3.The conditions are described in the order of 
the clinical/epidemiological divisions described above. 
 
1.5.1 CNS Disorders 
1.5.1.1 Movement Disorders 
1.5.1.1.1 Tremor Disorders 
1.5.1.1.1.1 Definition 
Tremor: the Rhythmical, involuntary oscillatory movement of a body part [86]. 
 
1.5.1.1.1.2 Clinical/Syndromic Classification of Tremor 
Practical classifications of tremor that are based upon aetiological or 
pathophysiological factors are not available therefore the gold standard remains a 
clinical classification. This is particularly relevant in epidemiological studies in 
developing countries where history and examination are, in the majority, the only tools 
40 
 
available for diagnosis. The clinical classification of tremor may be based upon the 
following factors that will make up a syndromic classification; 
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Table 1.1: Variants in the clinical analysis of tremor that dictates the Syndromic classification 
Variant Issues that indicate Syndromic classification 
Anatomic or topographic 
distribution 
 
 Head: Chin, Face, Tongue, Palate 
 Upper extremity: Shoulder, Elbow, Wrist, Fingers 
 Trunk 
 Lower extremity: Hip, Knee, Ankle joint, Toes 
Activities that activate 
tremor 
 
 Rest Tremor 
 Action Tremor 
 Postural Tremor 
 Simple Kinetic Tremor 
 Tremor during target-directed movements (intention tremor) 
 Task specific Tremor 
 Isometric Tremor 
Relative tremor frequency 
measured in cycles per 
second 
 
 Physiologic and enhanced physiologic tremors have a relatively high frequency, often 
ranging from approximately 7 to 12 cycles per second.  
 In contrast, the rate of many pathologic tremors is about 2 to 7 Hz.  
 Primary orthostatic tremor (OT) is a notable exception, with a 13 to 18 Hz  
 Cortical tremor, recognized as a form of rhythmic myoclonus, is characterized by 
irregular, postural and kinetic tremor-like jerks with a range between 7 to 18 Hz. 
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 Cerebellar and rubral or Holmes tremors tend to be of relatively low frequency, 
primarily occurring below 4.5 or 5 Hz.  
 The pure rest tremor seen in some with PD is characteristically greater than 4 Hz 
 In classic ET, the rate of tremor may vary between 4 to 12 Hz 
Specific data from the 
medical history 
 Onset 
 Family history 
 Alcohol sensitivity 
 Medication 
 Drug abuse 
Specific examination to 
detect concomitant 
neurologic conditions 
 
 Akinesia/bradykinesia 
 Muscle tone/dystonia 
 Postural abnormalities 
 Cerebellar signs 
 Pyramidal signs 
 Neuropathic signs 
 Systemic signs e.g. thyrotoxicosis 
 Gait and stance e.g. orthostatic tremor [86] 
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The syndromic classification of Tremors is as follows 
1. Essential Tremor (ET) 
2. Physiological Tremor 
3. Enhanced Physiological Tremor 
4. Indeterminate tremor syndrome 
5. Primary orthostatic tremor 
6. Dystonic tremor syndromes 
7. Task- and position-specific 
tremors 
8. Parkinsonian tremor syndromes 
9. Cerebellar tremor syndromes 
10. Holmes tremor 
11. Neuropathic tremor syndrome 
12. Drug-induced and toxic tremor 
syndromes 
13. Psychogenic tremor 
14. Myorrhythmia. 
[86] 
These are all detailed below: 
 
1.5.1.1.1.2.1 Essential Tremor (ET) 
The definition/clinical classification of ET is an ongoing, evolutionary process. Several 
classification schemes have been proposed, including the Tremor Investigation Group 
(TRIG) Criteria in 1995; the National Institutes of Health (NIH) Collaborative Genetic 
Criteria in 1996; the Consensus Statement of the Movement Disorder Society (MDS) on 
Tremor in 1997 and the Diagnostic criteria from Fahn et al proposed for use by Elan 
Louis et al in 1998. For epidemiological research it is important to have an agreed 
definition for both the diagnostic criteria of essential tremor and other forms of 
tremor. I produced diagnostic criteria based on the collaborative work of the above 
groups and this was the diagnostic criteria used in the study (table 1.2) [86-90]. 
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1.5.1.1.1.2.1.5 Simplistic Diagnostic Criteria for Essential Tremor based on the recognised published criteria from TRIG, NIH, and MDS 
Table 1.2: Simplistic Diagnostic Criteria for Essential Tremor based on the recognised published criteria from TRIG, NIH, and MDS  
ET (any of) Enhanced Physiological Tremor 
Head tremor No head tremor 
Postural and action tremor visible on examination and reported to 
interfere with tasks 
Lone postural tremor and/or barely noticeable action tremor not 
reported to interfere with tasks 
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1.5.1.1.1.2.2 Physiological tremor 
A normal phenomenon that occurs in all contracting muscle groups, ranges in 
frequency from 8 to 12 Hz. Although seldom visible to the naked eye, physiologic 
tremor may be detected when the fingers are firmly outstretched. 
 
1.5.1.1.1.2.3 Enhanced physiological tremor 
 Both of; 
o Easy visibility of the tremor, mainly postural and high frequency 
o No evidence of underlying neurological disease 
 8 to 12 Hz 
 Enhanced under conditions of stress, anxiety, fatigue, exercise, cold, hunger, 
stimulant use, alcohol withdrawal, or metabolic disturbances, such as 
hypoglycemia or hyperthyroidism. 
 Often difficult to distinguish from essential tremor and it is proposed by some 
authors that it is a forme fruste of ET. This issue remains unresolved and it is 
currently seen as a different clinical entity.   
 
1.5.1.1.1.2.4 Indeterminate tremor syndrome 
 Fulfill the criteria for classic ET and  
 Has additional neurologic signs that are insufficient for diagnosis of another 
neurologic disorder.  
 Previously categorized as "possible ET type Ib" by the TRIG criteria 
 
1.5.1.1.1.2.5 Primary orthostatic tremor 
 A postural tremor of lower limb, trunk, and, possibly, upper limb muscles 
during stance yet absent when sitting or reclining. 
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 Orthostatic tremor is suppressed upon walking but is present in severe cases 
during gait.  
 Sparse clinical findings – visible and occasionally only palpable fine amplitude 
rippling of legs when standing 
 High frequency, 13 to 18 Hz present when standing but absent during tonic 
activation when sitting.  
 
1.5.1.1.1.2.6 Dystonic tremor syndromes 
Although consensus has not been reached concerning the definition of dystonic tremor 
syndromes, authors of the MDS consensus criteria have proposed a number of 
definitions within this general category.  
 Dystonic tremor – tremor of a body part affected by dystonia 
 Tremor associated with dystonia – tremor occurs in a body part not affected 
by dystonia but the patient has dystonia elsewhere 
 Dystonia gene associated tremor – tremor as an isolated finding in a patient 
with a dystonic pedigree 
 
1.5.1.1.1.2.7 Task- and position-specific tremors 
 These tremors occur upon performance of specific, highly specialized, motor 
activities. 
o Writing tremors 
o Occupational tremors 
o Isolated voice tremors  
 
1.5.1.1.1.2.8 Parkinsonian tremor syndromes 
 Any form of pathologic tremor 
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 Patient has PD according to the brain bank criteria 
 
1.5.1.1.1.2.9 Cerebellar tremor syndromes 
 Pure or dominant intention tremor, uni or bilateral 
 Frequency mainly below 5Hz 
 Postural tremor may be present but no rest tremor 
 Other forms of tremor, such as postural tremor, are deemed of cerebellar 
origin only when coexistent with other cerebellar signs. 
 
1.5.1.1.1.2.10  Holmes tremor 
 A symptomatic rest, intention, and possibly postural tremor due to lesions 
affecting the cerebellothalamic and dopaminergic systems— the brainstem, 
cerebellum, and thalamus and, possibly, their pathways. 
 
1.5.1.1.1.2.11  Palatal tremor 
 These rhythmic movements of the soft palate may occur subsequent to lesions 
of the brainstem and cerebellum, they are associated olivary 
pseudohypertrophy. 
 
1.5.1.1.1.2.12  Neuropathic tremor syndrome 
 Certain peripheral neuropathies are commonly associated with tremor, 
primarily kinetic and postural tremor of the affected extremities. 
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1.5.1.1.1.2.13  Drug-induced and toxic tremor syndromes 
 Pharmacologic agents used to treat other medical conditions may induce 
tremor 
 
1.5.1.1.1.2.14  Psychogenic tremor 
 Suggested by a history of somatisation, the presence of unrelated neurologic 
signs, and sudden tremor onset or remissions.  
 Additional signs may include a decrease of amplitude or variation of frequency 
upon distraction, unusual combinations of postural/intention and rest tremors, 
and co-activation resembling voluntary co-contraction during passive 
movements of a trembling limb about a joint. 
 
1.5.1.1.1.2.15  Myorrhythmia 
 A slow tremor of 2 to 4 Hz as seen in patients with lesions of the brainstem 
(similar to Holmes tremor) [86]. 
 
1.5.1.1.1.3 The Epidemiology of Tremor 
ET is the most common pathologic tremor. The world-wide prevalence of ET (when 
including only community based studies which use a defined and accurate diagnosis of 
ET) ranges from 4.1–39.2/1000 across whole populations, becoming increasingly 
common with age; prevalence increases to 13.0-50.5/1000 in persons above 60 years 
of age [91]. The prevalence of ET appears to be higher in whites than blacks even 
within the same geographic location[92].  
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1.5.1.1.1.3.1. Tremor Literature Review 
In the review of the literature on the epidemiology of tremor, I looked for community 
based epidemiological studies from SSA on tremor in general, the only studies of this 
nature looked specifically at essential tremor. There are no epidemiological studies on 
the prevalence of other tremors. Literature on unspecified tremor, observed as part of 
general neurological disorder surveys have only been briefly included in this review as 
results of this nature are impossible to interpret, put into context and compare with 
other studies. Therefore this section of the thesis will focus on Essential tremor, as the 
most common and well described tremor disorder. Worldwide review articles were 
also included in this review and references listed in relevant publications examined. 
Hospital based data was not included.  
 
1.5.1.1.1.3.2. Why hospital based prevalence studies cannot be used specifically in 
ET epidemiology 
A large number of patients may have undiagnosed ET in the community. In prevalence 
studies from Finland [93] and Singapore [94], only 2% and 10%, respectively, had been 
previously diagnosed. Only 10 cases of ET were identified amongst 2.1 million patients 
seen in outpatient clinics in a teaching hospital in Nigeria over a 25 year period [95]. As 
with all the neurological disorders, hospital based studies will grossly underestimate 
the prevalence of ET in SSA, and perhaps, peculiar to ET, in the rest of the world as 
well.  
 
1.5.1.1.1.3.3 The Prevalence of Essential Tremor in SSA 
As described above estimates of the prevalence of ET vary widely. There are few 
existing data, from reliable community based studies, on the prevalence of ET in sub-
Saharan Africa (SSA) [91]. Previous community based studies in SSA investigated all 
neurological diseases, not just ET and were performed in the 1980s. The studies 
preceded the ongoing  increase in the elderly portion of the population in SSA which is 
likely to substantially increase the number of prevalent ET cases. Only two cases were 
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reported in Nigeria from a population of 20 000, which gave a crude prevalence rate of 
10/100 000 [3], and three cases in Ethiopia in a population of nearly 61 000 gave a 
crude prevalence rate of 5/100 000 [5]. Age standardised prevalence rates were not 
reported.  
 
There have subsequently been two reliable studies of ET conducted in SSA, one in 
Tanzania in the same study site as is the subject of this thesis in 2008 and one more 
recent study from Nigeria, published in 2012. 
 
Dotchin et al [96] completed the first large scale community based 2 phased 
epidemiological survey specifically of ET in SSA. The denominator population was 
accurately recorded as part of a census in this longstanding DSS as 161 071. A 
screening questionnaire was utilised but no effort was made to validate this 
questionnaire. Positive responders were examined by a UK physician and diagnoses 
were made in accord with the standard diagnostic criteria from the MDS. 
Unfortunately validation by a movement disorder expert was not possible. 222 
patients responded positively to the screening questions and other  methods were 
utilised to ensure no cases were missed, these identified a further  43. In all 65 (38 
men, 27 women) individuals were diagnosed with ET. The mean age was 72 years and 
mean duration of symptoms was 11.3 years. The crude prevalence rate was 41/100 
000 and age standardised prevalence compared with the UK population (2001) was 
82/100 000. 61.5% of cases were aged 70 years and over. 
 
The prevalence rates of ET in Hai were found to be higher than previously reported 
from SSA, but lower than those in the developed world. The methodology used may 
underestimate prevalence as people with mild symptoms may not have responded 
positively to the screening questions. In an American study, 13 of 46 patients 
diagnosed with ET had not reported tremor on screening questions [92] and further 
studies by Louis et al[97] reported that patients with mild tremor may not screen 
positively, stressing the importance of examining all subjects if possible. However 
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equally it could be argued that those persons with mild tremor may have physiological 
tremor, or tremor induced by the anxiety of seeing a doctor and therefore examining 
patients may increase false positives and reduce the specificity of screening. Dotchin et 
al's study had further limiting factors; a lack of video recordings or other methods of 
diagnosis verification by an expert physician and the lack of validation of the screening 
questionnaire, which might have been performed by examining a proportion of those 
participants that screened negative if a full pilot study was not possible.  
 
Subsequent to the work performed by Dotchin and colleagues, Okubadejo et al [98] 
performed a multi phased door-to-door survey investigating the prevalence of 
essential tremor (ET) in an urban Nigerian community. Selection bias was avoided with 
the random selection of 3000 residents of an urban centre in Lagos. The sample size 
was modest and was dictated by financial and logistic constraints, as well as 
commitment to robust methodology to ensure maximum case discovery . Screening 
was carried out using a questionnaire to detect symptoms of movement disorders. 234 
participants responded positively with regarding to tremors and were rescreened using 
an ET-specific questionnaire, a face-to-face interview and neurological examination, by 
an expert neurologist. This increased diagnostic accuracy. Although the performance 
of the ET specific questionnaire was examined and found to have very high sensitivity 
and specificity, the performance of the general movement disorder questionnaire used 
initially was not evaluated. Diagnosis of ET was based on the Movement Disorders 
Society (MDS) consensus diagnostic criteria for ET[86], allowing easy comparison of 
results. Of the 3000 participants, forty responded positively to the ET screening 
questionnaire, of which 36 (19 females and 17 males) had a final diagnosis of ET, giving 
a crude prevalence of 12 per 1000 (95% CI = 8.1- 15.9). Prevalence was age adjusted 
according to the "WHO New World population" and found to be 23.78/1000. Gender 
specific crude prevalence was 10.3 /1000 in males and 14.3/1000 in females. Age 
specific prevalence increased with advancing age in both sexes.  
 
This Nigerian study was conducted in an urban centre, therefore there is likely to be a 
smaller percentage of elderly participants than if it was conducted in a rural setting. 
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Age adjustment does however allow for the population structure to be accounted for 
enabling comparison of Okubadejo's findings with those of other researchers.  
 
The crude and age-standardized prevalence data obtained by Okubadejo et al. fall 
within the range previously reported from other populations (4.0 – 39.2/1000), but are 
higher than the values from earlier studies based in a rural community in the same 
ethno-geographical zone, but published three decades ago by Osuntokun et al[3]. The 
earlier study reported a crude prevalence rate (0.1/1000) ten times lower than the 
present study. It is likely that the latter more robust studies present much more 
reliable figures, more applicable to today's SSA society. In addition direct comparison 
of these data presupposes that the population structures of these countries are 
similar, they may not be. Further the lack of age-adjustment in the earlier West African 
study[99] and that of Tekle-Haimanot [40] make the conclusions that can be derived 
regarding differences in prevalence tentative.  
 
It is not obvious why there are such differences in prevalence rates  in the two SSA 
communities that are the focus of the two more recent studies in Tanzania and 
Nigeria. It is however worth noting that although age adjustment was carried out in 
both populations there is significant variation in the standard population used and so 
direct comparison of the results may be difficult. More studies are required to see if 
there is a true variation in the prevalence of ET in SSA, it is perhaps still likely that 
differences in prevalence estimates can be attributed to differences in study design 
and methodology, study population structure and diagnostic criteria. 
 
The more recent Nigerian study does present prevalence rates more in keeping with 
other world epidemiological data. A recent study in Sile, Turkey demonstrated a crude 
prevalence rate of 30/ 1000 in persons above 18 years of age [100]. A recent study 
from Italy reported age and sex adjusted prevalence rates of 12/1000 for women and 
19/1000 for men[101].  
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1.5.1.1.1.3.4 Risk factors for ET and the effect on prevalence 
Reasons other than methodological differences for varied worldwide prevalence could 
be differences in exposure to risk and aetiological factors. Different risk factors are 
explored below with relevance to the literature: 
 
1.5.1.1.1.3.4.1 . The effect of ageing on the prevalence of ET 
Aging is the most consistent documented risk factor associated with increasing 
prevalence of ET [102] a finding also corroborated by Okubadejo et al's[98] and 
Dotchin et al's [96] studies detailed above. There have been various studies specifically 
reporting the crude prevalence of essential tremor in the elderly (some where the 
aged population is the only focus of the study, some where the prevalence in this age 
group is specifically highlighted). Das et al [53] performed a study of 5430 people aged 
60 years and older in India and found the crude prevalence of ET to be 13.76/1000. 
Benito-Leon et al [103] reported a crude prevalence rate of 48/1000 amongst 5278 
people aged 65 years and older in a Spanish community study. Gilik et al reported a 
crude prevalence of 7.8/1000 in those aged 65 years and older, in a community door to 
door survey of 900 individuals. Louis et al [104] assessed the prevalence of essential 
tremor in 1965 people aged 66-102 in Manhattan US; they found that the crude 
prevalence rate in this whole population was 55/1000. However the prevalence for 
those aged over 95 was 217/1000 or approximately 1 in 5. Interestingly they found 
that for each 1 year of advancing age the risk of ET increased by 14%.  
 
1.5.1.1.1.3.4.2 . The effect of family history on the prevalence of ET 
Genetics have also been implicated in ET as demonstrated by clustering of the 
condition within families [105]. About a third of the participants with ET reported by 
Okubadejo et al[98] had a positive family history of tremor in a first degree relative 
and it is possible that undiagnosed ET and recall bias would have lowered the reporting 
of a positive family history. Dotchin et al's [96] ET patients also reported a family 
history in approximately one-third of patients (28%). In some cases the first degree 
relatives had died at a young age, making it possible that they may have developed 
tremor had they lived long enough. It is however difficult to obtain accurate data on 
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family history in ET, Prakash et al [106] report the inaccuracy of family history 
reporting, with patients tending to under report family members with tremor, 
especially in mild cases, resulting in a sensitivity of only 43%. However, the specificity 
of these reports were high (94%), so if a family member is recorded as having a tremor, 
they probably do have ET. 
 
1.5.1.1.1.3.4.3 . The effect of gender on the prevalence of ET 
A gender predilection has previously been reported in some ET studies; several studies 
have suggested ET is more common in men than in women [92, 93, 101, 107], but an 
older community based study in Papua New Guinea suggested women were more 
commonly affected than men [108]. Other studies [96, 98], have not found any male to 
female differences. The basis of a gender predisposition is unproven and there are no 
strong biological indications that could explain such findings. However, if such a 
difference does exist it is likely that environmental factors such as occupational and 
recreational exposures  may contribute. 
 
1.5.1.1.1.3.4.4 . The effect of ethnic variation on the prevalence of ET 
Significant ethnic variation has been reported by Louis et al [109] in the US where 
Caucasians were found to be five times more likely that African Americans to have 
physician diagnosed ET. It was however unclear from this study whether this reflects 
differences in access to medical care and health seeking behaviour of the communities 
or whether ethnic variation does exists. Another study in New York showed higher 
rates in whites compared with African Americans, with Hispanics having an 
intermediate prevalence [92]. 
 
1.5.1.1.1.3.5 The Phenotype of ET 
Dotchin et al [96]found that the location of tremor in their patients was similar to that 
reported from other studies. Upper limb tremor was most common (80% of cases), 
followed by head tremor (54%). Head tremor was significantly more common in 
women (p = 0.002), as has been reported in other studies[110, 111]. Louis et al [92] 
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reported that 73% of patients had arm tremor and 27% had arm and head tremor. 
Okubadejo et al [98]reported that 100% of their patients had upper limb tremor whilst 
none had tremor of any other body parts including their head. This probably 
demonstrates that they underestimated the prevalence of ET by failing to pick up 
those patients with head tremor as it was not included in their initial screening 
questions. 
 
Dotchin et al [96] found that some patients with severe tremor had a resting 
component (18.5%). In previous studies, up to 1 in 5 patients with ET have been 
reported to have a resting component [112]. 
 
Dotchin et al [96]reported that tremor was asymmetrical in 37% of patients. A study 
from New York reported that mild to moderate asymmetry was common in patients 
with ET, with nearly 90% of patients having a small but detectable difference between 
the two sides [113].  Okubadejo et al [98]also found that the majority of their patients 
reported that their tremors started asymmetrically but by the time of examination 
none of them demonstrated significant asymmetry, they speculate that ET is often 
thought to arise asymmetrically as it is noticed more in the dominant hand.  
 
Dotchin et al [96] found only a third of patients reported an improvement in their 
tremor in response to alcohol in comparison with 50% in a previous study [113]. 
However, when this low percentage was adjusted by removal of those that did not 
drink alcohol (25%), it was found that nearly half of those that did drink alcohol noted 
some improvement more in keeping with previous literature.  
 
1.5.1.1.1.3.6. The social implications of ET 
In SSA it has been found that patients suffer from stigma because of their tremor [96]. 
This may make them less likely to answer questions regarding the prevalence of 
tremor correctly. Tremor is often thought to be a sign of alcoholism or evil spirits. 
56 
 
Social stigma as a result of neurological problems is common in Tanzania and 
awareness of neurological conditions is low, as in most of SSA.  ET is associated with 
significant functional disability particularly in persons with an upper limb tremor [114]. 
Work and productivity can be significantly impacted by ET. In the UK and the US, up to 
25% of patients with ET have to change jobs or retire because of their symptoms [105, 
115]. The social and emotional burden can be partially relieved with treatment. To 
make progress, a change of local beliefs behind ET and other neurological conditions is 
necessary, as is education of the population and community health workers. 
 
1.5.1.1.1.4 Investigation of Tremor 
Routine investigations include thyroid function tests (TFTs) and copper and 
caeruloplasmin (if aged <50years). The indication for other investigation depends on 
clinical signs found on examination and differential diagnosis, they may include the 
following: cerebral MRI, genetic studies, Dopamine Transporter (DAT)  or Positron 
Emission Tomography (PET) scan, NCS, Investigation for causes of neuropathy, 
Porphyria screen, Toxicology studies [116].However none of these investigations are 
routinely available in SSA and clinical diagnosis remains the standard. 
 
1.5.1.1.1.5 Management of Tremor 
The management of tremor depends on its severity and underlying cause. Propranolol 
(up to 320 mg/day) and primidone (up to 250 mg three times daily) are the main 
treatments for essential tremor; they may also be used for patients with dystonic 
tremor. Clonazepam can also be useful for patients with essential tremor. The 
treatment of choice for severe head tremor is intramuscular botulinum toxin. 
Propranolol, primidone, anticholinergics, and botulinum toxin may all have a role in 
treating other tremors but their efficacy has not been subject to rigorous study. 
Anticholinergic medications, direct acting dopamine agonist drugs, and Levodopa 
preparations can all variably decrease Parkinson’s disease tremor.  
 
Neuropathic tremors, tremor associated with multiple sclerosis, and other cerebellar 
tremors are difficult to treat effectively; the medication mentioned above can be 
considered but is often ineffective. Primary orthostatic tremor can be  treated with 
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clonazepam. Phenobarbitone or levodopa can be tried as second line alternatives if 
clonazepam is ineffective, contraindicated or side-effects prohibit its use. Holmes’ 
tremor can be treated with levodopa, dopamine agonists or anticholinergic drugs. 
 
Stereotactic surgery can be effective in many of the tremor syndromes including 
Parkinson’s disease [116]. 
 
The only medications widely available for treatment in sub-Saharan Africa are non 
selective beta blockers e.g. propranolol, phenobarbitone and Levodopa and supply of 
these medications may be unpredictable. 
 
1.5.1.1.1.3.6. The diagnosis and treatment gap of ET 
Okubadejo et al [98] reported that only 1 (2.8%) person had a prior diagnosis of ET and 
this was the only individual on treatment. Dotchin et al [96] found that no one they 
identified was receiving medication for tremor and very few had sought any medical 
help. Several factors including differing severity and impact of ET on activities of daily 
living, non-recognition or poor awareness of ET as a neurological or medical disorder 
amenable to treatment, and limited access to care may contribute to the treatment 
gap, these all highlight that prevalence of ET derived from hospital-based studies will 
reflect an low assessment of prevalence. Low treatment levels are also seen in 
developed countries; as many as 75-99% of patients with ET detected through 
population-based studies are reported to be previously undiagnosed and untreated 
[92, 117].  No studies from SSA have assessed the responsiveness of symptoms to 
simple drug treatments. 
 
1.5.1.1.1.3.7 The epidemiology of ET in summary  
ET is a common disorder worldwide, with a similar clinical phenotype and is largely 
undiagnosed. Prevalence increases substantially with age, an important finding given 
the scope of this thesis. It may be that ET is less common in black communities but 
further data is required. Improved public awareness and physician education is 
required to ensure that ET is recognized, and treatment offered where appropriate. 
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1.5.1.1.2 Parkinsonism and Parkinson’s disease (PD) 
1.5.1.1.2.1 Features 
PD is a progressive neurodegenerative condition resulting from the death of the 
dopamine-containing cells of the substantia nigra. People with PD present with 
“parkinsonism”, this has 4 cardinal symptoms and signs; rest tremor, bradykinesia, 
rigidity, and postural instability. 
 
Parkinsonism can also be caused by drugs and other neurological conditions. These 
include multiple cerebral infarctions and degenerative conditions such as the 
Parkinson Plus syndromes, progressive supra-nuclear palsy (PSP) and multiple system 
atrophy (MSA). These are less common than idiopathic PD. 
 
Although PD is predominately a movement disorder, other impairments of body 
function are frequently associated including psychiatric problems such as depression 
and dementia. Autonomic disturbances and pain may also occur. As the conditions 
progresses, significant disability and impaired quality of life occurs [118]. 
 
1.5.1.1.2.2 Diagnostic criteria 
There is no consistently reliable test that can distinguish PD from other conditions such 
as Essential Tremor, Progressive Supranuclear Palsy, Multisystem Atrophy, 
Corticobasal Degeneration, Dementia with Lewy Bodies and drug induced 
Parkinsonism. The diagnosis is primarily clinical, based on history and examination 
[118]. Diagnosis of PD can be made without the aid of costly resources if clinical 
criteria are adequately applied, very useful in resource poor areas like SSA [13].It is 
generally accepted and recommended by the National Institute of Clinical 
Excellence(NICE) [73] that the diagnosis of PD should be based on clinical findings using 
the United Kingdom Parkinson’s Disease Society (UKPDS) Brain Bank Criteria (BBC). 
Most experienced specialists have adopted these criteria. Studies have compared the 
accuracy of UKPDS-BBC with post mortem diagnosis finding that its application 
improves accuracy from 70% to 82% [119, 120]. 
 
A more recent UK PDS Brain Bank study revealed the sensitivity of the final UKPDS 
clinical diagnosis was 91% and the specificity positive predictive value were 98% and 
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99% respectively. The accuracy of diagnosis using the Brain Bank criteria increases as 
the condition progresses [121, 122]. Shrag et al's study published in 2002 also used the 
UKPDS-BBC, they demonstrated the misclassification of Parkinson's disease in the 
community in London when this criteria is not always used. They found that when 
patients with a diagnosis of PD are reviewed by a specialist and strict clinical UKPDS 
criteria are applied they have other diagnoses in 15% of cases (Multi system atrophy 
2.3%, Progressive supranuclear palsy 3.1%, vascular parkinsonism 4.6%, non 
parkinsonian tremor 3.1%). The authors also found that approximately 20% of patients 
with PD who have already come to medical attention have received alternative 
diagnoses (atypical parkinsonism 0.8%, vascular parkinsonism 0.8%, non parkinsonian 
tremor 7.3%, on antiparkinsonian drugs 1.6%) [123].  
 
The UKPDS-BBC was used to diagnose PD in this study. 
 
1.5.1.1.2.3 Causes and Risk Factors 
The cause of PD is unknown. Pure genetic forms account for less than 10 to 15% of 
cases [124]. Risk factors have been suggested but evidence for them is not consistent, 
they include; exposure to toxins, head trauma, frequent infections, diets high in animal 
fat and midlife adiposity [125].The most consistent association is an inverse 
relationship between cigarette smoking and caffeine consumption suggesting a 
protective effect [126] 
 
1.5.1.1.2.4 Epidemiology 
1.5.1.1.2.4.1 Prevalence  
 In the literature the prevalence of PD was originally reported to be less in SSA than the 
rest of the world. Three original prevalence studies were conducted in SSA in the 
1980s and 1990s. Two (in Nigeria and Ethiopia) [3, 5] were part of community surveys 
for all neurological disease. One study from Togo [127] looked at the prevalence of 
neurological disorders along with endemic goitre. 
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All three studies used the WHO screening instrument and protocol for neurologic 
diseases. The screening questionnaire and protocol is not specific for parkinsonism, it 
includes one question on tremor and two related to bradykinesia (out of 15) and 5 (out 
of 7) tasks could relate to parkinsonism. The studies predated the HIV epidemic.  
 
Osuntokun et al [3] performed a pilot study and then a community prevalence study in 
a rural community (the Yoruba tribe) in Nigeria in 1986. A population of 20,000 was 
surveyed, 6% were over 60 years of age. The study used diagnostic criteria for PD (any 
three of four diagnostic signs; resting tremor, rigidity, bradykinesia and postural 
instability) this increased sensitivity and accuracy of the conclusions with regard to 
prevalence. The crude prevalence rate was 10/100,000. Indirect age adjustment to the 
black population in Copiah, Mississippi allowed direct prevalence rates to be compared 
in the two populations. The crude prevalence rate was 59/100,000 and the age 
adjusted prevalence rate was 67/100,000 for those over 39 in Nigeria, five times lower 
than the 341/100,000 reported from the US [3].  
 
Tekle-Haimanot et al [5] conducted a community survey in rural Ethiopia in the late 
1980s in a population of 60,820, the reported crude prevalence rate was 7/100,000. 
Age standardisation was not performed. The diagnostic criteria for PD or Parkinsonism 
were not specified. 
 
The two studies collectively reported from Togo in 1989 and 1995 both yielded crude 
prevalence rates of 20/100,000, they used the WHO protocol. No diagnostic criteria for 
PD were specified; however, two levels of diagnostic certainty were allowed (i.e., 
definite and possible) based on clinician’s judgment. Age standardisation was not 
performed [127]. 
 
 All of these studies were community based, hospital based surveys have not been 
included in this review (unless a community component was specified) as such studies 
are likely to greatly underestimate the prevalence rates. In SSA most patients with this 
chronic disease reside in the community and are not hospital in-patients (unless 
admitted because of a complicating or unrelated illness).Many do not present to 
hospital at all for geographical and financial reasons.  Further, in SSAs there are few 
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neurologists and little neurological education of primary care givers to allow accurate 
diagnoses to be made. Despite the inclusion of only community based studies 
methodological differences and inconsistent diagnostic criteria may  contribute to 
inaccuracies and differences in the prevalence rates. It is also unclear in some studies 
whether all cases of parkinsonism or just idiopathic PD were included.  
 
In 2006 authors from my research group conducted a prevalence study of PD in the 
whole population of the Hai district DSS [128]. The denominator population was 
gained from a prior census and was 161,071. The prevalence of essential tremor was 
also reported, however this study was designed to identify patients with PD and 
therefore a six question tool was specifically designed for this purpose by the authors. 
Standard diagnostic criteria were used (UKPDSBCC) and cases were verified by a doctor 
trained in movement disorders and a movement disorder expert (the latter through 
the use of scripted videos). Other means of case discovery were used to increase 
diagnostic yield and the accuracy of the prevalence rates presented. The sensitivity 
and specificity of the screening questionnaire were not studied or presented by 
Dotchin et al. Other limitations included possible under detection due to stigma  and  
one family member answered on behalf of the rest of the household which has been 
reported to reduce sensitivity [35, 129]. The age standardised (according to the UK 
population) prevalence rate found was 40/100,000. This figure is more in keeping with 
the rate of 67/100,000 reported in African Americans in Manhattan [130] but is still 
lower than other studies presented in the developed world. Dotchin et al's paper also 
presented male and female age specific rates in five year age bands. For the 
population aged 65 and over the crude prevalence rate was 2.22/1000 and age 
adjusted prevalence rate (according to the WHO standard population) was 2.07/1000. 
The authors felt that standardised methodology and more comparable diagnostic 
criteria played a part in the detection of more cases of PD in this population. 
 
Winkler et al[131] reported the prevalence of parkinsonism in a population of northern 
Tanzania in 2010. The fieldwork for this study was carried out between 2003 and 2005. 
They performed hospital and community studies. In the former all patients admitted to 
the Haydom Lutheran Hospital (HLH) in northern Tanzania over an 8 month period 
(n=8676) with neurological symptoms and signs were assessed by a neurologist for 
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symptoms and signs of PD using the UKPDSBBC. The exact timing of the 8 month 
period is not specified. No consistent assessment (i.e. formal questionnaire) for 
neurological symptoms and signs prior to referral for neurologist review was used. The 
UKPDSSBBC was used by the assessing neurologist however, the diagnosis was limited 
by lack of levodopa to allow a dopamine challenge to take place.  
 
The community section of the study involved selecting a population of nearly 1600 
subjects aged 50 years and over in the southwest corner of the Mbulu district using 
random and cluster sampling. Other efforts were made to eliminate bias in subject 
selection regarding distance from HLH. A pilot study was performed to assess the 
feasibility of a 12 point questionnaire specific to the identification of parkinsonism. 
Sensitivities and specificities were not presented or apparently tested in this 
population (Validation had previously occurred in Spain in a Caucasian population). In 
addition to these limitations authors state that many different language group were 
spoken to in the study region and Kiswahili was often not understood. The 
questionnaire was only translated and back-translated in Kiswahili. An additional 
caveat of "patients with symptoms and signs relating to acute alcohol should be 
excluded" is mentioned in the methodology; however this had not been validated in 
the original questionnaire. A western neurologist reviewed all positive responders for a 
diagnosis of PD using the UKPDSBCC criteria. No second opinion on diagnoses was 
sought in either the hospital or the community study.   
 
From the hospital study 2 patients were found to have definite Parkinson's disease, 1 
had possible PD, and 5 had parkinsonism (the possible cause of which was not 
elaborated). The denominator population was quoted to be 8676 admissions and the 
authors quote a crude prevalence rate of 1/1000 (the crude prevalence of Parkinson's 
disease is 0.35/1000). There were no details with regard to age groups and therefore 
adjustments cannot be made. Further, the study is hospital based which means it is 
not possible to report a prevalence rate relevant to the local community for the 
reasons given above. Other factors that would affect prevalence calculations include:  
 
All the patients were men; they are  presumed to have preferential health care access 
over women.  
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The subjects identified may have come from a very wide area and therefore the 
denominator population is ill defined. 
 
None of the patients identified presented to hospital because of their parkinsonism.  
 
For the community the questionnaire was vague, presumably to increase sensitivity, 
Even so, only 18 positive responders were found, in addition only one diagnosis of 
essential tremor and 2 diagnoses of motor neurone disease (MND) were made. None 
of the community based subjects were diagnosed with parkinsonism or PD, a  
prevalence of zero. The authors calculate 95% confidence intervals and conclude that 
prevalence could fall between 0 per 1000 (the best estimate based on their 
observation) and 2.5/1000. 
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Table 1.3: Community Prevalence Studies of Parkinsonism in SSA 
Country Crude Prevalence Age Standardised 
Nigeria[3] Parkinson's disease: 0.10/1000 
Parkinson's disease >39yrs: 0.59/1000  
Parkinson's disease 
>39 yrs: 0.67/1000* 
Ethiopia [5] Parkinson's disease: 0.07/1000  
Togo[127] Parkinson's disease: 0.20/1000  
Tanzania[131] Parkinsonism in hospital: 1.00/1000  
Parkinson's disease in hospital: 
0.35/1000 
Parkinsonism in community in the 50 
years and over population established 
using statistical analysis:2.35/1000  
Actual prevalence of Parkinsonism in the 
community: 0.00/1000 
 
Tanzania [96, 128] Parkinson's disease: 0.20/1000 
 
Parkinson's disease >64yrs: 2.22/1000 
 
Parkinson's disease: 
0.40/1000 
Parkinson's disease 
>64yrs: 
2.07/1000** 
* Indirect age adjustment to the black population in Copiah, Mississippi 
**Direct age adjustment to UK population for 2001 
 
The prevalence of parkinsonism and Parkinson's disease has been reported in other 
world regions however due to the extensive nature of this data, I have focussed on 
presenting and appraising data from key sources, namely Bharucha et al's [48, 132] 
prevalence study in Parsi Indians and Zhang et al's [133] prevalence study from rural 
and urban China to represent other developing countries and Wickremaratchi et al's 
[134] prevalence study and meta-analysis from the UK and the EUROPARKINSONISM 
Collaborative study from Europe [135].  
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Bharucha et al [132]performed a well-designed specific study on PD, they  estimated 
prevalence rates in Parsis, ethnically different from Indians, between 6-328/100,000 
[48, 132, 136-138]. Barucha et al used a standardised questionnaire specifically for PD 
and did not rely on the WHO generalised screen for neurological disorders [25].In 
addition they used standardised case definitions. Bharucha et al’s [132] results 
demonstrate that Parsis have an age-adjusted prevalence rate of PD similar to white 
Caucasians but this figure is two times higher than other Indian studies [51, 58, 132, 
137, 139-141]. The study differs from other Indian studies in terms of an urban setting 
but more significantly  it is an ethnically different population, originally from Persia 
(members of the Aryan or Indo-Germanic family). Prevalence of other neurological 
disorders including Multiple Sclerosis are also similar in the Parsis to Caucasians [132, 
142, 143]. Studies from non-Parsi communities in India show prevalence rates of PD, 
between 14-41/100,000 [136, 144]. PD forms 5-60% of total movement disorders with 
variations in geographical areas. PD was more prevalent in rural (41/105) than urban 
(14/105) population and was more common among men [144]. Age-specific rates 
increase from 28/100,000 in 4th decade to 573/100,000 in ninth decade [58, 145]. 
 
A large cross-sectional prevalence study of Parkinson’s disease in China was 
undertaken in 1997–98 [133]. The authors assessed 29,454 residents aged 55 years 
and over (identified via a census, it included those in institutionalised care) from 79 
rural and 58 urban communities in Beijing, Xian, and Shanghai. These are the 3 
regional centres which differ significantly in: economic and medical development, 
cultural beliefs, lifestyle and life expectancy. Participants were selected through 
stratified, multistage, cluster sampling. All these methodological considerations 
exclude bias. A one stage standardised diagnostic protocol was used with good inter-
rater reliability. This method was undoubtedly time consuming and expensive but 
would result in accurate prevalence figures. To increase accuracy  second opinions 
were sought and re-examination performed in the case of disagreement. Standard 
diagnostic criteria were used [146] and diagnoses were supported by treatment trials 
and investigations. The authors identified 277 people with the disease and estimated 
the prevalence of Parkinson’s disease for those aged 65 years and over to be 1·7% 
(95% CI 1·5–1·9)men and women combined, 1·7% (95% CI 1·4–2·0) for men, 1·6% (1·4–
1·9) for women. Prevalence for people aged 65 years or older that were standardised 
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to the 2000 US population was 2·1% (1·8–2·5) for men, 2·0% (1·7–2·3) for women, and 
2·1% (1·9–2·3) for both sexes. With the same standardisation method, prevalence for 
both sexes in Rotterdam, the Netherlands (2·2%), and in seven European studies 
(1·7%) shows that the prevalence of Parkinson’s disease in China is similar to that in 
developed countries[133]. Standardised estimates for both sexes from a previous 
Chinese study [147] based on a slightly different age group (60 years and over) were 
lower (0·1%–1·0%) than this study from Zhang et al even when utilising their data from 
their 55 years and over cohort which had a prevalence 1·3%. The authors attribute this 
to the  correction of several limitations of the earlier study, they surveyed urban and 
rural populations in diverse regions and reviewed  high numbers of participants to 
yield statistically precise estimates. Their entire sample (n=29 454) received 
standardised neurological examinations by trained neurologists, which although 
expensive does eliminate false negatives that may have been produced by the 
screening phase.  
 
Wickremaratchi et al [134] performed a prevalence study of PD amongst residents in 
Cardiff.  To locate cases they screened GP databases, prescriptions and neurology clinic 
notes. Standardised diagnostic criteria were used for final case verification which 
included a review of notes and direct clinical assessment and therefore had a very high 
accuracy. A high participation rate was obtained, with 45 out of 54 (88%) of the eligible 
primary care practices, this provided a population denominator of 292 637 (96% of the 
Cardiff population).The authors reported a crude prevalence rate of 130 per 100 000 
(95% CI 117 to 144) and an age standardised rate of 142 per 100 000 (95% CI 128 156), 
standardised to the 1997 England and Wales population.  Prevalence rates increased 
with age and the authors found  rates for men were greater at all ages; the male to 
female prevalence ratio was 1.43 (95% CI 1.17 to 1.76; p=0.001). The prevalence of PD 
in those aged 70-79 and 80+ was 738/100,000 and 1297/100,000 respectively when 
age adjusted. The authors found that the prevalence of young onset PD was high at 
5.4% and 31.2% for PD patients with disease onset below the age of 50 and 65 years 
respectively. However they concluded that the incidence of young onset PD may be 
low but disease survival is high and therefore this increases the overall prevalence in 
the community. The authors overall prevalence rates were very similar to previous UK 
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studies where the crude prevalence was 113-164/100,000 [148-154]. Differences were 
felt to be due to heterogeneous methodology.  
 
The authors acknowledge their main limitation was that they clinically examined only 
one-third of cases and older cases were less likely to be seen. In addition they did not 
invite cases with a diagnosis of essential tremor, a previous London study found that 
such patients may be incorrectly diagnosed tremor dominant PD[123, 150]. The 
authors conclude that there are no major geographical variations in the prevalence of 
PD in the UK and that the age adjusted prevalence rate has remained relatively stable 
over the past 40 years.  
 
The authors of the EUROPARKINSON collaborative study [135] assessed and compared 
the prevalence of parkinsonism and Parkinson's disease in five European populations 
(France, Italy, The Netherlands and 2 in Spain) using similar methodology and 
diagnostic criteria. The authors highlight the difficulty of comparing prevalence rates if 
heterogeneous study methods are used. They have attempted to standardise 3 main 
aspects of their methodology: screening/"case finding strategy", diagnostic criteria and 
participation rate. Given the huge scale of this project it is not surprising that there are 
some discrepancies particularly in France, with case finding and diagnostic criteria, and 
that participation rate is variable (68-84%). Despite this the authors performed a very 
reliable community survey (with an unprecedented level of methodological 
homogeneity) comprising of 14,636 participants aged 65 years or older (which 
included those institutionalised). The questionnaire was specific for the identification 
of Parkinsonism although the sensitivities, specificities and methods of validation are 
not presented in the paper. The authors stress the importance of a community survey 
with standardised 2 phased methodology rather than reliance on records from primary 
and secondary care and this is highlighted by the fact that 24% of the subjects with 
Parkinson's disease were newly detected through the surveys. Thus any study based 
on previously made diagnoses is likely to underestimate prevalence even in developed 
countries. Other methods were used to increase reliability across studies; for example 
the medical records of most parkinsonian subjects were reviewed, by an adjudication 
panel composed of neurologists from each of the participating centres. 
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The overall prevalence (per 1000 of the population), age adjusted to the 1991 
European standard population, was 23 for parkinsonism and 16 for Parkinson's 
disease.  After adjusting for age and sex, the prevalence figures did not differ 
significantly across studies, except for the French study in which prevalence was lower 
but statistically significant. In addition there was no variation in rural compared to 
urban communities. Prevalence was similar in men and women. Prevalence of both 
parkinsonism and Parkinson's disease increased steeply with age and authors feel this 
is the correct conclusion. They felt that studies that demonstrate a decline in the 
oldest age group have used poorer methods of case discovery and have failed to pick 
up cases in this age category. There were no significant differences between 
prevalence rates in men and women. A substantial proportion of patients with 
Parkinson's disease went undetected in the general population. Large variation in the 
differing causes of parkinsonism in the different study populations was not accounted 
for. 
 
1.5.1.1.2.4.1.1 Variations in the worldwide prevalence of parkinsonism 
Prevalence estimates vary widely across world populations. Recent reports, contrary to 
previous reports, suggest the prevalence in developed and developing countries may 
be similar. If the prevalence of PD is indeed lower in developing countries in 
comparison to developed countries despite age adjustment this may indicate potential 
differing risk factors, whether these be environmental or genetic they are potentially 
important. Comparing prevalence studies for PD throughout the world, PD is 
apparently more prevalent in Caucasians. The Mayeux study [130] from Manhattan 
was the only study to report an increased incidence (but a reduced prevalence) of PD 
in African Americans compared with whites, however this may be explained by the fact 
that the census figures for African Americans in this area were falsely low. In general 
there is a growing body of evidence that the prevalence (particularly diagnosed) is 
lower in blacks than whites.  A contrary note is that community studies suggest that 
42-75% of black individuals are undiagnosed. Further, cases of undiagnosed PD are 
twice as likely to be African American rather than white. Current strategies for 
screening and detection of PD are limited because they rely on recognition of 
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symptoms and signs by affected individuals and this may be affected by race, culture 
and socioeconomic status[130]. Studies have shown an association of lack of melanin 
with PD and this may explain racial discrepancies; however more investigation into 
genetics and the role of melanin and environmental causes of PD are required.  
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Table 1.4: The Worldwide Prevalence of Parkinsonism and Parkinson's Disease 
Country Crude Prevalence 
rate/1000 
Age Standardised 
prevalence rate/1000 
Nigeria[3] 0.1-0.59 0.67 (US population) 
Ethiopia[5] 0.07  
Togo[127] 0.20  
Tanzania[128, 131] 0.20-2.35 0.40-2.07 (UK population) 
Indians – Parsis[132] 0.46 1.92 (US population) 
Indians - Non Parsis[32, 53, 
137, 145] 
0.01-0.21 0.46-1.00 (US population) 
3.30 (aged 60 years and 
over) 
China[133] 17.00 (aged 65 years and 
older) 
21.00 (aged 65 years and 
older) 
(US population) 
UK[134, 148, 155] 1.30 1.39-1.42 (1997 England 
and Wales population) 
16 (aged 65 years and 
older) 
France, Italy, Netherlands, 
Spain[135] 
 16.00-23.00 (European 
population) (aged 65 years 
and older) 
USA [130, 156]  0.61-3.14 (US population) 
 
In conclusion prevalence estimates for Parkinson’s Disease (PD) were thought to vary 
widely across populations[125]. However recent credible reports, contrary to previous 
reports, suggest that the prevalence in developed and developing countries may be 
similar when standardised age prevalence rates are applied [124] . Those studies that 
reflect the prevalence in the whole population as compared with studies of the elderly 
demonstrate lower prevalence rates. Parkinson’s is a disease of the ageing brain,. it 
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becomes more common with increased age and is one of the many neurological 
conditions that demonstrate the importance of looking specifically at an elderly 
population [118].  
 
1.5.1.1.2.4.2 Incidence 
Few incidence studies have been performed and none in developing countries. In the 
United state incidence rates have been reported as 13 per 100,000 person-years. 
Incidence is lower in women, African Americans and by extension Africans, but this 
latter statement is controversial [157]. 
 
1.5.1.1.2.4.3 Mortality 
Most mortality estimates show a two-fold increased mortality with PD independent of 
age [158]. PD patients in SSA may be subject to a higher early mortality, contributed to 
by lack of diagnosis, treatment and support. Life expectancy for patients with PD in 
Europe was severely limited before the introduction of levodopa, a situation that still 
exists in SSA. Dotchin et al[128] report the mortality rate of their Parkinson's disease 
cohort in the Hai district to be 34% for untreated patients within the first year. They 
also report mortality rates to be higher in women than men, but acknowledge 
compounding factors; the women were older and had more advanced disease at 
baseline. Mayeux et al [130] demonstrated increased mortality in black incident cases 
of PD in comparison to whites or Hispanics.  
 
1.5.1.1.2.4.4 Burden of disease 
Mathers et al [30] estimate the worldwide Disability adjusted life years (DALYs) for PD 
are 2,325,000. As it is a disease of older ages those countries with a higher income and 
an older population are affected the most. However as the population ages in 
developing countries their DALYs as a direct relation to PD will also increase [159].  
Costs of PD include; medication, cost of physicians, cost of hospitals, chronic care 
facilities and loss of labour of patients and caregivers. 
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1.5.1.1.2.5 Interventions 
There are no effective preventative or curative measures for PD. All established 
interventions are directed at the relief/palliation of symptoms. 
 
1.5.1.1.2.5.1 Medications 
Levodopa (in a preparation with a dopa decarboxylase inhibitor to increase the central 
availability of levodopa) is the most widely used therapy for PD. It provides partial 
relief of PD symptoms. Despite its benefits, chronic side effects after long term use can 
cause significant morbidity. It is the only medication widely available and in use in 
developing countries, and is still the gold standard treatment in developed and 
developing countries alike. 
 
Many other treatments are now available for PD, but levodopa remains the most 
efficacious. These include; dopamine agonists, catechol-O-methyl transferase (COMT) 
inhibitors, monoamine Oxidase Type B (MAOB) inhibitors and amantadine. 
 
No medical treatment has a proven role in preventing progression, but all provide 
relief of symptoms. Effective management of PD in its early and intermediate stages 
can be achieved if available drugs are used sensibly [118]. 
 
1.5.1.1.2.5.2 Surgical Management 
Surgical treatment of PD in the form of deep brain stimulation is used in the developed 
world. In selected patients with advanced disease, responsive to Levodopa, not 
demented and in generally good health it may provide dramatic improvement [118]. 
 
1.5.1.1.2.5.3 Major challenges in the management of PD 
These are as follows; 
 Increasingly complex pharmacological or even surgical requirements as the 
disease progresses; 
 The need for a multidisciplinary team approach for comprehensive 
management, the consequent need for properly trained professionals (primary 
care physicians, neurologists, and PD-specialized neurologists, nurses, 
physiotherapists and speech therapists); 
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 Widespread access to current PD medications; 
 Adequate allocation of resources to establish comprehensive management 
programmes [13]. 
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Figure 1.3: National Institute for Health and Clinical Excellence (NICE) Guidelines: Interventions for people with Parkinson’s Disease 
(PD) [118] 
 
 
Intervention 
 
 
 
 
 
 
 
 
Disease  
Progression 
Diagnosis and early disease Throughout disease Later disease 
Communication 
Provide communication and information about: 
PD services and entitlements 
Falls, palliative care and end of life issues 
Reach collaborative care decisions by taking into account: 
Patient preference and choice 
Clinical characteristics, lifestyle and interventions available 
Refer untreated to a specialist who 
makes and reviews diagnosis: 
Use UK PDS Brain Bank Criteria 
Consider 123I-FP-CIT SPECT 
Specialist review diagnosis regular 
intervals (6-12 months) 
 
It is not possible to identify a 
universal first choice drug therapy 
for people with early PD. The choice 
of drug should take into account: 
Clinical and lifestyle characteristics 
Patient preference 
Consider management of non-motor symptoms, in 
particular; depression, dementia, psychosis, sleep 
disturbance 
Provide regular access to specialist care, particularly 
for: 
Clinical monitoring and medication adjustment 
A continuing point of contact for support including 
home visits 
Consider access to rehabilitation therapies to 
maintain independence, help gait and balance, 
manage communication and swallowing problems 
It is not possible to identify a 
universal first choice drug therapy 
for people with later PD. The 
choice of drug should take into 
account: 
Clinical and lifestyle characteristics 
Patient preference 
 
Consider apomorphine in people 
with severe motor complications 
unresponsive to oral medication 
Consider surgery: 
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1.5.1.1.2.5.3.1  Major challenges in the management of PD in SSA 
Dotchin et al [160] detail the "challenge of PD management in Africa". Their recent 
paper explored how  diagnosed and treated people (the great minority) have 
difficulty because of the intermittent availability of medication, in differing 
preparations, that is often unaffordable. Follow-up and education for patients, 
relatives and even healthcare professionals are often lacking. In a further paper 
[161] they documented their cohorts 3 year follow up; they do acknowledge that it 
is possible to identify and treat patients with PD in rural SSA but again the 
availability and affordability of medication needs to be addressed as does the 
education of healthcare providers. 
 
Cilia et al [162] report the findings of an initiative in Ghana to gain insights into the 
pathophysiology of PD. They identified patients with PD, provided free treatment 
and follow up, they improved the abilities of local physicians to manage PD. They 
identified 45 patients with PD but no denominator population or details of how 
these cases were identified, was reported. They conclude that a large international 
Task Force for the diagnosis and treatment of PD in developing countries would be 
of benefit to the local and world population; this would directly improve the quality 
of life for those in developing countries but indirectly benefit those worldwide by 
providing insights into aetiology, pathophysiology and complications. The project 
has been expanded to Zambia and is planned to include other regions in SSA and 
South America. 
 
1.5.1.1.2.6 Other Causes of Parkinsonism 
As mentioned above the symptoms of Parkinsonism are not only caused by idiopathic 
PD. There are alternative causes;  
 Parkinsonian-plus syndromes: 
o Progressive supra-nuclear palsy (PSP) 
o Multiple system Atrophy (MSA) 
o Corticobasal degeneration (CBD) 
 Secondary parkinsonism: 
o Vascular 
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o Drug-induced 
o Post-encephalitic 
o Hydrocephalus 
 Degenerative disorders: 
o Dementia with Lewy Bodies 
o Alzheimer’s disease 
o Parkinson-dementia-MND complex 
 Genetic disorders: 
o Wilson’s disease 
o Huntington’s disease (akinetic rigid (Westphal) variant) 
o Dopa-responsive dystonia [76, 163, 164]. 
 
There are red flags to suggest a diagnosis other than Parkinson’s disease; 
 Early falls – Parkinson plus syndromes 
 Early dementia – Dementia with Lewy Bodies, PSP, CBD 
 Early pronounced autonomic features – impotence, postural hypotension – 
MSA 
 Sudden onset of symptoms – vascular 
 No rest tremor 
 Symmetrical onset and signs 
 Predominance of axial symptoms 
 Poor therapy response 
 Rapid progression [164] 
 
1.5.1.1.2.6.1 Progressive Supra-nuclear Palsy (PSP)  
1.5.1.1.2.6.1.1 Clinical Features 
 Parkinsonism – particularly axial rigidity (neck and trunk movements are more 
affected than the limbs) 
 Early falls 
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 Loss of vertical eye movements (unable to look up or down on command but 
able to follow a moving target in the early stages) 
 Speech and swallowing difficulty 
 Dementia 
 Upper motor neuron signs in the limbs and bulbar musculature 
The median age of onset is 60 to 65 years. The median disease duration at death is 5.9 
to 9.7 years. The age adjusted prevalence is 6/10,000 
 
1.5.1.1.2.6.1.2 Pathological features 
Neurofibrillary tangles and neurophil threads in the basal ganglia and other parts of 
the brain stem and tau positive tufts. 
 
1.5.1.1.2.6.1.3 Response to Levodopa 
Good response is rare [76, 163-166] 
 
1.5.1.1.2.6.1.4 Diagnostic criteria 
Prior to the production of the National Institute of Neurological Disorders and Stroke 
and Society for Progressive Supranuclear Palsy (NINDS-SPSP) diagnostic criteria, seven 
different diagnostic criteria were proposed for PSP, they were derived from extensive 
clinical experience rather than systematically. The NINDS-SPSP rigorously produced 
diagnostic criteria after a systematic review of the literature and critique of existing 
diagnostic criteria. The performance of the NINDS-SPSP criteria has been evaluated 
retrospectively in a pathologically confirmed series and by their application to patients 
with other dementing and parkinsonian disorders. From this analysis, the NINDS-SPSP 
criteria appear to have superior specificity, sensitivity, and positive predictive value 
(50-83%, 93-100% and 83-100% respectively) when compared to other PSP diagnostic 
criteria. Their use is recommended by the movement disorders society and was 
therefore used in this study [167]. 
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1.5.1.1.2.6.2 Multiple system atrophy (MSA) (striatonigral degeneration, sporadic 
olivopontocerebellar atrophy, and Shy-Drager syndrome) 
1.5.1.1.2.6.2.1  Clinical Features 
 Parkinsonism 
o In the consensus statement – bradykinesia plus one of rigidity, postural 
instability or tremor is required 
o Tremor is present in 2/3 but <10% have the classic pill rolling resting 
tremor 
 Dysautonomia (early) 
o Orthostatic hypotension 
o Impotence 
o Bladder dysfunction 
 Cerebellar dysfunction – ataxia, Dysarthria, nystagmus 
 Pyramidal signs – brisk reflexes, up-going (extensor) plantar reflexes  
 Stimulus-sensitive Myoclonus 
 Extreme forward flexion of the neck (antecollis) 
Mean age of onset is 54 years. 
 
1.5.1.1.2.6.2.2  Response to Levodopa 
Good response seen in 20% and sustained in 13%. Dyskinesias or motor fluctuations 
may occur. Patients tend to require wheelchairs early due to loss of postural reflexes 
and ataxia [163, 164]. 
 
1.5.1.1.2.6.2.3  Diagnostic Criteria 
I have used the criteria from the second consensus statement on the diagnosis of 
multiple system atrophy in this study because these most recent guidelines were 
created by consensus methodology using the collective experience of active 
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investigators. It is important to recognise that the criteria do not result from an 
evidence-based approach and await further validation but high predictive accuracy is 
anticipated. These criteria are simplified and easier to use than the first consensus 
statement. They are now widely accepted and used, they are expected to enhance 
future assessments of the disease [168]. 
 
1.5.1.1.2.6.3 Corticobasal Degeneration 
1.5.1.1.2.6.3.1 Clinical features 
 Cognitive impairment is a dominant feature occurring within one to three years 
of onset 
 Apraxia 
 Cortical sensory changes 
 Alien limb behavior 
 Parkinsonism manifests as an akinetic-rigid syndrome which is unresponsive to 
levodopa. Unilateral bradykinesia and rigidity occur with or without tremor. 
 Limb dystonia 
 Stimulus sensitive Myoclonus 
Symptoms usually start after the age of 60. Symptoms spread contralaterally after one 
year. 
Structural imaging shows cortical atrophy and functional imaging shows reduced 
cortical blood flow in the left fronto-parieto-temporal cortex and striatal 
hypoperfusion 
There is no specific treatment, supportive care is required [76, 163, 164, 169]. 
 
1.5.1.1.2.6.4 Vascular Parkinsonism (VP) 
Typical cases are lower body Parkinsonism with history of repeated strokes. They often 
do not respond well to treatment.  
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Accounts for 3-12% of cases of Parkinsonism [170]. Incidence and prevalence increases 
with age. Patients with VP are more likely to be older and men are at increased risk. 
There are three different pathological patterns; 
 Multiple lacunar infarctions with gait disorder, frequently associated with 
cognitive impairment and pseudobulbar palsy 
 Sub-cortical arteriosclerotic encephalopathy (Binswanger’s disease) with 
multiple white matter lesions, together with dementia and progressive gait 
disorder. 
 Lacunar infarction of basal ganglia with clinical presentation indistinguishable 
from IPD. 
 
1.5.1.1.2.6.4.1  Clinical Features 
 Lower-body Parkinsonism with abrupt onset and stepwise progression, and 
without the classical resting tremor. 
 Tend to have upright posture and wide base compared to stooped and narrow 
in IPD. 
 Additional features may include pseudobulbar palsy, pyramidal signs with 
mixed increased tone of spasticity and rigidity, retropulsion, emotional lability, 
cognitive impairment and incontinence. 
 Acute onset only seen in 25% of cases. 
 Minimal response to levodopa [163, 164]. 
 
1.5.1.1.2.6.4.2  Diagnostic Criteria: 
I used the Winikates and Jankovic vascular rating scale along with typical clinical 
features to support my diagnoses of vascular parkinsonism. This is because there is no 
other clinically relevant scale or specific diagnostic criteria and the gold standard for 
diagnosis is pathological evidence of a vascular disease in the absence of typical PD 
lesions (e.g. Lewy bodies). The Winikates and Jankovic criteria allow a purely clinical 
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diagnosis to be made, although imaging is obviously beneficial it was not possible in 
this study[171] 
 
1.5.1.1.2.6.5 Drug Induced Parkinsonism 
1.5.1.1.2.6.5.1  Clinical Features 
May be clinically indistinguishable from idiopathic PD but a symmetrical presentation 
is typical. 
 
1.5.1.1.2.6.5.2  Culprit medication 
 Neuroleptics are most commonly implicated – Typical > Atypical 
 Anti-nausea agents (e.g. prochlorperazine, metoclopramide, cinnarizine) 
 Sodium valproate and tetrabenazine cause parkinsonism but at much lower 
rates. Antidepressants and calcium antagonists have been implicated largely 
through case reports  
 
1.5.1.1.2.6.5.3  Treatment 
Parkinsonism usually improves on withdrawal of the offending drug but this may take 
many months. If symptoms and signs persist for 6 months unmasked IPD is the likely 
diagnosis [163, 164, 172]. 
 
1.5.1.1.2.6.6 Normal Pressure Hydrocephalus 
Parkinsonism may occur with normal pressure hydrocephalus  
 
1.5.1.1.2.6.6.1  Clinical Features 
Urinary incontinence, gait apraxia and dementia 
It is clinically distinguished from PD by; 
 Rigidity, tremor and bradykinesia occur less commonly 
 No significant response to levodopa 
 Structural neuro-imaging 
 
1.5.1.1.2.6.6.2  Treatment   
 Surgical shunting should be considered. 
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 However, the risks of surgery may outweigh potential benefit particularly when 
poor prognostic features including dementia, longstanding symptoms and 
cortical atrophy are present [163, 164, 173]. 
 
1.5.1.1.2.6.7 Dementia with Lewy Bodies 
1.5.1.1.2.6.7.1  Clinical Features 
Dementia with Lewy Bodies accounts for about 20% of all dementia. It may present as 
a predominant dementia with some extrapyramidal signs or initially as parkinsonism 
with early onset dementia. The term Parkinson’s disease with dementia (PDD) has 
been used when parkinsonism predates the development of dementia by at least one 
year, and dementia with Lewy bodies (DLB) when dementia starts before that. Visual 
hallucinations, delusions and psychosis may occur in the absence of dopaminergic 
therapy. Cognitive decline is progressive but fluctuates. 
 
1.5.1.1.2.6.7.2 Diagnostic criteria 
Five previous clinical criteria produced through clinical experience have been used for 
the diagnosis of DLB. In 1996 the Consensus diagnostic criteria for DLB was produced, I 
used the criteria in this study as it is now the most widely used and has been validated 
against pathological confirmation. It has a reasonable diagnostic accuracy for this very 
challenging diagnosis. The sensitivity of a diagnosis of probable DLB varies from 0 to 
83% (mean, 49%), specificity 79 to 100% (92%), positive predictive value (PPV) 48 to 
100% (77%), and negative predictive value 43 to 100% (NPV) (80%). Prospective 
studies had a higher diagnostic accuracy than retrospective, and the sensitivity of 0% 
comes from one study with 4 clinical raters, the results of which substantially reduced 
the mean sensitivity [163].  
 
1.5.1.1.2.6.7.3 Management 
Atypical Neuroleptics, e.g. quetiapine, are often useful and cholinesterase inhibitors 
may also be effective [163, 164]. 
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1.5.1.2 Episodic and Paroxysmal Disorders 
1.5.1.2.1 Headaches 
Headache disorders are common, they have a neurological basis, but headache rarely 
signals serious underlying pathology.  
 
1.5.1.2.1.1 Epidemiology 
Headache disorders are among the most common disorders of the nervous system. 
The huge public health importance of headache disorders arises from their causal 
association with personal and societal burdens of pain, disability, damaged quality of 
life and financial cost [13]. Worldwide the "headache burden" is thought to be 
underestimated with headache disorders being often under-diagnosed and under-
treated. This is particularly true in developing countries including SSA. 
 
Headache has been highlighted as one of the top ten most disabling conditions 
worldwide by the WHO and as a result has been the subject of recent global 
initiatives[10, 174]. The most recent of these initiatives began in 2004, "Lifting the 
Burden: The Global Campaign to Reduce the Burden of Headache Worldwide" [174, 
175], is the collaboration between the WHO and the three major international 
headache organisations: the World Headache Alliance (WHA), the International 
Headache Society (IHS) and the European Headache Federation (EHF). The LTB 
campaign's main aims are to highlight the burden headache disorders represent 
despite their treatable nature and to improve quality of care worldwide, focussing on 
education. The LTB campaign's latest document, "Atlas of headache disorders" was 
published in 2011. An important part of this work was to obtain objective 
understanding of the scale of headache-related burden, to bring together all existing 
evidence of the burden of headache worldwide [174, 175]. 
 
The worldwide epidemiology of headache disorders is only partly documented. Many 
studies have been performed on migraine, but data on tension type headache (TTH), 
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(the most frequent headache disorder), are relatively sparse. In addition, most 
epidemiological studies have been performed in high income countries in Western 
Europe and North America.  This section of this thesis will describe the burden 
headache presents to SSA using critical appraisal of the current literature in the field 
referenced to the rest of the world utilising the recent WHO publications. Population-
based studies from SSA that investigate the prevalence of all types of headache have 
been included and two landmark papers from clinic populations in SSA will also be 
discussed. The recent publications specific to headache disorders in the elderly 
population will also be briefly described. 
 
1.5.1.2.1.1.1 Headache Literature Review 
In this  review I have included population based epidemiological studies from SSA on 
migraine (ICD-10 diagnosis G43) and TTH (G44.2), the two types that affect the great 
majority of headache patients. In many studies no distinction is made between 
migraine with (G43.1) and without (G43.0) aura, this differentiation is difficult in 
epidemiological studies. As the two types of migraine are probably equivocal with 
regard to disability, the divisions are only briefly described..  To cover all headaches I 
have included epidemiological studies that investigated headache in general, or 
unspecified. Worldwide review articles have been included and references listed in 
relevant publications examined. The most recent epidemiologically robust publications 
that examine the prevalence of headaches specifically in the elderly population; 
however none of these were from SSA. Cluster headaches cause significant burden to 
individuals, but due to their low prevalence they do not represent as much societal 
cost and so literature specific to them was not included. 
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1.5.1.2.1.1.2 Classification/diagnostic criteria 
The most widespread primary headache disorders include migraine, tension-type 
headache (TTH) and medication-over use headaches (MOH). The former two are 
particularly prevalent, globally widespread and are often chronic conditions [174]. 
 
The Headache Classification Committee of the IHS produced the gold-standard 
International Classification of Headache Disorders (ICHD-1) in 1988, they produced 
specific and unequivocal definitions of all headaches [176]. This classification was 
incorporated into the International Classification of Diseases in 1997 (ICD-10) [177]. 
The first edition of the classification has been shown to be reliable, valid and 
exhaustive. It has been modified to improve its performance in 2004 (ICHD-2) [178], 
but only minor changes were required to be made. This latest diagnostic criterion has 
been used to define headache in this thesis. On critical review of the literature the 
diagnostic criteria used has been noted whilst recognising that the IHS criteria is the 
international gold-standard.  
 
I have summarized the criteria of relevance in the following table, this is included in 
the body of the thesis to explain the prevalence figures presented later. 
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Table 1.5: The International Headache Society Diagnostic Criteria for Headache and its Sub-Types 
Main Division Main 
Division – 
IHS ICHD –II 
Code 
Main Division 
WHO ICD-
10NA code 
Subdivisions of importance Sub- Division 
– IHS ICHD –
II Code 
Sub-Division 
WHO ICD-
10NA code 
Part I: The Primary Headaches      
Migraine 1 G43    
Tension-type headache 2 G44.2    
Cluster headache and other trigeminal 
autonomic cephalgias 
3 G44.0    
Other primary headaches 4 G44.80    
Part II: The Secondary Headaches      
Headache attributed to head and/or 
neck trauma 
5 G44.88 Chronic headache attributed 
to other head and or neck 
trauma 
5.6.2 G44.88 
Headache attributed to cranial or 
cervical vascular disorder 
6 G44.81    
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Headache attributed to non-vascular 
intracranial disorder 
7 G44.82    
Headache attributed to a substance or 
its withdrawal 
8 G44.4 or 
G44.83 
   
Headache attributed to infection 9 G44.821 and 
G44.881 
   
Headache attributed to disorder of 
homeostasis 
10 G44.882 Headache attributed to 
arterial hypertension  
 
10.3 G44.813 
   Headache attributed to 
hypertensive crisis without 
hypertensive encephalopathy 
10.3.2 G44.813 
   Headache attributed to 
hypertensive encephalopathy 
10.3.3 G44.813 
Headache or facial pain attributed to 
disorder of cranium, neck, eyes, ears, 
nose, sinuses, teeth, mouth or other 
facial or cranial structures 
11 G44.84 Headaches attributed to 
disorders of the neck 
 
11.2 G44.841 
   Headaches attributed to 
disorders of the eyes 
11.3 G44.843 
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   Headaches attributed to 
disorders of the ears 
11.4 G44.844 
   Headaches attributed to 
disorders of the teeth, jaws or 
related structures 
11.6 G44.846 
Headache attributed to psychiatric 
disorder 
12 R51    
Part III: Cranial Neuralgias Central and 
Primary Facial Pain and other 
headaches 
     
Cranial Neuralgias and central causes of 
facial pain 
13 G44.847, 
G44.848 or 
G44.85 
Trigeminal Neuralgia 13.1 G44.847 
Other headache, cranial neuralgia, 
central or primary facial pain 
14 R51 Headache unspecified 14.2 R51 
[179] 
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The definition of when a headache becomes a "headache disorder" is variable within 
the literature, but is clearly defined by the WHO and is as follows;  
 
 "A current or active headache disorder" is one that has been "symptomatic at 
least once within the last year".  
 "A chronic headache disorder" comprises headaches  on 15 or more days per 
month. This is generally called Chronic Daily Headache (CDH). It is mainly used 
to describe TTH, but in many headache studies, the term is used regardless of 
whether the headache is TTH or not [174, 178].  
 
Most headache epidemiological studies provide 1-year prevalence estimates, i.e. 
headache occurring during the last year. In other studies, participants were asked 
about headache during their whole life (life-time prevalence).It is therefore very 
difficult to compare results from epidemiological studies of headache and there is a 
need to standardise data collection as with all epidemiological studies.  
 
For the purpose of this study we enquired about recurrent headaches that were 
problematic to the patient, i.e. the headache affected their daily activities.  
 
1.5.1.2.1.1.3 Level of burden of headache disorders 
Headache disorders impose substantial personal and society burden. In the Global 
Burden of Disease Study (GBDS) [159], migraine alone was found to account for 1.3% 
of years lost due to disability (YLD) worldwide. Current calculations indicate that the 
disability attributable to tension-type headache is even larger. Therefore according to 
the WHO headache disorders are amongst the top 10 disabling conditions for the 
whole population, and amongst the top five for women [180].There are of course 
regional variations but headache disorders are a worldwide issue, affecting people of 
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all ages, races, socio-economic groups and geographical areas. No significant mortality 
is associated with the great majority of headaches, particularly primary disorders, the 
cost is significant morbidity, disability and financial loss[174].  
 
1.5.1.2.1.1.4 The prevalence of headache disorders 
Globally, the percentages of the adult population with a current headache disorder 
are: general headache 46%-75%, migraine 11% (with male to female ratio 1:3, 
apparently hormonally driven), TTH 42% (on average but >70% in some 
populations)[181] and CDH 3% (range 1.0-4%) [180, 182]. Much of the CDH may be 
attributable to MOH but the epidemiological data is lacking. MOH is more prevalent 
than other secondary headaches affecting 1% of some populations[183, 184]. In 
general women more than men are affected by headache disorders. In epidemiological 
studies from Africa the prevalence of general headache is lower at 22%, as is the 
prevalence of migraine. These figures are generalisations and averages that are not 
applicable to many world regions, particularly SSA as limited data from these areas 
were included due to the paucity of good quality studies. Gaps in the knowledge need 
to be filled to inform health policy. Furthermore, many of the epidemiological studies 
focussed on migraine, while the more common TTH and the more disabling CDH 
received little attention.  
 
The table below demonstrates the mean 1 year prevalence (%) in adults aged 18-65 
years of all headaches, migraine, TTH and MOH from population-based studies by 
WHO region. This is from the recent WHO 2011 "Atlas of headache disorders" and 
includes only the most epidemiologically robust data. As a result there were very few 
studies from Africa (n=2) and there was no inclusion on data reporting headaches in 
elderly populations. The results are slightly confused and difficult to interpret; for 
example prevalence for individual headaches may be higher than that for all 
headaches, because they are the results of different studies. The studies looking at 
specific headaches may have made greater effort to detect and include less frequent 
headaches. This illustrates the need for more robust epidemiological data.  
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Table 1.6: Mean 1 year Prevalence (%) of All Headaches, Migraine, Tension Type 
Headache and Medication Overuse Headache in Adults Aged 18-65 years from 
Population-Based Studies by World Health Organisation Region 
 
 Africa Americas Eastern 
Mediterranean 
Europe South-
East 
Asia 
Western 
Pacific 
All 
Headache 
21.6 
(n=2) 
46.5 
(n=1) 
78.8 
(n=2) 
56.1 
(n=8) 
63.9 
(n=1) 
52.8 
(n=4) 
Migraine 4.0 
(n=2) 
10.6 
(n=1) 
6.8 
(n=2) 
14.9 
(n=9) 
10.9 
(n=1) 
10.4 
(n=6) 
TTH Nr 32.6 
(n=1) 
Nr 80.0 
(n=2) 
34.8 
(n=1) 
19.7 
(n=3) 
MOH Nr Nr Nr 1.0 
(n=3) 
1.2 
(n=1) 
Nr 
CDH 1.7 
(n=2) 
4.0 
(n=1) 
Nr 3.3 
(n=3) 
1.7 
(n=1) 
2.1 
(n=3) 
n=number of studies in the WHO region contributing to the reported mean 
Nr=not reported. Indicative of lack of relevant studies rather than absence of the 
disorder[174] 
 
The recent review article by Stovner et al [180] comprehensively documented the 
prevalence of headache worldwide and found the following results. The global 
prevalence of current headache to be 47%, current migraine 10%, current TTH 38% 
and current CDH 3%. Consideration of studies restricted to adults gave similar results 
(46%, 11%, 42% and 3% respectively). They found life-time prevalence, as expected, to 
be somewhat higher: 66% for general headache, 14% for migraine and 46% for TTH. 
The authors did find that the prevalence for lifetime CDH was actually lower than 
current CDH at only 2.9% but this was based on only two studies. The authors explored 
the different prevalence of headache in general in the different continents and found it 
to be 50% in Asia, Australia, Europe and North America, but markedly lower (20%) in 
Africa. They found migraine to be most prevalent in Europe (15%) and least prevalent 
in Africa (5%). TTH appears to be much more common in Europe (80%) than in Asia or 
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the Americas (20–30%) (data from Africa was found to be lacking- however there has 
been recent data published from Tanzania after this review was completed). The 
authors found data on CDH to be relatively scarce and therefore probably less reliable, 
but they estimate a global prevalence of 3.4%. This condition appears to be most 
common in Central/South America (5%) and least common in Africa (1.7%). MOH is 
common among those with CDH with a prevalence of 1% in the adult population, 
although diagnosis can never be certain in epidemiological studies unless follow up is 
performed to ensure that the headache resolves after 2 months.  
 
There are few properly conducted population studies based on IHS criteria for cluster 
headache but the recent review from Fischera et al. [185] reported a lifetime 
prevalence of 124/100,000 and a 1 year prevalence of 53/100,000. All the studies 
presented came from high income countries except for one from Malaysia [186] which 
found no cases and therefore a prevalence rate of 0/100,000 and Tekle-Haimanot's 
1995 paper[187] from Ethiopia which found 5 cases and a 1 year prevalence of 
32/100,000.    
 
Stovner et al's [180] principal objective was to summarise all worldwide population-
based studies on the most prevalent headache types. As a result their approach was 
uncritical and inclusive of many different studies with great variations in size, 
methodology and quality  Indeed to have allowed for methodological differences 
would have been difficult, especially as the method in many studies is incompletely 
described. In a previous meta-analysis of headache epidemiological studies worldwide, 
the relative contribution to variations in the results from variations in methodology 
(compared with variations in age, gender distribution, race and continent) has been 
estimated at around 30% [188].  
 
Although one can conclude that the burden of headache is large on all continents it is 
poorly described in large and populous regions, including SSA. Stovner et al [180]  
identified 107 population-based studies regarding headache (studies performed on the 
whole population or a representative sample) worldwide, of which only seven 
originated from the African continent, six of which were from SSA. As a result of the 
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limitations of Stovner's review and the subject matter of my thesis, I have reviewed 
the epidemiological studies of headache performed in SSA in more detail. There have 
been relevant publications since Stovner’s review. A search of the literature for studies 
on all headaches from SSA, irrespective of the applied methodology, retrieved 13 
studies. I was also able to retrieve 5 articles specific to the prevalence of headache in 
the elderly, although none of these were from SSA.   
 
1.5.1.2.1.1.5 Critical appraisal of the SSA literature 
1.5.1.2.1.1.5.1 The difficulty in interpreting hospital based headache studies: 2 
working examples from SSA 
Lisk et al [189] performed one of the first studies of headache in SSA, published in 
1987. Limited conclusions can be drawn as they studied the patterns of headaches in 
250 individuals that presented to a clinic, a biased population. The selection of the 250 
people was not detailed so further bias could be present. The main conclusions were 
there were more females than males with a sex ratio of 2.2:1. (It was presumed that all 
headaches were severe as they had resulted in consultation in a specialist clinic.) The 
commonest cause, >40%, was migraine, both common and classical.. Next most 
common was tension headache, 20%, Sinusitis,15.6%, and hypertension 4.4%. The 
authors thought the latter surprising given the widespread medical problem that 
hypertension represents, but given it is in the majority a symptomless disease until 
malignant stages are reached, this does not seem unusual. The authors do conclude 
that the proportion of headaches attributed to migraine is very high and they attribute 
this to environmental and cultural factors, although do not expand on this further. 
Further interpretation of this biased review with poor methodology would be unwise 
especially as there is little detail given of the diagnostic criteria used. This study 
demonstrates the importance of standard diagnostic criteria and unbiased sampling of 
community populations to estimate prevalence.. 
 
Another study with results that are difficult to interpret was performed by Matuja[190] 
in Tanzania in 1991 as it merely studied types of headaches admitted to a neurology 
clinic over a 2 year period. Patients with recurrent headaches accounted for 319 
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(20.6%) of all new referrals, consisting of 47 (34%) with migraine (ratio of common to 
classical 4:1), 38 (27%) with psychogenic disorders, 18 (13%) with post traumatic 
headache, 16 (11%) with vascular-muscular contraction and 11 (8%) muscular 
contraction. Headaches were more common in the young and migraine was more 
common amongst females. Over two thirds of patients experienced severe headaches. 
The "neurology clinic" sample is extremely biased. Consultation with a specialist care 
service in Africa requires the financial and geographical means to attend. Headaches as 
a result may be more severe and more likely to be associated with other symptoms 
that an individual may interpret as worrying (migraine as opposed to TTH). The Ad-Hoc 
Committee Criteria (AHC) were used to define the headache diagnosis and so ease of 
comparison with other studies is further hampered and consequently impossible due 
to these numerous methodological issues.  
 
1.5.1.2.1.1.5.2 Community prevalence studies in SSA in selected populations 
Matuja et al [191]subsequently performed a community based study in southern 
Tanzania in 1995. This however represents another selected population and so 
generalisation of results is difficult. Although the rationale behind studying a 
productive population is obvious, the urban working population and students of higher 
education are not representative of the majority of Tanzania (demonstrated by the 
large proportion of men) and so extrapolation of results to the rest of the country is 
not possible. To the authors credit random selection was utilised. A self-administered 
questionnaire was used, methodology which would subsequently be difficult to 
reproduce in a country in which a significant proportion of the population are illiterate. 
The AHC criteria were used to define headache types. A total of 815 (52%), (620 (51%) 
men, 195 (60%) women) admitted to having suffered a headache requiring medication 
or medical consultation in the last year (more affordable in this population). 366 
(23.7%) had recurrent headache, significantly more females than males 28.9% and 
22.4%, respectively, highlighting the impact of the heavily male weighted biased 
sample. The most common headache type was combined vascular-muscular-type 
(35.8% of cases), followed by migraine (30.8% of cases). The study did demonstrate the 
societal impact of headache detailing that cases (175) had an average of 11.3 lost work 
days per year in comparison to the control group with an average of 5.7 lost work days 
per year for reasons other than headache. 
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Adoukonou et al [192] performed a study measuring the prevalence of migraine 
among the students of the Faculty of Health Sciences of Abomey-Calavi University, in 
Cotonou, Benin. A small cross-sectional study of 336 students was performed. 
Systematic random sampling limited selection bias. The questionnaire used to screen 
participants was designed originally for a French epidemiological survey and had been 
validated in France but not in Benin. Although this is a Francophile African nation 
cultural interpretations of questions may be very different. The questionnaire was 
completed by the subjects themselves leading to risk of question misinterpretation. 
The study was 2 phased and consequently a positive questionnaire was followed by 
history and examination by a neurologist to confirm the presence of migraine. 
Migraine was defined according IHS criteria. Lifetime prevalence was measured making 
comparison of the results gained difficult.  
 
Among 336 students, 252 suffered from recurrent headache, and prevalence of 
headache was then 75.0% (95% CI: 69.9-79.5%). A total of 38 met migraine criteria. 
The lifetime prevalence of migraine was 11.3% (95% CI: 8.2-15.3%). The prevalence 
was significantly higher in females (18.3%) than males (6.8%). The mean age at onset 
of the disease was 15.0 years +/- 2.5. The mean attack frequency per month was 3.8 
(+/-3.4) and the peak attack duration was between 4 and 6 hours. Psychological 
tiredness was the most frequent triggering factors (92.1%). The factors associated with 
migraine in multivariate analysis were female sex (OR = 2.6 [95% CI: 1.2-5.3]), single 
marital status (OR = 3.7 [95% CI: 1.2-11.9]) and presence of a family history of 
headache (OR = 2.9 [95% CI: 1.0-8.1]). 
 
Migraine was frequent in students in Cotonou (Benin) compared with other studies in 
Africa. However this was a very limited study in a small and specialist sample of 
educated young individuals. The study did highlight the burden on a productive age 
group and the potential impact of psychological tiredness, but the results cannot be 
generalised or compared to the rest of the world’s data.  
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1.5.1.2.1.1.5.3Community prevalence studies in SSA in general populations 
Osuntokun et al [193]documented the prevalence of migraine headache as part of 
their pilot study to determine the feasibility of a survey to detect major neurologic 
diseases among rural populations in developing countries. They obtained data on the 
prevalence of migraine in a rural Nigerian population using the WHO screening 
questionnaire for neurological disorders. Subsequently a neurologist confirmed 
migraine using the AHC diagnostic criteria, in 62 out of 903 individuals, yielding a point 
prevalence rate of 69/1,000. The female to male ratio was 2:1. In 80%, a first-degree 
relative suffered from 'similar headaches'. The prevalence rate declined with 
increasing age once subjects were aged 40 or over. 
 
Osuntokun [194]subsequently performed another community based study of 
headache of much larger proportions in a Nigerian town in 1992, utilising a 
questionnaire with a 92% sensitivity and 95% specificity with no second phase. 18,594 
subjects were screened. The authors found that the lifetime prevalence of 1 
(unspecified) headache was 51% (50% in males and 52% in females) and the lifetime 
prevalence of migraine was 5.3% (5.0% for males and 5,6% for females). 
 
Levy et al [195]performed one of the first robustly designed prevalence studies of all 
cause headache alone in SSA, in an urban population of over 5000 from Zimbabwe, 
using a gold-standard 2 phased approach of questionnaire followed by interview. The 
AHC was used to define headaches and subtypes. The 1 year prevalence of headache 
was found to be 20.2% (17.6% in males and 27.0% in females). Headaches were 
defined as severe in one third of cases (more commonly younger age groups and 
women). The prevalence of migraine was found to be 4.2% with all of the cases being a 
common presentation. The prevalence of TTH was found to be only 0.7%.   
 
Tekle-Haimanot et al [187] performed a similarly well designed prevalence study.  The 
results can be generalised and compared to other rural populations. The IHS diagnostic 
criteria were used to develop a reliable and valid questionnaire for a door to door 
survey.  Fifteen-thousand-five-hundred adults aged 20 years and older, who were 
randomly selected from a rural Ethiopian population of 250,000, were interviewed by. 
trained lay health workers. The 1-year prevalence of migraine headache was 3.0% 
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(4.2% for females and 1.7% for males) with the peak age specific rate in the fourth 
decade and a male to female sex ratio of 1:3. Migraine with aura was rare. Family 
occurrence of migraine in first-degree relatives was 30%. The 1-year prevalence of 
chronic tension-type headache was 1.7%, the 1 year prevalence of TTH was not 
reported.  
 
Dent et al [196] performed a robustly designed door to door survey of the prevalence 
of headaches, (looking in more detail at migraine) in a general rural population of 
Tanzania in 1999. The authors used the gold standard IHS guidelines and questioned 
patients regarding headache in the last year making the findings of the study 
internationally comparable.  
 
They performed a door-to-door 2 phased epidemiological survey on 3551 persons aged 
over 10 years within 1047 households. Whole villages were selected and seen, but the 
details of the rationale behind selection were not reported and so raises the question 
of whether  bias was eliminated. The questionnaire was based on the  IHS criteria, but 
details of the validation of the questionnaire were not included, in addition the 2 
questions asked seemed to focus on lifetime prevalence despite the aim to detect 1 
year prevalence. Diagnostic certainty could have been compromised by the use of 
medical students who screened and confirmed cases with a local physician in an 
advisory role only. They interviewed one representative family member not each 
member of the household, this introduces risks e.g. under reporting of this subjective 
illness. Diagnoses were made through a standard interview, not detailed in the report,  
and no follow up examinations of the subjects were performed to diagnose secondary 
causes of headaches. Questions regarding the severity of the headaches were very 
subjective and open to interpretation; headaches were said to have affected activities 
of daily living (ADL) if the subject had reduced their ADLs by half. The diagnosis of the 
most frequent type of headache experienced in the last year was recorded and duel 
diagnoses were not allowed for.   
 
A total of 773 (23.1%; (95% CI 21.2-24.5)) responded positively to the screening 
question concerning the presence of headache during the previous year; 278 (18.8%; 
95% CI 16.2-20.8) were males and 495 (26.4%; 95% CI 24.4-29.0) females. Amongst the 
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773 headache sufferers, a total of 167 respondents met the case definitions of 
migraine, resulting in a 1-year prevalence of 5.0% (95% CI 4.3-5.7); 2.5% (n = 37; 95% CI 
1.5-3.6) in males vs. 6.9% in women (n = 130; 95% CI 5.4-8.5). The peak age specific 
prevalence rate was seen in males in the third decade of life (3.8%) and in females in 
the fourth decade (11.1%). 47 people (1.4% (95% CI 1.0-1.8) suffered from migraine 
headaches without aura and 120 people (3.6% (95% CI 3.0-4.2) fulfilled the criteria of 
migraine with aura. Of the 167 respondents reported to be suffering from migraine, a 
total of 128 individuals (76.6%) indicated they had experienced ‘severe or very severe 
and incapacitating headaches’. The remaining 39 persons (23.4%), reported ‘severe but 
not incapacitating headaches’. 
 
The authors only present crude prevalence rates which limits the comparability of the 
data, however the rates of migraine headache found were similar to those in other 
studies from SSA but substantially lower than reports from Europe and North America 
where prevalence ranges from 7.5% in Hungary [197] to 27% in Germany [198], and 
12–15% in the USA [199] and Canada [200]. Rates in this SSA population were higher 
than in China, where prevalence rates ranging from 0.6 to 1.0% have been reported 
[201-203]. This study adds substantially to the scanty data available from SSA, 
however, due to the retrospective character of data collection and the lack of personal 
interview with each study participant, there are some limitations 
 
Houinato et al [204] determined the prevalence of migraine in a rural community of 
Benin. A cross-sectional two phased study was completed on 1113 people (selected 
through random sampling to reduce bias) aged 15 and over. The questionnaire used 
had been validated in France and sensitivity was reported to be >80% but validation 
was not performed on the local population. Trained medical students carried out the 
survey followed by a full neurological examination by a neurologist for those that 
screened positive. Confirmed cases were defined by the IHS criteria [176]. Participation 
rate was good at 93.4% Substantially more females than males were included in the 
sample 63.4% and 36.6% respectively. apparently representative as in rural Benin 
there is male exodus to urban areas.. Of the 1113 persons, 37 had migraine. The 
lifetime prevalence of migraine was low at 3.3%, (males 2.2%, females 4.0%) despite a 
predominant female population. The study findings are difficult to compare with 
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worldwide data as lifetime prevalence rather than 1-year prevalence data was 
recorded.  
 
Winkler et al [205, 206] performed a robustly designed community door to door study 
to assess the prevalence of general headache, TTH and migraine using the IHS 
diagnostic criteria. The study was within the rural catchment area of the Haydom 
Lutheran Hospital in northern Tanzania. The close proximity of the study area to the 
hospital could introduce bias given the relative ease of medical consultation. The 
authors point out however that it is a unique study area as it has a very mixed 
population that based on their languages could represent all the main cultural groups 
of East Africa. The study used a Kiswahili questionnaire based on the IHS diagnostic 
criteria, however many of the population surveyed only spoke local languages 
complicating the accurate use of the questionnaire. Characteristics (sensitivity and 
specificity) of the validated questionnaire were not presented by the authors. 3 
questions about current, 1 year and lifetime headache were asked to the head of 
household with the concomitant risks discussed above.. Medical students made the 
diagnoses based on histories alone, however validation was provided by a neurologist. 
Only the primary headache diagnosis was recorded and other co-existing headaches 
were not included in the prevalence figures. An attempt was made to exclude 
secondary headache, positive responders were asked  if the headache was associated 
with any other disease.  
 
A total of 7412 participants were screened. 1404 of the study population stated that 
they had suffered from headaches in their lifetimes, corresponding to 18.9% 
(1404/7412; male 13.6%, 509/3731; female 24.3%, 895/3681). When patients who 
experienced headache exclusively related to a secondary medical condition were 
excluded, the remaining lifetime prevalence of overall primary headache was 13.5% 
(1004/7412; male 9.8%, 366/3731; female 17.3%, 638/3681). The 1-year prevalence 
rate of overall primary headache was 12.1% (895/7412; 95% CI 11.3, 12.8). After age 
adjustment to the WHO population, the 1-year prevalence rate was 17.5%. The 1-year 
crude prevalence of headache was significantly higher in females (15.8% (583/3681); 
95% CI 14.7-17.1) compared with males (8.4% (312/3731); 95% CI 7.5-9.3], resulting in 
a male to female ratio of 1:1.9.  The peak age-specific 1-year prevalence rate for all 
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individuals and for women was found in the fifth decade with prevalence rates of 
26.5% (109/411; 95% CI 22.3, 31.1) and 35% (75/214; 95% CI 28.7, 41.8), respectively. 
In men those aged 61 years and over showed the highest prevalence with a rate of 
19.8% (32/162; 95% CI 13.9, 26.7). 
 
Five hundred and twenty-one headache sufferers met the case definitions of TTH, 
resulting in a 1-year TTH prevalence of 7% (521/7412, 95% CI 6.5-7.6; age-adjusted 
rate 10.4%); 5.3% (196/3731; 95% CI 4.6-6) in men compared with 8.8% (325/3681; 
95% CI 7.9-9.8) in women with a gender ratio of 1:1.7. ETTH made up 5% (374/7412; 
95% CI 4.5-5.5; age adjusted rate 7.1%), CTTH 0.4% (27/7412; 95% CI 0.2-0.5; age-
adjusted rate 0.5%) and TTH, according to IHS 2.3, 1.6% (120/7412; 95% CI 1.3-1.9; age 
adjusted rate 2.8%). The peak 1-year prevalence rate TTH was 18.7% (59/316; 95% CI 
14.5, 23.4) and occurred in people aged 60 years and over.  
 
A total of 316 respondents met the criteria of overall migraine headache, including 
chronic daily migraine headache and migrainous disorders. The calculated 1-year 
prevalence was 4.3% (95% CI 3.8-4.7). The exclusion of children aged 0–5 led to a 1-
year prevalence of 5.4% (316/5858, 95% CI 4.9-5.9). Eighty-one of the patients with 
migraine headache were men (2.2%, 95% CI 1.7-2.7) and 235 women (6.4%, 95% CI 
5.6, 7.2), with a male : female ratio of 1:2.94 (P<0.001). After exclusion of seven people 
of unknown age, the 1-year prevalence rate of overall migraine headache was 4.2% 
(309/7405,95% CI 3.7-4.7) with an age-adjusted rate of 6.0%. As many western studies 
have dealt with adult populations starting between 12 and 20 years (23–30), the 
authors also calculated the crude prevalence rate for study participants aged 21 years 
and over, which was 8.5% (250/2927, 95% CI 7.5, 9.6). The age distribution of people 
with migraine demonstrated a peak in the fourth decade with a prevalence rate of 
10.3%.  The authors found that prevalence of migraine gradually increased to this 
point and then slowly declined with age.  132 patients did not fulfil all criteria for 
migraine headache; hence, these patients had to be classified as migrainous disorders 
with a crude prevalence rate of 1.8% (132/7412. 95% CI 1.5, 2.1). The remaining 184 
patients met all criteria for migraine resulting in a 1-year prevalence of 2.5%.  
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This study represents the first report of the prevalence of TTH in a rural Tanzanian 
population, and shows that headache in general and, more specifically, TTH and 
migraine are less prevalent than in Western countries; however they are still common 
and troublesome. The main limitations of the study, proxy reporting and the 
concurrent epilepsy prevalence study (a condition with known stigma)may have led to 
under-reporting of symptoms. The inclusion of young children (often excluded from 
headache prevalence studies) and the crude exclusion of secondary headaches may 
have also falsely lowered the prevalence results.  
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Table 1.7: Epidemiological Studies of Headache in Sub-Saharan Africa 
Country  
1st 
author 
year ref 
Populatio
n 
Diagnost
ic 
criteria 
used 
Method 
 
N Age 
year
s 
Prevalen
ce period 
Headach
e 
prevalen
ce 
% 
Migrain
e total 
% 
Classic
al 
(with 
aura) 
% 
Commo
n 
(withou
t 
aura)% 
TTH 
% 
Chronic 
headac
he % 
Benin 
Adoukon
ou 
2009 
[192] 
Cross 
sectional 
– 
students 
IHS Self 
administere
d 
questionnai
re 
336 16-
46 
Life 75.0 11.3 4.8 6.6 - - 
Benin  
Houinato 
2009 
[204] 
Communi
ty rural 
IHS Personal 
interview 
1113 15-
80 
Life - 3.3 1.1 2.2   
Ethiopia 
Tekle-
Haimanot 
1995 
[187] 
Communi
ty rural 
IHS Personal 
interview 
1500
0 
20+ 1 year 4.7 3.0 0.3 2.7 1.7 1.7 
Nigeria Communi AHC Personal 906 All Unknown  6.9 - -   
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Osuntoku
n 1982 
[193] 
ty rural interview 
Nigeria 
Ogunyem
i 1984 
[207] 
Students AHC  1756 16-
42 
Life  16.7 3.9 12.9   
Nigeria 
Longe  
1988 
[99] 
Communi
ty rural 
Unknow
n 
Personal 
interview 
2925 All Unknown  6.3 0.4 5.9   
Nigeria 
Osuntoku
n 1992 
[194] 
Communi
ty urban 
AHC Personal 
interview 
1895
4 
All Unknown 51.0 5.3     
Sierra 
Leone 
Lisk  
1987[189
] 
Clinic 
patients 
with 
headache 
? Personal 
Interview 
250 ? Unknown - 42.4 10 32.4 22  
Tanzania  Clinic AHC Personal 319 5-59 2 years 20.6 (34.0%   19  
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Matuja 
1991 
[190] 
patients 
with 
headache 
Interview of 
20.6%) 
Tanzania 
Matuja 
1995 
[191] 
Communi
ty urban, 
students, 
workers 
AHC Self 
administere
d 
questionnai
re 
1540 20-
40 
1 year 23.7 7.2   35.8  
Tanzania 
Dent 
2004 
[196] 
Communi
ty rural 
IHS Personal 
interview 
3351 11+ 1 year 23.1 5.0 3.6 1.4   
Tanzania 
Winkler 
2009-10 
[205, 
206] 
Communi
ty rural 
IHS Personal 
Interview 
7412 All 1 year 12.1 
(age 
adjusted 
rate 
17.5%) 
4.3 
(age 
adjuste
d rate 
6.0%) 
1.2 1.3 7.0 
(age 
adjuste
d rate 
10.4%) 
 
Zimbabw
e Levy 
1983 
[195] 
Communi
ty urban 
AHC Personal 
interview 
5028 5-70 1 year 20.2 4.2 0 4.2 0.7  
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AHC : Ad Hoc Committee Criteria[208], IHS: International Headache Society[179], All prevalence rates are crude unless otherwise stated  
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Detailed comparison of the prevalence of headache found in this study, SSA and the rest 
of the world is included in the discussion and so is not elaborated further here.  
 
1.5.1.2.1.1.6 The burden of the different headache types 
Stovner et al[180] attempted to translate prevalence into burden through data on 
duration and severity of symptoms. They found that although TTH is generally less 
burdensome than migraine to the individual sufferer, however the total societal burden of 
this headache type is larger than that of migraine because of its much higher prevalence. 
The higher prevalence of TTH vs. Migraine is observed worldwide but  to a much lesser 
extent by the SSA studies, this could result from variations in methodology and reporting 
as opposed to a true variation in the burden of different headache types.  
 
1.5.1.2.1.1.7 The Social and economic burden of headache 
Globally, information on the societal impact of headache exists in very few countries: 18 % 
of countries worldwide (and only 6% of African countries) surveyed as part of the WHO 
LTB campaign responded regarding the societal burden that headache represents[174]. 
 
Headache disorders are a public-health concern given the large amount of associated 
disability and financial costs to society. Headache is particularly burdensome as it 
predominantly affects those in their "productive years". In the United Kingdom, 25 million 
working/school days are lost every year because of migraine alone; this loss increases 
substantially when tension headache is included [174].  
 
The WHO state it would be highly informative to health policy if accurate information 
existed within countries on direct and indirect costs attributable to headache, given the 
huge disparity between the two. However, little such information exists worldwide 
especially from SSA. 
 
  
107 
 
1.5.1.2.1.2 Risk Factors for headache 
Globally, there are four categories of risk factor:  
 Social (20.8 %), including quality of life, domestic circumstances and life events 
 Other medical conditions (15.8 %), including hypertension, depression and 
infectious diseases 
 Drugs or medications (12.9 %), particularly medication overuse 
 Lifestyle factors (7.9 %), including substance abuse and dietary habits[174]. 
 
1.5.1.2.1.3 Diagnosis and Management 
History and examination is usually all that is required to diagnose headache disorders. 
Investigations are generally not required to support the diagnosis. Despite this a minority 
of people with headache disorders worldwide are professionally diagnosed. The diagnosis 
rates for migraine and TTH are about 40 % and for MOH only 10 %. Specialists use IHS 
diagnostic criteria [179] to support diagnosis in only 56 % of countries with lower usage 
reported in Africa. Failure in diagnosis is often due to help not being sought; a recent 
study in the US and the UK demonstrated only half of those identified with migraine had 
seen a doctor in the previous 12 months. The majority of people with headaches are 
reliant on self diagnosis and over-the-counter medications [174]. 
 
1.5.1.2.1.3.1 Treatment 
The main classes of drugs to treat headache disorders include: analgesics, anti-emetics, 
anti-migraine medications, and prophylactic medications - WHO found these were 
available in the majority of countries surveyed, however there was limited response to the 
surveys from SSA and the national availability of medications does not mean availability to 
all, especially in resource poor settings where access to healthcare is unequal. Globally, 
guidelines or recommendations are used for the management of headaches in 55% of 
countries worldwide; however this percentage is much less in SSA. 
 
  
108 
 
1.5.1.2.1.3.2 Barriers to effective management 
Barriers to care could be summarised as; 
1. Clinical Barriers  
 a. Lack of professional education (Worldwide, only four hours of undergraduate
 medical training are committed to headache disorders) 
 b. Patient-related problems including co-morbidities 
 c. Lack of health-care resources including non-availability of medications 
2. Social Barriers - Poor awareness of headaches in the general public 
3. Political/Economic Barriers - Many governments do not acknowledge the substantial 
burden of headache on society  
Suggested changes: 
1. Professional education 
2.Improved  awareness  
3. Improved availability of healthcare, including improved organisation and delivery of 
healthcare services for headache 
4. Political recognition that the problem exists 
5. Support of National professional organisations [173] 
 
1.5.1.2.2 Stroke 
1.5.1.2.2.1 Definition 
The WHO definition for stroke is “rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function with symptoms lasting 24 hours or longer, with no 
apparent cause other than vascular origin” [209]. 
 
Stroke is a syndrome caused by interruption in the flow of blood to part of the brain by 
either; 
1. Occlusion of a blood vessel – ischaemic stroke 
2. Rupture of a blood vessel – haemorrhagic stroke 
 
109 
 
The occlusion of the blood vessel can sometimes be temporary and present as a reversible 
neurological deficit, which is termed a transient ischaemic attack (TIA) [75, 76]. 
 
1.5.1.2.2.2 Diagnostic Criteria and Clinical Classification 
1.5.1.2.2.2.1 Ischaemic versus Haemorrhagic 
Stroke is a clinical diagnosis, brain imaging is required to accurately distinguish ischaemic 
from haemorrhagic stroke. When imaging is unavailable, clinical scores can be useful to 
identify patients with intracerebral haemorrhage e.g. The Siriraj Stroke Score [210]. 
However this score is only useful when patients are seen at the time of the stroke, its 
sensitivity and specificity were good in initial studies but have been reported as more 
disappointing since, particularly in SSA. Celani et al [211] argue scores such as the one 
above whilst useful to identify patients at low risk of haemorrhage, leaves many strokes 
where it is difficult to be certain of aetiology [211]. 
 
Ischaemic stroke can be secondary to embolism, thrombosis or rarely vertebral or carotid 
artery dissection [75]. 
 
Haemorrhagic stroke is usually secondary to rupture of the deep perforating arteries due 
to chronic hypertension. Rarely it is due to a subarachnoid haemorrhage but this is a 
distinct epidemiological entity [75]. 
 
1.5.1.2.2.2.2 Vascular localization in the cerebrum 
The cerebral circulation branches into anterior and posterior divisions, supplied by the 
internal carotid and the vertebrobasilar arteries respectively, and connected by the circle 
of Willis. 
 
The anterior cerebral branch from the internal carotid supplies the anterior and medial 
parts of the cerebral hemisphere and small branches also supply the hypothalamus, 
internal capsule and anterior part of the basal ganglia. A stroke in this territory may 
preferentially involve the contralateral leg. 
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The middle cerebral artery supplies the more lateral parts of the cerebral hemisphere so 
the patient is more likely to have their face and arm affected as well as sensory loss. 
Branches also supply the internal capsule and the basal ganglia. 
 
Vertebrobasilar disease may give rise to brainstem signs by impairment of the posterior 
cerebral artery supply affecting the circulation to the occipital lobe, inferior part of the 
temporal lobe, thalamus or hypothalamus [75, 76, 79]. 
 
1.5.1.2.2.3 Clinical Classification of Stroke 
The widely recognised clinical classification of stroke is the Oxfordshire Community Stroke 
Project (OCSP) (Bamford) Stroke Classification [212]. I used this to sub-classify stroke 
patients dependent on their symptoms and signs at the time of the stroke onset. Bamford 
classification is widely accepted and used in epidemiological studies; it is simple enough to 
use whilst it still recognises clinically useful subgroups. I understand that the subgroups 
relate to outcome in cerebral infarction and not haemorrhage so conclusions on outcome 
will not be accurate when no cerebral imaging is available.  
 
1.5.1.2.2.3 Epidemiology of stroke 
SSA is undergoing epidemiological development and a consequent health transition. 
Stroke and other vascular diseases increasingly contribute to the burden of disease and 
interventions to stop this rapid progression are urgently needed.  
 
The annual incidence of stroke in high income countries is 2-3/1000. There are few 
community stroke incidence studies from SSA but similar high incidence has been 
reported from one study from SSA, more specifically from the DSS that is the subject of 
this thesis [213]. Hospital incidence is lower than in high-income regions, but selection 
bias has to be considered and incidence appears higher in young people than in the rest of 
the world.  
 
111 
 
The prevalence rates range from 0.5% to >1% in those aged over 65 years in developed 
countries. Generally the prevalence is reported to be lower in SSA with age adjusted rates 
half that figure. However the prevalence of disabling stroke is reported in some studies to 
be as prevalent and with demographic transition it is thought that the overall prevalence 
will soon equal that of developed countries. 
 
Stroke is the third most common cause of death worldwide, and the leading neurological 
cause of death in SSA.  Hospital based studies from SSA demonstrate that stroke is one of 
the leading causes of neurological admissions and death [28]. Stroke mortality may 
surpass stroke mortality in high income countries, and as expected increases with age. The 
recently updated Global burden of disease study estimated that over 80% of stroke deaths 
occur in low-income and middle-income countries [214-216]. 
 
This section will describe the burden stroke presents to SSA. A critical appraisal of the 
literature is referenced to the rest of the world Population-based studies from SSA 
investigating the prevalence of all types of stroke have been included together with the 
most recent and epidemiologically robust publications specific to stroke prevalence in the 
elderly population. The review focuses on prevalence, however to fully describe burden 
and variations in prevalence, incidence and mortality will also be considered.   
 
1.5.1.2.2.3.1 What is the best way to measure stroke burden worldwide? 
Disease burden in SSA is best estimated by community populations. Hospital data is 
subject to selection bias through geographical and financial constraints on the general 
population of low income countries. The burden of stroke, a disease by definition of 
sudden onset, is at first glance best reflected by incidence, prevalence after-all depends 
on incidence and case fatality [216]. However in sub-Saharan Africa, incidence studies 
prove very difficult to perform in the community because of the lack of medical 
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infrastructure many "stroke victims" do not consult help; they go undetected unless 
specific systems for reporting exist [213]. Thus stroke prevalence studies, particularly in 
demographic surveillance sites with a known denominator population, have arguably 
provided the most accurate and up-to-date measures of stroke burden in SSA. It is 
however important to recognise their limitations: 
 
Firstly, stroke and its sub types prevalence estimations are complicated by the difficulty of 
retrospective diagnosis months or years after the event.  
 
Secondly, prevalence figures tend to under estimate because of  under-representation of 
fatal cases, and confusion with co-morbidities such as arthritis and dementia.  
 
Thirdly, the majority of stroke prevalence studies in developed countries are performed 
with very different methodology e.g. screening through postal questionnaires [217, 218]. 
Poor or non-existent postal services, low literacy level and lack of initial stroke diagnosis 
preclude this and other non "in-the-field" methodology in SSA. As in most low-income 
countries as for other neurological conditions, two phased door-to-door surveys are the 
gold-standard [34]. 
 
Fourthly the majority of recent stroke studies done in high income countries are incidence 
studies (for the reasons mentioned above) therefore to accurately document differences 
between burden in low and high income countries, population-based incidence studies 
with long-term follow-up and assessment of case fatality are required in SSA. 
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1.5.1.2.2.3.2 Stroke Prevalence 
The surveillance of stroke prevalence in SSA began in the 1980s, with landmark studies 
from Nigeria and Ethiopia.  
 
Between 1982 and 1989, Osuntokun et al's [3, 25, 99] work aimed to establish the 
prevalence of neurological disorders in rural Nigeria. The gold-standard two phased 
approach was used to perform three studies. Surveys were carried out by trained nurses, 
primary health-care officers, medical students or teachers using the Original 1981 WHO 
Neurological disorders screening instrument. This asked the following questions to detect 
stroke (the question numbers apply to those that were assigned on the original screening 
tool); 
 
Q3 Is your speech normal? 
Q6 Has your face or part of your face ever been paralysed for more than 24 hours? 
Q7 Have you ever had weakness in your arms or legs for more than 24 hours? 
Q9 Have you ever had loss of sensation of abnormal sensation affecting your arms or legs, 
lasting more than 24 hours? 
 
Other questions and examination points may have also detected stroke particularly stroke 
affecting the posterior circulation. The diagnosis of stroke was then confirmed (or refuted) 
in positive cases by a neurologist or a neuro-surgeon.   
 
The initial study was in Aiyete, a community of about 2000 people, 903 individuals were 
screened to pilot the research protocol. This study demonstrated that the screening tool 
had a sensitivity of 95% and a specificity of 80% for detecting general neurological 
disorders. The validity of the screening tool in specifically detecting stroke was not 
reported. Stroke cases could therefore have been missed. Four participants were found to 
have had a stroke, resulting in a crude prevalence of 443/100,000 [25]. In Udo, 2925 
people were screened and two had had a stroke resulting in a crude prevalence rate of 
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68.4/100,000.30 [99]. The largest study was performed in Igbo-Ora, stroke was diagnosed 
in 11 of 18 954 people screened, resulting in a crude prevalence of 58 per 100 000 [3]. 
 
There were two main limitations of these studies. Firstly their size, which at initial review 
appear more than adequate, but when one considers that typically 44% of the population 
in SSA was less than 15 years old [216] then the representation of the older age groups 
(those predominately affected by stroke) is limited. Secondly the diagnostic criteria used 
was not detailed, thus the accuracy of diagnoses is difficult to assess.   
 
Between 1986 and 1988, a door-to-door survey was done on a random sample of 60 820 
rural Ethiopians of all ages [5]. Lay health workers, who had been trained by neurologists, 
did a census and identified people with symptoms and signs of neurological disorders with 
the previously validated (in Nigeria) WHO questionnaire. Neurologists regularly verified 
diagnoses. Again a small number of stroke cases (9) were found, this time in the adult 
population ranging from 28-85 years, giving a crude prevalence 15 per 100 000. The low 
rate may reflect, low stroke incidence, high case fatality, recovery from stroke or failure to 
detect cases. Investigation as to the causation was not performed.  
 
Walker et al [34] performed the largest study (n=148 135) to date of the prevalence of 
stroke in SSA in the Hai district DSS (the study population that is the focus of this thesis). 
The authors limited their study to the detection of disabling hemiplegic stroke, which 
although practical, limits the comparability of the data with the rest of the world. The 
authors utilised the gold-standard two phased approach. Highly trained enumerators 
(experienced in epidemiological surveys and graduates of higher education but inhabiting 
the villages in which they surveyed) performed a screen for hemiplegic stroke at the same 
time as the 1994 census. This provided accurate denominator data at the same time. The 
questions were as follows;  
 
Is there anyone in the household with a history of stroke? 
Is there anyone in the household with weakness down one side of the body? 
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Does anyone in the household require assistance with dressing, eating or toileting?” 
These questions had not been validated in a pilot study and so their sensitivity and 
specificity for identifying stroke cases was not known.  
 
Cases were verified amongst positive responders by a UK Geriatrician, with extensive 
experience of stroke,  who used the WHO definition of stroke as diagnostic criteria. Other 
methods of case ascertainment were used to improve the reliability of the prevalence 
figures. 
 
108/148135 people were identified as having a disabling hemiplegic stroke, the crude 
prevalence of stroke in the whole population was therefore 73/100000. However the 
authors sensibly recalculated prevalence rates in those aged 15 years and over and a 
recalculated crude prevalence was found to be 127/100,000, (155 for men and 103 for 
women). Age standardisation was performed to the Segi world population giving a 
prevalence of disability from stroke of 154/100 000 in men and 114/100 000 
in women. The crude prevalence rates for those aged 65 and over were 876/100,000 
(975/100,000 for men and 786/100,000 for women). The median age of patients was 70 
years old and the median age at first stroke was 65. 21% of patients were bedbound. The 
age specific prevalence of stroke survivors requiring help with at least one activity of daily 
living (ADL) was 69/100,000 for men and 90/100,000 for women. 
 
Walker et al demonstrated that prevalence of disabling hemiplegic stroke was low in 
comparison to high income countries (age standardised rates for stroke with residual 
disability was approximately half that found by previous studies in high income countries), 
they felt this was mainly explained by the age structure of the population with <6% of 
participants being aged 65 and over. Mortality rates may have also been higher. 
 
The Southern Africa Stroke Prevention Initiative (SASPI) team [219] reported the 
prevalence of stroke survivors in rural South Africa. A demographic surveillance site, 
Agincourt (population 68 525) was utilised. Workers trained in DSS activity carried out a 
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screen for stroke  and completed the annual census which provided the demographic 
data. The questions asked of over 15s were used to detect hemiplegic stroke only; 
 
 Has (person) ever had weakness down one side of the body? 
Has (person) ever had a stroke? 
For those who screened positive to either question a clinician trained in stroke carried out 
a  clinical assessment with the diagnostic criteria defined by the WHO.   
 
A total of 42,378 individuals were aged over15 years. There were 982 positive responses 
to the questionnaire,  however the authors were only able to examine 724 individuals 
(74%), for various reasons including refusals and inability to re-identify, this could 
introduce bias.. 103 stroke cases were identified resulting in a crude prevalence of 
243/100 000. To their credit the authors did adjust for those they were unable to examine 
and the prevalence increased to 300/100 000 (95% CI, 250-357). The age-standardised (to 
the Segi World population) prevalence of stroke was 290 per 100 000 (95% CI 238–343). In 
men the prevalence was 281 per 100 000 (200–362), and in women 315 per 100 000 (243–
387). Sixty-six percent of stroke survivors needed help with at least 1 activity of daily living 
(Segi age-standardized prevalence, 200/100 000). The crude prevalence of those aged 65 
years and older was 1490/100,000. 
 
The Tanzanian and SASPI studies both have the advantage of accurate denominators and 
careful assessment of people who screened positive for stroke. However, the accuracy of 
the screening questions in the census has not been assessed and a large number of false 
positives were picked up during screening. This hopefully provides reassurance of the 
sensitivity of the questions but does mean reproduction of the studies will be time 
consuming and difficult. In addition both studies assessed the prevalence of hemiplegic 
stroke only, this is pragmatic as most patients who have ongoing disability from their 
stroke  are likely to be hemiplegic in nature. Other stroke types are more likely to recover 
or affect vital respiratory centres so result quickly in death. 
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Gradual health transition might explain differences in the prevalence of stroke in these 
most recent robust prevalence studies from SSA. Firstly the lifestyle risk factors of South 
Africans may be higher than Tanzanians, stroke risk factors have recently been shown to 
be common in all population groups in South Africa [220]. Secondly Tanzanians may have 
a higher case fatality than South Africans in rural areas.  
 
The age-standardized prevalence of stroke in high-income countries reported in a recent 
review of studies since 1990 ranged from 461 to 833 per 100 000. The largest of these 
came from Auckland, New Zealand, where age adjusted prevalence of stroke was found to 
be 833/100,000 [221]. 
 
Both SSA studies assessed the prevalence of stroke survivors who need help with at least 
one ADL, in order to demonstrate stroke burden more completely. This allows direct 
comparison with the Auckland Stroke Study [221] as shown in the table below; 
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Table 1.8: The Age-Standardised (Segi World Population) Prevalence/100,000 of Stroke 
and Stroke Survivors Needing Help with Everyday Activities in Tanzania, South Africa, 
and Auckland, New Zealand [216]. 
 Tanzania [34] South Africa [219] New Zealand [221] 
Stroke Survivors    
Men  154 281 991 
Women 114 315 706 
Total  290 833 
Stroke Survivors 
needing help with 
at least one ADL 
   
Men  69 218 156 
Women 90 188 188 
Total  200 173 
 
 
The prevalence of stroke in Tanzania is half that of South Africa which is in turn a third of 
that found in Auckland. The prevalence of stroke survivors who required help was higher 
in South Africa than in both Tanzania and New Zealand. This finding may reflect 
inadequate rehabilitation after stroke in rural South Africa in comparison to New Zealand, 
and increased death from disabling stroke in Tanzania, but may also reflect that many very 
disabling strokes were picked up in South Africa and mild strokes went unrecorded. 
Indeed methodological differences could explain the differences between the prevalence 
rates; the Auckland Stroke Study followed on from incidence studies and therefore 
probably recorded mild strokes which would not have been picked up by either of the SSA 
studies. However both sub-Saharan African countries may have a lower prevalence of 
stroke when compared with New Zealand, because of a  higher mortality and case fatality, 
these factors therefore need to be examined when reflecting on stroke burden [216].  
 
119 
 
The trend of overall lower prevalence rates of stroke in SSA vs. high income countries was 
supported by  Danesi et al's [222] robust 3 phased community based epidemiological 
study in Lagos, Nigeria in 2007. The authors used a modification of the WHO protocol in 
the first stage, a stroke-specific questionnaire in the second stage and neurological 
examination of all persons screening positive for stroke in the third stage. To validate the 
process and add strength to the prevalence figures the authors also examined an equal 
number of individuals that screened negatively. Overall, the crude prevalence rate of 
stroke in urban Nigeria was 114/100,000 (males: 151/100,000; females: 69/100,000). The 
authors calculated the age-adjusted prevalence rates according to the USA population and 
demonstrated the following prevalence rates per 100,000 amongst the different age 
groups: 35-44 years = 0.9, 45-54 years = 33, 55-64 years = 71, 65-74 years = 98, 75-84 
years = 204 and >85 years = 74. As expected prevalence generally increases with 
advancing age.  
 
In contrast a high prevalence of stroke was observed in Cossi et al's [223] recent robust 
two phased epidemiological study which assessed the prevalence of stroke amongst 
15,155 individuals aged 15 years and older. They utilised the WHO questionnaire. 321 
possible stroke cases were identified, however stroke was only confirmed in 70 cases. The 
crude prevalence of stroke was 460/100,000 (870/100,000 and 770/100,000 adjusted to 
the WHO and SEGI World Population). The mean age of the patients at onset was 56 
years. Sixty percent of stroke survivors had a Rankin score of 2 or more, indicating that 
even mild cases of stroke were identified. Although numbers are small, this study 
demonstrates a higher prevalence than previously reported in SSA, highlighting the 
increasing burden that stroke represents. 
 
1.5.1.2.2.3.3 Stroke Incidence 
Comparing incidence rates of stroke worldwide is difficult due to differing definitions, 
methodology and data presentation. The importance of complete, community-based case 
ascertainment to include strokes managed outside the hospital is key [224].  
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The recent review article by Feigin et al [225] shows a divergent trend in stroke incidence 
rates over the last 40 years, with a 42% decrease in stroke incidence in high-income 
countries and a greater than 100% increase in stroke incidence in low to middle income 
countries. In 2008, the overall stroke incidence rates in low to middle income countries 
have, for the first time, exceeded the level of stroke incidence seen in high-income 
countries, by 20% [226-230]. These trends are more pronounced in the older age groups. 
 
Walker et al [213] performed the first rigorous study of stroke incidence in SSA. It is the 
only study to date to include community-based identification of stroke in the region, it 
provides reliable data on the incidence of stroke in rural and urban Tanzania. The Tanzania 
Stroke Incidence Project (TSIP) recorded stroke incidence in two DSS (one rural (Hai) and 
one urban (Dar-es-Salam)) over a 3-year period from June, 2003. The rural DSS is also the 
subject of this thesis. 
 
A robust system of stroke identification was put in place. Trained experienced 
enumerators (present in each village) reported cases of stroke to clinical officers. Stroke 
cases were then assessed by physicians experienced in the diagnosis of stroke utilising the 
WHO diagnostic criteria. Diagnosis was made by clinical examination and CT scan in the 
majority of patients. Several other methods of case ascertainment were used to maximise 
cases identified. Patients who died from stroke during the data collection period were 
identified via verbal autopsy and included in the incidence numbers. There were 636 
strokes during the 3-year period (453 in Hai (in a population of 159,814) and 183 in Dar-
es-Salaam (in a population of 56,517)). Overall crude yearly stroke incidence rates were 
94·5 per 100 000 (95% CI 76·0–115·0) in Hai and 107·9 per 100 000 (88·1–129·8) in Dar-es-
Salaam. When age-standardised to the WHO world population, yearly stroke incidence 
rates were 108·6 per 100 000 (95% CI 89·0–130·9) in Hai and 315·9 per 100 000 (281·6–
352·3) in Dar-es-Salaam. Incidence rose sharply after 65 year of age, with only one age 
band exception in Dar es Salam. Incidence for age bands 65-74, 75-84, 85+ were 568.2, 
1392.6, 1980.5/100,000 per year respectively in Hai and 2291.7, 3809.5 and 
2439.0/100,000 per year in Dar es Salam.  
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There were a number of weaknesses to the study which limit conclusions. Firstly the urban 
population was small particularly in the older age bands. Secondly there were some 
refusals to take part and this might have introduced selection bias.  
 
Overall this was a landmark study of incidence in SSA and prompts discussion about 
incidence variation through its easy comparison to the rest of the world's data. The 
reasons for the much higher incidence of stroke in Dar es Salam have been speculated by 
the authors. It is known from the literature that risk factors for stroke are higher in urban 
areas, particularly diabetes, hypertension and obesity [231, 232].   
 
A stroke register was set up in the 1970s in Ibadan, Nigeria, covering a population of 803 
000 [233]. The crude yearly incidence of first stroke was 25 per 100 000 for men and 13 
per 100 000 for women.  However, small numbers of staff and reliance on patients 
presenting to western style medicine mean that these incidence figures are likely to 
substantially underestimate the problem.  
 
Incidence rates of individuals presenting to hospital with stroke in Harare, Zimbabwe were 
studied by Matenga [234]. The crude annual stroke incidence was 31/100 000 (95% CI 27–
34). Standardised to the world population, the incidence was 68/100 000. The 
denominator of the whole population of Harare was used but only those who presented 
to hospital with their stroke could be identified so the nominator was likely to be an 
underestimate and the denominator approximate. .  
 
Rosman [235] estimated the incidence of stroke from hospital admissions in South Africa 
and found a crude incidence of stroke of 101 per 100 000 in a population aged 20 years 
and over. 
 
The incidence rates reported by Walker et al [213] are higher than those seen in the 
previous hospital-based studies described above. Such studies do not seem to be 
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representative of the whole population as they are a select sample who can afford to 
choose to consult western medicine. Any accurate stroke incidence study must take place 
in the community, the reasons for this are highlighted by previous studies of stroke 
mortality which shows that only 56% of people in the Hai DSS and 30% in the Dar-es-
Salaam DSS who die from stroke do so in hospital, clearly a substantial number do not 
present to hospital at all [236].  
 
In general studies from SSA do support an expected marked rise in incidence with age,  a 
property of an ageing population. The age-standardised incidence rates in the Hai DSS are 
similar to those seen in many methodologically rigorous studies of European and North 
American populations [225]. However, age-standardised incidence rates in Dar-es-Salaam 
were higher than seen in most studies in developed countries. 
 
The Northern Manhattan Stroke study [237] in the 1990s reported an incidence for those 
aged 20 years or older of 93 per 100 000 in white people and 223 per 100 000 for black 
people. Assuming there are no strokes in people under age 20 years, these rates 
correspond to about 66 per 100 000 for whites and 158 per 100 000 for blacks across all 
ages.  In comparison to the population screened by Walker et al [213] incidence rates in 
Hai were lower for those aged 75 years and under than in Northern Manhattan. In general 
stroke incidence rates in rural Tanzania were comparable with blacks in Manhattan, but in 
urban Tanzania the incidence rate is substantially higher.  
 
I have presented evidence that worldwide, the incidence of stroke has been decreasing, 
but this decrease is occurring in developed countries due to improved prevention 
measures. However it seems that incidence rates in developing countries have increased 
substantially, although more, reliable incidence studies are required from many world 
regions. The reasons for the higher incidence of stroke in urban areas of developing 
countries are not yet clear but seem to be key to the reasons behind increased incidence 
in these countries overall. It seems that risk factors (including hypertension) are probably 
to blame. Urbanisation in Africa, as in other parts of the developing world, is increasing 
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rapidly. Without urgent installation of stroke prevention measures, incidence rates in 
developing countries will continue to increase and it will not be long before the trend of 
overall incidence rates reverses and starts to increase again [213, 225, 238]. 
 
1.5.1.2.2.3.4 Stroke Mortality and Case Fatality 
Stroke mortality data can come from a number of sources, including hospital data, death 
certifications, GBDS, verbal autopsy data from demographic surveillance sites and 
epidemiological studies. Hospital based studies have not been included in this review 
because as previously mentioned these are unlikely to be representative of the general 
African community. Universally, a large proportion of patients with stroke are not 
admitted to hospital [224]. Other studies excluded from this review were those that 
produced unreliable data due to flaws in methodology [239-242]. 
 
1.5.1.2.2.3.4.1 Stroke Mortality 
SSA is undergoing a demographic transition; with this causes of death will not only alter 
from infectious to NCD but in addition the pattern of vascular disease and death will 
change from one dominated by haemorrhagic stroke to one dominated by cardiovascular 
disease, peripheral vascular disease and ischemic stroke.  
 
Death certification in high income countries provides easily accessible stroke mortality 
data, although it may not be very reliable [243]. Death certification is certainly unreliable 
in SSA with many stroke deaths going unreported, as there is no formal death certification 
system this method substantially underestimates stroke burden [244]. Death certification 
data that does exist does not use appropriate diagnostic criteria making results hard to 
interpret [245]. Despite this the Global Burden of Disease study (GBDS) use vital 
registration data, sample death registration studies (predominantly from urban hospital 
populations), epidemiological studies, and the newly developed cause-of-death model 
(Cod-Mod) for estimating cause of death in regions with little or no cause-of-death data. 
GBDS 2002 found infectious diseases and perinatal disorders dominated the causes of 
death in Africa, while non-communicable diseases dominated in high-income countries. 
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There were estimated to be 359 000 stroke deaths (3% of all deaths) in Africa compared 
with almost 1.5 million (16% of all deaths) in Europe. Stroke caused an estimated 52% of 
vascular deaths (deaths caused by either stroke or ischaemic heart disease) in Africa 
compared with 38% of vascular deaths in Europe[214-216]. 
 
Studies have demonstrated that through verbal autopsies cause of death data from SSA 
can be produced [246]. This involves interview with a family member to ascertain 
symptoms leading up to and therefore the probable cause of death. Specific stroke death 
data has been published from two sites in SSA; The Agincourt Health and Population Unit, 
Bohlabelo, rural north-east of South Africa[219] and the three DSS in Tanzania [236] (Dar 
es Salaam [urban], Hai [prosperous rural], and Morogoro [impoverished rural])comprising 
the Adult Morbidity and Mortality (AMMP) (the focus of this thesis is the Hai district DSS). 
The former reported a sensitivity and specificity of verbal autopsies for stroke to be 87% 
and 97%, whilst the latter reported 100% for both parameters [236, 247]. However these 
validation calculations were based on very small numbers (only twelve strokes in the 
Tanzanian study) and the gold-standard was clinical diagnosis which did not include brain 
imaging. 
 
The South African site found stroke caused 6% of all deaths in a population of 63 000 
between 1992 and 1995. Stroke was the commonest cause of death in the age 55–74 
years group, and the second commonest cause of death in the 75 years and over group. 
Important statistics when considering the age group focussed on in this thesis. The crude 
stroke mortality was 127 per 100 000 (95% CI 93–160) over age 35 years [247]. 
 
The large AMMP found that stroke caused 5.5% of adult deaths in a total population of 
307 820. Age-adjusted stroke mortality for individuals over age 15 years in the prosperous 
rural and urban regions in Tanzania were up to 3-10 times higher than in the England and 
Wales (when rates age adjusted to the Segi world population), particularly in the 15-64 
years age group, although this was not statistically significant[236].  
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One can conclude that age-specific stroke mortality in SSA is at least as high as in England 
and Wales [248], and perhaps higher in younger age groups, but larger and more reliable 
studies are required given doubt has been cast on the accuracy of verbal autopsy data in 
general [249]. However, verbal autopsies do provide the only detailed mortality data from 
SSA, and stroke is potentially one of the easier diagnosis to confirm. 
 
A dated community epidemiological study on stroke mortality occurred between 1975 and 
1980. It was a detailed 5 year follow-up of 4075 people aged 15–64 years in Accra, Ghana. 
Cause of death was determined from death certificates, inquiry from health care workers, 
and lay recorders. Stroke was found to cause 8% of all deaths [250]. Limitations of this 
study meant that this probably underestimated the number of stroke deaths; there was 
no validated method of diagnosing stroke included and an undetermined number of 
people died outside the area. 
 
1.5.1.2.2.3.4.2 Is stroke mortality changing in sub-Saharan Africa? 
Based on vital registration data, there was little difference between stroke mortality 
amongst developed and developing countries in 1950s. However since then mortality in 
developed countries has improved substantially. It appears that there has been an 
improvement in stroke mortality in South Africa at least but more information is needed 
from the rest of SSA to base conclusions on mortality transitions [216, 251-255]. 
 
Although mortality rates may be higher in SSA than in high income countries, the absolute 
numbers of deaths due to stroke remain low, explained by the population structure, 44% 
of the population are under 15 years of age, and only 3–6% over 65 years[246, 247]. 
However with demographic transition this will change [216, 243, 256-258]. 
It is worth noting that mortality rate is of course influenced by incidence rate and case 
fatality [243]. 
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1.5.1.2.2.3.4.3 Case Fatality Rates 
Between 2000 and 2008, early (21 days to 1 month) case fatality ranged from 17% to 30% 
in high-income countries and from 18 to 35% in low to middle income countries. Early 
stroke case fatality has decreased in both high-income and low to middle income 
countries over the past decade but is now 25% higher in the latter [225, 238]. 
 
As with any epidemiological data from SSA the most reliable is community based and 
prospective. However only one community based study of case fatality exists, therefore 
prospective hospital-based studies were also included in this review. Retrospective studies 
were deemed too unreliable because of missed data.  
 
The Ibadan stroke register (the only community based study)reports case fatality at 3 
weeks as 35% for all stroke and highest for cerebral haemorrhage and subarachnoid 
haemorrhage at 61% and 62% There were significant limitations to the conclusions made 
from this study as CT scanning was not always performed and follow up showed a huge 
drop out with only 24% of participants traceable at 3 months [259].   
 
Early total stroke case fatality (up to 1 month) derived from prospective hospital studies, is 
approximately 33% [234, 235, 260]. 
 
Only one study from The Gambia has used long-term follow-up over 4 years to determine 
case fatality, time to death, and likely cause of death [261]. This study included all patients 
admitted to hospital with a diagnosis of stroke or who had a stroke as an inpatient over a 
period of 1 year. Both first-ever and recurrent strokes were included and patients with 
subarachnoid haemorrhage were excluded. None of the patients had a CT scan. Patients 
were followed up at home or hospital at 1 month and 6 months and again between 3 
years and 4 years after their stroke. Case fatality in the 106 cases at 1 month and 6 
months and 4 years was 27%, 44% and 75% respectively. Less than 4% of patients were 
lost to follow up. There are limitations of this study, it is hospital based and therefore mild 
or very severe strokes are likely to be excluded, in addition CT scanning was not 
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performed and this does limit the accuracy of the diagnosis made. However it does allow 
comparison to world data and at one month case fatality is not much higher than 
worldwide studies (27% vs. 23% respectively) [238].  
 
One recent hospital-based study from Senegal [216, 262, 263] found a hospital case 
fatality of 29% at 1 month and 51% at 1 year in 170 patients who had had CT, was recently 
reported from Senegal. However the CT scans were done up to 1 month after the event 
and therefore interpretation of the results is difficult [264, 265].  
 
Stroke seems to be an increasing problem in sub-Saharan Africa. A study from Accra that 
investigated stroke admissions from the early 1960s to the early 1990s found a large 
increase in both admissions and fatality in the early 1990s compared with the 1960s; in 
the 1990s, stroke was the leading cause of death, accounting for about 17% of deaths on 
medical wards, and fatality range from about 42% to 50% over this time period [266]. 
 
1.5.1.2.2.3.5 Stroke Subtypes 
Mensah et al's review [267] observes that assessment of stroke subtype is very 
challenging in SSA mostly due to limited availability of neuro-imaging. In general, studies 
examining this problem are small and hospital based [235, 260, 268, 269]. In the limited 
number of studies that are available cerebral haemorrhage accounts for 26% to 33% [269]  
of strokes, higher than in developed countries [268].  Hypertension is the single most 
important reversible risk factor for stroke, particularly haemorrhagic stroke. This is 
demonstrated by Mating et al's[268] study of admissions with stroke to two teaching 
hospitals in Harare. Hypertension was present in 27 (93%) of the 29 patients with cerebral 
haemorrhage and in 49 (53%) of the 93 patients with ischaemic stroke [268]. Detection, 
treatment and control of hypertension in these patients was poor but is paramount to 
reduce stroke mortality in SSA [270].  
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As part of their TSIP Walker et al [213] performed one of the only studies examining the 
proportion of ischaemic vs. haemorrhagic strokes in the community in SSA. Diagnosis of 
stroke was confirmed by CT scan in 159 of 201 patients (102 of 132 from Hai and 57 of 69 
from Dar-es-Salaam) identified by the TSIP system. 64 of 132 patients from Hai had a CT 
scan done within 15 days of stroke onset: 11 had evidence of a haemorrhagic stroke, 52 
were normal or had evidence of stroke caused by cerebral infarct, and one had a 
subarachnoid haemorrhage. In Dar-es-Salaam, 17 of 69 patients had a CT scan done within 
15 days: three had evidence of a haemorrhagic stroke and 14 were normal or had 
evidence of stroke caused by cerebral infarct. CT head scan done more than 15 days post-
stroke is unreliable because of the potential to misdiagnose haemorrhagic stroke [241]. 
Within the subgroup of patients who had a CT scan within 15 days of stroke, Walker et al 
found a lower incidence of haemorrhagic stroke (17.2% in Hai and 17.6% in Dar-es-Salam) 
compared with ischaemic stroke than reported in previous studies of stroke in sub-
Saharan Africa [260, 271-273]. The percentages of strokes caused by haemorrhage and 
infarct were similar to those seen in studies in the developed world [211, 274]. However 
these conclusions have some limitations: The number of patients who had a CT scan 
within 15 days of stroke was small and potentially not representative. Patients, who died 
soon after stroke included in the numbers those not having a CT scan), might have been 
more likely to have had a haemorrhage. Despite its limitations this community based 
study is the best representation of the true picture of disease burden.  
 
1.5.1.2.2.3.6 The Epidemiology of Stroke in Summary 
The prevalence of disabling stroke in sub-Saharan Africa is potentially at least as high as in 
high-income areas although the overall prevalence of stroke (114–460/100 000) is lower 
(just under half that found in high income regions). 
 
Stroke incidence from hospital-based studies is lower than in community-based studies in 
high-income regions, but it is higher in people under 65, although it is not as high as in age 
matched African Americans. 
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Although the absolute number of stroke deaths remains low as a result of the population 
structure (44% of people are under 15 years of age), the age-adjusted stroke mortality 
among adults in sub-Saharan Africa appears rather similar to that occurring in high-income 
regions, and stroke mortality may have increased however accurate data is lacking. 
 
Although comparable community-based case-fatality studies are lacking, the available 
case fatality data from hospital studies reveal a rate of approximately 30% at 1 month 
higher than 20% in the comparable older population of the rest of the world.  
 
Community based incidence studies with follow-up are required to determine whether 
the low overall prevalence of stroke results from low incidence or high case fatality or a 
combination of the two. As risk factors for vascular disease increase, and the populations 
age, so the burden of vascular disease will certainly increase in SSA. Indeed, without 
intervention, stroke and heart-disease-related deaths in developing countries are 
expected to increase from 3 million in 1998 to 5 million in 2020 [216]. The burden of 
stroke is likely to become epidemic unless interventions are put in place. 
 
1.5.1.2.2.3.7 Disability After Stroke 
85 percent of patients survive immediately after stroke, with approximately 10 percent 
recovering almost completely, and 25 percent recovering with minor impairments. Thus, 
approximately 40 percent experience moderate to severe impairments that require 
special rehabilitative care. About 10 percent will require care in a nursing home or other 
long term facility. [275] 
 
Mathers et al estimate the Disability Adjusted Life Years (DALYs) for cerebrovascular 
disease as 72,024,000 DALYS worldwide, with the burden being very similar for females 
(36,542,000) and males (35,482,000). The burden is highest in East Asia and the Pacific, 
followed by South Asia, Europe and Central Asia. The burden in SSA is higher than in the 
Middle East and North Africa [159]. Corresponding to the anticipated increase in the 
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number of stroke cases will be an increase in the number of people with disabilities 
surviving after stroke in low-income countries[276]. 
 
1.5.1.2.2.4 Risk Factors for Stroke 
 Increasing age – particularly after 
55 
 Hypertension 
 Previous cerebrovascular disease 
 Ischaemic Heart Disease (IHD) 
 Atrial Fibrillation (AF) 
 Diabetes Mellitus (DM) 
 Peripheral Vascular Disease (PVD) 
 High Cholesterol 
 High plasma fibrinogen 
 Sickle cell disease (SCD) 
 Rheumatic heart disease (RHD) 
 Smoking 
 Alcohol 
 Obesity [75, 76, 277] 
 
1.5.1.2.2.5 Investigations for Stroke 
Blood tests are important post stroke to identify modifiable risk factors. 
 
Electrocardiogram (ECG) is also necessary to detect atrial fibrillation and if present 
instigate treatment and anticoagulation if possible [75]. 
 
Non-contrast computerized tomography is a reliable diagnostic tool which allows accurate 
differentiation between ischaemic and haemorrhagic stroke and excludes other causes of 
brain damage [13]. However, it is not always available (or affordable for patients) in 
developing countries. 
 
Further investigation such as carotid Doppler and echocardiogram (echo) can also be 
important in determining causation and secondary prevention [75]. 
 
1.5.1.2.2.6 Interventions for Stroke 
Several intervention strategies are available for stroke, but only a few can be applied in 
developing countries. 
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1.5.1.2.2.6.1 Population-Based Interventions  
Public health policies to address risk factors for stroke include tobacco, alcohol, dietary 
and lifestyle education and control. Public health programs to control rheumatic fever will 
reduce rheumatic heart disease and the subsequent risk of embolic strokes [276]. 
 
1.5.1.2.2.6.2 Personal Interventions 
Treatment strategies for acute ischemic stroke include; 
1. General management [276] 
 Good nursing care 
 Attention to complications:  
o Bronchoaspiration/pneumonia 
o Fluid and electrolyte imbalance 
o Control of blood sugar 
o Prevention of deep vein thrombosis (DVT) 
2. Specialised Stroke Units[276] 
Experience in developed countries suggests that specialized stroke units provide the best 
care for acute stroke patients [278], but in developing countries such units are impractical. 
3. Platelet antiaggregants [276].  
 Aspirin can prevent early stroke recurrence if given during the acute phase of 
stroke (within 48 hours) [279, 280] 
 Low dose of aspirin is optimal to ensure positive benefit/risk ratio [281].  
 When a CT is not available simple guidelines for the use of aspirin should be 
developed based on the Siriraj score to identify those very unlikely to have had a 
haemorrhage and who would therefore benefit from aspirin [210]. 
4. Thrombolytic therapy [276]. 
Tissue plasminogen activator and recombinant tissue plasminogen activator (rt-PA) gives 
clear benefits when given within 3 hours of the first symptoms in patients with cerebral 
infarction. (Number needed to treat to prevent one death or disability = 9) [282]. The 
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requirement for a CT scan within 3 hours and highly qualified staff precludes it use in most 
developing countries, including SSA. 
 
Secondary prevention after a Stroke or TIA [276] 
1. Risk Factor Management  
Hypertension, diabetes, high lipid levels, smoking, and alcohol use modification is 
beneficial both for primary prevention and prevention of recurrence of stroke/TIA. 
2. Platelet antiaggregants 
 Aspirin therapy is effective in preventing recurrence of stroke, with low daily doses 
being at least as effective as higher daily doses [281].  
 Antiplatelet combination therapy using agents with different mechanisms of 
action, such as the combination of extended release dipyridamole and aspirin, 
have been shown to reduce the risk of stroke over aspirin alone [283]. 
o Combination therapy with aspirin and clopidogrel offers no advantage over 
aspirin alone and also increases the risk of haemorrhage [284]. 
3. Anticoagulant therapy 
 Warfarin is clearly effective in preventing embolic strokes in patients with atrial 
fibrillation it should therefore always be considered and the risk/benefit ratio 
calculated [285, 286]. 
 Anticoagulant therapy should also be considered in rheumatic heart disease.  
 However, many developing countries lack the facilities to monitor anticoagulation 
therapy and prohibit its use. This puts many at increased risk of stroke. 
4. Surgical Treatment 
 In patients with symptomatic carotid disease with stenosis of more than or 
equal to 70 percent, carotid endarterectomy has been shown to be of benefit 
[287-289]. 
5. Rehabilitation 
Rehabilitation aims to restore as much independence as possible to stroke patients. 
Rehabilitation in a multidisciplinary stroke unit reduces deaths, disability, and care 
requirements [278], but such facilities are very low in number in developing countries. 
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Home-based rehabilitation services can have some benefits but these are reported to be 
modest [290]. They may however be the only short term solution in many low-income 
countries, where at present the majority of patients will be treated either at home or in a 
small community hospital with no rehabilitation service. Some stroke victims will be 
unable to seek help at all [276]. 
 
There is a gap between developed and developing countries in terms of stroke prevention, 
diagnosis, treatment and rehabilitation caused by the lack of trained specialists and 
expertise, lack of equipment, inadequate diagnostic evaluation and insufficient funds in 
resource-poor countries. Stroke research and training are grossly underfunded [13]. 
 
1.5.1.2.3 Epilepsy 
1.5.1.2.3.1 Definition 
Epilepsy: Recurrent (i.e. two or more) unprovoked seizures [291] 
Seizures: Discrete events caused by transient hyper synchronous, abnormal neuronal 
activity [75]. 
Provoked seizures: Occur during, or closely related with, an acute cerebral or systemic 
insult such as cerebral infection, head injury, stroke, metabolic disturbance, or alcohol 
withdrawal. They may be isolated or recurrent [75]. 
Unprovoked seizures 3 types: 
 Secondary or symptomatic epilepsy: A late consequence of an antecedent 
condition such as cerebral infection, stroke or head injury 
 Idiopathic: No clear antecedent aetiology but takes the form of particular 
syndromes with specific clinical and EEG characteristics 
 Cryptogenic: No obvious cause and does not fit a specific syndrome [75]. 
 
1.5.1.2.3.2 Classification 
Seizures should be classified according to the International League Against Epilepsy (ILAE) 
classification which separates seizures into partial, generalised and unclassifiable. The 
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standard definition relies on clinical and EEG criteria [292]. Modification of this allows 
classification on purely clinical grounds where investigations are limited and it is this 
modification that is routinely used for epidemiological research in resource poor settings 
and was used in this thesis [291, 293]. 
 
Partial (focal) seizures  
 Simple partial seizures – no alteration of consciousness 
 Complex partial seizures-alteration, or loss, of consciousness 
 Partial seizures evolving to secondary generalised seizures 
Generalised seizures – involvement of both cerebral hemispheres from onset  
 Absence seizures 
 Myoclonic seizures 
 Clonic seizures 
 Tonic seizures 
 Generalised Tonic-clonic seizures (GTCS) 
 Atonic seizures  
Unclassified epileptic seizures [291, 292] 
 
1.5.1.2.3.3 Risk Factors and Causes 
 Family History 
 Prenatal and perinatal: Obstetric complications, prematurity, low birth weight, 
neonatal asphyxia, neonatal seizures 
 Traumatic brain injuries 
 CNS infections: Neurocysticercosis, Malaria, Onchocerciasis and other parasites 
 Brain tumours 
 Neurodegenerative conditions 
 Stroke 
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1.5.1.2.3.4 Epidemiology 
The main focus of the critical review of the literature presented here will be the 
prevalence of epilepsy in SSA with brief discussion on the incidence of epilepsy as this is 
also utilised to reflect the burden of disease. However it is appreciated that any discussion 
regarding epilepsy in Sub-Saharan Africa would not be complete without mentioning risk 
factors, the treatment gap and mortality related to the disease and how they contribute 
to the burden of disease. These will therefore be briefly discussed. 
 
There is a lack of reliable data on the incidence of and prognosis for epilepsy in sub-
Saharan Africa but prevalence data demonstrate that epilepsy is two or three times more 
common than in industrialised countries. The high prevalence of epilepsy and low life 
expectancy indicate incidence is high. Relative contributions of causes of epilepsy are 
difficult to determine, only a few case-control studies have been done in sub-Saharan 
Africa. Data indicates that infections particularly cysticercosis, cause the majority of cases. 
Accurate causal studies are urgently needed to implement informed prevention 
programmes, increase detection and reduce societal burden. In addition there is a need 
for relatively low cost treatment and education initiatives to reduce the treatment gap 
and associated stigma respectively [294, 295]. 
 
1.5.1.2.3.4.1 The burden of epilepsy 
Epilepsy affects approximately 50 million people worldwide, with 80% residing in resource 
poor settings, the majority of which are in SSA [296, 297]. Epilepsy was estimated to 
account for 0·5%-1% of the global burden of disease, accounting for 7,307,975 disability 
adjusted life-years in 2005[13, 297, 298]. However these figures are flawed given they did 
not take into account the limited data from low-income countries [295].  
 
1.5.1.2.3.4.2 Biased or non-representative studies 
There are many estimates of the burden of epilepsy using hospital based studies, including 
2 recently published in northern Tanzania by the same group of authors. They conclude 
that epileptic seizures account for 3% of all hospital admissions and 27% of neurological 
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diagnoses made in hospital[299] and febrile seizures and epileptic seizures account for 
20.6% and 13.9% of admissions with impairment of consciousness respectively [300]. It is 
however difficult to extract meaning from these figures as the majority of the population 
in low income countries do not present to hospital for reasons related to geography, 
finance and health beliefs. Hospital studies are not considered further in this review.  
 
The non-representative nature of hospital data is highlighted by Quet et al. [54, 301] as 
part of the Limoges studies (detailed below). Many differences were found to be 
statistically significant between people with epilepsy (PWE) surveyed from the general 
population and PWE recruited from hospitals. They showed that hospital-based surveys 
leads to a selection of a PWE, which is not representative of the entire population. 
However, this can also be the case for some community based studies where surveys in 
remote areas, which may be affected by particular environmental or hereditary factors, 
can produce results that are difficult to extrapolate to an entire country.  
 
1.5.1.2.3.4.3 Difficulties collecting accurate epidemiological data from developing 
countries; the additional complexities that epilepsy presents 
As previously mentioned in this thesis, deriving accurate epidemiological data on the 
prevalence of any neurological disorder is difficult as it requires time consuming cross-
sectional surveys and medical records are incomplete and unreliable. As a result of 
methodological constraints and inconsistencies, epidemiological studies on epilepsy are 
difficult to compare. Screening questionnaires used to identify patients with epilepsy, 
cannot be used across different populations with diverse social or cultural backgrounds. 
The lack of specialised personnel, particularly in neurology, and the almost complete 
absence of diagnostic equipment (there are 75 EEGs and 25 CT scanners in tropical Africa), 
means that the accuracy of diagnosis cannot be confidently assessed. The Stigma related 
to epilepsy adds an extra complexity to the derivation of incidence and prevalence data as 
this prevents victim identification even when directly questioned. In addition most studies 
that have been performed have focussed on convulsive epilepsies, as they are the easier 
to detect reliably through the increased morbidity suffered by the patient. Unfortunately 
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as a result there are limited accurate estimates of non-convulsive epilepsies (difficult to 
accurately detect through simple questioning and clinical examination alone) and 
reported prevalence rates should be considered underestimates of the true burden of 
disease. The use of different terminologies to classify seizures and epilepsy also hinders 
study comparison. High income countries do not have such data collection problems and 
regular censuses, well established medical records systems and lack of stigma through 
education means collection of incidence and prevalence data is relatively easy [294, 295]. 
 
Preux and Druet-Cabanac [294] state multiple source analyses can also be used to 
complement door-to-door surveys, even this gold-standard may underestimate epilepsy 
burden. For example Debrock et al. [302] used multiple sources including a door to-door 
survey, medical registries, and interviews of key informants to estimate the prevalence in 
two villages (3000 inhabitants) in Benin. 50 patients were identified by the door-to-door 
method, the prevalence was therefore 15·9 per 1000 (95% CI 11·8–20·4). Key informants 
found 16 more PWE and prevalence rose to 21·1 per 1000 (95% CI 16·5–26·9). The 
capture-recapture method was then utilised and the prevalence was finally found to be 
35·1 per 1000 (95% CI 23·3–46·9), which shows that the door-to-door survey could have 
underestimated the true prevalence of epilepsy by up to 50%. 
 
Attempts to standardise epidemiological data on epilepsy: The Limoges questionnaire 
The best way to collect complete, prospective and standardised epidemiological data is 
the use of a standardised questionnaire and methodology. The Limoges questionnaire was 
just such a questionnaire, it was produced in 1994, it was created to detect epilepsy as 
part of a 2 phased survey, and has been employed since in various continents in tropical 
latitudes in order to produce a people with epilepsy (PWE) database. Its sensitivity and 
specificity have been reported as 95.1% and 65.6% respectively [301]. In Africa between 
1994 and 2004, 13 epidemiologic surveys in 12 countries were performed using this 
prescribed methodology. 7 of these (recruiting 1,118 PWE) were carried out in the 
community rather than the hospital population, (two cross sectional and five case control 
studies), 6 of these have been published. The location of these published studies was as 
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follows; Benin [302], Burkina-Faso [303], Burundi [304], Cameroon[305],  Mali [306],  
Central African Republic [307]. Further studies have been performed using this 
questionnaire since 2004, namely Crespin et al's [308] study in Benin. The prevalence 
data, when present, is detailed in the table below with specific reference that they were 
performed using the Limoges questionnaire. 
 
The use of such a questionnaire needs to be continued as it has been validated for use in 
SSA and it facilitates easy comparability of burden levels. The authors do acknowledge 
that it is a very lengthy questionnaire, much of which concerns generalised data not 
specific to the epilepsy prevalence. They therefore recommend that study coordinators 
identify which specific items of data they wish to collect (other than those for the 
diagnosis of epilepsy, which should be left intact). The authors do also state that to 
improve this questionnaire and its use, information on anti-epileptic drug (AED) use 
should always be recorded and new questions could be integrated to study socio-cultural 
aspects of epilepsies such as representations, stigmatisation, and quality of life. 
 
1.5.1.2.3.4.4 Incidence 
In a recent review and meta-analysis, the incidence of epilepsy ranged from 49 to 215 per 
100 000 people per year in five well undertaken studies in SSA which appears to be the 
extent of such studies in this region [294, 309].  
 
The demographic characteristics of the populations studied were similar but the methods 
were different. Two studies repeated cross-sectional surveys with an interval of 2·5 years 
in Uganda [310] and 3·5 years in Ethiopia [311]. The three others were retrospective and 
used the onset of seizures to estimate the average annual incidence over 5–10 years [312-
314]. The significant heterogeneity in the incidence of epilepsy in these studies can 
partially be accounted for by the different and sometimes biased (in the case of 
retrospective reporting) methodology. However this heterogeneity was also observed 
between the Ugandan and Ethiopian studies, it may be, therefore, in part at least, be a 
true reflection and could have  resulted from variations in risk factors: for example, the 
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highest incidence of epilepsy was reported from Uganda (twice that found in Ethiopia) in 
an area with a high prevalence of onchocerciasis. However this specific risk factor as a 
cause remains a unproven theory and  further research is required in this area [309]. 
 
Winkler et al's[315] more recent study demonstrated average yearly incidence rates to be 
81/100,000. However, again these results need to be interpreted with care as they are 
based on retrospective medical history only.  
 
Prospective studies including a register of epilepsy ascertained by a neurologist would give 
a more realistic estimate of the incidence of epilepsy in sub-Saharan Africa[294]. 
 
In general the annual incidences were high (49–215 per 100 000 inhabitants) compared 
with those found in industrialised countries in non-tropical areas (40–70 per 100 000 
inhabitants) [316].  
 
1.5.1.2.3.4.5 Prevalence 
The prevalence of active epilepsy in people of all ages from Europe and North America is 
5–8 per 1000 [317, 318]. Higher rates have been reported in studies from Asia, South and 
Central America and in particular from SSA. More data are available on the prevalence 
rather than incidence of epilepsy in low income countries, explained by the methods 
required to gain accurate epidemiological data in these regions, as described above. 
Prevalence estimates vary widely from country to country in SSA depending, in particular, 
on the methods used. Preux and Druet-Cabanac's 2005 review[294], only looked at door-
to-door surveys, acknowledging any methodology, other than the gold-standard, could 
lead to misleading results. The authors observed that studies with data from only medical 
registries or passive ascertainment systems gave lower estimates and a falsely reassuring 
picture of the true burden of disease. The median prevalence of epilepsy in SSA has been 
reported as 14-15/1000 with an inter-quartile range of 10-21 [294, 295].That is not to say 
that the rates were consistent, rates were highly varied from 5 to 75 per 1000, higher 
rates were seen in children and young adults, rural areas, and studies with small 
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population sizes. Therefore, the prevalence of epilepsy in the whole population of sub-
Saharan Africa cannot be generalised [294].  
 
1.5.1.2.3.4.5.1 Reasons for variations in the prevalence of epilepsy 
Wide variations in epilepsy could be due to; 
1. Differing definitions of epilepsy/The nature of epilepsy studied (lifetime vs. active, 
generalised vs. all cause) 
Most of the studies in SSA assessed only convulsive epilepsies. This exclusion of non-
convulsive seizures (along with under-reporting levels secondary to stigma) is said to 
underestimate the prevalence of epilepsy by two to four times[295, 319, 320]. Focal 
epilepsy seems to be more common in low income countries although comparison of the 
proportion of seizure types is difficult because of the different sources of epidemiological 
data and types of investigations [294, 321]. This conclusion is even in spite of the fact that 
many focal seizures are not detected in the surveys given the exclusion of non-convulsive 
seizures and the fact that there are few facilities for, and expert interpreters of, 
electroencephalography and neuro-imaging in poor regions [322]. The increased 
prevalence of focal epilepsy is likely to be secondary to the increased prevalence of risk 
factors that cause secondary epilepsy, which in turn may be more amenable to cure [295]. 
 
2. The differences in the samples of populations studied; a general vs. selected population, 
urban vs. rural 
Consistent findings from epidemiologic studies of epilepsy in developing countries 
including SSA indicate that the prevalence is higher in rural than urban areas of the same 
country [323-325]. The higher prevalence of epilepsy in rural areas might be caused by an 
increase in risk factors in these populations but may also reflect the fact that many people 
who develop epilepsy do not migrate to urban areas for work, or if they develop epilepsy 
whilst in urban areas, might lose their jobs and return to their rural homes [326]. 
 
 
141 
 
3. The methodological quality of the study: not allowing for stigmatisation and the quality 
of clinical assessment. 
The underreporting levels secondary to stigma and the exclusion of non-convulsive 
seizures may possibly underestimate the prevalence of epilepsy by two to four times[295, 
319, 320]. 
 
4. Risk factors 
In some sub-Saharan Africa areas, consanguinity is reported to be very high amongst 
epileptic patients, for example in some areas of Mali it is thought to be as high as 96% 
[306]. The stigmatization of PWE potentially forces them to intermarry thereby increasing 
the genetic transmission of epilepsy and prevalence rates in pockets of the community. 
 
The prevalence of epilepsy has been observed to be variable in the same country and 
ethnic community under the same methodology. Two Nigerian studies, used the same 
protocol to investigate two population groups from the same community living 20 km 
apart. They observed very different results 5.3/1000 in Igbo-Ora [25] and 37/1000 in 
Aiyété[327]. The researchers felt this highlighted the impact of risk factors on prevalence 
particularly sanitary conditions, neonatal infections and birth trauma. In contrast the 
prevalence may be very similar, as observed in Togo [314, 328-330]. 
 
Ngugi et al. [331] quantify that over 50% of the variation in the global estimates of the 
lifetime prevalence of epilepsy can be attributed to the differences between studies in 
rural and urban areas, between children and adults, and in the size of the denominator in 
the study  
 
The true prevalence of epilepsy in SSA is still hotly debated. A few large-scale studies 
showed prevalence nearer that found in industrialised countries. The question is; have 
these studies underestimated the prevalence because of non-ascertainment of cases or 
are the smaller scale studies misleading because of genetic influences of inbreeding and 
consanguinity, consequences of specific aetiological factors or over inclusion of provoked 
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seizures? There is also the possibility given the reasons outlined above, that this 
discrepancy lies in factors specific to different geographic zones in sub-Saharan Africa 
[294]. 
 
1.5.1.2.3.4.5.2 Critical review of the recent prevalence literature 
The section below discusses the recent prevalence studies in SSA in more detail and 
attempts to draw meaningful conclusions  from their data: 
 
Edwards et al [319] present the results of their very large study in a poor rural area on the 
coast of Kenya, which adds substantially to the data on the burden of epilepsy in SSA. The 
population represents the entirety of a demographic surveillance system with regular 
enumeration being performed every 4 months, eliminating bias. They assessed those 
people aged 6 years and older of which only 3% of the population were aged 65 or older. 
Their methodology was reasonably robust and standardised. They undertook a three 
phased study. The initial phase consisted of asking the head of the household 2 questions. 
Unfortunately the authors only present the sensitivity of these questions in children, but 
they do report this to be 100%, although it is not known how this conclusion was drawn. 
As discussed previously, surveys of the head of the household has its limitations compared 
with asking the patient themselves especially with a stigmatising condition like epilepsy. 
They then go on to state that there was a second screening phase, they do not report the 
qualifications of the screeners, and the details of the screening instrument were not 
included in the paper, instead the reader is directed towards a webpage. To their credit 
the sensitivity and specificity of the second phase is reviewed by re-examining a 
proportion of those who screened negative, this was found to be 94.8% and 52.3% 
respectively. Therefore although the sensitivity is reassuring about the prevalence figures 
presented the specificity may preclude replication of this study given the number of false 
negatives likely to be identified. The diagnosis made was unfortunately only clinical, but 
this does represent the majority of encounters in SSA and it was verified by a number of 
neurologists to add to its reliability. The standardised diagnostic criteria from the ILAE, 
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was used. The authors reported the prevalence of active convulsive epilepsy (non-
convulsive seizures were excluded from the prevalence figures.) 
 
The overall prevalence of active convulsive epilepsy was 2·9 per 1000 (95% CI 2·6–3·2); 
after adjustment for non-response and sensitivity of the questionnaire, prevalence was 
reported to be 4·5 per 1000 (4·1–4·9). Substantial heterogeneity was noted in prevalence, 
with evidence of clustering, this was thought to be due to environmental and genetic 
factors. The prevalence of those aged 50 and over was 2.1 (95% CI 1.7-2.7). Crude 
prevalence alone was presented, no attempt was made to age adjust and the distribution 
of population by age was not presented in full.  
 
The authors go on to describe the clinical and neurophysiologic features of patients with 
active compulsive epilepsy in a further paper in 2010 [332]. They found that: 
Approximately half of the 445 people with active compulsive epilepsy (ACE) were children 
aged 6 to 18 years. Seizures began in childhood in 78% of those diagnosed. Overall 71% of 
patients with ACE had evidence of focal abnormality. The authors conclude that: The 
predominance of focal features suggests that much of the epilepsy in this region has 
identifiable causes, many of which could be prevented [332]. 
 
Hunter et al [333] present the findings from their very large 2009 community based 
prevalence study performed in the same demographic surveillance site as is the subject of 
this thesis. Robust methodology supports their conclusions, although there were a 
number of limitations that the authors acknowledge and that will be explored below; 
 
The authors utilised a previously validated questionnaire which to their credit they 
validated again in a Tanzanian Kiswahili speaking population. Unfortunately this was only 
performed on a small number of cases and controls from a hospital population. They 
obtained a very favourable sensitivity of 100% but the specificity of 54.5% explained the 
time consuming nature of the work and how this study might be difficult to replicate.  
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A large and unbiased adult population of 103,026 were assessed using the gold standard 2 
phased methodology. Additional case finding methodology was also used to pick up cases 
which adds to the validity of the prevalence rates but calls into question the sensitivity of 
the questionnaire as a further 82 cases were found in this way. 
 
Seizure types and epilepsies were classified according to current recommendations 
of the ILAE and use of CT, EEG, and verification of cases by neurologists added to the 
robust nature of each diagnosis.  
 
The prevalence of active epilepsy in this population was estimated with age-
standardisation to the WHO standard population to allow ease of comparison to other 
world regions. Two hundred and ninety-one cases of active epilepsy, all with convulsive 
seizures, were identified. The age-standardised prevalence was 2.91/1000 adults (95% CI 
2.58–3.24); the crude prevalence adjusted for non-response was 3.84/1000 adults (95% CI 
3.45–4.20).The crude prevalence of those aged 60 years and older was found to be 
1.17/1000 (95% CI 0.66-1.68) 
 
Unfortunately the authors were not able to assess nearly one third of those who 
responded positively to the screening questionnaire, an inability to trace these individuals 
may be related to stigma and may indicate why the prevalence rate presented is low.  
 
Focal-onset seizures accounted for 71.5% of all cases identified. The high proportion of 
focal onset seizures indicates a large burden of acquired, and possibly preventable, 
epilepsy in this population. 
 
The key limitations of the studies by Edwards et al [319] and Hunter et al [333] that 
hamper comparison with other findings are the exclusion of people with non-convulsive 
epilepsy (non intentionally in the case of Hunter et al). In high income countries partial 
epilepsies (with focal onset) are more common than generalised onset epileptic disorders 
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or that account for at least account for 50% of all epileptic disorders [320, 334]. If this 
pattern also applies in Africa an estimated total prevalence would be 6-10 per 1000 
population.  
 
Winkler et al [315] performed a study of 7,399 people. They reported the prevalence of 
epilepsy using robust methodology in 2003-2004. The authors avoided bias by utilising 
random sampling and allowing for representation of villages of varying distances from a 
health centre. A previously validated questionnaire was used, modified  and validated 
further for their population. In hospital, clinic and community pilot studies they found it to 
have a high sensitivity and specificity of 92.5% and 97.5% respectively. The specificity was 
however substantially lower in the main study. The authors utilised standardised 
diagnostic criteria, however all diagnoses made were purely clinical but were performed 
by an experienced neurologist.  
 
The prevalence rates were age standardised to the WHO standard population to allow 
ease of interpretation. The prevalence rate of epilepsy was 11.2/1,000 (95% CI 8.9–
13.9/1,000) and the age-adjusted prevalence rate was 13.2/1,000. The prevalence rate of 
active epilepsy was 8.7/1,000 (95% CI 6.7–11/1,000), with an age-adjusted rate of 
9.1/1,000. The crude prevalence rate of active epilepsy for those aged 55+ was 6.0/1000. 
 
Prevalence rates of epilepsy were reported recently from 3 villages in Burkina Faso from a 
study conducted in 2007 of 888 individuals aged 7 years and over [335]. However due to 
the rather flawed methodology the results need to be interpreted with caution. The 
selection of villages was based on pig rearing practices and hearsay that the villages had a 
high prevalence of epilepsy and therefore the authors admit that the prevalence rates 
may not represent that from the rest of the country. 
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The authors used a previously validated questionnaire but it was not adapted for or 
validated in this community. They used the standard definition for epilepsy from the ILAE 
and utilised the two phased gold standard approach. A study physician, who was not a 
neurologist, confirmed or refuted the purely clinical diagnosis. 14/70 people who 
screened positive were not examined by the physician for various reasons, thus cases may 
have been missed.  
 
The lifetime prevalence of epilepsy was 4.5% (95% CI 3.3%-6.0%). Thirty-four (87.2%) of 
the 39 PWE had active seizures, giving an overall prevalence of 3.9% (95% CI = 2.8%; 5.4%) 
for active epilepsy. 
 
The main limitations were acknowledged by the authors as being; 
1. Biased selection of villages 
2. Stigmatisation of disease resulting in probable under-reporting 
3. Limited detection of non-convulsive epilepsy due to the methods used.  
 
The authors acknowledge that their estimates are higher than those reported in Burkina 
Faso study in 1993 (1.1%; 95% CI 0.9%-1.2%). The methodology of this study was more 
robust involving random selection of 18 villages in 2 provinces and therefore it may be 
that the former study's prevalence figures are more representative of the entire country. 
However it may also be that there is a true difference in prevalence of epilepsy between 
the investigated areas and the nearly 20-year time lapse between the studies. 
 
Crepin et al [308] not only performed a well executed community prevalence study in 
amongst 11,668 individuals in a rural area of Benin they also explored the relationship 
between epilepsy and malnutrition in the form of a case control study. Unfortunately the 
denominator population was achieved from a census that preceded the study by 3 years. 
A questionnaire (the Limoges) validated for detecting epilepsy in tropical countries was 
used but it was not validated further in this specific population. The entirety of a 
population was screened with a 94% ascertainment so no bias was produced through 
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sampling errors. The initial screen was performed by trained local physicians and 
confirmation of cases in the second phase was performed by a neurologist. Final diagnosis 
was purely clinical but took into account a collateral history and internationally recognised 
criteria. All types of seizures were included adding to the comparability of their results. 
The prevalence of epilepsy was 12.7/1000; 95% CI: 10.8 – 14.8. Most subjects with 
epilepsy had generalized tonic– clonic epilepsy. All, but one, had had at least one seizure 
during the last 5 years (active epilepsy). A certain degree of neurological impairment 
(abnormal mild neurological signs, cognitive impairment) was found in 26% of the 
subjects. Almost 82% had had their first seizure before the age of 20. The median number 
of seizures per year was 12. Both the high number of seizures per year and the fact that 
the majority of the cases were convulsive indicates that the prevalence of epilepsy may 
have been underestimated.  
 
Sims et al [336] performed a nationally representative population based survey of the 
prevalence of epilepsy in Rwanda of the whole population in 2005. They used random 
sampling across the country and screened 6757 people with an impressive 80.8% 
response rate. They did use a standard questionnaire but this was in the majority used to 
pick up musculoskeletal impairment and had only one question that related to epilepsy 
which had not been validated for this purpose. To their credit they did validate it partially 
by re-examining a further 10% of those who screened negative and reassuringly picked up 
no further cases. They used standardised diagnostic criteria, however a physiotherapist 
made the diagnosis on a clinical basis with no verification using investigation or expert 
review by a neurologist.  
 
Fifty-one people responded ‘yes’ to the screening question, and 47 of them (92%) were 
confirmed to have epilepsy based on follow-up questions, giving a prevalence of epilepsy 
in the screened population of 0.7% (0.5–0.9%). With a population of 8.44 million, this 
extrapolates to around 59,000 people in Rwanda affected by epilepsy [95% CI 42,000–
76,000]. Prevalence was adjusted to the European Standard Population. The overall age-
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adjusted prevalence was 0.6. For those aged 50 years and older the crude prevalence was 
4.7/1000. 
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Table 1.9: The Prevalence Data of Epilepsy from Sub-Saharan Africa Over the Last Thirty 
Years, Demonstrating its Heterogeneous Nature.  
Country (with 
reference below) 
Year N Prevalence 
per 1000 
(crude 
prevalence 
is 
presented 
unless 
otherwise 
stated) 
95% 
CI 
% age 
<20years 
Or more 
details on 
age if 
specified 
Population 
Benin (Agbogbome) 
[337] 
1995 
 
530 
 
24.5 10.9-
38.1 
 Rural 
Benin (Savalou) 
[338] 
1996 1443 15.2 8.7-
21.7 
 Rural 
Benin (Zinvie)* 
[302] 
2000 3134 33.5 22.3-
44.3 
 Rural 
Benin* 
[308] 
2007 11668 12.7 10.8-
14.8 
 Rural 
Burkina Faso 
[312] 
1993 16627 10.6 9.1-
12.2 
76.3 Rural 
Burkina Faso 
[335] 
2007 888 45.0 
Active 
epilepsy 
39.0 
33.0-
60.0 
 
28.0-
54.0 
 Rural 
Cameroon 
[339] 
1989 500 70.0 46.3-
93.6 
 Rural 
Cameroon (Bilomo)* 2000 1900 58.4 46.9-  Rural 
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[340] 69.1 
Ethiopia (Butajira) 
[341] 
1990 60820 5.2 4.6-
5.8 
59.8 Rural 
Ivory Coast 
[342] 
1988 1176 7.6 2.5-
12.7 
 Rural 
Ivory Coast 
[343] 
1990 920 59.0 43.0-
75.0 
 Rural 
Ivory Coast (M'Brou) 
[344] 
1995 2960 18.2 13.2-
23.2 
 Rural 
Kenya 
[345] 
1988 2960 18.2 13.2-
23.2 
50+  
2.1 (95% CI 
1.7-2.7) 
Rural 
Kenya 
[319] 
2003 151408 2.9 2.6-
3.2 
Populations 
aged 6+ 
years. 
3% aged 
65+ years. 
Prevalence 
those aged 
50+ 2.1 
(95% CI 
1.7-2.7) 
Rural 
Liberia 
[346] 
1983 4436 28.0 23.0-
33.0 
 Rural 
Madagascar 
[347] 
2001 925 20.8 11.3-
30.3 
 Urban 
Mali* 
[306] 
2000 5243 15.6 12.2-
19.0 
 Rural 
Nigeria 
[99] 
1989 2925 6.2 3.3-
9.1 
 Rural 
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Nigeria (Aiyete) 
[25] 
1982 903 37.0 24.2-
49.8 
 Rural 
Nigeria (Igbo-Ora) 
[327] 
1987 18954 5.3 4.2-
6.4 
 Urban 
Rwanda 
[336] 
2005 6757 7.0 
Adjusted 
to 
European 
population 
6.0 
5.0-
9.0 
Prevalence 
of those 
50+ years 
4.7 
Urban and 
Rural 
Senegal 
[348] 
1986 7682 8.3 6.2-
10.4 
 Rural 
Senegal 
[349] 
1996 2903 21.0 15.5-
26.5 
 Rural 
Tanzania 
[313] 
1992 18183 10.2 8.7-
11.7 
 Rural 
Tanzania 
[294] 
1999 4905 8.6 6.0-
11.1 
 Rural 
Tanzania 
[315] 
2003-
2004 
7399 Crude 11.2  
Age-
adjusted 
13.2 
Crude 
active 
epilepsy 
8.7 age-
adjusted 
rate of 9.1 
crude 
prevalence 
8.9–
13.9 
Prevalence 
of those 
55+ years 
6.0 
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rate of 
active 
epilepsy 
for those 
aged 55+ 
was 6.0 
 
Tanzania 
[333] 
2009 103026 Age 
adjusted  
2.9 
Crude 2.8 
Crude 
adjusted 
for non 
response 
3.8 
(2.6-
3.2) 
 
(2.5-
4.0) 
 
 
 
(3.5-
4.2) 
Crude 60+ 
1.2 (0.7-
1.7) 
Rural 
Togo (Akebou) 
[328] 
1996 4182 13.1 9.6-
16.6 
 Rural 
Togo (Kloto) 
[314] 
1991 19241 12.3 10.7-
13.9 
 Rural 
Togo (Kozah) 
[329] 
1989 5264 16.7 13.1-
20.3 
 Rural 
Togo (Tone) 
[330] 
2000 9143 18.6 15.7-
21.5 
 Rural 
Uganda 
[350] 
1996 4743 13.0 9.7-
16.3 
 Rural 
Zambia (Chikankata) 
[351] 
2004 55000 12.5 11.5-
13.5 
 Rural 
*Those studies utilising the Limoges questionnaire 
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1.5.1.2.3.4.5.3 The potential of prevalence to underestimate burden due to high 
mortality 
Although the prevalence of epilepsy is two to three times higher in low income countries 
in comparison to high income countries, it is not as high as the incidence would suggest. 
This discrepancy is probably because mortality from epilepsy is substantially higher in the 
former although cure from resolution of secondary epilepsy (which is also more common 
in low-income countries) is also a possibility [295]. In high income countries mortality in 
PWE (as measured by the standardised mortality ratio [SMR]) is two to three times that of 
the population without epilepsy after adjustment for age [352]. The ratio is markedly 
higher in low income countries; however, only limited data are available, and what is 
available is based on very small numbers. In Uganda, the SMR is as high as 7·2, although 
this calculation was based on only 18 deaths [353]. In Ethiopia, the crude mortality in 
patients with epilepsy was 31·6 per 1000, twice the mortality rate estimated in people 
without epilepsy which was 16·4/1000 [311]. This observation was based on 20 deaths in a 
population of 316 patients in 2 years. 
 
There is very little information on long-term follow-up of PWE, however the 2 studies that 
have been performed found PWE had a significantly increased risk of death. Jilek-Aall and 
Rwiza [354] performed a 30-year follow-up of 164 patients in an outpatient clinic in rural 
Tanzania. They reported mortality in PWE as 2 times the general population and that 
treatment significantly reduced the number of deaths due to epilepsy-related events. 
 
In Cameroon Kamgno et al [355] found that 128 PWE had a six-times greater risk of dying 
than controls, but most of the patients did not receive appropriate and regular treatment. 
 
In conclusion the mortality associated with epilepsy in low-income countries is 
substantially higher than in high-income countries. In the majority this is felt to be a 
consequence of untreated epilepsy however this is another under-researched area [295]. 
Mortality will hopefully decrease as effective treatment for epilepsy becomes widespread. 
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It is not only the chronic management of epilepsy that is fundamental but also the 
management of epileptic emergencies such as status epilepticus as demonstrated by the 
recent article by Mpimbaza et al with commentary from Herman [356]. 
 
1.5.1.2.3.4.6 Risk Factors 
The literature reports that the main contributor to the increased prevalence of epilepsy in 
low income countries in comparison to high, is the higher number of risk factors e.g. 
infections such as, neurocystercercosis, onchocerciasis, falciparum malaria, meningitis, 
encephalitis and opportunistic infections related to HIV, trauma, particularly head injury 
related to road traffic accidents, falls and violent attacks, prenatal and perinatal injury, 
malnutrition, brain tumours and genetic factors.  
 
The majority of studies that assess risk factors for epilepsy are purely descriptive in nature 
and therefore the contribution that each of the risk factors represents is difficult to 
measure as the evidence is often purely circumstantial [294]. 
 
There have been a few case control studies in SSA providing more than inferred 
relationships between each of the risk factors specifically prior febrile seizures [357-359], 
family history [304, 359], head injury [357, 358], perinatal complications [304, 359], CNS 
infections[359], Onchocerciasis[360], Cysticercosis [304, 360]. However, a high proportion 
of the case control studies did not find a cause [305-307]. 
 
A more recent nested case–control study was performed by Edwards et al[319], the 
factors associated with increased risk for convulsive epilepsy in adults and children were 
family history of febrile or non-febrile seizures and head injury. In children aged 6–18 
years, adverse perinatal events and their mother being a widow were potential risk 
factors. 
 
All studies had small numbers with limited power to detect any differences between 
cases, control and methodological bias as other variables were not considered. The true 
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impact of each specific risk factor still needs to be assessed in more detail. Many of these 
risk factors can be prevented with inexpensive interventions yet few studies have 
focussed on the impact of risk factor reduction, there is need for research and follow up 
action in this area [295]. 
 
The need for more research is supported by Winkler et al's recent review article [361]. 
They claim that neurocysticercosis (NCC) accounts for 30-50% of acquired epilepsy in SSA; 
their recent case controlled imaging study demonstrated definitive and probable NCC in 
14% of epileptic cases in comparison to only 2% in the control group. The study was 
potentially open to bias,  a hospital population may have more severe epilepsy than a 
community epileptic population and the control group, also from the hospital and imaged 
for another reason, were potentially from a wealthier cohort than average and therefore 
would have less exposure to taenia solium. The authors conclude that NCC is the most 
important cause of secondary epilepsy in SSA and feel that identification of cases through 
appropriate diagnostic tools (specifically serology and neuro-imaging) followed by 
appropriate treatment is urgently required. Further prevention of this disease would 
significantly reduce the epilepsy burden.  
 
However Pal et al [362] in their article "Neurocysticercosis and epilepsy in developing 
countries" conclude that for both neurocysticercosis and epilepsy, there is a dilemma 
about whether limited public resources would better be spent on general economic 
development, which would be expected to have a broad impact on the health and welfare 
of communities, or on specific programmes to help individual affected people with 
neurocysticercosis and epilepsy. The approaches require detailed economic evaluation 
and comparison. 
 
Neurocysticercosis is however unusual with respect to the clinical management 
conundrum that it represents. The other causative infections appear to be more 
straightforward with the general message being prevention and cure of neuro-infections, 
should be the priority in the fight against epilepsy in SSA. In her recent article Singhi [363] 
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concludes that central nervous system infections and epilepsy are the main cause of 
seizures and acquired epilepsy worldwide and that prevention of CNS infections is the only 
definitive way forward to reduce the burden of epilepsy in developing countries.  
 
1.5.1.2.3.4.6.1 Malnutrition and Epilepsy 
Crepin et al[308] compared malnutrition rates in PWE with controls in Benin in 2005. 
Standard diagnostic criteria were used for epilepsy and for malnutrition and controls were 
age and sex matched although it was not possible to match for poverty and sanitary 
facilities. The investigators were not ‘blinded’. 
 
A total of 131 cases and 262 controls were included. This failed to reach the minimum 
estimated number of subjects required but achieved sufficient power due to a higher than 
expected malnutrition odds ratio. The authors found that malnutrition was significantly 
more frequent in cases than controls (crude pOR=2.9; 95% CI: 1.6-7.4) (crude prevalence 
22.1% vs. 9.2%, p = 0.0006). Feeding difficulties were more frequent and health status was 
worse in cases. Because problems relating to malnutrition might be secondary to feeding 
difficulties due to cerebral palsy, cognitive impairment, head injuries, or a history of 
cerebral malaria, these co-morbidities should have been accounted for but were not.  
 
The authors found an association between epilepsy and nutritional status but no inference 
can be made about the direction of this association because of the study design (cross-
sectional study sampling on prevalent epilepsy status correlated with prevalent 
malnutrition). The best design for the study would have been a cohort study in order to 
test one direction of the hypothesis (malnutrition as the exposure factor or epilepsy as the 
exposure factor) but this kind of study is more difficult to carry out in a developing 
country. It is difficult to establish the direction of the link between epilepsy and 
malnutrition in developing countries because the few studies on this relationship that 
have been published have conflicting methodologies Further, conclusions disagree on the 
direction of this link. 
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In conclusion additional differently designed studies, such as a cohort study, need to be 
done to further clarify the direction of the association between malnutrition and epilepsy. 
However Crepin et al's [308] study does suggest that it is important to pay attention to the 
nutritional status of people with epilepsy in order to implement global programs to fight 
against this condition.. 
 
Earlier studies using the Limoges methodology have also shown an association between 
epilepsy and malnutrition but have found this to predominate in children rather than 
adults, it is not known if this is a result of improvement of nutrition or death in childhood 
[301].  
 
1.5.1.2.3.4.6.2 Age and epilepsy 
There is a marked difference in the age of onset of epilepsy in low income countries in 
comparison to high. The latter has a bimodal distribution with peaks of incidence in 
childhood and those aged over 65 [316]. In the former it is generally understood that 
incidence is increased in children and young adults. Age at seizure onset is reported in few 
studies, but is usually susceptible to recall bias. When available, seizure onset was before 
age 20 years in more than 60% of cases. This young incidence results from the initial 2 risk 
factors presented above, infection and trauma. However it is worthy of note, especially for 
this thesis with its focus on the older population, that studies in the older age groups are 
limited. As the population of developing countries continue to age and the prevalence of 
NCDs such as stroke increases as will the burden of epilepsy in these age groups, again 
demonstrating the impact that the "double burden" of disease will have on SSA [25, 295, 
311, 327, 341]. 
 
1.5.1.2.3.4.7 Treatment of epilepsy in SSA and reducing the treatment gap 
It is estimated that up to four-fifths of the potential market for anti-epileptic drugs (AEDs) 
is in low-income (LI) and lower middle income countries (LMICs).The proportion of PWE 
who require treatment but who are not receiving it is known as the treatment gap (TG) 
[364]. Substantial global disparities in the epilepsy treatment gap were identified by 
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recent systematic reviews that show that 60-90% people with epilepsy in low-income 
countries and fewer than 10% in high-income countries were untreated or insufficiently 
treated for their epilepsy [295, 365-368]. 
 
Studies using the Limoges protocol found the TG to be 55.7% (95% CI 52.7–58.7), this was 
identified by simple questioning which may be unreliable[301]. 
 
In northern Tanzania more than three quarters (75.9%) of the people with epilepsy 
identified through a community based study did not take antiepileptic drugs (AEDs), 
despite proximity to a hospital that stocked them [315]. Another study from northern 
Tanzania reported the TG to be 68.4% (95% CI 63.0–73.7) [333]. In the Gambia, the 
continuous treatment rate in PWE was less than 10% [369]. In the Kilifi district of Kenya 
the TG has recently been reported to be 62.4% (95% CI 58.1–66.6)[364, 370]. In Rwanda it 
was found that 41% had or were currently receiving treatment and 38% had been to a 
traditional healer [336]. In Benin only 42% of patients took antiepileptic treatment at the 
time of the study and this included traditional treatment (54% of cases were on 
phenobarbitone, 39% on traditional treatment, and 7% on both traditional and modern 
treatment) [308]. A study from Senegal, however, shows a narrower TG with 23% of 
patients not receiving adequate treatment [371].  
 
Even if patients are supposedly on treatment in SSA, in the majority this may not be 
optimal. In an urban zone of Nigeria only 30% of patients were seizure-free after 2 years 
of treatment [372]. Factors contributing to this low remission rate were poor treatment 
compliance and a history of six or more seizures before treatment onset. This 
demonstrates that the identification of treatment gap requires more than questioning  a 
patient if they are on treatment, as is done in the majority of studies..  
 
Information on individual compliance with AEDs is usually gathered just by asking the 
patient and was done in this manner in all the studies described above except for the one 
in the Kilifi district of Kenya. Recognising that self-reported drug adherence is heavily 
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biased Mbuba et al [370]also measured the presence or absence or AEDs in the blood. 
They found that that sensitivity and specificity of self-reported adherence compared with 
AEDs detectable in the blood was 38.1% (95% CI 31.1–45.4] and 80.8% (76.0–85.0) 
respectively. They state that assessment of adherence to treatment calls for an objective 
measure, like AED levels in the serum, although they appreciate how difficult this is in the 
majority of clinical encounters in SSA. They found the TG as defined by the presence of 
therapeutic levels of AEDs in the serum was 70.3% (65·9–74·5) (92% of PWE agreed to 
have their blood taken). Mbuba et al's study has its own limitations;  
 
1. Compliance is typically characterised by highly variable AED serum concentration, which 
increased after supervised drug intake, this would require more than one blood test and 
would be even more difficult to perform in SSA.  
 
2. It is not known what the normal therapeutic range of AEDs are in an indigenous African 
population and the study presumes them to be the same as a white population which 
might not be correct, particularly as malnutrition and protein deficiencies might influence 
concentrations.  
 
3. Drugs with a long half life might still be detectable in the serum long after medication 
has actually been taken.  
 
Derivation of a true objective surrogate measure for the epilepsy TG could prove very 
difficult in resource-poor countries, but remains an important goal if the TG is to be 
identified and closed.  
 
The TG has been found to be typically twice as high in rural areas in comparison to urban 
areas, this is presumed to be because medical infrastructure, resources, and personnel are 
largely focused in urban regions [323-326]. 
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The general message for the treatment of epilepsy in SSA is that there is an urgent need to 
reduce the TG by modification of the factors that contribute to it; these are mainly two 
fold access to healthcare and  adherence to treatment. Both of  these were expanded in a 
recent systematic review, and were (in order); 
 
1. Inadequate skilled manpower 
2. Cost of treatment 
3. Unavailability of medications 
4. Cultural beliefs about the causations 
5. Use of traditional medicine 
6. Distance from the health centre 
7. Stigma attached to taking anti-epileptic medication [364] 
 
These factors all need to be addressed as part of government initiatives [300, 373]. 
 
The recent study performed by Mushi et al [374] concludes that poor knowledge and 
strong cultural and religious beliefs characterise the experience of PWE in SSA. Epilepsy-
related stigma contributes to overall disease burden, and PWE face many degrees of 
exclusion. There is a need to educate communities and change attitudes. 
 
These studies highlight that any epilepsy treatment programme needs to be about more 
than just the distribution of drugs; it is also fundamentally important to address lack of 
knowledge in patients, communities and healthcare workers. 
 
1.5.1.2.3.4.7.1 Treatments available in SSA 
It is the older AEDs that are available in the majority of low income countries, namely 
phenobarbital, phenytoin, carbemazepine, and sodium valproate, over 70% of patients 
will respond to one of these AEDs [375].  
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The cheaper of these drugs, phenobarbital and phenytoin are available in SSA and have 
been the focus of programmes to reduce the TG. They are not however without their 
problems, e.g. side-effects and interactions to other drugs used to treat co-morbidity such 
as HIV [376, 377].  
 
Chisholm and Saxena's [378] recent article explores cost effective strategies to combat 
neuropsychiatric conditions in sub-Saharan Africa and South East Asia, they performed 
simultaneous evaluations of the cost effectiveness of 44 individual or combined 
interventions for five key neuropsychiatric conditions. They established that alcohol 
control measures and drug treatment for epilepsy and depression were the most effective 
and proposed that these should be the focus of neuro-psychiatric treatment campaigns.  
 
1.5.1.2.3.4.8 The epidemiology of epilepsy in summary 
Epilepsy in SSA is a disorder with high prevalence and incidence, severe prognosis in terms 
of morbidity and mortality, and a strong link to infection. The burden of epilepsy can be 
reduced in poor parts of the world by alleviating poverty and by reducing the preventable 
causes, namely perinatal insults, parasitic diseases, and head injuries. Education of 
medical professionals, particularly primary healthcare workers and local communities is 
fundamental to address the diagnosis and treatment gap and reduce stigma.  
 
Reviewing the literature highlights the need for further studies, with good methodological 
design and standardised questionnaires. General population surveys with a sufficient 
number of participants should be prioritised, and population groups not previously 
focussed on, like the elderly should be highlighted. Longitudinal studies are also needed to 
better estimate incidence, morbidity, mortality and causation.  
 
1.6 Epidemiology of "All Cause" Neurological disorders 
It is fundamental to know about the prevalence of Neurological Disorders as ever-
increasing demand for health services forces health planners to make choices about 
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resource allocation. Information on relative burden of various health conditions and risks 
to health is an important element in strategic health planning [13]. 
 
The WHO’s Global Initiative on Neurology and Public Health highlights the paucity of 
information about the prevalence and burden of neurological disorders and a lack of 
policies, programmes and resources for their treatment and management [379].  
 
There are few publications from SSA in international journals of neurology and 
international collaboration is often relied upon to forward research in this area. The WHO 
acknowledges the fact that there is a vast gap in the knowledge concerning the public 
health of neurological disorders. Their 2006 document entitled ‘Neurological Disorders: 
Public Health Challenges’ provides the public health perspective for neurological disorders 
in general and presents updated estimates and predictions of the global burden. Their 
figures are however estimates and predictions and worldwide prevalence data are lacking 
[13]. 
 
With awareness of the massive burden associated with neurological disorders came the 
recognition that neurological services and resources were disproportionately scarce, 
especially in low income and developing countries. Furthermore, a large body of evidence 
shows that policy-makers and health-care providers may be unprepared to cope with the 
predicted rise in the prevalence of neurological and other chronic disorders and the 
disability that results from the extension of life expectancy and ageing of populations 
globally [380]. The neurologist-population ratio in African countries varies from 1 per 
162,885 persons to none in 11 countries, compared with 1 per 29,200 in the US [11].  
 
In response to the challenge posed by neurological disorders, WHO launched a number of 
global public health projects; these include the Global Initiative on Neurology and Public 
Health whose purpose is to increase professional and public awareness of the frequency, 
severity and costs of neurological disorders and to emphasize the need to provide 
neurological care at all levels including primary health care. This global initiative has also 
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highlighted the paucity of information on the burden of neurological disorders but in 
addition has demonstrated the lack of policies, programmes and resources for their 
management [379, 381, 382]. Limited workforce, poor equipment and little research 
blight SSA's ability to cope with neurological disorders. Capacity needs to be built in 
research, diagnosis and treatment of neurological diseases which will undoubtedly require 
education of the primary healthcare workforce [383].  
 
In response to these findings, WHO and the World Federation of Neurology (WFN) 
recently collaborated in an international Survey of Country Resources for Neurological 
Disorders involving 109 countries and covering over 90% of the world’s population. The 
survey collected information from experts on several aspects of the provision of 
neurological care around the world, ranging from frequency of neurological disorders to 
the availability of neurological services across different countries and settings. The 
findings highlight the inadequacies and inequalities for patients with neurological 
disorders worldwide (especially in SSA) including access to healthcare [384, 385].  
 
This prevalence study aimed to identify a complete list of neurological disorders as 
defined by the WHO ICD 10 (see figure 1.1); 
 
The diagnostic criteria  and epidemiology of the most common and public health relevant 
conditions namely, tremor, parkinsonism, cerebellar disorders, headache, stroke and 
epilepsy have been described in full as these have been highlighted as particularly 
burdensome by the WHO and the WFN in their most recent publications. [13, 384, 385]. 
 
This prevalence study also aimed to identify, dyskinesias, motor neuron disease, spinal 
cord dysfunction including injury, infection resulting in CNS dysfunction, 
polyneuropathies, nerve, nerve root and plexus disorders and inflammatory/infectious 
diseases of the PNS e.g. polio and leprosy.  A more superficial review of the diagnostic 
criteria and epidemiology of these conditions has been included in appendices 1.2 and 1.3. 
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In this part of the literature review, I focussed on community based epidemiological 
studies that investigated the prevalence of "all-cause" neurologic disease in SSA. Due to 
lack of up-to-date data from SSA I have included robust community based epidemiological 
studies from other developing countries. Worldwide review articles were included. and 
references listed in relevant publications examined.  The data from the GBDS was also 
utilised. 
 
It is justified to review most of the literature from SSA and exclude other world regions 
because of the following factors; 
 
Despite diverse socioeconomic and environmental factors, there are many common traits 
across SSA, namely: 
 The wide-based age-specific pyramid with high fertility and mortality and short life 
expectancy. Over 680 million people live in sub-Saharan Africa, more than half are 
under age 15 years. Life expectancy was 45·8 years in 2002 and the mortality of 
children under age 5 years was 164·2 per 1000 
 Mainly rural populations despite rapid urban migration 
 Widespread poverty and unequal distribution of the health services. Only 46·4% of 
the rural population have access to drinkable water and 55% have access to 
sanitation facilities. These extreme conditions of poverty facilitate the transmission 
of parasitic and bacterial infections. 
 The absence of sound infrastructures for collection of epidemiological data.  
 
A review at this almost continental level is justified because the lack of studies limits 
analysis at a sub-regional or country level. Data from SSA differ from those gathered in the 
north of Africa probably due to lower rates of infectious disease and better medical 
infrastructures [294].  
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1.6.1 The Global Burden of Disease Study and its ability to reflect the burden of 
neurologic disease in SSA 
The Global Burden of Disease Study (GBDS) has recently produced evidence that pinpoints 
neurological disorders as one of the greatest threats to public health, highlighting that 
unless immediate action is taken globally, the neurological burden is expected to become 
an even more serious and unmanageable problem in all countries[7, 13]. 
 
The Global Burden of Disease study (GBDS) is the on-going international collaborative 
project between the WHO, the World Bank and the Harvard School of Public Health which 
started in 1993 by carrying out a study to assess the global burden of disease for the year 
1990. The methods and findings of the 1990 GBD study have been widely published [7, 
386, 387]. The GBD approach is one of the most widely used frameworks to provide 
information on population’s disease burden. The GBD framework is based on the use of a 
common metric and mathematic model (DisMod) to summarize the disease burden from 
diagnostic categories of the WHO ICD in order to prepare consistent estimates of 
incidence, prevalence, duration and mortality [388]. A time based metric was designed 
that measures both premature mortality (years of life lost because of premature mortality 
or YLL) and disability (years of healthy life lost as a result of disability or YLD, weighted by 
the severity of the disability). The sum of these two components, disability-adjusted life 
years (DALYs), provides a measure of the future amount of healthy life (years expected to 
be lived in full health) lost as a result of the incidence of specific diseases and injuries [7]. 
One DALY can be thought of as one lost year of healthy life. Neuropsychiatric disorders 
were concluded to be major causes of lost years of healthy life as measured by DALYs, and 
were significantly underestimated when measured by mortality alone [7]. 
 
As a follow-up to the 1990 GBDS, WHO undertook a new global assessment of the burden 
of disease for the year 2000 and subsequently in 2002. The GBDS 2000 drew on a wide 
range of data sources to develop internally consistent estimates of incidence, prevalence, 
severity, duration, and mortality for over 130 major diseases, for 14 epidemiological sub 
regions of the world [159]. 
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There is limited epidemiological data that addresses the burden of "all-cause" neurological 
diseases in SSA. There is a scarcity of community based prevalence, incidence and 
mortality studies. This is evidenced by the GBDS where data on adult mortality was absent 
in 42 of the 53 countries [389]. However despite these limitations the GBDS makes the 
following estimations that outline the impact of neurological disease: Neurologic disorders 
affect 250 million people in the developing world, this number is expected to increase as 
the infectious burden of disease (HIV and malaria contribute significantly to neurologic 
disease burden) is coupled with the NCD epidemic and the ageing population [390],[391]. 
The leading causes of disability as indexed by DALYs in Africa include primary neuro-
psychiatric disorders, and infectious and cardiovascular diseases with neurologic 
implications [389]. In 2005 6.29% of DALYS were attributed to neurological disorders 
worldwide, this is projected to increase to 6.39% in 2015 and subsequently to 6.77% in 
2030. Half the burden of the DALYs is attributed to cerebrovascular disease, 12% to 
Alzheimer’s disease and other dementias, 8% to epilepsy and 8% to migraine. When this is 
divided up and expressed as an overall percentage, dependent on the countries income, it 
is projected to be higher in high income countries, 10.9% in comparison to 4.5% in low 
income countries. However DALYS per 100,000 are highest for neurological disorders in 
lower middle and lower income countries at 1514 and 1448/100,000 in 2005 respectively. 
Neurological Disorders account for 12% of total deaths, of which 85% are due to 
cerebrovascular disease. This is also projected to increase from 2005 to 2030. YLDs are 
projected to be 14% in 2005 and still be 14% in 2030 [30]. 
 
The use of the GBDS in SSA is weakened by a number of factors; much of the data is 
extrapolated from South Africa to the rest of SSA, arguably a very different socioeconomic 
population, the rest of the data is based on very few poor quality studies and 
consequently inaccuracies result. Relevance and accuracy of data is very important in 
programme planning, understanding of disease process including the role of risk factors. 
Calculation of burden of risk factors based on inappropriate models will result in 
misdirected disease-prevention strategies. However in the absence of other information, 
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it is appropriate to use model based estimates as nothing else exists. However such 
estimates are not effective monitoring devices and therefore quality data collection on 
adult health in SSA is required [392, 393]. 
 
In conclusion, Neurological Disorders represent a much higher burden than digestive 
disease, respiratory disease and malignant neoplasms when measured using the GBDS. 
They are a serious threat to public health. Most burden is in low and low middle income 
countries and strategies to improve world health should concentrate on this issue [30]. 
 
1.6.2 "All Cause" Neurological Disorder Prevalence data 
1.6.2.1 Hospital based studies 
Winkler et al. [394] recently reviewed hospital-based prevalence studies of neurological 
disorders in rural African settings. They concluded that out of 8676 admissions 740 
patients (8.5%) were given a neurologic diagnosis, the most frequent of which were 
seizures (26.6%) and infectious diseases (18.1%). The overall mortality of neurologic 
disease was 21%.  
 
Other hospital-based studies from SSA estimate that neurological disorders make up 3.0– 
33.1% of all hospital admissions and 4.2–7.5% of out-patient reviews and conclude that 
the most common reasons for admissions are stroke and neurological conditions occurring 
secondary to infection[28, 395]. 
 
These studies and Winkler et al's review do emphasise that neurological disease 
contributes substantially to morbidity and mortality burden however, it is not possible to 
elaborate on them further as their joint methodology and consequently their conclusions 
are highly biased. Poor access to healthcare for the majority of the population of SSA 
means that hospital based studies are a poor reflection of overall morbidity burden.  
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1.6.2.2 Community prevalence studies from SSA 
The only community-based studies from SSA on the prevalence of all cause neurological 
diseases are from over 20 years ago. 
 
Osuntokun et al [3] performed the first large scale community based 2 phased 
epidemiological survey of all major neurological disorders in SSA reporting a crude 
prevalence rate of 11.1/1000 or 62.1/1000 if lifetime prevalence of headache is included. 
A whole Nigerian town with a stable population of 19,954 was surveyed, with almost 
100% participation rates, eliminating selection bias. All ages were surveyed including 
children. The neuroepidemiological protocol developed by the neurosciences programme 
of the WHO was utilised, it had previously been piloted in this community and had a 
sensitivity of 95% and a specificity of 80%. The population surveyed had significant input 
from medical practitioners from local medical schools which although beneficial for 
project acceptability potentially introduced population bias and therefore it is difficult to 
extrapolate results to the rest of the country. However all other demographic parameters 
like age and sex distribution matched the rest of the country. Diagnostic criteria were 
used, however a mixture of lifetime prevalence (for headache) and point prevalence rates 
were included.  
 
Tekle-Haimanot et al [5] subsequently performed a larger "all-cause" neurological disorder 
prevalence study in the community in rural central Ethiopia between 1986 and 1988. All 
ages were surveyed. The authors reported a crude prevalence rate of 14.9/1000. Again 
the neuroepidemiological protocol developed by the neurosciences programme of the 
WHO was utilised, it had been previously piloted in this community and found to have a 
good sensitivity and specificity (91% and 85% respectively). All major neurological 
disorders were identified. The study was large, surveying 60,820 inhabitants, who were 
randomly sampled, eliminating selection bias. Every effort was made to ensure good 
participation rates (95-100%), including recruitment of enumerators (which were then 
highly trained) from the local population and treatment of treatable neurological 
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disorders.. The head of the household answered on behalf of the household members, 
thus as discussed previously stigmatising or subjective conditions could be under-
reported. Cases were confirmed by expert neurologists. The study area had very low levels 
of literacy in comparison to the general Ethiopian population (88.6% vs. 40%) perhaps an 
indication that the population surveyed was not representative of the Ethiopian 
population as a whole.  
 
Both epidemiological studies were landmark studies of their time however the age of the 
data limits its use today. In the Nigerian study 58% of patients were aged below 20 years 
and only 2.82% of the population were aged 70 years and over. In the Ethiopian study, 
59% of the inhabitants were aged below 20 years, with a median age of 14.5 years. 
Although this represented the age distribution of SSA at the time, demographics have 
changed since these studies were performed, the ageing of the population will impact 
significantly on the relative contribution of neurological disorders. This population 
structure with the lack of age adjustment means that prevalence rates reported are 
difficult to compare with worldwide prevalence rates, particularly those from our 
prevalence study which reports on a purely elderly population.  
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Table 1.10: The prevalence of Neurological disorders in Nigerian and Ethiopian 
Community Populations in the 1980s 
Neurological Disorder Nigeria Crude prevalence 
rate/1000 [3] 
Ethiopia Crude prevalence 
rate/1000[5] 
All 11.10 
(Including lifetime 
prevalence of headache 
62.1) 
14.90 
Headache Lifetime prevalence 51.00  
Epilepsy 5.33 5.19 
Speech disturbance 
Deaf Mutism 
Other speech 
0.15 2.56 
1.25 
1.31 
Poliomyelitis 0.15 2.41 
Mental retardation 0.10 1.69 
Peripheral Neuropathy 
Leprosy 
Traumatic Peripheral 
Neuropathy  Injury 
Bell's Palsy 
Hereditary PN (including 
Charcot-Marie-Tooth) 
Others  
2.68 
 
 
 
 
0.10 
1.54 
1.03 
 
0.24 
0.13 
0.10 
 
0.30 
Complications of 
spondylosis 
1.12  
Hemi paresis 
Early childhood 
Cerebrovascular 
Post-traumatic 
Unknown aetiology 
 
 
0.58 
0.62 
0.29 
0.15 
0.30 
0.15 
171 
 
Cerebral palsy 0.10 0.20 
Optic atrophy  0.16 
Perceptive deafness  0.12 
Tropical spastic paraparesis  0.10 
Syncope 0.10  
Parkinson's disease 0.10 
(aged 40+ 0.59) 
0.07 
Motor Neurone disease 0.15 0.05 
Chorea/athetosis  0.05 
Ataxia  0.05 
Tremors 
Essential Tremor 
Cerebellar degeneration 
0.20 
0.10 
0.10 
0.05 
Torticollis  0.02 
Myopathy  0.02 
Hemifacial spasm  0.02 
Organic psychosis 0.10  
Muscular dystrophy 0.05  
Pyomyositis 0.05  
Spina bifida 0.05  
Alcohol dependence 0.05  
Cerebral malaria 0.05  
 
1.6.2.3 Community based prevalence studies from multiple low income country sites 
Mateen et al [396] documented reportable neurologic diseases in refugee camps in 19 
countries including Burundi, Cameroon, Central African Republic, Democratic Republic of 
Congo, Chad, Ethiopia, Guinea, Kenya, Namibia, Rwanda, Tanzania, Uganda, Zambia from 
SSA. The data presented is difficult to interpret as it is presented in the format of the 
number of health visits required for neurological disease rather than in terms of 
prevalence. It does however indicate that non-communicable neurological diseases 
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including epilepsy and cerebrovascular disease contributed far more to morbidity burden 
than neurologic infectious disease in refugee camps and targeted programmes to address 
stroke and epilepsy in the camps should be a priority. The authors highlight the issues of 
under-reporting of all neurologic diseases in these settings.  
 
1.6.2.4 Community based prevalence studies from developing countries other than SSA 
In 1985 Attia Romdhane et al[397] carried out a neuroepidemiologic population based 
prevalence study in Tunisia using the WHO protocol as used in the Nigerian and Ethiopian 
studies described above. The study site of Kelibia was chosen as it was broadly 
representative of the general population of Tunisia. The major neurological survey in 
Tunisia was followed by a control survey to check the reliability of the initial survey's 
results. Random sampling, training of interviewers, diagnostic criteria and review by 
neurologists all added to the reliability of results. The age adjusted (according to the WHO 
population) prevalence of "all-cause neurological disorders was found to be 59.5/1000 
inclusive of migraine and 25.5/1000 exclusive of headache disorders 
 
Using two phased methodology, Gourie-Devi et al. [52] screened a randomly sampled 
102,557 urban and rural dwellers from Bangalore, India, for neurological disorders and 
quote an age-adjusted prevalence of 33.6 per 1000 in the general population and 50.1 per 
1000 in the >60 years population. Interestingly, they found prevalence rates to be almost 
twice as high in rural areas (40.7 per 1000) compared to urban dwellers (21.9 per 1000) 
and linked this to lower socioeconomic status. They utilised an acceptable and 
standardised screening instrument and claim their large study population is representative 
of the rest of India.  
 
Das et al [43, 53] quote a crude prevalence of 60.9/1000 in the 60 and over age group in 
Kolkatar, India and 11.79/1000 in the general population with an age adjusted rate of 
15.2/1000, but this was performed in the US 2000 population. A two-phased approach 
was used with random sampling, trained interviewers, case verification by neurologists 
and use of diagnostic criteria all of which increased the reliability of the results. However 
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the screening questionnaire used was only designed to pick up stroke, essential tremor, 
epilepsy, parkinsonism and dementia. The exclusion of other less common neurological 
disorders complicates the interpretation of results and their comparability to other study 
data.  
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Table 1.11: The Prevalence of Neurological Disorders from Developing Countries  other 
than Sub-Saharan Africa 
Neurological 
disorders 
Tunisia age 
adjusted 
prevalence 
rate/1000 
[397] 
Bangalore, 
India age 
adjusted 
prevalence 
rate/1000 
[52] 
Bangalore, 
India age 
adjusted 
prevalence 
rate/1000 
Over 60 
population 
[52] 
Kolkata 
crude 
prevalence 
rate/1000 
[43] 
Kolkata 
crude 
prevalence 
rate/1000 
60+ 
population 
[53] 
Total 59.50 33.60 50.10 11.79 60.9 
Headaches 
Migraine 
 
34.00 
9.67    
Epilepsy 3.64 8.26  5.58 2.57 
Febrile 
Convulsions 
0.52     
Dementia 0.47   0.88 7.89 
Parkinsonism 0.68 0.76  0.46 3.30 
Tremors 
Essential 
Tremor 
 
3.57 
4.08    
13.76 
Huntington's 
chorea 
0.43     
Other abnormal 
movements 
0.29     
Stroke 1.84 2.62  4.87 33.93 
Transient 
Ischaemic 
attack 
0.27     
CNS tumour 0.44     
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Head trauma 0.36     
Multiple 
sclerosis 
0.12     
Hereditary 
spinocerebellar 
disease 
0.30     
Intracranial 
infection 
Including 
encephalitic 
and meningitic 
sequelae 
 0.30    
Other or 
unspecified CNS 
disorder 
0.62     
Cerebral palsy 0.83     
Metabolic 
encephalopathy 
0.15     
Mental 
retardation 
1.06 1.16    
Chromosomal 
anomaly 
0.24     
Congenital CNS 
malformation 
0.47     
Late effects of 
poliomyelitis 
0.37     
Anterior horn 
cell disorder 
0.20 0.95    
Hereditary 
muscular 
0.32     
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dystrophy 
Peripheral 
nerve disorders 
 0.99    
Hereditary 
peripheral 
neuropathy 
0.19     
Diabetic 
polyneuropathy 
0.97     
Upper-or lower 
limb 
mononeuritis 
0.34     
Trigeminal 
neuralgia 
0.21     
Facial nerve 
disorders 
Bell's palsy 
 
 
2.62 
0.77    
Optic nerve 
disorder 
0.31     
Ocular 
movement 
disorder 
0.23     
Perceptive 
deafness 
1.26     
Vestibular 
disorder 
0.20     
Nerve root 
radiculopathy 
1.78     
Other 
neurologic 
disorder 
0.41     
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Older studies from India include those performed by Razdam et al[137] in Kashmir and 
Saha et al[61] in West Bengal. Both studies utilised the WHO protocol in the general 
population. They yielded crude prevalence rates of 9.67/1000 and 29.07/1000 
respectively. 
 
Gourie-Devi [52] and Das[53] both present data specific to the elderly population, they 
demonstrate significantly higher rates of neurological morbidity. However no study 
performed to date has been designed specifically for and carried out only in the aged 
population. This is despite the fact that many neurological conditions are more prevalent 
in the elderly and an ageing population will further increase their prevalence. This is 
particularly true for stroke, Parkinson’s disease, essential tremor and peripheral 
neuropathy. Some conditions, however, are not represented in this age group in low-and 
middle-income countries as the mortality rate in this environment precludes those with 
these conditions from living to old age. These include traumatic spinal injuries and 
hereditary disorders.  This highlights the unique nature of the elderly population. 
 
These recent population based studies from India demonstrate that in terms of 
methodological issues it is possible and necessary to conduct population based "all-cause" 
neuroepidemiological studies in situations of low income, scarce resources and address 
the need to focus resource on the elderly. 
 
1.6.2.5 Community prevalence studies from developed countries 
Broe et al. [155] quoted the prevalence of neurological disorders as 214.1 per 1000 in the 
65 and over age group in the UK. In the general population of developed countries, 
prevalence rates vary from 68 to 142 per 1000 [398, 399]. 
 
Hospital studies in developed countries are a much better reflection of disease burden 
than in developing countries because of better access to healthcare. Perkin [400] reported 
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that in a survey undertaken by the association of British Neurologists, 16 conditions, 
namely, epilepsy, headaches other than migraine, migraine, cerebrovascular disease other 
than transient ischaemic attacks, multiple sclerosis, faints and blackouts, cervical disk 
disease, peripheral nerve palsies, transient ischaemic attacks, dizziness and giddiness, 
Parkinson's disease, lumbosacral spinal disease, cranial nerve palsy, peripheral 
neuropathy, facial pain, dementia, constituted 74% of the outpatient workload. 
 
1.6.3 Deaths from Neurological disorders 
Neurologic disorders cause 12% of deaths globally [401]. The burden of neurological 
disorders is substantially underestimated by mortality, morbidity is a much better 
reflection. In 2005, over 92 million years of healthy life were lost as a result of neurological 
disorders worldwide.  
 
1.6.4 The Epidemiology of "All Cause" Neurological Disorders in Summary 
The current literature attempts to demonstrate the high burden that neurological 
disorders represent to SSA, contributing significantly to the NCD epidemic. However it is 
either outdated, predictive or not conducted in general populations. Further accurate 
community based epidemiological studies are required to accurately document burden 
and facilitate the evidence-based healthcare planning that is needed for neurological 
disorders and other NCDs in resource-poor settings [383]. 
 
1.7 Treatment of Neurological Disorders 
Most neurological problems are dealt with by general practitioners (GP) and hospital 
physicians, not by neurologists [402]. Developments in the management of neurological 
disorders are therefore relevant to doctors without specialist neurological training 
particularly in places with few neurologists like SSA [403]. 
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In the past 5 years, new treatments have become available for neurological disorders 
previously considered untreatable (multiple sclerosis, Alzheimer's disease, motor neurone 
disease). Although the high cost of these treatments has sometimes led to issues with 
health budgeting and precludes their likely use in SSA in the near future[403]. 
 
The World Health Organization has launched a programme to scale up the treatment of 
people with neurological disorders, especially in poor countries, where more than 75% of 
people affected receive no treatment or care. The agency says that rich nations also have 
substantial gaps in treatment, with up to half the patients affected by these conditions left 
untreated [404]. 
 
1.8 The Cost of Neurological Disorders 
A study conducted in Europe estimated that the annual economic cost of neurological 
diseases (dementia, epilepsy, migraine and other headaches, multiple sclerosis, 
Parkinson’s disease and stroke) amounted to €139 billion (approximately US$ 180 billion) 
in 2004. This study only partially included direct non-medical costs (e.g. community care 
and informal care) and indirect costs. The results also demonstrated that the cost of 
dementia increases by 25% when informal care is included. In the same study, the annual 
cost of traumatic brain injuries was estimated at €3 billion; this figure is, however, a gross 
underestimate as it was based only on hospitalization attributable to trauma and omitted 
rehabilitation and lost workdays. Unfortunately, no equivalent estimates are available for 
developing countries [13]. 
 
1.9 Research Funding for Neurological Disorders 
The research interest in rare neurological conditions is disproportionately larger than that 
in common conditions. There should be a change in the focus of medical research towards 
the most common conditions that are responsible for the greatest disability, death, 
economic cost, and loss of quality of life [405]. It is recognised that funding for research 
into a disease should be proportional to that disease's burden on society [406]; however, 
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conditions that account for 90% of the global burden of disease receive less than one 
tenth of the world's health budget [407]. 
 
1.10 Services available to support patients with neurological disorders in Africa 
23 African Nations, with a population totaling 270 million people, had only 1-4 
neurologists per country. Eleven nations with a population totaling 26 million have no 
neurologist [11]. There are less than 0.01 neuro-surgeons per 100,000 people in Africa, 
compared to 1.02/100,000 people in Europe [12].  
 
1.11 Background information about Tanzania 
Tanzania lies in sub-Saharan East Africa and has a population of 45 million (see figure 1.4).  
It covers an area of 945,087 square kilometres.  Life expectancy is 55yrs for men and 56yrs 
for women.  By 2025 the population is expected to rise to 67.4 million. 45% of the 
population are less than 15 years of age and 3% are over 65 years.  The infant mortality 
rate is 58/1000 and 5.0%  of men and 7.6% of women have HIV/AIDS [408]. Tanzania is 
one of the poorest countries in the world; approximately 90% of the population live off 
less than $2 US per day. Tanzania is defined by the WHO as within Mortality stratum Afr-E, 
having a high child and a very high adult mortality. Their broad group is High Mortality 
Developing. Tanzania’s income category is low. 
 
The Hai district lies in the north-east of the country on the slopes of Mount Kilimanjaro, 
the highest mountain in Africa. The Chagga are the predominant tribe, and most work as 
subsistence farmers, growing maize or bananas on “shambas” (small holdings).  The 
majority of the population are Christian, but there are some Muslim and other 
denominations. Most of these people are born, brought up and live their entire life in the 
same village. Most villages have either a health centre or a village dispensary; there are 3 
small local hospitals within the district. The main tertiary referral hospital is Kilimanjaro 
Christian Medical Centre (KCMC) in the town of Moshi in the adjacent district of 
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Kilimanjaro. It serves a population of 11 million people and has 450 inpatient beds. KCMC 
has a resident consultant Neurologist. 
 
Within the Hai District there is a Demographic Surveillance Site with a population of 
161,119 within 52 villages at the latest census on 1st June 2009. Further details of this 
unique epidemiological site are included in the methods section of this thesis. 
 
Figure 1.4: Map of Tanzania 
 
[409] 
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1.12 The Ageing Population; The Elderly in Africa 
Populations worldwide, but particularly in developing countries, are ageing rapidly. In 
2050, an estimated 2 billion people will be aged 60 and over and 80% will reside in 
resource poor settings [1]. The numbers of elderly people in sub-Saharan Africa are 
growing rapidly with increasing life expectancy while at the same time the proportions of 
children in the populations are declining. The number of people 80 years and above has 
increased tenfold in large parts of Africa since the 1950's, and the number of widows is 
growing fast. All this has several implications, including erosion of the social support from 
extended families and a dramatic change in the disease pattern. Multiple illness and 
permanent disability will become more common. African health care systems are ill-
prepared for this transition, and social security for the elderly needs to be improved in the 
coming years. Local and regional research into morbidity and well-being is important for 
policy formulation. Improved health in childhood and middle age will probably be 
followed by improved health in old age, and this may offset the burden on the health care 
system of the growing number of elderly [410]. 
 
The extension of life expectancy and the ageing of populations globally are predicted to 
increase the prevalence of many non communicable, chronic, progressive conditions 
including neurological disorders. The increased capacity of modern medicine to prevent 
death has also increased the frequency and severity of impairment attributable to 
neurological disorders. This has raised the issue of restoring  a life of acceptable quality for 
people who suffer from the sequelae of neurological disorders [13]. 
 
In the United Kingdom, the proportion of people over the age of 65 is expected to 
increase from 18% in the current population to 30% by 2030 [411]. By the year 2050 in the 
United States an estimated 15 million people will be over the age of 85 alone, compared 
with 3 million in 1990 [412]. The world population aged over 55 years increases by one 
million people per month. Eighty per cent of growth is in developing countries where, by 
the year 2020, the elderly population is likely to exceed one billion. Over the next 30 years 
the proportion of the world's elderly population living in developing countries is projected 
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to increase from 58% to 72% [413]. Since 1900 life expectancy has increased by 30 years in 
the US [414]. 
 
1.12.1 The cost of the ageing population 
The ageing population produces substantial ethical and economic problems. Dworkin 
[415] states that $80 billion was spent treating patients with Alzheimer's disease in the 
United States alone in 1991. Hacker [412] reports that in the United States “spending on 
hip fractures, for example, is projected to increase from $1.6 billion in 1987 to as much as 
$6 billion in the year 2040 (in constant US dollars)” [412]. In view of these statistics, it is 
hardly surprising that there are increased calls for age to be used as the principal criterion 
for rationing [416]. 
 
More than half of the patients in hospital are 65 years or over. There are proposals to 
decrease innovations to increase life expectancy and increase innovations to increase 
quality of life. Additionally the importance of value conscious innovation is increasingly 
stressed. This is very applicable to developed countries but in developing countries the 
elderly population often do not have access to cheap long standing treatments which 
could in turn prolong and increase the quality of their lives [414].   
 
1.12.2 Arguments against ageism.  
Some form of rationing is necessary in medicine, and to use age as a criterion for rationing 
has been suggested. The adoption of ageist policies, however, may not result in the 
implied savings unless care is also withdrawn and ageist policies, which deny elderly 
people treatment because of their age, are both unfair and discriminatory.  
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It is the mark of a civilized society to look after its most vulnerable members, which 
includes the elderly. Treatment should still be rationalised based on patient benefit and 
this often is irrespective of age  [416]. 
 
1.12.3 Healthcare for the elderly in Africa 
Current public health policies in many Third World countries, supported by international 
agencies, focus on maternal health, contraception, and infant health. Ageing of society in 
Africa, Asia, and South America will result in more chronic, non-communicable diseases 
and these will become a prime health concern. . 
 
There is an urgent need for research into the health care needs of elderly people 
worldwide. The ageing population will have a dramatic effect on the patterns of health 
care required and we need to make plans to deal with the medical problems associated 
with ageing in high and low income countries. 
 
Some developing countries are proposing legislative measures to tackle the problems of 
ageing; these include Botswana, Mauritius, South Africa and Zimbabwe. These countries 
have developed policies and programs that will provide health, economic and social 
services to the elderly population. For example; Botswana’s government has 
commissioned a study on the needs and care of the elderly in order to guide further policy 
on elderly care, Mauritius has produced an initiative to promote integration of the elderly 
into society and the Zimbabwe National Population project has listed the following 
strategies to be implemented;  
 The introduction of legislation on care of the elderly;  
 The provision of the elderly with pensions and some form of public assistance 
 Making the health system more sensitive to the needs of the elderly 
 The provision of adequate resources for the elderly looking after AIDS orphans 
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 Identifying ways in which the elderly can continue to make active contributions to 
the economic, social and cultural life of their families and communities. [417] 
 
In Africa, family provides the majority of care for the sick and elderly population. Few 
formal systems for care exist. An increase in the dependent elderly and a change in social 
structure from extended to nuclear families will be detrimental to this current care 
provision and the need for institutionalisation of the elderly will present itself. Most 
African countries will be unable to deal with this due to a lack of social and economic 
infrastructure. This therefore requires government action  [418]. 
 
1.12.4 Screening of the Elderly population 
The MRC trial of the assessment and management of older people in the community 
reported a high frequency of unreported and unmet needs of elderly people. Recurrent 
review of elderly people is required [419]. 
 
1.12.5 Aids and the Elderly 
Elderly Africans have HIV and AIDS too is the overall message from Awofeso et al [420]in 
their correspondence to the British Medical Journal (BMJ) in 2010. They call for the myth 
that HIV is only a problem for the under 50s and elderly Africans are not sexually active to 
be dispelled.  
 
Many patients who were infected with HIV as youths now live into their 50s, 60s, and 
longer, and the average age at infection has increased [421]. The demographic health 
surveys (DHS) conducted between 2003 and 2007 contain limited data on self reported 
prevalence of HIV in men aged 50-59 in 13 African nations. On the basis of these data, the 
average HIV prevalence was 5%. However, self reporting grossly underestimates HIV 
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status, as exemplified by a 2001-2 study of 133 male Ethiopian cataract patients aged 50-
59, which found an HIV prevalence of 9.1%, higher than the 1% prevalence reported in the 
DHS, as well as a 6.3% HIV prevalence in Ethiopians aged 15-49 years[422]. 
 
It is true that elderly Africans are more likely to live in rural areas outside the urban 
populations with increased (and rising) prevalence rates.[423] However, HIV education, 
diagnosis and treatment initiatives need to consider the needs of the elderly who as a 
group are still susceptible[424]. 
 
Not only do the elderly populations personally suffer from HIV and AIDs, they endure the 
impact the epidemic has on junior members of their family. The loss of children and 
grandchildren to the HIV epidemic results in reduced support and the lack of carers for 
dependent elderly. Additionally the elderly often become the sole carers of orphaned 
grandchildren [425].  
 
1.13 Disability 
Current data estimate 10% of the world’s population are disabled [18] however, there are 
few data on true prevalence of disability in developing countries, particularly amongst the 
elderly [62] despite the association between disability, increasing age and poverty (both 
cause and effect). In 2006, the United Nations (UN) highlighted the importance of 
disability to governments and international development agencies [18]. The availability of 
high quality, internationally comparable up to date data on disability is integral for the 
planning, implementation, monitoring, and evaluation of inclusive policies. The Royal 
College of Physicians (RCP) has recognized the impact of disability and the importance of 
addressing it since the 1980s. They highlighted that the subject is administratively 
complex and that many different organizations are involved when this problem is 
addressed in developed countries. The Working Party on Rehabilitation Medicine of the 
RCP (1978) was of the opinion that rehabilitation is an integral part of total patient care, 
and is therefore the concern of all clinicians [63]. 
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1.13.1 The Impact of ageing on disability 
Populations worldwide, but particularly in developing countries, are ageing rapidly [1]. 
This epidemiological transition will include increases in non-communicable disease 
including neurological disorders [2]. These diseases have the potential to result in 
increased disability and dependence. Prevalence of disability does indeed increase with 
age worldwide[63],[64],[65], but supportive data from the African community is required.  
 
1.13.2 Defining disability 
One can define the different aspects and effects of disability;  
Impairment - the specific deficit 
Activity limitation (formerly 'disability') - limitation in functional capacity 
Participation restriction (formerly 'handicap') - the impact on function and quality of life  
[426]. 
 
The social model of disability (the outcome of the interaction of a person and their 
environment) is replacing the medical model of disability  [18], and is highlighted by the 
International Classification of Functioning, Disability and Health (ICF) developed by the 
World Health Organisation (WHO) [17].   
 
1.13.3 Treating disability 
Interventions should be aimed at both the individual level and the societal level [18]. 
Many disabling conditions can be prevented or treated readily and inexpensively. There 
are cost-effective measures for rehabilitation and disability improvement. Identification of 
those with disability and diseases that result in disability is clearly an important 
component in reducing the morbidity burden in SSA [66].  
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Rehabilitation is an integral part of “total patient care” [63]. WHO defines rehabilitation as 
an active process by which those affected by injury or disease, realize their optimal 
physical, mental and social potential [17]. Rehabilitation is best administered by 
specialised multidisciplinary services however, such services are limited or non-existent in 
many developing countries so knowledge transfer from experts to primary caregivers or 
family members is fundamental, clearly the western model of rehabilitation cannot be 
copied in SSA. To address this situation, a community-based rehabilitation strategy has 
been introduced by the WHO in many low income countries worldwide successfully 
influencing the quality of life of persons with disabilities. 
 
1.13.4 Different methods of measuring disability- why use the Barthel Index (BI)? 
Reported disability prevalence rates around the world vary significantly because of 
different definitions, study designs, and lack of a universal assessment tool, leading to 
difficulty making comparisons. The complex model of social disability is hard to measure. 
Clinical evidence shows that in most elderly people, independence and quality of life are 
strictly related with motor function. According to the WHO, health status in the elderly is 
best defined in terms of function, physical mobility is the milestone in preserving function 
[19]. To generate meaningful general prevalence one must determine which component 
most reflects a person’s level of disability and allows it to be easily comparable to another; 
arguably physical function in an elderly population of a rural community in a developing 
country [18].  
 
The BI, developed in 1965 [427] is an ordinal scale comprising ten Activities of Daily Living 
(ADL) with varying weighting. The original BI was scored in steps of five points to give a 
maximum total score of 100. A widely adopted modification (converted by dividing by 5) 
revised the score to range from 0-20 [428]. The Barthel Index (BI) is widely used and 
recommended by the British Geriatric Society (BGS) and the Royal College of Physicians for 
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routine use in the assessment of older people [426] [429] [430]. It is culturally and disease 
non-specific and simple modification allows easy use in developing countries. This allows 
easy comparison between disability levels worldwide and reduces the need for validation 
in SSA. It has good inter-rater (a skilled observer is unnecessary) and inter-disorder 
reliability [431] [428]. 
 
In view of its simplicity, high validity, reliability, sensitivity and utility, the BI has been 
proposed as the standard measure of disability and the gold standard to which new 
measures should be compared [67] [68]. 
 
There is little consensus on the cutoffs of the BI for level of disability for epidemiological 
studies or medical trials. Uyttenboogaart et al [432] compare the BI to the Modified 
Rankin Score (MRS) demonstrating that MRS 1 (No significant disability) corresponds with 
BI 19+, MRS 2 is equivalent to BI 18, MRS 3 to BI 15. Celani et al [433] suggest a score of 19 
or above as a pivotal score for not requiring help from another person. Kay et al [434] 
conclude that a score of 16 or less was the optimal cutoff for self reported dependency. 
There is consensus that MRS of 2 or less reflects independence (equivalent to BI 18 or 
more). Heslin et al reported cutoffs of <15 as severe disability, 15-18 as moderate 
disability, 19 or 20 as mild/no disability [435]. 
 
In summary, I selected the BI for use in this thesis because it is recommended by the RCP 
and the BGS for use in the elderly, it is quick and easy to do and it is possible for a wide 
range of surveyors to perform it consistently. The use of a simple and commonly used 
screening tool and the focussed population group allowed direct comparison to a 
European population studied by Heslin et al [435]in 2001. They measured BI on 4004 
elderly aged 70+. I used their cut offs for mild, moderate and severe disability as described 
above as they are roughly equivalent to other cut offs described and approved in the 
literature and it facilitated comparison. 
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1.13.4.1 The World Health Organisation Disability Assessment Schedules (WHO-
DAS) 
The WHO has designed a set of Disability Assessment Schedules (known as the WHO-DAS) 
which have a long series of activity and participation based questions. While some of 
these questions are internationally comparable (e.g., standing for long periods), some are 
less so (e.g., conducting household responsibilities). Furthermore, even the 12-question 
WHO-DAS is too long to be of use for a census, which many countries must rely on due to 
limited resources for carrying out household surveys [436]. The 10/66 research group also 
observe problems with over and under “zero” reporting in their disability studies [62]. 
 
Whilst the most recently proposed screening tool I felt the WHO-DAS was not appropriate 
for our study given its length and lack of current recommendations from geriatric 
organisations.  
 
1.13.5 Published literature on disability levels 
Overall, as generally defined, disabled people represent a significant proportion of the 
world's population. Data from developed countries and some recent studies in developing 
countries (Brazil, Ecuador, India, Nicaragua, Vietnam, and Zambia) suggest that an 
estimated 10-12% of the population are disabled. This estimate is in line with the United 
Nations’ often cited figure of 10%, an informed guess based on data from developed 
countries [18]. 
 
Reported disability prevalence rates around the world do however vary dramatically but in 
general are lower in developing countries. Rates reported in Kenya [437] and Bangladesh 
are <1% [438]. Allain et al’s Zimbabwean study who found less than 4% of people aged 60 
and over experienced difficulty with self maintenance of ADLs [20]. Fitaw et al looked at 
the prevalence of disability in Ethiopia, reporting the crude disability rate of 3.8% using 
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the WHO international classification functioning disability and health (ICF) when all age 
groups were studied [21]. Rates in developed countries are substantially higher, 20% in 
New Zealand [22] and using the Townsend disability scale, The Medical Research Council 
Cognitive Function and Ageing Study and Resource Implications Study found 11% of men 
and 19% of women aged 65 and over were disabled in the UK [23]. This variation may be 
caused by several factors: differing definitions of disability, different methodologies of 
data collection, and variation in the quality of study design and population group studied 
[438],[437],[22], however our directly comparable study indicates a real difference 
between disability rates in developed and developing countries in the elderly population 
at least. Comparable data from younger age groups is required to extrapolate this 
conclusion to the general population. 
 
1.13.6 Disability levels in the elderly 
The previously mentioned Cognitive Function and Ageing Study report that 38% of 
disabled people were aged 85 or over. They concluded that very elderly people make up a 
large proportion of those in need of long term care, demonstrating the economic and 
social burden that an ageing population represents [23]. Heslin et al in 2001 reported 
disability levels using the BI on 4004 elderly aged 70+ in multiple European centres. Of the 
total sample, 9% (10% of women and 7% of men) and 26% were severely and moderately 
disabled respectively [435], demonstrating significant functional impairment in this age 
group that is substantially higher than levels quoted in the general adult population.  
 
1.13.7 Disability levels in Non Communicable Disease (NCD) 
The 10/66 dementia research group concluded in their recent paper that NCD particularly 
(in decreasing order) dementia, stroke, limb impairment, arthritis, depression and 
eyesight problems are significantly associated with disability [62]. Further research needs 
to be done in developing countries. 
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1.14 Stigma: The Perception of Neurological Disorders in Africa 
Stigma has been defined as “a deeply discrediting attribute that reduces a person to one 
who is in some way tainted and can therefore be denigrated.” It is a problem that affects 
the health of individuals and society globally. It has an impact on individual’s social, 
psychological, physical and spiritual wellbeing. It prevents individuals presenting with 
diseases that carry stigma, it is detrimental to healthcare and research studies designed to 
benefit the local and global population [439]. 
 
In Africa stigma may result from a history of neurological disorder and the consequent 
physical or mental abnormality. For most chronic neurological disorders, the stigma is 
associated with the disability rather than the disorder itself. Exceptions are epilepsy and 
dementia which are directly associated with stigma and discrimination. The amount of 
stigma associated with chronic neurological illness is determined by:  
 The attribution of responsibility for the illness 
 The degree to which it creates discomfort in social interactions (often how visually 
alarming the condition is) 
 The amount of disability that the condition creates reducing the individuals 
perceived “social value.” 
 
Stigma has social, psychological and physical effects; 
Social – people may be prevented from being part of the community, children may be 
taken out of school, marriages may be prevented and whole families may be ostracised. 
Psychological – Isolation and depression can result. 
Physical – the patient does not present to healthcare professionals due to the stigma 
attached to the condition and therefore it remains untreated and a disabling factor in the 
patient’s life.  
 
Tackling stigma is often about addressing the views of those who stigmatise or 
discriminate against others. Education on causation is one of the key factors as beliefs of 
witchcraft, contagious or hereditary nature of illnesses are often strongly held especially 
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within developing countries such as Africa. Mshana et al report the stigma associated with 
stroke and the common beliefs that stroke is often seen as a result of witchcraft. The 
association with supernatural phenomenon means that this disease is not only disabling 
physically but also stigmatising [440]. Studies have shown that programmes to reduce 
stigma related to epilepsy in African communities through education and treatment can 
successfully reduce the stigma attached to the condition[441]. 
 
Stigma is also a major issue within the ageing population, Butler in his book from 1975 
reports a deep and profound prejudice against the elderly [442], which is supported by 
more up to date reports of ageism in communities particularly with regard to health care 
rationing [416]. This problem has been established and published in developed countries 
since the 1970s, however the perceived burden of the elderly has only just begun to 
impact on the developing world and has the potential to change attitudes from one of 
respect to one of discrimination and resentment.  
 
1.15 Summary 
• The Burden of Neurological Disease is high and increasing further as a result of the 
ageing population. Data are however based mostly on predictions, studies from 
developed countries and outdated studies. Accurate data from SSA are lacking but 
are required for evidence based healthcare planning in resource poor areas.  
• Cost effective interventions (either treatment or prevention) for many neurological 
conditions are available. Resources are inadequate and unequally distributed in 
low income countries. Accurate prevalence figures will help resource prioritisation.  
• Current screening tools for the detection of neurological disorders are 
unsatisfactory particularly for use in the elderly population of low income 
countries and for use by NMI.  
• Neurological disease and an ageing population produce an increased burden of 
long term disability – the extent of disability has not been measured in the elderly 
population of SSA or in the majority of other developing countries. 
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• Stigma and discrimination is associated with neurological disease, particularly in 
developing countries and this needs to be addressed. 
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Chapter 2. Methodology 
 
2.1 Literature Search Strategy 
I performed an all encompassing literature review focused on my research aims. Given the 
broad nature of the research subject, it was important to break down reviews based on 
the main aim and the subsidiary aims and this is described in detail below. Actual MESH 
headings/text words have been listed as well as a flow chart of the number of hits and 
exclusions. The inclusion and exclusion criteria have also been detailed. Given the number 
of literature reviews performed, those displayed below are limited to the key searches of 
the main and primary subsidiary research aims. 
 
Literature searches were performed using "all resources" from The University of 
Newcastle upon Tyne databases, including Books at Ovid, Journals at Ovid, Medline, 
Embase, EBM Reviews, NHSEED, CAB Abstracts, Embase, Health Management Information 
Consortium and PsycINFO. Literature was also found following references from sourced 
articles.  
 
With regard to the primary aim of the study; "to determine the prevalence of Neurological 
Disorders and Consequent Disability in the 70 and over population of the Hai District 
Demographic Surveillance Site (DSS) in Northern Tanzania", the key conditions of Tremor, 
Parkinsonism, Stroke, Headache and Epilepsy were the focus,  details of the searches are 
described below 
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Table 2.1: Literature Search for Neurological Disorders 
Search Order Search Term Hits 
1 Neurological Disorder 58873 
2 Neurological Disease 26672 
3 Neurological Disability 4740 
4 Prevalence  1686144 
5 Sub-Saharan Africa 45800 
6 1 or 2 or 3 83126 
7 4 and 5 and 6 173 
7 Limit 6 to English Language, Human  169 
8 Of 7 Excluded all those only identifying 1 
neurological disorder and those relating 
only to children or using investigations 
16 
9 Neurological disorders (title) 345 
10 Neurological disability (title) 213 
11 Neurological disease (title) 2504 
12 Prevalence (title) 238628 
13 9 or 10 or 11 3062 
14 12 and 13 21 
15 Limit 14 to English Language, Human 19 
16 Of 15 Excluded all those only identifying 1 
neurological disorder and those relating 
only to children or using investigations 
9 
17 Additional from references - 
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Table 2.2: Literature Search for Tremor 
Search Order Search Term Hits 
1 Tremor 90903 
2 Prevalence 1686144 
3 Sub-Saharan Africa 45800 
4 1 and 2 8646 
5 1, 2 and 3 56 
6 Limit 6 to English Language, Human  55 
7 Of 7 Excluded all those only identifying 1 
neurological disorder and those relating 
only to children or using investigations 
18 
 Additional from references - 
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Table 2.3: Literature Search for Parkinsonism and Parkinson's disease 
Search Order Search Term Hits 
1 Parkinsonism 61872 
2 Parkinson's Disease 180734 
3 Prevalence 1687302 
4 Sub-Saharan Africa 45827 
5 1 or 2 218758 
6 3 and 5 17444 
7 3, 4 and 5 77 
8 Limit 7 to English Language, Human  76 
9 Of 8 Excluded all those relating only to 
children or not related to prevalence 
38 
10 Additional from references - 
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Table 2.4: Literature Search for Epilepsy 
Search Order Search Term Hits 
1 Epilepsy 358963 
2 Prevalence 1686144 
3 Sub-Saharan Africa 45800 
4 1 and 2 22197 
5 1, 2 and 3 325 
6 Limit 6 to English Language, Human  308 
7 Of 7 Excluded all those relating only to 
children or not related to prevalence 
43 
 Additional from references - 
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Table2.5: Literature Search for Stroke 
Search Order Search Term Hits 
1 Stroke 724709 
2 Prevalence 1687302 
3 Sub-Saharan Africa 45827 
4 1 and 2 88053 
5 1, 2 and 3 612 
6 Limit 6 to English Language, Human  597 
7 Of 7 Excluded all those relating only to 
children or not related to prevalence 
62 
 Additional from references - 
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Table 2.6: Literature Search for Headache 
Search Order Search Term Hits 
1 Headache 357798 
2 Prevalence 1687302 
3 Sub-Saharan Africa 45827 
4 1 and 2 36998 
5 1, 2 and 3 481 
6 Limit 6 to English Language, Human  479 
7 Of 7 Excluded all those relating only to 
children or not related to prevalence 
5 
8 Headache (title) 46309 
9 Prevalence (title) 238798 
10 8 and 9 977 
11 Sub-Saharan Africa (title) 7542 
12 10 and 11 0 
13 3 and 10 0 
14 Developing countries 1754928 
15 10 and 14 15 
16 Additional from references - 
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With regard to the first subsidiary aim of the study; "To produce a validated and improved 
screening tool for the detection of Neurological Disease specific to the 70 years and older 
population", the search is detailed below. 
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Table 2.7: Literature Search for Screening Tools for Neurological Disorders 
Search 
Order 
Search Term Hits 
1 Neurological Disorder 58873  
2 Screening tool  43256 
3 Screening questionnaire  14646 
4 Screening instrument 10611 
5 2 or 3 or 4 65341 
6 1 and 5 720 
7 Limit 6 to English Language, Human 697 
8 Of 7 Excluded all those only identifying 1 neurological disorder 
and those relating only to children or using investigations 
13 
9 Sub-Saharan Africa  45800 
10 5 and 9 22 
11 Limit 10 to English Language, Human 20 
12 Of 11 Excluded all those only identifying 1 neurological disorder 
and those relating only to children or not related to prevalence 
3 (all my 
articles) 
13 Neurology (title) 24261 
14 Neurological (title) 59236 
15 13 or 14 82963 
16 Screening (title) 289698 
17 15 and 16 233 
18 Limit 17 to English Language, Human 174 
19 Of 18 Excluded all those relating only to children or not related to 
prevalence 
7 
20 Additional from references - 
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Additional references were gained from journal, website specific search engines and from 
recommendations. Several references were obtained through the British Library after 
assistance from North Tyneside General Hospital Library. 
 
It is important to highlight that searches were limited to studies from SSA unless research 
in the field was limited in which case the search was extended to include developing 
countries. Studies from developed countries were only included where literature was 
extremely limited or studies were recommended and deemed of very high importance. 
Review articles from developed countries were otherwise used for comparison. 
 
2.2 Ethical Approval 
Ethical approval was sought in the UK from Newcastle and North Tyneside Health 
authority Joint Ethics Committee, locally in Tanzania from Tumaini University, Moshi and 
nationally in Tanzania from the National Institute of Medical Research (NIMR) ethics 
committee (Dar-es-Salaam).  Ethical approval was granted from Tumaini University and 
from NIMR but the UK committee deemed it unnecessary to be considered as all the 
research was being carried out it Tanzania. All participants were given an information 
sheet in Kiswahili. All participants signed written consent forms in Kiswahili (in the case of 
those who could not write, a thumb print was obtained). Any patient who could not speak 
Kiswahili had the information sheet and the consent form translated verbally into their 
tribal language and understanding was checked. All participants were free to withdraw 
from the study at any stage. Written consent was gained for photography and video 
recording as appropriate.  All information sheets and consent forms were translated by 
the Neurology Nurse Specialist and then back translated by another specialist research 
nurse to ensure accurate translation. Please see appendices 2.1-2.7 for information sheets 
and consent forms. 
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2.3 Inclusion and Exclusion Criteria 
2.3.1 Inclusion Criteria 
In order to be included in the study, patients had to;  
 Be alive and living within the Hai district project area and within one of the 12 
randomly selected villages on January 1st 2010 
 Be aged 70 or over on January 1st 2010 
 Have given informed consent or assent provided by a family member in the case of 
cognitive impairment 
 Have neurological symptoms or signs in keeping with a World Health Organisation 
International Classification of Disease (ICD 10) Neurological Diagnoses 
 
2.3.2 Exclusion Criteria 
Patients who were excluded from the study were as follows; 
 Those who were not aged 70 or over on January 1st 2010 
 Those who did not live in the Hai district project area and who were not within one 
of the 12 randomly selected villages 
 Those who did not have symptoms or signs in keeping with a World Health 
Organisation ICD 10 Neurological Diagnosis   
 
2.4 Prevalence Studies 
Point prevalence of a disorder is defined as the number of live cases suffering from that 
disorder, expressed per 100,000 of the population (or per 1000 of the population if the 
disease is more common), at a specified time.  There are a number of methods of 
accurately determining prevalence; the appropriate method depends on the study setting. 
 
  
206 
 
2.5 Deciding on the Basic Methodology 
2.5.1 Flawed Methods 
Case finding studies use primary care or hospital notes to pick up known disease cases.  
This approach fails to pick up undiagnosed cases in the community. This is particularly 
relevant in developing countries where presentation to health care is limited by financial 
and geographical constraints and many people remain undiagnosed. In Tanzania, there 
are no formal general practitioners (GP) or GP registers so use of such a system would not 
be possible. 
 
Pharmacy searches can be utilised when diseases are treated with specific medications, 
which are primarily used for that disease. There are limitations to this approach which 
render it unsuitable., It would fail to identify undiagnosed cases and many neurological 
diseases cannot be treated within the western world let alone developing countries.  
Further, local pharmacies in Hai often do not stock medication for neurological disorders 
and their records are likely to be unreliable. Finally dispensary workers do not have 
adequate knowledge to diagnose neurological conditions and prescribe appropriate 
medications.  
 
2.5.2 The Gold standard approach 
A door-to-door study is the best way to find diagnosed and undiagnosed cases in the 
community. However, this is time and labour intensive; therefore, the two-phased 
approach to community prevalence studies has been long established as the gold standard 
to document true prevalence in low income countries [24, 25]. An initial screening phase 
with a tool that is feasible (acceptable, brief and easily administered by NMI) and valid 
(sensitive- to detect all neurological cases and specific-to reduce second phase costs) 
precedes physician confirmation of disease in positive responders. NMI are ideal screeners 
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as they are cheaper to employ, readily available, know the geography of the community, 
and are more likely to be accepted by the population so as to increase participation rate.  
 
I followed a two step approach, with a screening tool designed specifically for use within 
the elderly and not based on the flawed WHO tool. I worked through the WHO ICD 10 
criteria for Neurological Disease [71] to ensure that all relevant diseases were addressed 
by at least one question. 
 
2.6 Geographical area 
The Hai district is in northeast Tanzania on the slopes and surrounding plains of Mount 
Kilimanjaro. It lies between Moshi and Arusha, with an area of 13,000 km2. It stretches 
over three ecological zones delineated by altitude; these are as follows; 
  The lowland zone  
o 750 and 1000 m above sea level (asl),  
o Minimal rainfall (about 325 mm a year) 
o Warm to hot temperatures  
o Sparse population density (about 70 people per km2).   
 The midland zone  
o 1000 and 1600 m asl and 
o Higher rainfall (about 1560 mm a year) 
o Moderate temperatures  
o Higher population density (about 150–160 per km2). 
  The high zone is within Kilimanjaro National Park 
o Above 1600m 
o Uninhabited 
o Heavy rainfall 
o It provides water to the lower zones via springs and rivers. 
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o Cool temperatures 
Piped water is available in most villages and is plentiful in the highland and midland zones 
but is often polluted with chemical and biological waste. The lower zones often have 
water shortages and droughts.  
 
The district has 4 administrative divisions, 11 wards, and 61 villages. The Hai demographic 
surveillance site (DSS) covers three of the four divisions of the district, and has permanent 
boundaries. It has a population of 161,119 (January 2009) within 52 villages. 8869 were 
aged 70 and over (5.50%). Most villages in the DSS area are rural and the remainders are 
peri-urban. The main tribal groups are the Chagga and the MMasai. Major religious groups 
in the area are Christians (79% of people) and Muslims (20% of people). The tribal 
languages are commonly spoken in the villages, but the national language, Kiswahili is 
widely understood and spoken. Arable, livestock and cottage industries are the main 
economic activities, with the majority of inhabitants subsistence farmers. The district has 
139 primary schools, 13 secondary schools (both public and private) and 5 post-primary 
technical schools.  
 
The district has three hospitals, two large health centres, 39 dispensaries and 61 village 
health posts. The tertiary referral hospital is Kilimanjaro Christian Medical Centre (KCMC) 
and this is located in Moshi 8km from the nearest border of the Hai district. About 85% of 
children below the age of five are vaccinated against five major communicable diseases. 
Community-based data show that main causes of death in the district are: HIV/AIDS, 
cancer, perinatal, acute febrile illness including malaria, pneumonia, diarrhoeal diseases, 
injuries (both intentional and unintentional), nutrition and maternal. Wood is the main 
source of fuel. 36 of the 61 villages have electricity, but the use is limited because of cost 
and very few households have electricity. 
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There are 710 kilometers of road and an international airport (The Kilimanjaro 
International Airport) 10km from the nearest border. Most roads are unpaved and are 
often impassable for vehicles during the rainy season. [443]. 
 
2.7 The Adult Morbidity and Mortality Project (AMMP) 
The Hai district was one of three DSS in Tanzania used in the AMMP [443]. The other two 
sites were an urban population in Dar-es-Salaam and a poor rural area in Morogoro; Hai 
was originally chosen as a relatively affluent rural area.  The AMMP was originally funded 
by the UK Department for International Development (DFID) and was carried out in 
partnership between the Tanzanian Ministry of Health and the University of Newcastle 
upon Tyne.  The same staff were employed for this research as were by the AMMP.   
 
2.8 The Research Team 
The Research Staff on the project were as follows; 
 
The District Medical Officer (DMO): Approval was sought from the DMO to carry out 
research in his administrative district. This ensured a good relationship and increased the 
likelihood that he would act on the findings to improve healthcare in the district. Indeed 
the relationship gave us an excellent opportunity to feedback findings, recommend 
treatment guidelines and capacity requirements.. 
 
Two Assistant Medical Officers (AMOs) and 3 Clinical Officers (COs) acted as project 
supervisors. They had previously worked on the AMMP and so were highly trained in DSS 
activity. They were clinicians within the rural community (roughly equivalent to western 
general practitioners). On the project, they facilitated the day to day running of the 
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research and provided a translation service and local advice as required. A supervisor 
worked with the Research Doctor (RD) (myself) each day I was in the field. 
 
The Project Study Nurse (SN): A Neurology Specialist Nurse from KCMC worked with the 
RD (myself) each day I was in the field. She provided a nursing and translation service. 
 
The Enumerators/Non Medical Investigators (NMI): Each village had one or two (large 
villages only) local people trained in DSS activity and have been involved in prior 
prevalence studies. There are a total of 60 enumerators. They are healthcare 
professionals, teachers or village administrators. They had carried out the 2009 census 
within each of their villages and knew the composition of each household within their 
village. They were the target administrators of the demographic details, neurology 
screening and disability questionnaires.  
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2.9 Timing of the Study: 
 Figure 2.1: Timeline of the Study 
 May 2009 1st June 
2009 
June 2009 – 
October 
2009 
November 
2009 – 
January 2010 
January 2010 
– February 
2010 
February 
2010 – July 
2010 
July 2010 – 
August 
2010 
Pilot of previously used screening 
tools in the Proposed Population  
      
2009 Household Census of the 
Hai District Surveillance Site 
 
 
     
Production of new screening tool 
specific to the Elderly/ A 
developing country/ Use by lay 
community workers 
  
 
    
The Pilot Study    
 
   
Two  workshops on the use of 
the screening tool 
    
 
  
The Main Prevalence Study      
 
 
Follow up of Cases       
 
 
 
 
 
 
 
 
1st January 2010 – The prevalence 
Date 
1st June 2010 – The Census Date 
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2.9.1 Justification of the Timescale 
There were multiple reasons for this timescale.  Firstly it was realistic. A full Neurological 
history and examination took on average one hour to complete. During the pilot study it 
was estimated that a maximum of 8 patients could be seen per day as all patients would 
have to have the neurology screening questionnaire followed by a full neurological history 
and examination to confirm whether the patient was a true or false, positive or negative. 
For the main study it would  be possible to see a maximum of eight patients per day as 
these patients would have been screened positive and so a full neurological history and 
examination would have to be performed to assign them true or false positive. All patients 
would have to be seen by the RD (myself) to ensure continuity. The numbers of working 
days were limited by religious celebrations, public holidays and severe weather in the 
rainy season which precluded transportation. 
 
2.10 The Census 
The initial census in the Hai DSS was in 1992, to provide baseline information. Between 
then and 2003 an annual door-to-door census has been carried out by the AMMP by the 
60 enumerators. Each household and each individual has a unique identifying number. 
The census in August 2005, funded by the Tanzanian Stroke Incidence Project (TSIP) 
demonstrated a population of 161,000, of whom 7829 were 70 years and over (70 – 74 = 
3208, 75 – 79 = 1790, 80 – 84 = 1528, 85 – 89 = 636, 90+ = 667). The last census in June 
2009 demonstrated a population of 161,119, of whom 8669 were 70 years and over (70 – 
74 = 3159, 75 – 79 = 2531, 80 – 84 = 1447, 85+ = 1732). This updated the demographic 
data and enabled us to “target” households where there was an individual 70 years and 
over.  
 
According to the leading data analyst for the 2009 Census and the supervisors in Hai no-
one refused to give information for the census.   
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2.11 The Pilot of Previously used screening tools in the proposed population 
Preliminary work took place in May 2009 to pilot other previously published neurological 
screening tools in the target population (people aged 70 and over in the DSS) with the 
target administrators – the NMI with advice from the Supervisors. It was felt that pre-
existing tools would not be specific enough to be used in the 70 and over population 
because their high level of co-morbidities would result in a high false positive rate, the 
reasons for this are discussed in the introduction. Additionally, the NMI felt that screening 
tools that included an examination section would be too complicated for their use. Direct 
questioning of the target population informed me that they would not accept examination 
(however superficial) by someone who was not a medical professional. The  negative 
aspects of an examination section are discussed in detail in the introduction. Overall it was 
concluded that using a screening tool without an examination section would not only be 
fundamental for the success of our project it would ensure that such a tool was 
transferrable for use in other developing countries where funding may be limited and 
utilisation of screeners with limited training/NMI would be required.  This extends the 
niche of the screening tool and its use in neuro-epidemiological studies in the future. 
 
2.12 The Production of a New screening Tool 
I produced a completely new screening tool. Question wording was built on experience of 
the type of questions that had worked in previous prevalence studies in this community 
[34, 96, 128, 213, 333]. Question content was informed by systematically working through 
the WHO ICD 10 criteria for neurological diagnosis to ensure that the screening tool was 
all inclusive i.e. all neurological disorders of public health significance in this age group 
were covered. Direct questions on burdensome, easily identified neurological disorders 
were asked at the end of the questionnaire. The production of the screening tool was 
therefore all my own work and was not produced through modification of another 
screening tool published or otherwise. 
214 
 
Table 2.8: Conditions the Neurological Screening Questionnaire was Designed to Identify 
WHO ICD Code  Neurological Disorders 
G00 – G09  Sequelae of inflammatory/infect diseases of CNS  
G10 – G13  Systemic atrophies primarily affecting the CNS  
G20 – G26  Extra-pyramidal disorders  
G30 – G32  Other degenerative diseases of CNS  
G35 – G37  Demyelinating diseases of the CNS  
G40 – G47  Epilepsy and paroxysmal disorders  
G50 – G59  Nerve, Nerve root and Plexus disorders  
G60 – G64  Polyneuropathies and  PNS disorders  
G70 – G73  Diseases of myoneural junction and muscle  
G80 – G83  Cerebral palsy and other paralytic syndromes  
G90 – G99  Other disorders of the CNS  
H 2.4  Ptosis of the eyelid  
Chapter XIX - XX  Injury resulting in CNS dysfunction  
[71]
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Table 2.9: Conditions the Neurological Screening Questionnaire was not Designed to Identify 
Condition Reason for Omission 
Conditions whose 
symptoms and signs 
had resolved 
completely. 
It would not be possible to get an accurate enough history to secure a positive diagnosis due to 
problematic recall in this community and language barriers. Additionally very few participants would 
have medical records to confirm or refute the diagnosis. This does not include those conditions that 
have symptoms or signs that recur e.g. epilepsy and recurrent headaches. 
Visual problems As a separate part of the study all patients were asked if participants had problems with their vision. 
46.9% answered positively to this question. Including a question regarding vision in a neurological 
screening questionnaire for use in the elderly would substantially reduce specificity and would pick 
up many people with ocular diagnoses.   
Hearing problems A majority of elderly people will report deterioration /problems with their hearing it was felt, 
therefore, that it would not be appropriate to include a question about hearing. This would pick up a 
large amount of people with presbyacusis and would reduce the specificity of the tool. 
Disorders of the 
autonomic nervous 
system 
These conditions are notoriously difficult to screen for and diagnose with limited resources. 
Treatment is not available in developing countries. Additionally conditions that produce problems 
with the autonomic nervous system e.g. Parkinson’s Disease will have other neurological symptoms 
and signs and they will therefore be picked up with other questions. 
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2.12.1 Question Modifications 
Each of the Questions was modified from its original form in order to increase the sensitivity and the specificity of the tool; 
these modifications are detailed in the table below, which demonstrates the original question, the final question and the 
reason for modification. 
Table 2.10: Neurological Screening Questionnaire Individual Question Modification Performed Prior to the Pilot Study in 
Order to Increase Sensitivity and Specificity 
Original Question Final Question Reasons for modification 
Do you have 
attacks in which 
you fall with loss 
of consciousness 
and have violent 
shaking of the 
limbs? 
Do you have recurrent attacks in 
which you fall with loss of 
consciousness and have violent 
shaking of the limbs?  
 
Attacks have to be recurrent (more than 1) for a diagnosis of epilepsy 
to be made. Participants had to have all three aspects of a seizure to 
answer positively i.e. falls, loss of consciousness and violent shaking 
of the limbs. This had to be stressed in the question otherwise there 
were a high number of false positives ranging from simple falls or 
syncope to shivering or rigors. 
Do you have brief 
attacks of shaking 
or trembling in 
one arm or leg or 
in the face? 
Do you have recurrent attacks of 
violent shaking in one arm and/or 
one leg and/or in one side of the 
face that are not just brief 
tremors of the hands after 
working hard?  
Attacks have to be recurrent (more than 1) for a diagnosis of epilepsy 
to be made. Importance of violent shaking on one side of the body 
stressed to ensure specificity not reduced by shivering or rigors. 
Initially many people answered positively to this question when they 
had been working hard – their dominant hand was particularly 
affected so this was included as a negating factor. 
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Do your arms or 
legs shake, apart 
from maybe when 
you have drunk 
alcohol? 
Do your arms or legs shake 
multiple times every day not just 
when you have drunk alcohol or 
have been working hard? 
Many people reported that they were occasionally tremulous- this 
was often after a period of illness, hard work or having consumed 
alcohol. Using these as negating factors and adding in the 
requirement for the tremor to be present multiple times every day 
increased the specificity of this question substantially. People often 
reported shaking of the legs due to pain – this was excluded in the 
introductory paragraph again increasing the specificity of the 
question. 
Do you shuffle 
your feet and/or 
take tiny steps 
when you walk? 
Do you shuffle your feet and take 
tiny steps when you walk not just 
because of pain?  
Often elderly people reported tiny steps “because they were old” and 
occasionally shuffling was reported due to tiredness. Both of these 
when asked alone had a low specificity. When asked together (shuffle 
your feet and take tiny steps) they were very specific and sensitive 
for neurological gait disorders as long as pain was excluded as an 
underlying cause.  
Does your head 
shake? 
Does your head shake all or most 
of the time (outside so it is visible 
not inside because of dizziness 
and not just when you are or have 
been carrying something on your 
head)? 
“All or most of the time” was added to the question to increase the 
specificity as many false positives reported head shaking when they 
had been carrying something on their head or when they were saying 
no to someone. The addition of outside so it is visible, not inside 
because of dizziness, was also very important to ensure specificity of 
the question, as many elderly people reported dizziness.  Also the 
vocabulary in Swahili is not as extensive as English, so many words 
have multiple meanings and the Swahili for shaking can also be taken 
218 
 
to mean dizziness.  
Do you have 
recurring 
abnormal 
movements that 
you cannot 
control? 
Do you have recurrent abnormal 
movements anywhere on your 
face or body multiple times every 
day that you cannot control and 
that are not just brief shivers or 
brief jerks of your whole body 
when you are resting?  
Many elderly people reported jerks of their body when they were 
falling asleep at night or when they were resting, these were thought 
to be myoclonic jerks and non-pathological. Thus this was specified in 
the question to increase specificity. The addition of multiple times 
every day was important in order to exclude shivering. 
Do you have 
weakness down 
one side of your 
body? 
Do you have constant weakness 
down one side of your body that 
is there now? 
Often elderly people reported weakness at the end of the day, or due 
to tiredness – the use of the word constant excluded these people. 
General body weakness was occasionally reported due to age – the 
phrase ‘one side of the body’ maintained the specificity of this 
question. Pain was a common cause of a positive answer and this had 
to be excluded in each case. 
Do you have 
persistent 
weakness in any of 
your arms or legs? 
Do you have constant weakness 
in any of your arms or legs or 
hands or feet that is there now? 
Constant and persistent have very similar meanings in Swahili. 
Specifying the weakness was in the arms or legs or hands or feet was 
important to exclude those people who reported whole body 
weakness due to age or tiredness. 
Is one side of your 
face weak? 
Do you have constant weakness 
of one or both sides of your face 
that is there now?  
Facial weakness was often reported due to tiredness, ensuring that it 
was constant and there at the time when the question was asked 
established that the problem was pathological and maintained the 
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specificity of the question.  
Do you have 
persistent 
weakness of your 
eyelids? 
Do you have persistent weakness 
of one or both of your eyelids that 
is there now or that gets worse 
towards the end of the day that is 
not just because you are tired?  
Weakness of the eyelids was often reported due to tiredness and so 
this had to be included in order to maintain specificity of the 
question. The worsening of the problem towards the end of the day 
ensured that the ocular Myaesthenia patients were picked up.  
Do you have 
problems 
speaking? 
Do you have persistent problems 
speaking not just because you 
have a sore throat or mouth and 
that affects you most of the time?  
It was important to include the word persistent, this ensured that 
people who lost their trail of thought were not picked up as positive – 
this was a commonly described problem. Some people also reported 
problems when they were drunk, cold or ill and so the word 
persistent helped to exclude these potential false positives. It was 
very common for people to report problems speaking due to oral 
pathology such as tooth pain and so this was excluded by the 
question. . 
Do you have 
altered sensation 
(tingling or 
numbness) in your 
arms or legs? 
Do you have constant loss of 
sensation (numbness) in your 
arms or legs or hands or feet that 
is there now and not just due to 
cold or pain?  
Cold and pain in the legs/arms were a common cause for a positive 
response to this question before they were excluded. It was 
important to ensure that the numbness was constant as people often 
reported numbness from sitting too long or lying on one side. Almost 
everyone reported tingling sensation that occurred daily in their arms 
or legs and consequently for a patient to answer positively to the 
question they had to report a loss of sensation. 
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Do you have 
difficulty with your 
coordination, such 
as stirring tea with 
a spoon or 
buttoning clothes? 
Do you have persistent problems 
with your coordination such as 
stirring tea with a spoon or 
buttoning clothes that is not due 
to pain in your hands or arms or 
because of drinking alcohol?  
Alcohol was a common cause of coordination problems and so this 
had to be specifically excluded. Coordination was a difficult concept 
for people to grasps and therefore it was important to include 
culturally non-specific examples of how this may come across – 
“stirring tea and buttoning clothes.” 
Do you have 
sustained 
contractions of 
your muscles that 
you have no 
control over? 
Do you have sustained/persistent 
contraction of your muscles that 
you have no control over and that 
produce abnormal positions of 
part of your body, that are not 
just in your legs or just at night or 
just cramp?  
If they happen whilst doing a 
certain task do they occur most of 
the times you do that task?  
Many elderly patients reported pain and stiffness in their hands and 
so this had to be excluded as a positive response. Occasional hand 
cramps/spasms were also thought to be non pathological and the 
wording of the question was modified to exclude them. Leg cramps 
and nocturnal cramps were also incredibly common but thought to 
be non pathological so it was also important to exclude them. It was 
important to include a sub- question to pick up task specific 
dystonias. This question was subsequently removed from the 
screening tool altogether and the reasons for this are elaborated on 
later in the thesis. 
Do you have 
severe pain 
affecting one side 
of your face? 
Do you have recurrent short 
attacks of severe shock like pain 
affecting one side of your face?  
The inclusion of this question was to pick up trigeminal neuralgia. It 
had to be very specific in its wording to ensure that oral pain, ocular 
pain and ear pain were excluded as potential causes as these were 
common complaints. Occasional facial pain was a common symptom 
so the inclusion of the word recurrent was very important. 
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Do you have 
recurrent 
headaches? 
Do you have severe recurrent 
headaches that stop you doing 
your normal daily activities? 
Almost everyone reported recurrent headaches at some point – this 
was commonly associated with working in the sun and not drinking 
frequently. Specifying that they had to be severe and recurrent and 
affect ADLs meant that only disabling headaches were picked up. 
Has anyone ever 
told you that you 
have a 
neurological 
disorder (a 
disorder affecting 
your brain, spinal 
cord or nerves)? 
What is it? 
Is it still there? 
Has anyone ever told you that you 
have a neurological disorder (a 
disorder affecting your brain, 
spinal cord or nerves)? 
a) What is it  
b) Is it still there? 
The sub questions were very important as often people did not know 
whether a disorder affected their brain, spinal cord or nerves and 
consequently they answered positively – often due to arthritis. 
Education of the enumerators was important in ensuring this 
question worked. 
Have you ever 
been told that you 
have or had 
epilepsy or 
epileptic fits or 
seizures? 
Have you been told that you have 
epilepsy or epileptic fits or 
seizures?  
To ensure that the problem of epilepsy (controlled or not controlled) 
was ongoing the word ever was removed from the question, this 
ensured people who reported febrile convulsions as children or 
seizures in times of illness were excluded. 
 
 
 
222 
 
Has anyone ever 
told you that you 
have Parkinson’s 
disease? 
Have you been told that you have 
Parkinson’s Disease? 
This is a very specific question and it remained the same. 
Have you ever had 
a stroke? 
Have you ever had a stroke that 
resulted in long term 
problems/disability?  
As mentioned above we only wanted to pick up patients with stroke 
with lasting deficit, this was because many patients reported a stroke 
that they had previously recovered from completely and it was very 
difficult to ascertain if this was actually the case, or if a stroke had 
been wrongly diagnosed when relying on history alone.  
Have you ever had 
polio? 
Have you ever had polio that 
resulted in long term 
problems/disability?  
Many people reported polio outbreaks as a child, so it was important 
to specify that a positive answer should only be in someone with 
lasting problems/disability as a result of polio. 
Have you ever had 
leprosy? 
Have you ever had leprosy that 
resulted in long term 
problems/disability? 
People reported that they were aware of people who used to live in 
their community with leprosy whom they came into contact with and 
so they may have had it at some point. Some people reported that 
they had previously had a strange rash which may have been leprosy. 
It was therefore very important to ensure that leprosy had resulted in 
long term problems/disability before a positive response was 
confirmed.  
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Three questions were removed altogether: 
1. Do people tell you that you have episodes when you are distant or unreachable? 
During the first days in the field it was found that the majority of people answered 
positively to this question. Elderly people in Tanzania often felt that they were distant 
when they were thinking about something or because they could not hear properly. This 
appears to be a cultural interpretation of the phrase. After discussion with our translators 
it was felt that there was no other way to enquire about the phenomenon of absence 
seizures, which this question was attempting to identify.. After repeat literature review it 
was felt that absence seizures were very rare in the elderly and that if present they were 
associated with generalised tonic clonic or partial seizures. Therefore this question was 
removed and it was not felt that this would affect the sensitivity of the tool but would 
greatly improve the specificity. 
 
2. Do you have severe wasting of your muscles? 
During the first days in the field it was found that everyone answered positively to this 
question. They all stated their muscles had reduced in size because they were old. 
Additionally there was a problem with translation of this question – wasting and loss of 
weight have the same translation in Swahili and consequently many people felt they had 
lost weight as they had got older and therefore answered positively. Its removal did not 
reduce the sensitivity, because if severe wasting was present due to a neurological 
disorder this was picked up by one of the questions with regard to weakness. 
 
3. Do you have problems understanding 
This question was put in to pick up patients with receptive dysphasia. This is notoriously 
difficult to diagnose alone and is unlikely to occur without another symptoms or signs 
associated with stroke. It was also non specific as it picked up people with hearing 
problems. Even when the question was changed to – do you have problems 
224 
 
understanding (not due to hearing problems), it continued to have poor specificity as it 
picked up participants with cognitive impairment. 
 
2.12.2 The Final Screening Questionnaire 
This comprised of 22 questions, 16 of which enquire about symptoms and were as follows; 
1. Do you have recurrent attacks in which you fall with loss of consciousness and 
have violent shaking of the limbs?  
2. Do you have recurrent attacks of violent shaking in one arm and/or one leg and/or 
in one side of the face that are not just brief tremors of the hands after working 
hard?  
3. Do your arms or legs shake multiple times every day not just when you have drunk 
alcohol or have been working hard? 
4. Do you shuffle your feet and take tiny steps when you walk not just because of 
pain?  
5. Does your head shake all or most of the time (outside so it is visible not inside 
because of dizziness and not just when you are or have been carrying something 
on your head)? 
6. Do you have recurrent abnormal movements anywhere on your face or body 
multiple times every day that you cannot control and that are not just brief shivers 
or brief jerks of your whole body when you are resting?  
7. Do you have constant weakness down one side of your body that is there now?  
8. Do you have constant weakness in any of your arms or legs or hands or feet that is 
there now? 
9. Do you have constant weakness of one or both sides of your face that is there 
now?  
10. Do you have persistent weakness of one or both of your eyelids that is there now 
or that gets worse towards the end of the day that is not just because you are 
tired?  
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11. Do you have persistent problems speaking not just because you have a sore throat 
or mouth and that affects you most of the time?  
12. Do you have constant loss of sensation (numbness) in your arms or legs or hands 
or feet that is there now and not just due to cold or pain?  
13. Do you have persistent problems with your coordination such as stirring tea with a 
spoon or buttoning clothes that is not due to pain in your hands or arms or 
because of drinking alcohol?  
14. Do you have sustained/persistent contraction of your muscles that you have no 
control over and that produce abnormal positions of part of your body, that are 
not just in your legs or just at night or just cramp?  
If they happen whilst doing a certain task do they occur most of the times you do 
that task?  
15. Do you have recurrent short attacks of severe shock like pain affecting one side of 
your face?  
16. Do you have severe recurrent headaches that stop you doing your normal daily 
activities?  
A further 6 questions enquired directly about specific diseases. These were as follows; 
17. Has anyone ever told you that you have a neurological disorder (a disorder 
affecting your brain, spinal cord or nerves)? 
a) What is it  
b) Is it still there? 
18. Have you been told that you have epilepsy or epileptic fits or seizures?  
19. Have you been told that you have Parkinson’s disease?  
20. Have you ever had a stroke that resulted in long term problems/disability?  
21. Have you ever had polio that resulted in long term problems/disability? 
22. Have you ever had leprosy that resulted in long term problems/disability?  
 
 Direct questions were not asked as part of the original WHO screening tool [6] and it has 
been criticised for this omission. Therefore we felt that the addition of these latter 6 
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questions was important, they act as “double check” for those patients with the 
conditions specified. 
 
The questionnaire was translated into Swahili and back translated to ensure accurate 
interpretation. The questions were to be asked in Swahili with a local tribal interpretation 
if necessary. 
 
The questionnaire above had been modified from the original one to increase specificity 
without reducing sensitivity as detailed below. The form that is described above is the 
questionnaire that was used and analysed in the pilot study and the results section of this 
thesis. 
 
A preliminary paragraph on the screening instrument reminded each NMI of the purpose 
of the screening instrument, that participants should have symptoms or signs at the time 
of screening or a disorder in which the symptoms or signs occur recurrently, that 
substance abuse, arthritis, and pain should always be ruled out as a cause for the 
symptoms and that a carer can answer on behalf of the patient if the patient is not able to 
answer accurately themselves. This final point was left up to the discretion of the trained 
interviewer, who recorded who answered the questions. The exact wording of the 
paragraph was as follows; 
 
For use to pick up the prevalence of neurological disorders resulting in disability in the 
elderly population aged 70 and over. Participants should have symptoms or signs at the 
time of screening or a disorder in which the symptoms or signs occur recurrently. A carer 
can answer on behalf of the participant if the participant is not able to answer accurately 
themselves. This is left up to the discretion of the trained interviewer, who records who 
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answers the questions. Arthritis and pain should always be ruled out as a cause for the 
symptoms. 
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Table 2.11: Description of what Each Question of the Neurology Screening Questionnaire was Designed to Pick Up 
Question Condition it was designed to pick up. Non Neurological Conditions that 
we did not want to pick up – 
conditions that the enumerator 
was instructed to ensure the 
problems were not caused by. 
Do you have recurrent attacks in which you 
fall with loss of consciousness and have 
violent shaking of the limbs?  
Generalised Tonic Clonic Seizures 
(GTCS). 
Falls AND Loss of Consciousness AND 
Violent Shaking. 
If the patient loses consciousness they 
will not remember hitting the floor. 
The attacks should still be occurring or 
the patient should be on medication to 
control them. 
Falls with no Loss of 
Consciousness (LOC).  
Falls with LOC but no shaking. 
Shaking with no LOC. 
Fainting. 
Patients unwell with 
infection/Malaria. 
Do you have recurrent attacks of violent 
shaking in one arm and/or one leg and/or in 
one side of the face that are not just brief 
tremors of the hands after working hard?  
Partial seizures 
Hemifacial spasm 
Violent shaking of one side of the body. 
Violent twitching of one side of the 
face. 
 
Brief tremor of the hand after 
working hard or when tired. 
Very brief jerks of one side of the 
body. 
Brief occasional tremors. 
Shaking when standing because of 
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pain or weakness. 
Do your arms or legs shake multiple times 
every day not just when you have drunk 
alcohol or have been working hard? 
Parkinson’s Disease. 
Essential Tremor. 
Other Tremor disorders. 
Tremor occurring multiple times every 
day.  
Tremors occurring every time hands are 
at rest. 
Tremors occurring every time person 
does certain actions like drinking tea or 
eating with a spoon. 
Constant tremor whether resting or 
doing something. 
Tremor that only occurs 
occasionally 
Tremor only occurring after  
working hard 
Tremor only occurring when 
unwell e.g. with an infection like 
malaria. 
Tremor occurring only when just 
got up in the morning. 
Tremor occurring only when 
drunk. 
Tremor only occurring in certain 
specific situations, e.g. those that 
makes the patient anxious. 
Do you shuffle your feet and take tiny steps 
when you walk not just because of pain?  
Parkinson’s Disease 
Abnormal walking due to weakness of 
the legs, e.g. previous stroke. 
Tiny steps AND shuffling NOT caused by 
pain. 
Abnormal walking caused by pain 
or arthritis. 
Abnormal walking caused by 
frailty due to old age. 
Do you have recurrent abnormal 
movements anywhere on your face or body 
Dyskinesias 
Occurring multiple times every day. 
Shivering of the body caused by 
cold. 
230 
 
multiple times every day that you cannot 
control and that are not just brief shivers or 
brief jerks of your whole body when you are 
resting?   
Occasional brief jerks of the whole 
body when resting. 
Abnormal movements occurring 
very infrequently. 
Does your head shake all or most of the 
time (outside so it is visible not inside 
because of dizziness and not just when you 
are or have been carrying something on 
your head)? 
Essential Tremor. 
Shaking of the head occurring all or 
most of the time. 
Shaking of the head that is visible.  
Shaking of the head when saying 
no. 
Shaking of the head caused by 
carrying something on the head. 
Shaking of the head inside - 
dizziness 
Brief shivers of the whole body. 
Do you have constant weakness down one 
side of your body that is there now?  
Stroke. 
Injury to one side of the brain or spinal 
cord resulting in hemiplegia. 
Pain. 
Injury to the bones or muscles on 
one side causing pain. 
Being less strong on left hand side 
JUST because right handed and 
vice versa. 
Previous weakness that has now 
completely resolved. 
Deformity on one side without 
weakness. 
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General body weakness due to old 
age. 
Do you have constant weakness in any of 
your arms or legs or hands or feet that is 
there now? 
Monoplegia/paralysis. 
Paraplegia/paralysis. 
Hemiplegia/paralysis. 
Quadriplegia/paralysis. 
Pain. 
General body weakness due to 
tiredness or age. 
Deformity of the fingers due to 
arthritis or farming. 
Deformity without weakness.  
Do you have constant weakness of one or 
both sides of your face that is there now?  
Upper or lower motor neuron facial 
palsy. 
Asymmetry of one side of the face 
that has always been there – with 
no actual weakness. 
Weakness of the eyes/loss of 
vision. 
Do you have persistent weakness of one or 
both of your eyelids that is there now or 
that gets worse towards the end of the day 
that is not just because you are tired? 
Ptosis caused by cranial nerve 
pathology or Horner’s syndrome. 
Ocular Myaesthenia gravis. 
Unilateral or bilateral. 
Tiredness. 
Visual problems – weakness of the 
eyes. 
Wrinkles. 
Do you have persistent problems speaking 
not just because you have a sore throat or 
Dysphasia. 
Dysarthria. 
Very occasional problems. 
Problems with speech due to sore 
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mouth and that affects you most of the 
time?  
Dysphonia. tongue, mouth or problems with 
teeth. 
Slurred speech when drunk. 
Problems when cold/teeth 
chattering. 
Very occasional difficulty finding 
the right word. 
Problems only when ill or that has 
now resolved. 
Do you have constant loss of sensation 
(numbness) in your arms or legs or hands or 
feet that is there now and not just due to 
cold or pain? 
Loss of sensation – multiple causes e.g. 
Peripheral neuropathy. 
Mononeuropathy. 
Polyneuropathy. 
Stroke. 
Brain or spinal cord injury. 
CONSTANT Loss of sensation THAT 
DOES NOT GO AWAY. 
LOSS of sensation NOT JUST pricking 
sensation. 
Pain. 
Cold. 
Sitting in particular positions. 
Lying on part of body 
Loss of sensation of whole body. 
Do you have persistent problems with your 
coordination such as stirring tea with a 
spoon or buttoning clothes that is not due 
Cerebellar ataxia. 
Sensory ataxia. 
Problems with precise actions due 
to pain. 
Problems when drunk 
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to pain in your hands or arms or because of 
drinking alcohol? 
Lack of coordination when using 
non-dominant hand. 
Do you have sustained/persistent 
contraction of your muscles that you have 
no control over and that produce abnormal 
positions of part of your body, that are not 
just in your legs or just at night or just 
cramp?  
If they happen whilst doing a certain task do 
they occur most of the times you do that 
task?  
Dystonia. 
Constant or frequent. 
Contraction of the muscle with twisting 
movements and distorted postures of 
parts of the body that the person 
cannot control.  
If get spasms of the hand when doing 
actions such as pruning, washing, 
should happen every time do that 
action. 
Should cause distortion of position of 
the body. 
Cramps. 
Infrequent cramps when been 
working hard. 
Leg cramps at night or just at rest. 
Cramps anywhere just at rest. 
Stiffness when just got up/cramps 
when been sitting for a long time. 
Just in legs. 
Pain in joints. 
Pain in muscles. 
Spasms of hands occurring very 
occasionally – often when been 
working for a long time. 
Do you have recurrent short attacks of 
severe shock like pain affecting one side of 
your face? 
Trigeminal neuralgia. 
Facial pain - Severe AND Recurrent AND 
Very brief (lasting less than one second) 
AND Stabbing or shock like 
Often triggered by touch, eating and 
talking. 
Eye pain/symptoms. 
Sinus pain/symptoms. 
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Do you have severe recurrent headaches 
that stop you doing your normal daily 
activities?  
Disabling headaches –multi-factorial. 
Migraine. 
Other headache syndromes. 
Severe AND recurrent headaches THAT 
Affect ADLs. 
Headaches when the person can 
still carry on normal daily activities 
despite the headaches. 
Headaches just when ill for 
another reason e.g. Malaria. 
Has anyone ever told you that you have a 
neurological disorder (a disorder affecting 
your brain, spinal cord or nerves)? 
What is it  
Is it still there? 
All neurological disorders. 
The chance to describe the disorder 
ensures that the problem is still present 
and that the problem is a neurological 
disorder. 
Patients with a disorder affecting their 
brain, spinal cord or nerves 
that is causing ongoing problems,  
Constant or recurrent symptoms. 
Need to document what they say the 
diagnosis is. 
Need to document if it is still there. 
Disorders that are not 
neurological. 
Disorders that have completely 
resolved. 
 
Have you been told that you have epilepsy 
or epileptic fits or seizures?  
Epilepsy with ongoing seizures or 
controlled on treatment. 
People who had epilepsy when 
they were a child or a young adult 
but do not have seizures now AND 
are not on treatment. 
Have you been told that you have Parkinson’s Disease.  
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Parkinson’s Disease?  
Have you ever had a stroke that resulted in 
long term problems/disability? 
Stroke with residual deficit. Symptoms that have completely 
resolved. 
Have you ever had polio that resulted in 
long term problems/disability? 
Polio with long term disability e.g. LMN 
weakness/Monoplegia/paraplegia.  
Polio that has not resulted in 
disability. 
Polio that just gave the person flu 
like symptoms. 
Polio that caused weakness at the 
time but from which the patient 
has completely recovered.  
Have you ever had leprosy that resulted in 
long term problems/disability?  
Leprosy that has resulted in disability. 
Paraesthesia. 
Amputations. 
Leprosy with no long term 
disability. 
Leprosy with rash only and no 
numbness. 
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2.12.3 Modification of the screening tool at the end of data collection 
One question; Question 14 “Do you have sustained contraction of your muscles that you 
have no control over and that produce abnormal positions of part of your body, that are 
not just in your legs or just at night or just cramp? If they happen whilst doing a certain 
task do they occur most of the times you do that task?” was designed to pick up dystonia 
and other rare conditions such as paramyotonia which cause abnormal contraction of 
muscles. It was removed after the data collection part of the study was completed. It was 
felt that accurate and practical use of this question was problematic for the following 
reasons;  
1. As detailed in the introduction these conditions are very rare. The estimates on 
prevalence of dystonia vary from 0.007 – 0.391/1000 depending on the type of 
dystonia and the population group studied [444-447]. The prevalence of 
paramyotonia is even less, approximately 1/100,000, it is classed as a rare disease 
by the National Institutes of Health (NIH) Office of Rare Diseases Research (ORDR) 
[448].  
2. These conditions require the following for a definitive diagnosis; 
a. A very accurate history with an accurate family history – difficult in this 
setting when using interpreters and where many patients hide symptoms 
due to fear of stigma and therefore do not disclose them to family 
members. Admitting positive family history has implication for future 
marriages in the family and consequently is frequently not disclosed 
despite direct questioning 
b. An examination that allows reproduction of the conditions that produce 
the symptoms. This was very difficult as the condition’s symptoms often 
only occurred in certain circumstances or on exposure to cold. These were 
both difficult phenomenology to reproduce during village fieldwork in SSA. 
c. Specialized investigations 
i. Neurophysiology – NCS and EMG 
ii. Blood tests – Voltage Gated Sodium Channels in Paramyotonia 
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These investigations are not widely available in Tanzania, SSA and most 
developing countries. Their use is not practical in simple low budget prevalence 
studies. 
3. Complex wording of this question was required in order to maintain its 
specificity. Consequently this question was very difficult to teach to NMI and if this 
was not done carefully it was felt this question still had the potential to produce a 
large number of false positives and have a low specificity.  
 
It was also felt that identification of these conditions was not beneficial to the individual 
patients. Patients picked up using this question appeared to have task specific dystonia 
and paramyotonia. Accurate confirmation of these diagnoses was not possible for the 
reasons detailed above. It seems more probable given the rarity of these conditions the 
symptoms were caused by simple (and more common) musculoskeletal problems. In 
addition these patients did not find the problems disabling and had practical solutions to 
resolve the symptoms.  
 
In summary it was felt that the removal of this question would be beneficial to maintain 
the simplicity and specificity of the questionnaire whilst it would not compromise the 
sensitivity of what the questionnaire was designed to do; identify patients with disabling 
neurological conditions.  
 
The final screening questionnaire in English and Swahili is attached in appendix 2.8 and 2.9 
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2.12.4 Training the NMI in the use of the screening questionnaire 
Fifteen people (ten females) were recruited from the local population to act as NMI. All 
NMI were graduates of higher education and their occupations included teachers, village 
administrators, and those running small businesses. 
 
2.11.4.1 The Workshop 
Formal training of the NMI on the use of the screening questionnaire occurred over 2 
days. Two workshops were held for the NMI involved in the pilot study in October 2009 
and a further two workshops were held in January and February 2010 for the NMI 
involved in the main study (the pilot NMI were also invited to attend these workshop to 
share their expertise). Each was one day long and they were a week apart. Their purpose 
was to teach the NMI how to use the screening questionnaire and what diseases needed 
to be identified. The NMI and the supervisors, were invited to participate and all attended. 
Each question from the screening tool was presented as part of a power point 
presentation. The audience was shown text, pictures and videos where appropriate of the 
conditions relevant to each question. They were also shown a video demonstrating how 
the question should be asked and typical positive and negative responses to the question. 
Prior to the result of whether the question should be scored positively or negatively the 
enumerators were asked to score it themselves and to give reasons for their score. Small 
group and one to one teaching was then performed to ensure each NMI was competent 
to perform the screening questionnaire. Question and Answer sessions were held for any 
queries. Teaching material was given to be taken home with full explanations of positive 
and negative responses to each question. These could be referred to in the field. Please 
see appendices 2.11 to 2.13. 
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2.12.4.2 Further training in the field  
Further training and observation was provided in the villages.  The NMI screened under 
direct observation of the RD and the SN for the initial visits to a village. The number of 
days this took place depended on the enumerator’s competence. The NMI was allowed to 
screen alone when deemed competent to do so by both the RD and the SN. NMI were 
deemed competent to screen independently when their responses were consistent with 
that of the RD. Once the NMIs were deemed competent their response to the screening 
questionnaire was taken as final and not modified. When independent screening was 
taking place in a village the RD and the SN were present to answer any queries that the 
enumerator may have. On the rare occasion that this was not the case they were always 
directly contactable by mobile phone. All enumerators had their own mobile phone.  
  
 In conclusion this comprehensive training programme reduced any filtering that might be 
done by the NMIs and provided assurance that positive cases would be detected. 
 
2.12.4.3 Blinding of the RD to the results of the screening questionnaire 
In both the pilot and the main study, the RD was blinded to the results of the 
questionnaire prior to the completion of a full history, examination and conclusion as to 
the presence or absence of a neurological disorder. In the pilot study the RD did not know  
if the patient was a positive responder and which question they had responded positively 
to. In the main study population, as all participants seen by the RD were positive 
responders,  the RD was blinded only to which question the participant had answered 
positively.  
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2.13 The Pilot Study 
The pilot study took place between November 2009 and January 2010. We initially carried 
out final question modifications as detailed above. Then all participants in the pilot village 
were assessed using the final questionnaire to evaluate its sensitivity and specificity. The 
village of Mudio was selected to be the Pilot Village. It was randomly selected using a 
random number generator. To our benefit it was a convenient village 20 minutes drive off 
the main road, it had its own health centre which made it easier to see the ambulant 
patients and 2 enumerators facilitated work in the village up to 5 days per week. 
 
From the census it was reported that 345 patients aged 70 and over resided in Mudio, but 
it became evident that 5 were recorded twice.  32 people aged 70 and over who lived in 
Mudio but were not on the census were also seen. The main reason for them not being on 
the census was that they had turned 70 between the census date and our prevalence date 
of the 1st January 2010. In a minority of cases patients had travelled to another area 
during the census. Collecting accurate information on patient age can be difficult in SSA, 
as few people have a birth certificate [443].  Age was calculated from birth year and 
confirmed using memory prompts (e.g. age at independence) where necessary. This 
method has been previously validated [449]. We do recognise that there was a potential 
incentive for participants to say they were aged 70 or over in order to be included in the 
study but all possible attempts were made to try to eliminate this cause of bias. It is 
however impossible to say this problem was eradicated completely.  
 
In total it was not possible to see 95 patients for the following reasons; 40 refused to be 
seen, 21 had died, 22 had moved and 12 were too young. Therefore altogether 277 
patients were seen. 
 
All these pilot participants were seen by the RD with the SN and a NMI. A demographic 
section with an age ascertainment section preceded the screening tool itself. Subsequent 
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to this a full Neurological History and Examination was performed by the RD. The level of 
Disability was also investigated with a Barthel Index. Patients were either seen at the 
village health centre, central large houses that could accommodate numerous patients 
after consent from the home owners or patient’s own homes. None of the patients who 
answered the screening questionnaire refused to take part in the full history and 
examination. As a result of the screening questionnaire and the full neurological history 
and examination patients were allocated to one of four groups, true positives, false 
positives, true negatives and false negatives. From this sensitivity, specificity, positive 
predictive value and negative predictive value were calculated.  
 
2.13.1 The Pilot Study Proforma 
All sections of the Pilot Study Proforma (appendix 2.10) were asked by the RD and the SN 
to all people in the Pilot Study. The sections were as follows; 
 Demographics 
 The Barthel Index 
 Measurement of blood pressure – 3 
supine and 1 standing 
 Height and Weight Measurement 
 Neurological history 
 Past medical history 
 Drug history 
 Social history 
 Family history 
 Neurological examination 
 Summary 
 Diagnosis  
 Management plan 
 
The Neurology screening questionnaire was asked by the NMI after 2 days of workshops 
and further training within the village until the NMI was deemed competent by the RD as 
detailed above. 
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2.14 The Random Selection of the Main Study Villages 
We planned to see one-quarter of the entire population aged 70 years and over in the 
DSS. The number required was calculated from the numbers of people aged 70 and over 
on the census in June 2009. Using a random number generator and stratification for 
upland and lowland villages, 12 villages in total (1 in pilot and 11 additional), with a total 
census population of 2425 aged 70 and over were selected. Exclusions, refusals and 
additions are shown in Figure 3.2, giving a final cohort of 2232 people. Villages were 
stratified to ensure there were representative proportions from each of the upland and 
lowland areas that reflected the proportions in the whole DSS. In the DSS, of those aged 
70 years and over, 76.2% live in upland areas and 23.8% in lowland areas. We studied 
eight upland villages (n=1683, 75.4%) and four lowland villages (n=549, 24.6%). 
Stratification for upland and lowland was felt necessary because of different trial origins 
and socioeconomic status, with those in upland areas being more prosperous due to them 
having better agricultural land. 
 
2.15 The Prevalence Date  
The prevalence date was January 1st 2010 selected to enable the majority of patients with 
neurological conditions identified from screening to be included in the prevalence figures. 
As many Neurological disorders are progressive and some elderly people are likely to have 
died in the nine months during which the study was ongoing the early prevalence date 
ensured that the majority of patients screened could be included in the study. To ensure 
the prevalence data was accurate patients were only included in the numbers if they had 
their neurological condition on or before January 1st 2010. This did not exclude any 
patients with neurological diagnoses, this is to be expected since most neurological 
diseases are chronic in nature.  No patients seen during the pilot study died before the 
prevalence date.  
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2.16 The Main Prevalence Study  
We performed the main prevalence study from February to July 2010. It was felt that the 
most accurate way of screening would be to bring all patients aged 70 and over (who were 
able) within a village to a central meeting place (often a village dispensary and more than 
one was utilised in large villages) to be screened whilst the RD and SN were there seeing 
positive responders. The RD and the SN saw those that screened positive, as previously 
stated, they were blinded to the results of the screening questionnaire prior to 
neurological assessment. Those that screened negative were also observed walking, 
providing consent and holding a conversation by the RD or SN to ensure that no obvious 
diagnoses were missed. Approximately two weeks were spent in each of the remaining 
villages. The duration varied dependent on the size of the village. The days were not 
usually consecutive as enumerators were often not available all days of the week as they 
had other employment. Therefore two or even three villages were often “active” at the 
same time to ensure flexibility and continued work. Using this method we were able to 
organise our time so that villages that were problematic to access in the rainy season 
were seen before or after this period. The rainy season, although unpredictable, usually 
starts at the beginning of March in Northern Tanzania, and lasts for two months or more. 
During this time many of the dirt roads higher up the mountainside become impassable, 
thus access to patients that live in very remote rural areas was problematic. Even with this 
prioritisation and organisation, due to the prolonged rains in 2010 which lasted from early 
March to mid July, access to many of the villages, particularly along smaller roads to 
patient’s houses, was difficult, but with the use of a four wheel drive vehicle it was 
achieved. On some days, field work had to be abandoned due to extreme weather. 
However all of the patients, from the 11 villages in the main study, were seen despite 
inclement weather. 
 
As Neurological disorders and other co morbidities common to “old-age” have the 
potential to cause severe disability it was anticipated that a proportion of the elderly 
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patients would have to be seen in their own home. This would obviously take longer and a 
few days at the end of the allocated two weeks in each village were set aside for this.  
 
None of the patients that responded positively to the screening questionnaire refused to 
take part in the study.  However there was one patient who was screened when the study 
doctor was in mobile phone contact only and subsequently could not be traced as she had 
travelled out of the district. 
 
The breakdown of patients seen in the Main Study is shown in the results section (table 
3.17). This table includes data on those who refused to be seen, those who had died, 
those who had moved away and new additions to the village’s 70 and over population 
since the census was performed 6 months earlier. The reasons for the new additions were 
mostly due to participants turning 70 between the census date and the prevalence date as 
described in the section  Pilot Study Population above. 
 
2.16.1 The Main Study proforma 
The Main Study Proforma (Appendix 2.14 and 2.15) was very similar to the Pilot study 
Proforma. The difference was that it was divided into 2 main sections; 
1. Sections that were asked by the Enumerator to all people aged 70 and over 
(Appendix 2.14 The Participant Selection Proforma for the Main Study) 
2. Sections that were asked by the RD and SN only to those people that screened 
positive (Appendix 2.15 The Main Study Proforma) 
 
The other difference was the addition of a sub-section in the initial section which included 
questions that asked people to self report visual problems, diabetes, hypertension and 
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hypertension treatment. This was not required in the Pilot Study as all patients were 
asked a past medical history and drug history section which explored these problems.  
 
Sections in the participant selection proforma that were asked by the Enumerator/NMI to 
all people aged 70 and over were; 
 Demographics 
 Neurology Screening Questionnaire 
 The Barthel Index 
 Height and Weight Measurement 
 Simple questions on Visual 
problems, diabetes, hypertension 
and daily compliance with 
hypertension treatment 
 Measurement of blood pressure 
 
Sections in the Main Study proforma that were asked only to those people that screened 
positive were;  
 Check box for true positives or false 
positives 
 Details of responses to Neurology 
screening questionnaire 
 Neurological History 
 Past medical history 
 Drug history 
 Social history 
 Family history 
 Neurological examination 
 Summary 
 Diagnosis 
 Management plan.  
 
The Past Medical History (PMH), Drug History (DH), Family History (FH) and Social History 
(SH) sections allowed risk factors and health beliefs to be explored.  
 
The proforma ensured that the questions were carried out in the same order with each 
patient.  A scoring system was defined for each closed question: 1=no, 2=yes.  For more 
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detailed questions, possible answers were thought out in advance and also assigned a 
numerical value e.g.  
Traditional Healer Intervention? Yes No 
Type of Treatment     Length of Treatment: 
1. Oral medication   |___| 
2. Bath     |___|  1.  Less than one wee k |___| 
3. Inhalation    |___|  2.  1 – 2 weeks  [___] 
4. Topical     |___|  3.  2 weeks – 1 month  [___] 
5. Roots/leaves    |___|  4.  More than one month [___] 
6. Scarification   |___| 
7. Other (state):____________  |___| 
 
This ensured that it was quick and easy to complete the proforma and to enter results 
from the proforma into Excel and SPSS databases. 
 
For specific neurological conditions, the gradation of severity through the use of scoring 
systems was performed and additional classification systems were utilised. 
 Essential Tremor – Movement Disorder Society (MDS), National Institutes of Health 
(NIH), Tremor Investigation Group (TRIG) [86-90, 450] 
 Other Tremors – Movement Disorder Society (MDS) [86] 
 Parkinson’s Disease – UK PDS Brain Bank Criteria/Modified Hoehn and Yahr [118, 
122] 
 Vascular Parkinsonism – Winikates criteria [171] 
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 Progressive Supranuclear palsy – National Institute of Neurological Disorders and 
the Society for Progressive Supranuclear Palsy (NINDS-SPSP) [167] 
 Stroke – The Oxford Community Stroke Project Classification (OCSP)/Bamford 
Classification [212] 
 Tardive Dyskinesias – American Psychiatric Association Task Force [451] 
 Headaches – International Headache Society (IHS) [179] 
 Epilepsy – International League Against Epilepsy (ILAE) [291, 292] 
 Motor Neuron Disease – National Institute of Neurological Disorders and Stroke 
(NINDS) [452] 
 Spinal Injury – American Spinal Injury Association (ASIA) [453, 454] 
 Myaesthena Gravis – Myaesthenia Gravis Foundation of America (MGFA) [455] 
 
The Bamford Classification [212] is designed to classify the type of stroke at the time of 
presentation. Patients were therefore put into categories based on the symptoms and 
signs they described when they initially had the stroke rather than at the time they were 
seen by the RD and the SN. This relies on retrospective information from the patients and 
the patient’s family and so has its limitations in terms of accuracy but it was felt this was 
the most appropriate way of using this classification system.  
 
All data was entered into a specially designed Microsoft Excel database which used 
numerical values to save time and to allow direct conversion into the Statistical Package 
for the Social Sciences (SPSS) version 17 for analysis. Data entry was performed by the RD 
whilst on location in Tanzania on a lap top computer.  This ensured that little time had 
passed between seeing the patient and entering their results. It also allowed any missing 
values or further questions to be followed up by the RD while still in Tanzania. Additionally 
each true positive had a word document completed about them, this detailed in depth 
their neurological history, examination, diagnosis, treatment plan and plans for follow up. 
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2.17 Examination  
Examination was performed either in a health centre, dispensary or private house. 
Adequate privacy was ensured at each place.  This comprised basic medical and detailed 
neurological examination, followed by height, weight, BP and ECG recording. The latter 
were completed because the study was performed in association with my colleague Dr 
Matthew Dewhurst who studied these records in the same population, the protocols for 
these are therefore described below but will not be elaborated on further. 
 
2.18 Photographs and Video recording 
Pictures and videos were taken if relevant to the case and the patient consented.  There 
were standardised scripted video examinations: one for patients who screened positive 
for tremor, another for patients who were thought to have Parkinson’s disease or 
Parkinsonism, another specified movement disorder or if the diagnosis was in doubt.  All 
videos were reviewed by a movement disorder expert (RW) or a Neurologist (NW or WH) 
who was blinded to the diagnosis made by the RD.  
 
2.19 Blood pressure recording 
Blood pressure (BP) was recorded after the patient had been sitting quietly for 5 minutes. 
It was recorded 3 times with 1 minute between each recording. If possible, the patient 
was asked to stand for 3 minutes and a further blood pressure was recorded. The mean BP 
was recorded as the mean of the 2nd and the 3rd blood pressure recordings. This is as per 
the standard research protocol [456, 457]. 
 
2.20 ECG Recording  
A standard 12 lead ECG was recorded after the patient had been lying down for 5 minutes. 
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2.21 Nutritional examination 
The patients’ height and weight was recorded to calculate a body mass index (BMI).  Some 
patients were physically unable to stand; therefore, height and weight could not be 
measured.  In these cases demi-span was recorded and approximate height was 
subsequently calculated.  Demispan is the distance from the midline of the sternal notch 
to the tip of the middle finger along either horizontally outstretched arm. The following 
equations calculate height: for a man: height = (1.40 x Demispan in cm) + 57.8 and for a 
woman, height = (1.35 x Demispan in cm) + 60.1 [458].  
 
2.22  Diagnosing Neurological Disorders 
There are diagnostic tests available for some Neurological Disorders, however, even 
within the western world clinical diagnosis is often the gold standard. As resources within 
sub-Saharan Africa are limited by a lack of facilities and additionally by the patient’s 
finances, neurological investigation in a population mainly made up of subsistence farmers 
is impossible and in any case, does not reflect normal circumstances. As discussed above 
multiple clinical criteria for each disease were used to make each diagnosis. CT scans are 
available in Northern Tanzania as are basic blood tests. However our patients could not 
afford these investigations. Magnetic resonance imaging, nerve conduction studies, 
electomyelography and blood tests diagnostic of specific neurological disease are not 
available in this region of Tanzania. 
 
2.22.1 Ensuring the correct neurological diagnoses were made 
All true positives, false positives and all pilot study patients were discussed with a 
consultant geriatrician, neurologist or movement disorder expert depending on the 
diagnosis made by the RD, for example all movement disorders were discussed with a 
movement disorder expert , all stroke patients were discussed with a consultant 
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geriatrician, and all remaining  neurology cases  were discussed with a Consultant 
Neurologist either within Tanzania (Dr William Howlett) or back in the UK (Dr Naomi 
Warren) . Full neurological history and examination were discussed in each case. Scripted 
videos were recorded and shown to the expert where appropriate e.g. movement 
disorders. The expert was blinded to the diagnosis made by the RD in each case, however 
this is limited by the fact that the movement disorder expert and the geriatrician knew 
that the cases that they were to assess had been identified as movement disorder and 
stroke respectively. 
 
2.23 Patients with Neurological Diagnoses 
Patients with a Neurological diagnosis were given a full explanation of their condition. 
Those that were amenable to treatment that was routinely available within Tanzania were 
given a month’s supply of treatment along with a full explanation of side effects, any 
monitoring required and a prescription to obtain more when they ran out. Unfortunately 
due to our financial constraints we were not able to offer a longer supply except in the 
case of Parkinson’s disease. Although patients often could not afford repeat prescriptions, 
there were 3 opportunities for them to get free or cheaper health care and these 
possibilities were pointed out to them as there was limited awareness of these schemes. 
They were as follows; 
 Free health care is available to all patients aged 70 and over through application to 
their local village council. This then has to be approved by the district medical 
officer. This process is often lengthy and logistically difficult 
 Families of government workers, or those people who have ever been government 
workers, are entitled to free health care 
 10,000 Tanzanian shillings (£5) can be paid per year to the local government 
dispensary or health centre and this entitles a person and their whole family to 
free health care for one year.   
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Table 2.12: Neurological diagnoses with available treatment in Tanzania. 
Neurological 
Diagnosis 
Additional 
investigations offered 
Treatment 
Available 
Cautions Side effects Follow up 
offered as 
part of the 
study? 
Stroke BP 
BM 
Aspirin. 
BP treatment. 
Diabetes 
treatment if 
diabetic. 
Walking aid 
requirement 
assessment. 
Aspirin given if no CTH 
done based on best 
evidence if no CT scan 
available. 
Side effects of BP 
treatment, diabetes 
treatment and 
aspirin explained. 
No 
Essential tremor BP 
ECG 
Propranolol Propranolol given unless 
contraindicated by BP, PR 
interval or other ECG 
abnormalities or h/o 
cardiac syncope. 
Hypotension  
Syncope 
Wheezing  
Claudication 
Yes 
Parkinson’s 
Disease 
BP Levodopa Not to be stopped 
suddenly. Ongoing supply 
available. 
Postural 
hypotension 
Nausea 
Yes – long 
term with 
ongoing 
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Dyskinesias 
Hallucinations 
treatment 
Epilepsy BP  
ECG 
24 hour or 7 day event 
recordings to exclude 
other causes of 
collapse if indicated by 
the history 
Phenobarbitone 
or Phenytoin 
Not to be stopped 
suddenly. Ongoing free 
supply available as part of 
Tanzanian Government 
Strategy. 
As per medication 
prescribed. 
Yes 
Orthostatic 
Tremor 
 Phenobarbitone 
or Clonazepam 
Not to be stopped 
suddenly. 
As per medication 
prescribed. 
Yes 
Hemifacial spasm  Carbemazepine  Nausea and 
vomiting 
Dizziness 
Tiredness 
 
Trigeminal 
Neuralgia 
 Carbemazepine    
Polyneuropathies BM/Diabetic screen Diabetic 
treatment 
Vitamin/food 
 As per medication 
prescribed 
No 
253 
 
supplements 
Headache  Simple 
analgesia 
 As per medication 
prescribed 
No 
 
Infectious diseases like leprosy were deemed treatable if in the acute phase. Other conditions were deemed treatable if 
effective rehabilitation strategies would improve morbidity. 
 
254 
 
2.23.1 Questioning those with neurological disorders about health seeking behaviour, 
previous diagnoses and treatment 
All participants identified with a neurological dosorder were asked if they had sought 
treatment for their condition, whether they had recieved a diagnosis and whether they 
were currently being treated.  Treatment seeking included visiting traditional healers and 
un-registered private pharmacies and dispensaries as well as more formal healthcare 
facilities. If patients responded that they had recieved a diagnosis details of the diagnosis 
given were taken, a diagnosis was deemed correct if it corresponded with that of the RD 
and the consultant expert. If patients responded that they were receiving treatment the 
type and level of treatment was checked and recorded. Patient handheld records were 
reviewed where possible but this was in a limited number of cases as very few patients 
had them or if they did very little was recorded in them. Other formal records did not exist 
except in the tertiary referral hospital (KCMC) which very few of the participants had 
visited. 
 
A correct diagnosis was defined as a diagnosis that corresponded to that made by the 
research doctor and the expert consultant this was expressed as a percentage of all of 
those people with a neurological disorder, not just those who had sought treatment, this 
was because this reflects the true diagnosis gap as most people did not seek help for their 
symptoms for geographical and financial reasons, therefore this is also a failing of the 
healthcare system in Tanzania.  
 
Correct treatment was defined as the treatment that was recommended by the WHO and 
expert review articles for the condition diagnosed [459] this was expressed as a 
percentage of all of those people with a neurological disorder, not just those who had 
sought treatment, this was because this reflects the true treatment gap as most people 
did not seek help for their symptoms for geographical and financial reasons, therefore this 
is also a failing of the healthcare system in Tanzania[460]. 
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2.24 Patients with multiple Neurological Diagnoses 
For every patient who responded positively to the screening questionnaire, or was 
brought to our attention by an alternative method, a diagnosis was reached.  In some 
cases patients had more than one diagnosis, and each diagnosis was taken into account in 
the analysis of results and the prevalence of multiple diagnoses was also recorded. 
Whether the patient was a true positive, false positive, false negative or true negative was 
established by reflecting on what answers were given to the questionnaire in order to 
bring them to the attention of the RD.  For example, one patient had essential tremor, a 
previous stroke and osteoarthritis.  However, in this case the reason he had answered 
positively to the screening questions was because of his tremor, abnormal gait and 
weakness following his stroke.  Arthritis contributed to pain when walking, but he was 
more limited by the stroke.  The most disabling neurological diagnosis was recorded as the 
primary diagnosis, in this case the stroke. The essential tremor was recorded as his 
secondary diagnosis. Other incidental non neurological diagnoses were also recorded. All 
True Positives were assigned a WHO ICD 10 code and were split into epidemiological and 
clinical diagnostic divisions (see appendix 3.1). 
 
2.25 False Positives and True and False Negatives 
As with the Neurological cases, many of the false positives and the true and false 
negatives had no access to medical care for their medical needs. As much information and 
explanation about their condition was imparted at the time of examination by the RD as 
possible. If the patient was deemed negative by the enumerator but had a medical 
problem they wanted to discuss with the RD this service was offered. As part of another 
project which was ongoing at the same time each patient had their Blood Pressure 
measured and an Electrocardiograph (ECG) performed. Treatment for any problems 
demonstrated by their investigations was given, as was a prescription which described 
ongoing medication requirements. This was always fully discussed with the patient (and 
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their family if necessary and, if appropriate, with consent from the patient). Many patients 
had severe arthritis and had limited access to analgesia due to financial constraints. A 
small supply of analgesic (paracetamol) was given in each of these cases following 
assessment for contraindications.  In some cases further investigations would be needed 
to make the diagnosis and these were explained to the patient and their family if present, 
and appropriate referral letters were given. 
 
2.26 Other case finding methods 
Multiple other case finding methods were used to guarantee no cases were missed to 
ensure our prevalence data was as robust as possible.  
 
2.26.1 Positive family history 
In the Main study proforma a family history of neurological disorders/symptoms was 
taken (either similar to the symptoms of the patient or other neurological symptoms). This 
was particularly relevant to conditions such as essential tremor.  Any patients who 
mentioned relatives living within the studied villages who were 70 or above and who had 
neurological symptoms were asked for the relative’s details. It was anticipated that if the 
patients had not already been picked up by the screening questionnaire then these 
individuals would be visited by the RD.  The supervisors assisting with the study would be 
able to contact the relative and gain permission for the visit and explain again about the 
project before the assessment. This system was not however required as all patients 
brought to our attention by this method had already been identified by the screening 
questionnaire. 
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2.26.2 Tanzanian stroke incidence project  
The Hai DSS has been the site of the Tanzanian stroke incidence project (TSIP) which 
began in June 2003. An area of Dar es Salaam was also studied [213, 461]. The last follow 
up for this project was in July 2008. The stroke project research doctor was able to tell us 
about any patients aged 70 and over on our prevalence date who had confirmed strokes 
within our randomly selected villages and who were still alive with neurological deficit at 
last follow up. These names were checked against our positive list, again all these patients 
had already been identified by the screening questionnaire and they had all been seen by 
the RD.   
 
2.26.3 The Hai Parkinson’s disease and Essential Tremor Project 
The Hai DSS had been the site of the Hai Parkinson’s Disease Prevalence Project with a 
prevalence date of the 1st March 2006 [96, 128].The last follow up for this project was in 
January 2010. The Parkinson’s disease project research doctor was able to tell us of any 
patients aged 70 and over on our prevalence date who had Parkinson’s disease or 
Essential Tremor within our randomly selected villages and who were still alive at last 
follow up. These names were checked against our positive list, again all of these patients 
had already been identified by the screening questionnaire and they had all been seen by 
the RD. 
 
2.26.4 The Hai Epilepsy Prevalence project 
The Hai DSS has been the site of the Hai Epilepsy Prevalence project which began in 
January 2009.The last follow up for this project was in August 2010. The Epilepsy project 
research doctor was able to tell us of any patients aged 70 and over on our prevalence 
date who had confirmed Epilepsy within our randomly selected villages. These names 
were checked against our positive list, again all these patients had already been identified 
by the screening questionnaire and they had all been seen by the RD. 
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2.26.5  Local village elder reporting 
In each village there are a number of elderly, respected individuals in positions of 
authority and there is a "Ballozi”, each village is split into “cells” consisting of ten 
households and the elected Ballozi is in charge of those cells. Both of these groups of 
people inform the enumerators of any significant events, (including illnesses) in the 
village. This reporting system was utilised to identify potential false negatives.  
 
2.26.6 Methods not used 
At the start of the methods section, I have discussed various alternative methods for 
detecting cases of Neurological Disorders including medical records and pharmacy 
searches.  These were not employed in this study because they were not felt to be able to 
add anything to the methods already described.  For example, following up prescriptions 
of medication for Neurological Disorders, as we felt so few patients would know their 
diagnosis and be on treatment this would be futile and in any case pharmacy records were 
not accessible. We were unable able to chase up death certificates as less than 5% of 
deaths are certified, or use disease registers as no formal systems exist. We did not try to 
find patients through hospital records. The only hospital with formal accessible hospital 
records was KCMC. We did ask a sample of the 70 and over population in Mudio, the Pilot 
Village, if they had ever been to KCMC. The response was low thus the potential to find 
cases this way would also be low.. Most local hospitals, health centres and dispensaries 
employed the system that the patients carried their records with them in the form of an 
exercise book and no other records were kept. Consequently they were asked to bring this 
with them when they were seen and these were reviewed. 
 
  
259 
 
2.27 Follow up 
All participants identified as having a neurological (or other) disorder were given 
information on the condition and possible treatments at the time of diagnosis, by the RD. 
The patients were given the NMI's contact details and instructed to contact the NMI who 
would contact the RD if they had any further questions.  Information sheets on each 
condition were not used as the majority of patients were either illiterate or had limited 
skills in reading and writing. However all patients were provided with a written piece of 
paper detailing their condition and relevant treatment options if available. This could be 
used to inform healthcare professionals that may be involved in their future care. Patients 
were followed up if they were diagnosed with Parkinson’s disease, epilepsy, orthostatic 
tremor and essential tremor if the patient wished to be treated. 
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Table 2.13: Details of Patient Follow up Performed as Part of the Prevalence Study 
Disease Details of follow up 
Parkinson’s 
Disease 
Ongoing lifelong follow up and treatment provided 
Monthly follow up and treatment provided by local Assistant Medical Officer. Yearly follow up to be 
provided by a UK PD specialist. 
At initial follow up visit diagnosis was confirmed based on the UKPDS Brain Bank Criteria and response to 
treatment was assessed. 
Essential 
Tremor 
One follow up visit 
Assessed response to treatment 
Assessed for side effects to treatment 
Provided more treatment if required/appropriate 
Reiterated information about the condition 
Epilepsy One follow up visit 
Assessed response to treatment 
Provided more treatment if required – reiterated free treatment available from all government hospitals, 
health centres and dispensaries 
Reiterated information about the condition 
Orthostatic 
tremor 
Two follow up visits 
Assessed response to treatment 
If unresponsive a further medication supplied/ if responsive a resupply given 
Response assessed again at second visit 
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Assessed for side effects at each visit 
Reiterated information about the condition 
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2.28 Statistics 
Statistical advice was sought from Dr Keith Gray from Northumbria Health care 
Foundation Trust. Statistical analyses were performed using Statistical Package for the 
Social Sciences SPSS software, version 17.0. 
 
2.28.1 Calculation of age standardised prevalence rates 
Direct age standardisation to the World Health Organisation (WHO) standard 
population (table 2.14) was calculated to give age-standardised prevalence rates. Using 
WHO data for the percentage of the population in each age band, an expected number 
of cases could then be calculated for the standard population. Dividing the number of 
cases in each age band by the proportion of people in the Hai population in that age 
band and then multiplying by the proportion of people in that age band from the 
standard population gave the expected total number of cases were the population age 
structure to follow that of the standard population. The age-standardised prevalence 
rate per 1000 of the population was then calculated. 
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Table 2.14: WHO World Standard Population 
n Distribution (%) based on world average population between 2000-2025 
Age group World Average 2000-2025 
0-4 8.86 
5-9 8.69 
10-14 8.60 
15-19 8.47 
20-24 8.22 
25-29 7.93 
30-34 7.61 
35-39 7.15 
40-44 6.59 
45-49 6.04 
50-54 5.37 
55-59 4.55 
60-64 3.72 
65-69 2.96 
70-74 2.21 
75-79 1.52 
80-84 0.91 
85-89 0.44 
90-94 0.15 
95-99 0.04 
100+ 0.005 
TOTAL 100 
[462] 
2.28.2 Calculating the Standard Error and Confidence Intervals 
Confidence intervals (CIs) for prevalence and odds ratios were calculated based on the 
assumptions of the binomial distribution. 
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Since this was a point prevalence study, the distribution of cases within the population 
would be most closely approximated by a binomial distribution rather than a Poisson 
distribution, this was because patients either had or did not have a neurological 
disorder on the point prevalence date 
The standard error was therefore calculated using the formula; 
Standard Error=√p(1-p)/n 
p=proportion=number of cases/background population 
95% Confidence intervals = p+/-1.96xSE (multiple p and SE by 100 for a percentage or 
by 1000 for CI per 1000) 
Using the binomial distribution, some 95% CI report a negative rate, as this is 
impossible these values have been corrected to zero.  
If I had been calculating incidence or period prevalence I would have used the Poisson 
distribution. 
 
2.28.3 Calculating Sensitivity, Specificity, Positive Predictive Value and Negative 
predictive value 
A number of measures of the performance of my screening questionnaire is given. 
Sensitivity is the proportion of those with a neurological disorder who screened 
positive.  
Sensitivity=true positives/(true positives + false negatives) 
Specificity is the proportion of those without a neurological disorder who screened 
negative.  
Specificity=true negatives/(true negatives + false positives) 
Positive predictive value is the proportion of subjects with a positive test that are 
correctly diagnosed 
Positive predictive value=number of true positives/(number of true positives + number 
of false positives) 
Negative predictive value is the proportion of subjects with a negative test that are 
correctly diagnosed 
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Negative predictive value=number of true negatives/(number of true negatives + 
number of false negatives) 
The accuracy of a test is the proportion of all cases correctly classified by the screening 
instrument. 
Accuracy=(true positives + true negatives)/(true positives + false positives + true 
negatives + false negatives) 
 
2.28.4 The use of other statistical tests 
Chi squared and Odds Ratios were used to test the significance of differences found in 
disability data between different groups, i.e. those with neurological disorders and 
those without.  
 
Odds Ratio definition=the ratio of the odds of an event occurring in one group 
compared to another 
 
Cohen's Kappa was used to determine the level of agreement between two tests. In 
this study I used Cohen’s kappa to indicate the level of agreement between our tool 
and clinical opinion. A value of 1 indicates complete agreement and a value of 0 
indicates a level of agreement that would be no better than chance. 
 
Dr Keith Gray constructed a logistic regression model to help identify independent 
predictors of moderate or severe disability. Stepwise methods were used to construct 
the model and the robustness of the model checked by examination of residuals, 
Cook’s distances, loading of variables on individual eigenvalues and collinearity 
diagnostic tests. I understand the basis of these tests and their application for this 
purpose. 
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2.29 Critique of study design 
2.29.1 Limitations of study design 
A main concern was that the screening questionnaire would fail to pick up patients 
with neurological disorders because they incorrectly answered negatively to a 
question. We attempted to prevent this from happening by making the questionnaire 
as sensitive as possible, making the questions as simple as possible and by teaching the 
NMI about the conditions we wanted to identify therefore they could challenge the 
patient about answers they felt were incorrect. We also utilised multiple other case 
finding methods and briefly observed all participants who screened negative to 
eliminate this potential error as much as possible. Thus I did not rely solely upon the 
screening questionnaire, even though I was confident it would be highly sensitive as 
well as specific.  However, it is worthy of note that if patients wished to hide their 
symptoms because of the stigma associated, they might not be discovered. It was not 
possible with the time or resources available for a medically trained individual to visit 
each person within the population of 2232, so some form of screening would have to 
take place first. The screening questions covered all the main neurological disorders 
apart from poor vision, deafness (not specifically neurological diagnoses) and disorders 
of the autonomic nervous system as these were either felt to be too common in the 
elderly or too difficult to detect, as detailed above. 
 
To rely on history and examination and not utilise investigation, limits the accuracy of 
diagnosis particularly when the diagnosis is dependent on subjective symptom 
reporting such as sensation. However this does accurately reflect clinical work in SSA. 
 
2.29.1 Strengths of study design 
Every history and examination was undertaken by the same RD with the same SN. This 
ensured all participants in the study were treated in exactly the same way.   
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The community based two phased approach is the gold standard for recording 
prevalence of Neurological disorders in resource poor settings [6, 25]. This robust 
methodology ensured that we identified previously undiagnosed patients something a 
hospital based approach fails to do. All patients too frail to attend medical facilities 
were seen within their own home, particularly important to truly reflect prevalence in 
conditions such as neurological disorders which have the potential to be very disabling. 
 
The team of enumerators/NMI and supervisors employed within this study had 
previously worked on a stroke incidence study [213], a PD prevalence study [96, 128] 
and an Epilepsy prevalence study in the same area. This ensured the team were 
competent and confident in their roles in the research team. It also meant that the 
population studied were familiar with regular censuses and medical studies and so 
were not only happy to be involved in the study also understood it would potentially 
be to their benefit. This ensured the maximum possible participation rate. The use of 
local personnel ensures capacity building in the local area which is very important 
when studying a population.  
 
The WHO ICD criteria are a widely recognised and used set of criteria for making the 
diagnosis of Neurological Disorders; other more specific criteria that are internationally 
recognised were also used for specific neurological disorders.  This not only adds to the 
accuracy of the diagnosis, but also adds to the comparability with other studies where 
the same criteria have been used.    
 
The number of different case finding methods covered were from as wide a variety of 
sources as possible, to try and prevent missed cases.  Whilst I recognise that it is 
possible that  cases may have been missed, especially those in the early stages of 
disease, I believe I have covered as many of the options available as possible. 
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2.30 Wheelchair and walking aid provision 
Whilst performing the Pilot and Main Study, I found many people who were disabled 
as a result of neurological disorders and other conditions (most commonly arthritis). 
For financial and logistical reasons appropriate walking aids and wheelchairs were not 
available to them. The RD was able to assess everyone involved in the study for their 
need for walking aids and wheelchairs. Through charitable donation the RD was able to 
assess these patients again with a walking aid and wheelchair expert from KCMC who 
was able to produce customised walking aids and wheelchairs for all those who 
needed them. A total of 21 wheelchairs, 25 walking frames and 6 pairs of crutches 
were supplied. 
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Chapter 3. Results 
3.1 The Census and the Demographics of the Hai District DSS Census Population 
The date of completion of the Hai District DSS census was the 1st of June 2009 with a 
remarkable 100% response. There were no households who refused to take part in the 
survey. The population of the Hai district DSS was 161,119. 58,093 (36.06%) were aged 
less than 15, 103025 (63.94%) were aged 15 and over and 8869 (5.50%) were aged 70 
and over. 3159 (1.96%) were 70-74, 2531 (1.57%) were 75-79, 1447 (0.90%) were 80-
84 and 1732 (1.07%) were aged 85 and over. 83,180 (51.63%) were female and 77939 
(48.37%) were male. Of the 70 and over population 4844 (54.62%) were female and 
4025 (45.38%) were male. This is shown in detail in the table below. 
Table 3.1 Age and Sex divisions In the Hai District DSS from the 01/06/2009 census 
Age group Female % Male % Total (Males and Females) % 
0-14 28794 34.6 29299 37.6 58093 36.1 
15-19 8114 9.8 8648 11.1 16762 10.4 
20-24 5225 6.3 4719 6.1 9944 6.2 
25-29 5487 6.6 4467 5.7 9954 6.2 
30-34 5381 6.5 4961 6.4 10342 6.4 
35-39 5216 6.3 4852 6.2 10068 6.3 
40-44 4800 5.8 4234 5.4 9034 5.6 
45-49 4156 5.0 3630 4.7 7786 4.8 
50-54 3727 4.5 2986 3.8 6713 4.2 
55-59 2911 3.5 2437 3.1 5348 3.3 
60-64 2390 2.9 1949 2.5 4339 2.7 
65-69 2135 2.6 1732 2.2 3867 2.4 
70-74 1684 2.0 1475 1.9 3159 2.0 
75-79 1351 1.6 1180 1.5 2531 1.6 
80-84 824 1.0 623 0.8 1447 0.9 
85+ 985 1.2 747 1.0 1732 1.1 
TOTAL 83180 100 77939 100 161119 100 
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A census can only identify those living in the area on a certain date. Those who were 
temporarily away for work or other reasons were not included if deemed to be no 
longer living in the area by other household members. Of those aged 70 years and over 
very few were likely to work away from home and so this was not deemed to be a big 
problem. Those who had travelled on the census date and who had since returned by 
the prevalence date were included in the study and denominator. They were 
requested to present themselves by the NMI who had extensive knowledge of the 
village. These inclusions and exclusions are shown in figure 3.1, "Identification of the 
pilot population" and figure 3.2, "Identification of the main study population". 
 
3.1.1 Division of the Census Population by village 
The populations of the villages of the Hai District DSS are shown in the following table. 
The number of patients aged 70 and over in each village is also described as is the 
geographical location of the village (upland or lowland). The villages highlighted in bold 
are those 12 that were randomly selected to take part in the study. They represent a 
quarter of the 70 and over population of the Hai District DSS. As previously discussed 
the population of these villages recorded on the census was slightly different from the 
population seen as part of the pilot and main study. This is for multiple reasons all of 
which were explained in the methods and are elaborated on further in the results.
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Table 3.2: Division of the Hai District DSS population by village demonstrating representation from the 70 and over population  
Village Whole 
population 
of Each 
Village 
Percentage 
of whole 
population 
of Hai 
District DSS 
represented 
in each 
village 
Population 
aged 70 
and over 
from the 
census 
Percentage 
of 
population 
70 and over 
represented 
in each 
village 
Population 
aged 70 
and over 
seen as 
part of the 
Pilot and 
Main Study 
Percentage 
of 
population 
aged 70 and 
over 
represented 
in each of 
the Pilot and 
Main Study 
Villages 
Geographical 
location 
Altitude 
BOMANG`OMBE 11558 7.2 216 2.4 136 1.53 LOWLAND 995 
FOO 3969 2.5 394 4.4 N/A N/A UPLAND 1565 
ISUKI 1853 1.2 126 1.4 N/A N/A UPLAND 1399 
KAWAYA 2722 1.7 88 1.0 N/A N/A LOWLAND 851 
KIA 1501 0.9 16 0.2 N/A N/A LOWLAND 919 
KIKAVU CHINI 3743 2.3 116 1.3 N/A N/A LOWLAND 805 
KILANYA 1848 1.1 151 1.7 N/A N/A UPLAND 1588 
KIMASHUKU 2452 1.5 79 0.9 N/A N/A LOWLAND 909 
KWA SADALA 3018 1.9 78 0.9 83 0.94 LOWLAND 1033 
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KWARE 3251 2.0 189 2.1 148 1.67 LOWLAND 1071 
KWATITO 1083 0.7 28 0.3 N/A N/A LOWLAND 909 
KYEERI 2959 1.8 195 2.2 N/A N/A UPLAND 1670 
KYUU 1778 1.1 120 1.4 118 1.33 UPLAND 1396 
LEMIRA KATI 1514 0.9 139 1.6 N/A N/A LOWLAND 1420 
LENGOI 2013 1.2 62 0.7 N/A N/A LOWLAND 833 
LOSAA 1345 0.8 77 0.9 N/A N/A UPLAND 1560 
LUKANI 1272 0.8 116 1.3 115 1.30 UPLAND 1594 
LYAMUNGO KATI 2254 1.4 190 2.1 N/A N/A UPLAND 1520 
LYAMUNGO 
SINDE 
1869 1.2 138 1.6 N/A N/A UPLAND 1315 
MAMBA 1952 1.2 157 1.8 N/A N/A UPLAND 1340 
MASHUA 2394 1.5 137 1.5 N/A N/A UPLAND 1353 
MBATAKERO 669 0.4 18 0.2 N/A N/A LOWLAND 940 
MBORENI 1371 0.9 86 1.0 N/A N/A UPLAND 1330 
MBOSHO 1740 1.1 139 1.6 N/A N/A UPLAND 1295 
MBWEERA 3297 2.0 194 2.2 194 2.19 UPLAND 1330 
MIJONGWENI 3681 2.3 130 1.5 N/A N/A LOWLAND 820 
MKALAMA 2605 1.6 91 1.0 N/A N/A LOWLAND 864 
MTAA WA 
SHABAHA 
1023 0.6 33 0.4 N/A N/A LOWLAND 915 
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MTAKUJA 1685 1.0 43 0.5 N/A N/A LOWLAND 920 
MUDIO 5522 3.4 345 3.9 277 3.12 UPLAND 1257 
MULAMA 1824 1.1 123 1.4 N/A N/A UPLAND 1274 
MUNGUSHI 7884 4.9 184 2.1 N/A N/A LOWLAND 1050 
MUROMA 1874 1.2 119 1.3 N/A N/A UPLAND 1296 
NGIRA 2234 1.4 160 1.8 N/A N/A UPLAND 1275 
NGOSERO 968 0.6 35 0.4 N/A N/A LOWLAND 822 
NGUNI 2498 1.6 159 1.8 N/A N/A UPLAND 1580 
NKUU NDOO 2038 1.3 222 2.5 N/A N/A UPLAND 1620 
NKUU SINDE 2132 1.3 234 2.6 N/A N/A UPLAND 1314 
NKWANSIRA 2080 1.3 133 1.5 N/A N/A UPLAND 1240 
NRONGA 2299 1.4 287 3.2 N/A N/A UPLAND 1670 
NSHARA 7805 4.8 411 4.6 386 4.35 UPLAND 1170 
ROO 5308 3.3 305 3.4 265 2.99 UPLAND 1250 
RUNDUGAI 7686 4.8 225 2.5 N/A N/A LOWLAND 861 
SAAWE 2609 1.6 185 2.1 192 2.16 UPLAND 1476 
SANYA STATION 3219 2.0 91 1.0 N/A N/A LOWLAND 933 
SHARI 3611 2.2 318 3.6 N/A N/A UPLAND 1390 
SHIRI NJORO 2841 1.8 111 1.3 N/A N/A LOWLAND 1018 
SHIRIMGUNGANI 3090 1.9 118 1.3 182 2.05 LOWLAND 860 
SONU 2926 1.8 257 2.9 N/A N/A UPLAND 1306 
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TELLA 2692 1.7 163 1.8 N/A N/A UPLAND 1241 
TINDIGANI 1250 0.8 25 0.3 N/A N/A LOWLAND 915 
UDURU 2289 1.4 167 1.9 N/A N/A UPLAND 1296 
URORI 2825 1.8 142 1.6 136 1.53 UPLAND 1086 
USARI 2231 1.4 134 1.5 N/A N/A UPLAND 1190 
USWAA 3218 2.0 269 3.0 N/A N/A UPLAND 1190 
WARI 3745 2.3 401 4.5 N/A N/A UPLAND 1440 
Total 161119 100.0 8869 100.0 2232 25.2 N/A  
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The table below records the percentage of the whole population that resides in upland 
and lowland villages. It also shows separately the percentage of the 70 and over 
population that resides in upland and lowland villages and the percentage of the 70 
and over population from the studied villages that reside in upland and lowland 
villages – both from the census and from the actual study numbers. This is to 
demonstrate that more elderly live in upland villages. There is no documented reason 
for this although we can speculate that this is because those in the lowland villages die 
earlier and/or there is a younger population in lowland villages as many of them are 
near to the main transport links and there are more opportunities for employment 
away from the subsistence farms. The table also demonstrates that the studied 
population is representative of the 70 and over population in the whole of the Hai 
District DSS with regard to the percentage of people that come from upland and 
lowland areas. 
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Table 3.3: Representations from geographical areas in the whole Hai District DSS population, the whole 70 and over population, and 
the 70 and over population in the studied villages   
Geographical 
Location 
Whole Hai 
District DSS 
Population 
– All Ages – 
Frequency 
Whole Hai 
District DSS 
Population – 
All Ages - 
Percentage 
Whole Hai 
District DSS 
Population 
– Aged 70 
and over - 
Frequency 
Whole Hai 
District DSS 
Population – 
Aged 70 and 
over – 
percentage 
Study 
Villages 
Population 
Aged 70 and 
over from 
the census – 
frequency  
Study 
Villages 
Population 
Aged 70 and 
over from 
the census – 
Percentage 
Study 
Villages 
Population 
Aged 70 and 
over 
actually 
seen– 
frequency 
Study 
Villages 
Population 
Aged 70 and 
over actually 
seen– 
Percentage 
Lowland 69456 43.1% 2115 23.8% 601 24.8% 549 24.6% 
Upland 91663 56.9% 6754 76.2% 1818 75.2% 1683 75.4% 
Total 161119 100.0% 8869 100.0% 2419 100.0% 2232 100.0% 
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3.2 The Pilot Study 
From the census, it was reported that 345 patients aged 70 years and older resided in 
Mudio, but it became evident that 5 were recorded twice.  32 people aged 70 and over 
who lived in Mudio but were not on the census were also seen. The main reason for 
them not being on the census was they had turned 70 between the census occurring 
and our prevalence date of the 1st January 2010. In a minority of cases patients had 
travelled to another area during the census. Collecting accurate information on patient 
age can be difficult in SSA, as few people have a birth certificate [443].  Age was 
calculated from birth year and confirmed using memory prompts (e.g. age at 
independence) where necessary. This method has been previously validated [449]. I do 
recognise that there was a potential incentive for participants to say they were aged 
70 or over in order to be included in the study but all possible attempts were made to 
try to eliminate this cause of bias. It is however impossible to say this problem was 
eradicated completely. In total it was not possible to see 95 patients for the following 
reasons; 40 refused to be seen, 21 had died, 22 had moved and 12 were too young. 
Therefore altogether 277 patients were seen. 
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Figure 3.1 Identification of the pilot study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
  
 
 
 
 
 
 
 Population Identified Via Census 
n =345 
 Refused 
n=40 
 Died 
n=21 
 Moved 
n=22 
 Too Young 
n=12 
 Appeared 
Twice 
n=5 
 Census Population 
n=245 
 Total on Census Not Seen 
n =100 
 Population Turned 70 after Census Conducted/ 
People Omitted due to Age Inaccuracy/ People 
who had travelled on the Census Date 
n=32 
 Total Pilot Population 
n =277 
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3.2.1 The Demographics of the Pilot Population 
3.2.1.1 Age breakdown 
The proportions of patients aged 70 and over in the different age brackets are shown 
in the table below. This is expressed as a percentage of the 70 and over population and 
as a percentage of the whole pilot village population. This can be compared to the 
percentage of people in the age brackets in the whole Hai District Demographic 
Surveillance site. This demonstrates that from an age point of view the pilot village is 
representative of the whole DSS population.  
 
Table 3.4 Demonstration that the age breakdown of the 70 and over population in 
the Pilot study was representative of the whole Hai District DSS population 
Age 
Divisions 
People in 
the Pilot 
Study  
Percentage 
of the 70 
and over 
population 
in the Pilot 
Village 
Percentage 
of the 
whole 
population 
in the Pilot 
Village 
People 
in the 
whole 
Hai 
District 
DSS 
Percentage 
of the 70 
and over 
population 
in the 
whole Hai 
District 
DSS 
Percentage 
of the 
whole 
population 
in the 
whole Hai 
District 
DSS 
70-74 109 39.4 2.0 3159 35.6 2.0 
75-79 75 27.1 1.4 2531 28.5 1.6 
80-84 38 13.7 0.7 1447 16.3 0.9 
85+ 55 19.9 1.0 1732 19.5 1.1 
Total 277 100.0 5.0 8869 100.0 5.5 
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Table 3.5 Further Division of the older age bracket in the Pilot Village Population 
Age Divisions Frequency Percentage 
70-74 109 39.4 
75-79 75 27.1 
80-84 38 13.7 
85-89 33 11.9 
90-94 9 3.2 
95-99 11 4.0 
100+ 2 0.7 
Total 277 100.0 
 
This is representative of the background Hai District DSS population.  
 
3.2.1.2 Sex breakdown 
The proportion of males and females in the pilot population was also representative of 
the background Hai District DSS population.  
 
Table 3.6: Demonstration of the comparable breakdown of the 70 and over 
population by sex in the Pilot Village and the Hai District DSS population 
Sex People Aged 70 
and over in the 
Pilot Village 
Percentage of 
the 70 and over 
population of 
the  Pilot 
Village 
People Aged 70 
and over in the 
Hai District DSS 
Percentage of 
the 70 and over 
population in 
the Hai District 
DSS 
F 152 54.9 4844 54.62 
M 125 45.1 4025 45.38 
Total 277 100.0 8869 100.0 
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3.2.1.3 Tribe 
In the Pilot Study 275 (99.3%) people were from the Chagga Tribe and 2 (0.7%) were 
from other tribes. This is representative of the background Hai District DSS population 
in that the majority of the population were from the Chagga tribe. However, there was 
not appropriate representation from the other tribes. This is one of the disadvantages 
of choosing a pilot population from one village for geographical and logistical 
convenience.  
 
3.2.1.4 Religion 
In the Pilot Study 182 (65.7%) people were Christian and 95 (34.3%) were Muslim. This 
was representative of the whole Hai District DSS population. 
 
3.2.1.5 Marital Status 
Of the people in the Pilot population 131 (47.3%) were married, 131 (47.3%) were 
widowed, 7 (2.5%) were divorced, 5 (1.8%) were separated and 3 (1.1%) were single.  
 
3.2.2 Where the Pilot Population were seen 
As described in the methods section we attempted to see all the patients in a place of 
convenience for them. In the majority of cases it was possible and practical for them to 
come to the village health centre or dispensary. When the village was large people 
were also seen at another convenient central location e.g. a private house that we had 
been given permission to use. If the person was unable to travel to a central location 
they were seen in their own home. Due to our level of flexibility on the place patients 
were seen and our ability to see patients in their own home, there was no introduction 
of bias. The most disabled, and potentially patients with neurological disorders would, 
have to be seen in their own homes. Of the Pilot population 118 (42.6%) people were 
seen in a central large private house, 109 (39.4%) were seen at the local health centre 
and 50 (18.1%) were seen in their own homes. 
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3.2.3 Proportion of the pilot population born in, and ever lived outside, the Hai 
District DSS 
The population of the Hai District DSS and the pilot and main study population are 
fairly static especially with reference to the 70 and over population.  The majority of 
the people (97.8%) were born within the Hai District DSS and few (21.3%) had lived 
outside the Hai District DSS at any point in their lives. 
 
3.3 The screening questionnaire 
3.3.1 Analysis of the performance of the screening questionnaire when used in the 
Pilot Study 
3.3.1.1 Analysis of sensitivity and specificity of the screening questionnaire in the 
Pilot Study 
The screening tool had a high sensitivity and specificity. As already described in the 
methodology the screening questionnaire was modified before the pilot study. It was 
subsequently modified with the removal of one question (question 14) after the main 
study because it identified non disabling rare conditions the diagnosis of which is very 
difficult to confirm in these circumstances. Presented below is the sensitivity and 
specificity of the screening tool with and without the question. The final performance 
of the questionnaire is without question 14; sensitivity is 87.8% and specificity 94.9%. 
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Table 3.7: The overall sensitivity and specificity analysis of the screening questionnaire in the Pilot Population  
 True 
Negative 
True 
Positive 
False 
Negative  
False 
Positive 
Sensitivity Specificity Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Accuracy 
Screening 
tool including 
original Q14 
180 77 10 10 88.5 94.7 88.5 94.7 92.8 
The Final 
Screening 
tool - 
Screening 
tool 
excluding 
original Q14 
185 72 10 10 87.8 94.9 87.8 94.9 92.8 
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3.3.1.2  The ability of the questions to identify key disorders 
There was only one question to pick up headache (Q15), this correctly identified all 22 
cases of headache. It incorrectly identified 2 false positives, this question therefore 
had a sensitivity of 100% and a specificity of 99.2% if used on its own  to identify 
patients with headaches that affect their ADLs. 
 
Tremor was identified by Q3, Q5 and Q6, they identified 12 out of the 19 cases of 
tremor, 7 cases were not identified, these were only identified on examination by the 
RD, the participant themselves had never noticed them and was not concerned by 
them. The sensitivity of the questions for tremor was 63.4% and the specificity was 
99.6%. 
 
As there are many different types of strokes, stroke can be identified by many of the 
questions (Q4, Q7-Q10, Q11-Q13, Q19). All 12 cases of stroke were correctly identified 
by these questions giving a sensitivity of 100%. However the questions identified 7 
false positives giving them an overall specificity of 97.4%. 
 
Parkinsonism was identified by Q3, Q4 and Q6, all 5 cases of Parkinsonism were 
identified giving these questions a sensitivity of 100%,  1 false positive was also 
identified giving a specificity of 99.6%. 
 
Two questions were designed to identify cases of epilepsy (Q1 and Q2). There was only 
one case of epilepsy in the pilot study and this was a case of partial epilepsy with 
secondary generalisation, this was found by both questions, therefore questions 1 and 
2 had 100% sensitivity for picking up epilepsy. The direct question regarding epilepsy 
did not identify the patient as they had not been previously diagnosed.  
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3.3.1.3 Conditions not represented in the Pilot Population 
It is worth noting that some conditions were not present in the pilot population and 
therefore the true sensitivity for identification of these conditions could not be 
established. Additionally, because of the diagnosis gap in most of the neurological 
conditions, patients with a clear diagnosis had often not been told that they had a 
certain condition and if they had the diagnosis was often forgotten. Therefore, in the 
latter direct questions on the presence of neurological disease the response was not 
recorded as a false negative if the patient responded negatively due to a lack of a 
diagnosis. After all, the questions ask if the patient had ever been told they have a 
certain condition. In all these circumstances the patients were identified by other 
questions. The latter questions therefore act merely as a double check to ensure that 
patients with a diagnosis are not missed. 
 
3.3.1.4 False Negative Patients 
All the False Negative patients from the pilot study (described below) would not have 
benefitted from screening positive. They did not want to be brought to the attention 
of medical personal as they did not find their conditions disabling and there was no 
immediate concern from an individual health perspective.  However, there could be 
longer term benefit for such patients  e.g. in the case of the tremors progression may 
occur and these people could be forewarned and informed of potential future 
treatments should their condition become disabling. In the case of sensory peripheral 
neuropathy causative factors like diabetes could be investigated and treatment offered 
to stop the condition progressing. Standard foot care could also be explained. The 
exact nature of the false negative patients is described in the table below. 
 
There is a high level of under-diagnosis of neurological conditions in SSA. Patients with 
a clear diagnosis were often not aware of their diagnosis. Therefore, the direct 
questions had a low yield. The response was not recorded as a false negative if the 
patient responded negatively due to lack of diagnoses. All cases were picked up using 
other questions. These questions merely acted as a double check, in this population 
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but their inclusion is justified because these conditions are of high public health 
significance and if this screening tool is proposed for use in other developing countries 
the level of awareness of neurological conditions and  diagnosis will vary. It is still 
beneficial to identify patients that have been previously diagnosed to record 
prevalence and also because some of these patients may not have received treatment 
for a number of reasons which could be rectified.. 
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Table 3.8: False negatives and explanation for their lack of detection by the screening tool 
Diagnosis Number 
of 
Patients 
Explanation for why the patient was not picked up Could the sensitivity of the screening tool be 
improved to pick up this condition? 
Multiple 
Mononeuropath
ies – traumatic 
1 Patients did not describe weakness or loss of 
sensation of the arm. This was because the condition 
did not bother him. He was still able to work as a 
farmer and had ways of coping with his disability 
which ensured he could function fully. Therefore, 
when asked he denied any problems. 
As this patient did not appreciate that he had 
weakness and sensory loss in his arm, there is no 
alternative way of picking up this problem through 
simple questioning. Any examination section 
would pick this patient up, but for reasons already 
discussed it would limit a screening tool’s use by 
NMI. 
Enhanced 
physiological 
Tremor 
5 All patients denied any tremor when questioned as 
part of the questionnaire and when questioned as 
part of a full neurological history. The presence of 
tremor was only found on examination and a 
secondary history after the tremor had been 
discovered. In all cases the tremor did not bother the 
patient and had not been noted by the patient. 
Therefore, it was non-disabling.  
As the patients denied any tremor when directly 
questioned and had not noticed any tremor the 
only way of picking up these problems would be to 
include an examination section. Again this would 
limit a screening tool’s use NMI. 
Essential Tremor 2 All patients denied any tremor when questioned as 
part of the questionnaire and when questioned as 
As the patients denied any tremor when directly 
questioned and had not noticed any tremor the 
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part of a full neurological history. The presence of 
tremor was only found on examination and a 
secondary history after the tremor had been 
discovered. In all cases the tremor did not bother the 
patient and had not been noted by the patient. 
Therefore, it was non-disabling. 
only way of picking up these problems would be to 
include an examination section. Again this would 
limit a screening tool’s use by NMI. 
Median Nerve 
Damage - 
Traumatic 
1 Patient was not aware that there was loss of 
sensation in a median nerve distribution in his hand 
as a result of a laceration. He stated that it did not 
alter his ability to work as a farmer so it was 
therefore not a problem for him. The condition was 
non-disabling to the patient so was not reported as a 
response to direct questioning as part of the 
screening tool or as part of a neurological history.  
An examination section would be the only way of 
bringing this patient to the attention of 
investigators.  
Peripheral 
Neuropathy 
1 The patient denied any sensory disturbance when 
asked as part of the screening questionnaire or on 
direct questioning as part of a neurological history. 
The condition was only revealed on examination. 
A detailed examination section would be required 
to pick up this condition. This would make a 
screening questionnaire lengthy and would require 
highly trained investigators. 
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3.3.1.5 False Positive Patients 
The patients that screened false positive are described in the table below. All efforts to increase the specificity of the screening 
questionnaire (i.e. to stop false positive results occurring) had been made prior to the pilot study. Other options to increase the specificity 
of the tool are explored in the table – along with their flaws and the fact that they are impractical without complicating the screening tool 
further.   
 
Table 3.9: False positives and explanation for their false detection by the screening tool 
Brief description of the case Questions 
which were 
falsely 
positive 
Could the specificity of the screening tool be improved to 
prevent this false positive? 
Patient who described weakness of his right hand side 
since he had an abscess in his neck. When asked as part of 
the screening questionnaire he stated that the weakness 
was constantly there and present at the time of screening. 
There was no evidence of weakness on examination. 
When asked again he stated the weakness was only there 
during times of ill health.  
Questions 7 
and 8 
The questions both stress that the weakness should be 
constant and should be there at the time of questioning. 
Despite this the patient still answered positively. An 
examination section would be the only way of ensuring 
that weakness was definitely present. 
The patient had recently recovered from a period of ill Questions 3 The question regarding headaches specifies that they 
290 
 
health caused by a tooth abscess. This had resulted in 
severe headaches and rigors. These were both picked up 
as positive despite full resolution and only present for a 
short period of time. 
and 15 should be recurrent, not brief periods of ill health. Despite 
this the patient still answered positively. There is no way of 
eliminating this problem. The question regarding tremor 
specifies that the tremor should occur multiple times every 
day. This was not the case with this patient and despite this 
she still answered positively. There is no way around the 
discrepancy between the response to the questionnaire 
and the history other than to stress the emphasis and 
wording of each question. 
A patient who had mild occasional headaches responded 
positively when asked if he had severe recurrent 
headaches that stopped him from doing his activities of 
daily living. When asked again he answered negatively to 
the question. When asked why he had initially answered 
positively he replied that he wanted to ensure that he saw 
the doctor.  
Question 15 Some patients may answer positively to questionnaires just 
to bring themselves to medical attention that they would 
normally have to pay for/would not be available to them. 
There is no way of getting around this problem except to 
stress the wording of each individual question and to clarify 
if a positive result is really positive. 
A patient described eyelid weakness. On examination 
there was no ptosis present. On further questioning it was 
revealed that he meant weakness of his eye (poor 
eyesight) not weakness of his eyelids. 
Question 10 When the enumerators were trained to use the screening 
tool it was stressed that we were looking for weakness of 
the eyelids and not the eyes. This seemed to be the only 
way of getting around false positives caused this way 
without unnecessarily complicating the question.  
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A patient described brief violent shaking episodes of his 
right arm. He stated that these episodes had been 
recurrent. When asked as part of a full neurological history 
he subsequently denied actual shaking and stated he felt 
as though the arm was shaking due to severe pain coming 
from his shoulder.   
Question 2 Emphasis of the question is the only way to try to eliminate 
false positives of this nature. 
A patient with a psychiatric history described seizures and 
a loss of sensation in his whole body. This positive 
response was not backed up when a collateral history was 
obtained and when a full examination was performed. 
Questions 1 
and 12 
A collateral history should always be obtained when there 
is doubt as to the patient’s competence of answering 
questions correctly. This was stressed to the enumerators 
during training.  
A patient described leg weakness. On further questioning 
and on examination this was found to be pain and not 
actual weakness. 
Question 8 Patients find it difficult to distinguish pain and weakness. 
The importance of the difference was stressed to the 
enumerators during training. This was felt to be the only 
way round this potentially common problem. 
A patient described weakness of his left hand side as a 
result of an accident. On further questioning, and on 
examination, this turned out to be pain alone. 
Questions 7 
and 8 
Patients find it difficult to distinguish pain and weakness, 
the importance of the difference was stressed to the 
enumerators during training. This was felt to be the only 
way round this potentially common problem. 
A patient described loss of sensation from his knees down. 
On examination this was not present and he stated that 
Question 12 There is no way of eliminating this kind of false positive 
other than to stress the wording of the question. 
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this was only when it was cold. This is stressed as a 
negative factor in the question and it is also stressed that 
the numbness should be constant. 
A patient described loss of sensation of the right index 
finger and middle finger. On examination this was found to 
be normal. The patient denied any loss of sensation when 
asked again.  
Question 12 Inconsistency of response is inevitable. Re-questioning of 
patients in view of a positive response was a factor 
highlighted to the enumerators in training. A detailed 
examination would eliminate these false positives but 
would make screening lengthy and unpractical. 
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3.4 The Main Study 
We elected to see one quarter of the Hai District DSS population in the main study due 
to resource limitations and time constraints. 2232 Patients were seen from the 12 
randomly selected villages. Every opportunity was taken to ensure that the main study 
population was representative of the background population. 
 
3.4.1 Identification of the Main Study Population 
The village breakdown of the main study population is demonstrated in the table and 
diagram below. As described with regard to the pilot population additional people 
were seen as part of the study for three main reasons; 
1. People that had turned 70 after the census was conducted on 01/06/2009 and 
before or on the prevalence date of the 01/01/2010 
2. People that had been omitted on the census due to inaccuracy, recorded as 
falsely young – again every effort was made to ensure age was reported 
correctly through date sign posting. 
3. People that had travelled on the census date but had returned by the 
prevalence date. 
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Table 3.10: Identification of the Main Study Population  
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Boma  136 216 -80 Lowland 20 40 20 5 17 1 0 103 23 
Kware  148 189 -41 Lowland  12 13 12 4 0 0 0 41 0 
Kwasadala  83 78 5 Lowland  1 10 12 0 0 0 0 23 28 
Kyuu  118 120 -2 Upland  8 4 10 0 0 0 0 22 20 
Lukani  115 116 -1 Upland  9 4 12 2 0 0 0 27 26 
Mbweera  194 194 0 Upland  1 1 7 0 0 0 0 9 9 
Mudio  277 345 -68 Upland  40 22 21 12 0 0 5 100 32 
Nshara  386 411 -25 Upland  47 3 32 3 0 0 0 85 60 
Roo  265 305 -40 Upland  10 14 14 2 0 0 0 40 0 
Saawe  192 185 7 Upland  0 11 6 0 0 0 0 17 25 
Shirumgung
ani  
182 118 64 Lowland  0 2 6 0 0 0 0 8 72 
Urori  136 142 -6 Upland  0 4 2 5 0 0 2 13 6 
Total  2232 2419 -187 N/A 148 128 154 33 17 1 7 494 301 
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Figure 3.2 Identification of the Main Study Population 
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3.4.1.1 Upland and Lowland Villages 
The representation of the upland and lowland villages in the main study population is 
representative of the background Hai District DSS 70 and over population. In the main 
study, 75.4% of people were from upland villages and 24.6% were from lowland 
villages. In the background Hai District DSS 70 and over population 76.2% were in 
upland villages and 23.8% were in lowland villages.   
 
3.4.2 The Demographics of the Main Study Population 
3.4.2.1 Age breakdown 
The mean age of Males was 77.9 (77.4 to 78.3) n = 976. The mean age of females was 
77.7 (77.3 to 78.1) n = 1256. The mean age of the whole population was 77.7. The 
proportions of patients aged 70 and over in the different age brackets are shown in the 
table below. This is expressed as a percentage of the 70 and over population and as a 
percentage of the whole main study population. This can be compared to the 
percentage of people in the age brackets in the whole Hai District Demographic 
Surveillance site. This demonstrates that from an age point of view the main study 
population is representative of the whole DSS population. 
  
297 
 
Table 3.11: Demonstration that the age breakdown of the 70 and over population in 
the Main study was representative of the whole Hai District DSS population 
Age 
Divisions 
People in 
the Main 
Study 
Percentage 
of the 70 
and over 
population 
in the 
Main 
Study 
Percentage 
of the 
whole 
population 
in the 
Main 
Study 
People 
in the 
whole 
Hai 
District 
DSS 
Percentage 
of the 70 
and over 
population 
in the 
whole Hai 
District 
DSS 
Percentage 
of the 
whole 
population 
in the 
whole Hai 
District 
DSS 
70-74 877 39.3 1.7 3159 35.6 2.0 
75-79 625 28.0 1.2 2531 28.5 1.6 
80-84 344 15.4 0.7 1447 16.3 0.9 
85+ 386 17.3 0.8 1732 19.5 1.1 
Total 2232 100.0 4.4 8869 100.0 5.5 
 
Table 3.12: Demonstration of the further Divisions of the older age bracket in the 
Main Study Population 
Age Divisions Frequency Percentage 
70-74 877 39.3 
75-79 625 28.0 
80-84 344 15.4 
85-89 221 9.9 
90-94 89 4.0 
95-99 40 1.8 
100+ 36 1.6 
Total 2232 100.0 
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3.4.2.2 Sex Breakdown 
The proportion of males and females in the main study population was also 
representative of the background Hai District DSS population.  
 
Table 3.13: Demonstration of the comparable breakdown of the 70 and over 
population by sex in the Main Study and the Hai District DSS population 
Sex People Aged 70 
and over in the 
Main Study 
Percentage of 
the 70 and over 
population of 
the  Main 
Study 
People Aged 70 
and over in the 
Hai District DSS 
Percentage of 
the 70 and over 
population in 
the Hai District 
DSS 
F 1256 56.3 4844 54.6 
M 976 43.7 4025 45.4 
Total 2232 100.0 8869 100.0 
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3.4.2.3 Males and Females age structure 
Although the study has more females than males, there were no differences between 
males and females in terms of the age structure of the participants. 
 
Table 3.14 Demonstration of the comparable age structure of males and females in 
the main study population  
Sex Age Frequency of 
participants in the 
main study population 
Percentage of the 
participants in the 
main study 
population 
Male 70-74 384 39.3 
75-79 285 29.2 
80-84 135 13.8 
85+ 172 17.6 
Total 976 100.0 
Female 70-74 493 39.3 
75-79 340 27.1 
80-84 209 16.6 
85+ 214 17.0 
Total 1256 100.0 
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3.4.2.4 Tribe 
The tribal divisions of the main study population were more representative of the Hai 
District DSS than the pilot study population was. There was however still an 
underrepresentation of the MMasai tribe. However, overall the majority tribe was 
MChagga and this was appropriate.  
 
Table 3.15: Tribal representations of the Main Study Population  
Tribe Number of People in each Tribe 
aged 70 and over in the Main 
Study 
Percentage in each tribe aged 
70 and over in the Main Study 
MZARAMO 6 0.3 
MNDENGEREKO 4 0.2 
MCHAGGA 2033 91.1 
MMASAI 7 0.3 
MPARE 38 1.7 
MNYAMWEZI 7 0.3 
MSUKUMA 2 0.1 
OTHER 135 6.0 
Total 2232 100.0 
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3.4.2.5 Religion 
The religious divisions were representative. This was particularly important when 
considering health seeking behaviour. 
Table 3.16: Religious Representations of the Main Study Population  
Religion Number of People in each Religion 
aged 70 and over in the Main Study 
Percentage in each Religion aged 
70 and over in the Main Study 
CHRISTIAN 1763 79.0 
MUSLIM 466 20.9 
PAGAN 3 0.1 
Total 2232 100.0 
 
3.4.2.6 Marital Status 
In the main study population 1103 (49.4%) were married, 1050 (47.0%) were widowed, 
32 (1.4%) were separated, 27 (1.2%) were single and 20 (0.9%) were divorced. The 
main reason for divorce was the woman was perceived to be infertile.. 
 
3.4.2.7 Proportion of the Main Study Population that was Ambulant 
A simple record of ambulance was recorded for each patient in the main study. The 
great majority (85.8%) of patients remained ambulant. This finding is in keeping with 
the level of disability in this population group which is described in detail later.  
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3.4.3 Analysis of the performance of the screening questionnaire when used in the 
main study 
This analysis excluded the Pilot village. 
 
3.4.3.1 Establishing if patients were true negatives or false negatives – the sensitivity 
check of the main study 
Eight patients were identified to have  neurological conditions, during general 
observation, that had answered negatively to the screening questionnaire, these were 
recorded as false negatives. There were no cases picked up by alternative methods so 
all the remaining negatives were recorded as true negatives. All established cases in 
this population diagnosed in previous disease-specific prevalence studies were 
correctly recognised by the questionnaire. All patients brought to our attention by 
family history, and by discussion with the village elders, were also correctly picked up 
by the screening questionnaire. All these methods reinforced the excellent sensitivity 
of the questionnaire. We were unable to trace 1 patient who had responded positively 
to question 12. For purposes of analysis this patient was presumed to be a false 
positive. 
 
3.4.3.2 Analysis of sensitivity and specificity of the screening questionnaire in the 
Main Study 
Again the screening tool had a high sensitivity and specificity. As already described 
above, the original question 14 was removed after the main study. Presented below is 
the sensitivity and specificity of the screening tool with and without the question. The 
final performance of the questionnaire, without the question is: sensitivity 97.0% and 
specificity 90.4%. 
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Table 3.17: The overall sensitivity and specificity analysis of the screening questionnaire in the Main Study Population  
 True 
Negative 
True 
Positive 
False 
Negative  
False 
Positive 
Sensitivity Specificity Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Accuracy 
Screening 
tool 
including 
original  
question 14 
1519 265 8 163 97.1 90.3 61.9 99.5 91.3 
The final 
screening 
tool: 
Screening 
tool 
excluding 
original 
question 14 
1526 259 8 162 97.0 90.4 61.5 99.5 91.3 
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Table 3.18: Summary of the performance of the screening tool across the pilot and the 
main study population 
 ICD 10 diagnosis of neurological disorder 
 Present  Absent  Total 
Screening instrument diagnosis of Neurological disorders 
Pilot Study 
Present  72 10 82 
Absent  10 185 195 
Total 82 195 277 
K 0.827 
Positive Predictive 
Value 
0.878 
Negative Predictive 
Value 
0.949 
Sensitivity 0.878 
Specificity 0.949 
Accuracy 0.928 
Main Study/Study 
Extension 
Present  259 162 421 
Absent  8 1526 1534 
Total 267 1688 1955 
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K 0.703 
Positive Predictive 
Value 
0.615 
Negative Predictive 
Value 
0.995 
Sensitivity 0.970 
Specificity 0.904 
Accuracy 0.913 
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3.4.3.3 Conditions represented in the Main Study Population that were not represented 
in the Pilot Population 
Conditions that were not represented in the pilot population, e.g. dyskinesias, motor 
neurone disease, Myaesthenia gravis, polio and leprosy, were subsequently represented 
in the main study population and questions dedicated to picking up these conditions did 
so which is further validation of the tool. However, as this was not a pilot, and every 
patient did not receive a full neurological history and examination, I cannot say with 
certainty that no patients with these conditions were missed. 
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3.5 Description of the cases/true positives from the Main Study 
It is important to recognize the WHO ICD 10 for epidemiological studies especially when 
devising a screening tool as this allows completeness and full inclusion and consideration 
of all neurological diagnosis. Therefore all patients diagnosed with a neurological 
condition have been allocated a WHO ICD 10 diagnosis (see appendix 3.1). However for 
practical reasons description of all the patients and the prevalence rates is often best 
performed with a more clinically relevant method to divide up the cases. This is done with 
a combination of the clinical and anatomical pictures that the individual conditions 
produce. I used a practical combination of clinical classification and the ICD10 criteria 
(recorded in brackets) to describe the prevalence rates. This is described in the 
introduction (figure 1.1). 
 
Prevalence rates are presented in table format below, including tables which demonstrate 
age and sex distributions. Rows are missing in tables where there were no individuals to 
record 
 
3.5.1 All cause Neurological Disorders 
There were 384 cases of neurological disorders recorded in the main study population. 
The crude prevalence (95% confidence intervals (CI)) was 172.04/1000 (156.39 to 187.70). 
The age adjusted prevalence (95% CI) according to the WHO standard population was 
168.94/1000 (153.39 to 184.48)  
 
3.5.1.1  Age and Sex Distribution 
The age and sex distribution of all the neurological disorders is demonstrated in the table 
below: 42.7% were female and 57.3% were male.
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Table 3.19: Age and Sex distribution of all-cause neurological disorders  
Age 
Catego
ry 
Total 
Frequ
ency 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence per 
1000 (95% CI) 
Female 
Freque
ncy 
Female 
Prevalence 
per 1000 
(95% CI) 
Female Age 
adjusted 
prevalence per 
1000 (95% CI) 
Mal
e 
Freq
uenc
y 
Male 
Prevalenc
e per 1000 
(95% CI) 
Male Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
70-74 141 160.8  
(136.5 to 
185.1)  
74 150.1 
(118.6 to 
181.6)  
67 174.5 
(136.5 to 
212.4)  
75-79 97 155.2 
(126.8 to 
183.6)  
49 144.1 
(106.8 to 
181.4)  
48 168.4 
(125.0 to 
211.9)  
80-84 60 174.4 
(134.3 to 
214.5)  
33 157.9 
(108.5 to 
207.3)  
27 200.0 
(123.5to 
267.5)  
85+ 86 222.8 
(181.3 to 
264.3)  
46 215.0 
(159.9 to 
270.0)  
40 232.6 
(169.4 to 
296.0)  
Total 384 172.0 
(156.4 to 
187.7). 
168.9 (153.4 to 
184.5) 
202 160.8 
(140.5 to 
181.1) 
157.8 (137.7 to 
178.0) 
182 186.5 
(162.0 to 
210.9) 
183.2 (159.0 
to 207.5) 
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3.5.2 Total Number of People with a Neurological Disorder 
Some people had more than one neurological disorder so the prevalence of people with a 
neurological disorder was less than the overall prevalence of neurological disorders. There 
were 349 people with one or more neurological diagnoses, 314 people with 1 neurological 
diagnosis and 35 people with 2 neurological diagnoses. The crude prevalence (95% CI) of 
people with one or more neurological diagnoses was 156.36/1000 (141.29 to 171.43). The 
age adjusted prevalence (95% CI) according to the WHO standard population was 
154.14/1000 (139.16 to 169.12). The crude prevalence (95% CI) of people with one 
neurological diagnosis was 140.68/1000 (126.26 to 155.11). The age adjusted prevalence 
(95% CI) according to the WHO standard population was 139.34/1000 (124.97 to 153.71). 
The crude prevalence (95% CI) of people with two neurological diagnoses was 15.68/1000 
(10.53 to 20.84). The age adjusted prevalence (95% CI) according to the WHO standard 
population was 14.79/1000 (9.79 to 19.81). 
 
3.5.2.1  Age and Sex Distribution 
The age and sex distribution of all the patients with one or more neurological disorder is 
shown in the table below: 42.7% were female and 57.3% were male. 
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Table 3.20: The age and sex distribution of all patients with one or more Neurological Disorders 
Age 
Categ
ory 
Total 
Frequ
ency 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Freque
ncy 
Female 
Prevalence 
per 1000 
(95% CI) 
Female Age 
adjusted 
prevalence per 
1000 (95% CI) 
Male 
Frequ
ency 
Male 
Prevalenc
e per 1000 
(95% CI) 
Male Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
70-74 127 144.8 
(121.5 to 
168.1) ) 
68 137.9 
(107.5 to 
168.4)  
59 153.6 
(117.6 to 
189.7)  
75-79 89 142.4 
(115.0 to 
169.8)  
47 138.2 
(101.5 to 
174.9)  
42 147.4 
(106.2 to 
188.5)  
80-84 58 168.6 
(129.0 to 
208.2)  
32 153.1 
(104.3 to 
201.9)  
26 192.6 
(126.1 to 
259.1  
85+ 75 194.3 
(154.8 to 
233.8)  
40 186.9 
(134.7 to 
239.1)  
35 203.5 
(143.3 to 
263.7)  
Total 349 156.4 
(141.3 to 
171.4). 
154.1 (139.2 to 
169.1) 
187 148.9 
(129.2 to 
168.6) 
146.9 (127.3 to 
166.5) 
162 166.0 
(142.6 to 
189.3) 
163.5 (140.3 
to 186.7) 
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3.5.3 Central Nervous System Disorders 
3.5.3.1 Movement Disorders 
3.5.3.1.1 Tremor 
3.5.3.1.1.1 Prevalence and disease subtypes 
There were 110 people in the study population with tremor. The consequent prevalence, 
age adjusted prevalence and confidence intervals, for tremor and the subtype breakdown 
are presented in the table below. 
 
Table 3.21: Tremor Prevalence and Subtype Breakdown 
Diagnosis Frequency in the 
Main Study 
Population/n=223
2 
Crude Prevalence per 
1000 (95% CI) 
Age adjusted 
prevalence per 
1000 (95% CI) 
All Tremors 110 49.28 ( 40.30 to 
58.26) 
48.22 (39.34 to 
57.11) 
Essential Tremor 67 
30.02 (22.94 to 37.10) 
30.10 (23.01 to 
37.18) 
Enhanced physiological 
tremor 
16 
7.17 (3.67 to 10.67) 6.40 (3.10 to 9.71) 
Tremor secondary to 
Parkinsonism/Parkinson's 
disease 
12 
5.38 (2.34 to 8.41) 5.13 (2.16 to 8.09) 
Tremor secondary to 
cerebellar disease 
11 
4.93 (2.02 to 7.83) 4.87 (1.98 to 7.76) 
Orthostatic tremor 3 1.34 (0 to 2.86) 1.27 (0 to 2.74) 
Iatrogenic tremor 1 0.45 (0 to 1.33) 0.46 (0 to 1.35) 
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3.5.3.1.1.2 Age and Sex Distribution 
The age and sex distribution of all the patients with tremor is given in the table below: 
42.7% were female and 57.3% were male. 
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Table 3.22: Tremor Prevalence with Age and Sex Breakdown 
Age 
Categ
ory 
Total 
Frequ
ency 
Total 
Prevalenc
e per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence per 
1000 (95% CI) 
Femal
e 
Frequ
ency 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female Age 
adjusted 
prevalence per 
1000 (95% CI) 
Male 
Frequ
ency 
Male 
Prevalenc
e per 1000 
(95% CI) 
Male Age 
adjusted 
prevalence per 
1000 (95% CI) 
70-74 31 35.3 (23.1 
to 47.6)  
15 30.4 (15.3 
to 45.9) 
 16 41.7 (21.7 
to 61.7)  
 
75-79 31 49.6 (32.6 
to 66.6)  
11 32.4 (13.5 
to 51.2) 
 20 70.2 (40.5 
to 99.8) 
 
80-84 22 64.0 (38.1 
to 89.8)  
11 52.6 (22.4 
to 82.9)  
 11 81.5 (35.3 
to 127.6 
 
85+ 26 67.4 (42.4 
to 92.4)) 
 
 
10 46.7 (18.5 
to 75.0) 
 16 93.0 (49.6 
to 136.4)  
 
Total 110 49.28 
(40.30 to 
58.26) 
48.22 (39.34 to 
57.11) 
47 37.42 
(26.9 to 
47.9) 
37.1 (26.6 to 
47.5) 
63 64.5 (49.1 
to 80.0)  
62.6 (47.4 to 
77.8) 
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3.5.3.1.1.3 Description of Essential Tremor patients and follow up 
The average age of the patients with Essential Tremor was 78.8 years: 37 (55.2%) were 
male and 30 (44.8%) were female.  
 
The Average length of symptoms of tremor that the patients had experienced was 8.3 
years with a range of 3 months to 55 years. 
 
The following tables and charts provide the distribution of signs and symptoms  
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Table 3.23: The anatomical location of tremor on history and examination in patients with essential tremor 
 History of 
Limb 
Tremor 
History 
of Limb 
Tremor 
% 
Examination 
demonstrates 
Limb tremor 
Examination 
demonstrates 
Limb tremor 
% 
History of 
Head 
tremor 
History of 
Head tremor 
% 
Examination 
Demonstrates 
Head tremor 
Examination 
Demonstrates 
Head tremor % 
Y 57 85.1 64 95.5 23 34.3 38 56.7 
N 10 14.9 3 4.5 44 65.7 29 43.3 
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All patients experienced either an action limb tremor or a head tremor for diagnostic purposes. However some patients also 
had a resting tremor. The percentage of which is given below. 
 
Table 3.24: Presence of atypical features on history and examination of essential tremor patients 
 History of  
Asymmetry 
of Limb 
Tremor 
History of 
Asymmetry 
of Limb 
Tremor % 
Examination 
demonstrates 
Asymmetry 
of Limb 
tremor 
Examination 
demonstrates 
Asymmetry of 
Limb tremor 
% 
History of 
Resting  
tremor 
History of 
Resting 
tremor % 
Examination 
Demonstrates 
Resting tremor 
Examination 
Demonstrates 
Resting tremor 
% 
Y 23 34.3 12 17.9 11 16.4 13 19.4 
N 44 65.7 55 82.1 56 83.6 54 80.6 
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Worthy of note is that history and examination findings do not always correlate, this 
demonstrates the importance of examination in order to make an accurate diagnosis. 
 
16 patients (23.9%) admitted to having a family history of tremor. 24 (35.8%) stated their 
tremor was alcohol responsive, 13 (19.4%) stated it was not alcohol responsive and 30 
(44.8%) said they could not comment as they were Tee-total. 
 
Beta blockers are the1st line treatment (2) and the only recommended treatment routinely 
available in Tanzania. They were given to 39 (58.2%) patients. The other patients did not 
want treatment or Beta blockers were contraindicated due to obstructive airways disease, 
hypotension or heart block. All patients that received medication were made aware of the 
side effects profile and told to stop the medication if they experienced any ill effects. They 
had a direct point of contact in the NMI if they had any problems, and the NMI could in 
turn contact the RD. 
 
3.5.3.1.1.3.1 Follow up of Essential Tremor Patients 
We attempted to follow up all patients who had been put on Beta blockers to assess their 
response and to check if they had experienced any side effects. Of the 39 patients we 
were able to follow up 35 patients. 1 patient had travelled, I had died and the remaining 
two could not be seen due to their work and social commitments. Of the 35 patients that 
were followed up, 1 had never taken their medication as he did not feel it would help and 
did not want to try it. Therefore 34 patients were assessed: 
 
29 (85.3%) patients reported that they had improved on medication. 5 (14.7%) felt that 
there had been no change as a result of treatment. All patients were asked to give their 
tremor a mark out of ten when they were on treatment, with 10/10 being the severity of 
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their tremor prior to the treatment and the subsequent mark being what it was as a 
severity out of ten whilst they were on treatment. From this we could work out a point 
score that the patient’s tremor had reduced by. The results are shown in table 3.25. 
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Table 3.25 Tremor Reduction Score in Patients with Essential Tremor treated with Beta 
Blockers 
Mark out of ten on 
treatment 
Number of points 
score improved by 
Number of patients Percentage of 
patients 
0 10 6 17.6 
1 9 0 0.0 
2 8 0 0.0 
3 7 1 2.9 
4 6 2 5.9 
5 5 3 8.8 
6 4 2 5.9 
7 3 7 20.6 
8 2 5 14.7 
9 1 3 8.8 
10 0 5 14.7 
 
Patients were prescribed a variety of propranolol doses for their essential tremor 
dependent on their blood pressure and level of general frailty. This varied from 10mg TDS 
to 80mg TDS. Higher doses were utilised if the patient required beta blockers for 
hypertension as well as tremor. Although beta blockers are not a first line treatment 
option for hypertension (especially in the black elderly) compliance in this population is an 
issue and therefore if a medication dose can be optimised for a dual purpose then this was 
felt to be appropriate. Despite full explanations of how to take the medication patients 
often took a different dose than what was prescribed, in the majority of cases this was in 
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order to “spread the tablets out and make them last longer". In other cases the dose 
taken simply had little correlation to what was prescribed. The variation in dose taken is 
described in the table below along with the average reduction in severity score for that 
dose group.  
 
Table 3.26: Variation in Beta Blocker dose prescribed and average improvement in 
tremor severity score 
Total dose of Beta 
blockers taken in 24 
hours 
Number of patients Percentage of 
patients 
Average 
improvement in 
severity score 
1mg to 40mg 6 17.6% 4.5 
41mg to 80mg 12 35.3% 4.3 
81mg to 120mg 14 41.2% 3.0 
>120mg 2 5.9% 8.0 
 
Side effects were only experienced by 2 (5.9%) patients. One patient felt well and 
experienced a reduction in his symptoms on 10mg TDS but when he increased to 20mg 
TDS he felt lightheaded. When the dose was reduced back down he had  no side effects 
and felt happy to continue on this dose. One woman experienced “whole body weakness” 
and did not gain any benefit from the beta blockers. Consequently, she wished to stop the 
medication, a decision supported by the RD. 
 
Follow up took place at varying times from the initial assessment for logistical reasons 
related to the completion of the rest of the study. This varied from 1 to 6 months. All 
patients had received an initial one month supply of beta blockers with a prescription and 
instruction on how to get more. Only 7 (20.6%) people were still taking beta blockers 
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when they were reviewed. The remaining 27 (79.4%) had discontinued the medication, for 
the following reasons; 10 (37.0%) – stated they had no money to get more (despite 
systems in place for free health care for the over 70s), 5 (18.5%) – had gone to get more 
but there was no available supply, 5 (18.5%) – had not experienced any improvement on 
the medication , 2 (7.4%) – had briefly discontinued the medication as they were taking 
other medication for an alternative problem, 2 (7.4%) – had experienced side effects as 
detailed above, 1 (3.7%) – was unable to get to the health centre due to leg pain, 1 (3.7%)  
had forgotten and 1 (3.7%)  had lost the prescription. 
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3.5.3.1.2 Parkinsonism 
3.5.3.1.2.1 Prevalence and disease subtypes 
Of the patients with Parkinsonism, 12 (85.7%) had idiopathic PD (IPD), 1  (7.1%) had 
vascular parkinsonism diagnosed clinically with the Winikates vascular rating scale (3) and 
1 (7.1%) had a Parkinson’s plus syndrome – progressive supra-nuclear palsy diagnosed 
clinically with the NINDS-SPSP diagnostic criteria [167]. The consequent prevalence, age 
adjusted prevalence (based on the WHO standard population) and confidence intervals for 
Parkinsonism and the subtype breakdown are given in the table below. 
 
Table 3.27: Parkinsonism Prevalence and Subtype Breakdown 
Diagnosis Frequency   Crude Prevalence per 
1000 (95% CI) 
Age adjusted 
prevalence per 1000 
(95% CI) 
Parkinsonism 14 6.27 (3.00 to 9.55) 5.94 (2.75 to 9.12) 
Parkinsonism with 
tremor 12 5.38 (2.34 to 8.41) 5.13 (2.16 to 8.09) 
Parkinsonism without 
tremor 2 0.90 (0 to 2.14) 0.81 (0 to 1.99) 
Parkinson's Disease 12 5.38 (2.34 to 8.41) 5.13 (2.16 to 8.09) 
Vascular Parkinsonism 1 0.45 (0 to 1.33) 0.31 (0 to 1.04) 
Progressive Supra-
nuclear palsy 1 0.45 (0 to 1.33) 0.50 (0 to 1.43) 
 
3.5.3.1.2.2 Age and Sex Distribution 
The age and sex distribution of patients with Parkinsonism is shown in the table below: 
42.9% were female and 57.1% were male. 
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Table 3.28: Parkinsonism Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequenc
y 
Total 
Crude 
Prevalenc
e per 1000 
(95% CI) 
Total Age 
adjusted 
prevalenc
e per 1000 
(95% CI) 
Female 
Frequenc
y 
Female 
Crude 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalenc
e per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Crude 
Prevalenc
e per 1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 1000 
(95% CI) 
70-74 2 2.28 (0 to 
5.44)  
 2 4.06 (0 to 
9.67)  
 0 0 0 
75-79 2 3.20 (0 to 
7.67)  
 1 2.94 (0 to 
8.70)  
 1 3.51 ( 0 to 
10.37)  
 
80-84 5 14.52 
(1.88 to 
27.18) 
 1 4.78 ( 0 to 
14.14) 
) 4 29.63 
(1.03 to 
58.23) 
 
85+ 5 12.95 
(1.67 to 
24.23)  
 2 9.35 (0 to 
22.34)  
 3 17.44 ( 0 
to 37.01)  
 
Total 14 6.27 (3.00 
to 9.55) 
5.94 (2.75 
to 9.12) 
6 4.78 (0.96 
to 8.59)  
4.51 (0.81 
to 8.22)  
8 8.20 2.54 
to 13.85)  
7.77 (2.26 
to 13.28) 
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3.5.3.1.2.3 Parkinsonism and Idiopathic Parkinson’s disease patient data analysis 
The average age of the patients with Parkinsonism was 83.1 years, while the average age 
of those with IPD was 83.0 years. The duration of symptoms of the patients with 
Parkinsonism was on average 4.4 years with a range from 1 to 10 years and the patients 
with IPD had a mean duration of 4.9 years with a range of 1 to 10 years. 1 patient with IPD 
was unable to comment on how long she had had symptoms for.  
 
The sex breakdown of the patients was as follows; 
Table 3.29: Sex representation of Patients with Parkinsonism 
Sex  Parkinsonism – 
frequency 
Parkinsonism - 
percentage 
PD – frequency PD – 
percentage 
M 8 57.1 6 50.0 
F 6 42.8 6 50.0 
 
The Severity of Parkinsonism is routinely described using the Modified Hoehn and Yahr 
Scale (5). 
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Table 3.30: Hoehn and Yahr Score of Patients with all-cause Parkinsonism and Idiopathic 
Parkinson’s disease 
Scale Rating Parkinsonism 
– frequency 
Parkinsonism 
- percentage 
PD - 
frequency 
PD – 
percentage 
Hoehn and 
Yahr 
2.0 3 21.4 3 25.0 
 2.5 1 7.1 1 8.3 
 3.0 4 28.6 3 25.0 
 4.0 2 14.3 2 16.7 
 5.0 4 28.6 3 25.0 
Severity Mild to 
Moderate 
(Hoehn and 
Yahr I-III) 
8 57.1 7 58.3 
 Severe 
(Hoehn and 
Yahr IV-V) 
6 42.9 5 41.7 
 
Medication was prescribed initially for 13 out of 14 (92.9%) patients with Parkinsonism 
including 11 (91.7%) out of 12 patients with PD. The remaining patient stated she did not 
want to take tablets despite full explanation as to the possible benefits. 
The average dose of Levodopa that patients required for relief of their symptoms was 
223.2mg/24 hours for Parkinsonism patients and 229.2mg/24 hours for PD patients. 
However, some patients had ceased medication as shown in the table below. 
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Table 3.31: Medication Compliance of patients with Parkinsonism 
Still on 
medication? 
Parkinsonism – 
frequency 
Parkinsonism - 
percentage 
PD – frequency PD – 
percentage 
Yes 8 57.1 7 58.3 
No 4 28.6 3 25.0 
Not applicable 
(never started) 
1 7.1 1 8.3 
Died 1 7.1 1 8.3 
 
Of those that were no longer on medication the following reasons were given; 1 
experienced distressing dyskinesias, 2 did not feel the medication made any difference – 
one of these included the patient with PSP and 1 did not want to take tablets anymore. 
The following side effects were experienced by patients; dyskinesias (1),  nausea (2), 
dizziness (2) and vivid dreams (1). 
 
3.5.3.1.3 Cerebellar Disorders 
3.5.3.1.3.1 Prevalence and disease subtypes 
There were 11 people in the main study population with cerebellar disorders. The 
consequent prevalence, age adjusted prevalence (based on the WHO standard 
population) and confidence intervals for cerebellar disorders and the subtype breakdown 
are given in the table below. 
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Table 3.32: Cerebellar Disorder Prevalence and Subtype Breakdown 
Diagnosis Frequency in the 
Main Study 
Population/n=22
32 
Crude Prevalence per 
1000 (95% CI) 
Age adjusted 
prevalence per 
1000 (95% CI) 
Cerebellar disorders 
total 11 4.93 (2.02 to 7.83) 4.87 (1.98 to 7.76) 
Secondary to alcohol 
or idiopathic 7 3.14 (0.82 to 5.46) 3.14 (0.82 to 5.46) 
Idiopathic 5 2.24 (0.28 to 4.20) 2.20 (0.25 to 4.14) 
Secondary to alcohol    2 0.90 (0 to 2.14) 0.94 (0 to 2.21) 
Secondary to stroke 4 1.79 (0.04 to 3.55) 1.73 (0.01 to 3.46) 
 
3.5.3.1.3.2 Age and Sex Distribution 
The age and sex distribution of patients with cerebellar disorders is given in the table 
below: 27.3% were female and 72.7% were male. 
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Table 3.33: Cerebellar Disorder Prevalence and Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequenc
y  
Total 
Crude 
Prevalenc
e per 1000 
(95% CI) 
Total Age 
adjusted 
prevalenc
e per 1000 
(95% CI) 
Female 
Frequenc
y  
Female 
Crude 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalenc
e per 1000 
(95% CI) 
Male 
Frequenc
y  
Male 
Crude 
Prevalenc
e per 1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 1000 
(95% CI) 
70-74 1 1.14 (0 to 
3.37)  
0 0 0 1 2.60 (0 to 
7.70)   
75-79 6 
9.60 (1.96 
to 17.24)  
1 
2.94 (0 to 
8.70)  
5 17.54 
(2.30 to 
32.79)  
80-84 2 5.81 (0 to 
13.85)  
1 4.78 (0 to 
14.14)  
1 7.41 (0 to 
21.87)  
85+ 2 5.18 (0 to 
12.34)  
1 4.67 (0 to 
13.81)  
1 5.81 (0 to 
17.18)  
Total 11 4.93 (2.02 
to 7.83) 
4.87 (1.98 
to 7.76) 
3 2.39 (0 to 
5.09 
2.26 (0 to 
4.89) 
8 8.20 (2.54 
to 13.85) 
8.23 (2.56 
to 13.89) 
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3.5.3.1.4 Dyskinesias 
3.5.3.1.4.1 Prevalence and disease subtypes 
There were 5 people in the main study population with dyskinesias. The consequent 
prevalence, age adjusted prevalence (based on the WHO standard population) and 
confidence intervals for dyskinesias and the subtype breakdown are demonstrated in the 
table below. 
 
Table 3.34: Dyskinesia Prevalence and Subtype Breakdown 
Diagnosis Frequency in the 
Main Study 
Population/n=22
32 
Crude Prevalence 
per 1000 (95% CI) 
Age adjusted 
prevalence per 100 
(95% CI) 
Dyskinesias 5 
2.24 (0.28 to 
4.20) 2.02 (0.16 to 3.88) 
Unspecified chorea 1 
0.45 (0 to 1.33) 0.31 (0 to 1.04) 
Tardive dyskinesias/ 
iatrogenic 2 
0.90 (0 to 2.14) 0.77 (0 to 1.92) 
Orofacial dyskinesias – 
idiopathic 2 
0.90 (0 to 2.14) 0.94 (0 to 2.21) 
 
3.5.3.1.4.2 Age and Sex Distribution 
The age and sex distribution of patients with dyskinesias is shown in the table below: 
60.0% were female and 40.0% were male. 
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Table 3.35: Dyskinesia Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-74 1 1.14 (0 to 
3.37)  
0 0  1 2.60 (0 to 
7.70)  
75-79 2 3.20 (0 to 
7.63)  
1 2.94 (0 to 
8.70)  
1 3.51 (0 to 
10.37)  
85+ 2 5.18 (0 to 
12.34)  
2 9.35 (0 to 
22.24)  
0 0 0 
Total 5 2.24 (0.28 
to 4.20) 
2.02 (0.16 to 
3.88) 
3 2.39 (0 to 
5.09) 
1.92 (0 to 
4.34) 
2 2.05 (0 to 
4.89) 
2.15 (0 to 
5.05) 
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3.5.3.2 Episodic and Paroxysmal Disorders 
3.5.3.2.1 Headaches 
3.5.3.2.1.1 Prevalence and disease subtypes 
There were 92 people in the main study population with headaches that affected activities 
of daily living (ADLs). The consequent prevalence, age adjusted prevalence (based on the 
WHO standard population) and confidence intervals for headaches that affected ADLs and 
the subtype breakdown are demonstrated in the table below. 
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Table 3.36: Headache Prevalence and Subtype Breakdown 
Diagnosis Frequency in 
the Main 
Study 
Population/n=
2232 
Crude Prevalence per 1000 
(95% CI) 
Age adjusted prevalence 
per 1000 (95% CI) 
All Headaches 92 41.22 (32.97 to 49.47) 41.79 (33.49 to 50.09) 
Primary headaches – total 44 19.71 (13.95 to 25.48) 19.86 (14.07 to 25.64) 
Migraine 8 3.58 (1.10 to 6.06) 3.77 (1.22 to 6.31) 
Tension Type headaches 36 16.13 (10.90 to 21.36) 16.09 (10.87 to 21.31) 
Cluster headaches 0 0 0 
Other Primary Headaches 0 0 0 
Secondary headaches – total 48 21.50 (15.49 to 27.52) 21.93 (15.86 to 28.01) 
Headaches attributed to head and/or neck 
trauma 3 1.34 (0 to 2.86) 1.40 (0 to 2.95) 
Headaches attributed to infection 0 0 0 
Headache attributed to arterial hypertension 3 1.34 (0 to 2.86) 1.10 (0 to 2.47) 
Headache attributed to hypertensive crisis 
without hypertensive encephalopathy 0 0 0 
Headache attributed to hypertensive 
encephalopathy 0 0 0 
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Headache attributed to disorders of the neck 34 15.23 (10.15 to 20.31) 15.53 (10.40 to 20.66) 
Headache attributed to disorders of the eyes 4 1.79 (0.04 to 3.55) 1.98 (0.14 to 3.83) 
Headache attributed to disorders of the ears 1 0.45 (0 to 1.33) 0.48 (0 to 1.39) 
Headache attributed to disorders of the teeth or 
jaw 2 0.90 (0 to 2.14) 0.98 (0 to 2.28) 
Trigeminal neuralgia 1 0.45 (0 to 1.33) 0.46 (0 to 1.35) 
 
3.5.3.2.1.2 Age and Sex Distributions 
The age and sex distribution of patients with headaches that affect ADLs is given in the table below: 78.3% were female and 
21.7% were male. 
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Table 3.37: Headache Prevalence with Age and Sex Breakdown 
Age 
Categ
ory 
Total 
Frequ
ency 
Total 
Prevalenc
e per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence per 
1000 (95% CI) 
Female 
Freque
ncy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female Age 
adjusted 
prevalence per 
1000 (95% CI) 
Male 
Frequ
ency 
Male 
Prevalenc
e per 1000 
(95% CI) 
Male Age 
adjusted 
prevalence per 
1000 (95% CI) 
70-74 40 45.61 
(31.80 to 
59.42)  
32 64.91 
(43.16 to 
86.65)  
8 20.83 
(6.55 to 
35.12)  
75-79 28 44.8 
(25.58 to 
61.02)  
25 73.53 
(45.79 to 
101.27)  
3 
10.53 (0 to 
22.38)   
80-84 12 34.88 
(15.49 to 
54.27)  
6 28.71 
(6.07 to 
51.35)  
6 44.44 
(9.68 to 
79.21)  
85+ 12 31.09 
(13.77 to 
48.40)  
9 42.06 
(15.16 to 
68.95)  
3 
17.44 (0 to 
37.01)  
Total 92 41.22 
(32.97 to 
49.47) 
41.79 (33.49 to 
50.09) 
72 57.32 
(44.47 to 
70.18) 
58.00 (45.07 to 
70.93) 
20 20.49 
(11.60 to 
29.38) 
20.93 (11.95 to 
29.91) 
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3.5.3.2.2 Stroke 
3.5.3.2.2.1 Prevalence and disease subtypes 
There were 54 people in the main study population with stroke with residual disability 
(any neurological symptoms or signs). The consequent prevalence, age adjusted 
prevalence (based on the WHO standard population) and confidence intervals for stroke 
with residual disability, and the subtype breakdown are demonstrated in the table below. 
Table 3.38: Stroke Prevalence and Subtype Breakdown 
Diagnosis Frequency in the 
Main Study 
Population/n=2232 
Prevalence per 1000 
(95% CI) 
Age adjusted 
prevalence to WHO 
standard population 
(95% CI) 
Stroke 54 24.19 (17.82 to 30.57) 22.95 (16.74 to 29.17) 
LACS 19 8.51 (4.70 to 12.32) 8.10 (4.38 to 11.82) 
PACS 16 7.17 (3.67 to 10.67) 6.62 (3.26 to 9.99) 
TACS 12 5.38 (2.34 to 8.41) 5.40 (2.36 to 8.44) 
POCS 7 3.14 (0.82 to 5.46) 2.83 (0.63 to 5.04) 
POCS 
cerebellar 4 1.79 (0.04 to 3.55) 1.73 (0.01 to 3.46) 
POCS non 
cerebellar 3 1.34 (0 to 2.86) 1.10 (0 to 2.47) 
 
3.5.3.2.2.2 Age and Sex Distribution 
The age and sex distribution of patients with stroke with residual deficit is given in the 
table below: 46.3% were female and 53.7% were male. 
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Table 3.39: Stroke Prevalence with Age and Sex Breakdown 
Age 
Category 
Total 
Frequency 
Total 
Prevalenc
e per 
1000 
(95% CI) 
Total Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
Female 
Frequenc
y 
Female 
Prevalenc
e per 
1000 
(95% CI) 
Female 
Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-74 15 17.10 
(8.52 to 
25.69)  
5 10.14 
(1.30 to 
18.99)  
10 26.04 ( 
10.11 to 
41.97)  
75-79 13 20.80 
(9.61 to 
31.99)  
3 
8.82 (0 to 
18.76)  
10 35.09 
(13.73 to 
56.45)  
80-84 9 26.16 
(9.29 to 
43.03)  
5 23.92 
(3.21 to 
44.64)   
4 29.63 
(1.03 to 
58.23)  
85+ 17 44.04 
(23.57 to 
64.51)  
12 56.07 
(25.25 to 
86.90)  
5 29.07 
(3.96 to 
54.18)  
Total 54 24.19 
(17.82 to 
30.57) 
22.95 
(16.74 to 
29.17) 
25 19.90 
(12.18 to 
27.63)( 
17.77 
(10.47 to 
25.08) 
29 29.71 
(19.06 to 
40.37) 
29.62 
(18.99 to 
40.26) 
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3.5.3.2.3 Epilepsy 
3.5.3.2.3.1 Prevalence and disease subtypes 
There were 10 people in the main study population with epilepsy, 9 with Generalised 
Tonic Clonic Seizures (GTCS) and 1 with partial epilepsy with secondary generalisation. The 
consequent prevalence, age adjusted prevalence (based on the WHO standard 
population) and confidence intervals for epilepsy, and the subtype breakdown, are given 
in the table below. 
Table 3.40: Epilepsy Prevalence and Subtype Breakdown 
Diagnosis Frequency in the 
Main Study 
Population/n=2232 
Prevalence per 
1000 (95% CI) 
Age adjusted 
prevalence to WHO 
standard population 
(95% CI) 
Epilepsy 10 
4.48 (1.71 to 
7.25) 4.44 (1.69 to 7.20) 
GTCS 9 4.03 (1.40 to 6.66) 3.97 (1.36 to 6.57) 
Partial with 
secondary 
generalization 1 0.45 (0 to 1.33) 0.48 (0 to 1.39) 
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3.5.3.2.3.2 Age and Sex Distribution 
The age and sex distribution of patients with epilepsy is demonstrated in the table below. . 
Table 3.41: Epilepsy Prevalence with age and sex breakdown 
Age 
Cate
gory 
Total 
Frequency in 
the Main 
Study 
Population/n=
2232 
Total 
Crude 
Prevalen
ce per 
1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Female 
Frequency in 
the Main 
Study 
Population/
n=2232 
Female 
Crude 
Prevalen
ce per 
1000 
(95% CI) 
Female Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequency 
in the Main 
Study 
Population/
n=2232 
Male 
Crude 
Prevalen
ce per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-
74 
8 9.12 
(2.83 to 
15.41) 
 
 
4 8.11 
(0.19 to 
16.03)  
4 10.42 
(0.26 to 
20.57) ) 
85+ 2 
5.18 (0 
to 12.34)  
1 
4.67 (0 
to 13.81)  
1 
5.81 (0 
to 17.18) 
0.31 (-
0.42 to 
1.04) 
Tota
l 
10 4.48 
(1.71 to 
7.25) 
4.44 (1.69 
to 7.20) 
5 3.98 
(0.50 to 
7.46) 
3.95 (0.48 
to 7.42) 
5 5.12 
(0.64 to 
9.60)  
5.08 (0.62 
to 9.54) 
339 
 
3.5.3.2.3.3 Description of Epilepsy Patients and Follow up 
All patients with epilepsy were established on antiepileptic medication (phenobarbitone 
or phenytoin) according to national guidelines. At follow up all patients were still on 
medication, but 3 had had breaks in medication. All patients had experienced reduced 
seizure frequency and had had no seizures whilst compliant on medication, while 1  
patient had experienced side effects whilst on medication (drowsiness on 
phenobarbitone). After discussion with the patient the RD found that he was taking an 
inappropriately large dose which had not been prescribed. He was told to reduce back to 
an appropriate dose and was given means for local follow up. All patients were aware of 
local follow up and were aware they should attend. They were also aware that epilepsy 
medication was free, how to obtain it and the importance of compliance.  
 
3.5.3.3 Systemic Atrophies/Degenerative Diseases affecting the Central Nervous System 
3.5.3.3.1 Motor Neuron Disease 
There were 2 people in the main study population with motor neuron disease, a 75 year 
old man and an 80 year old woman with Barthel indexes of 15 and 16 respectively. The 
crude prevalence was therefore 0.90/1000, 95% CI (0 to 2.14) and the age adjusted 
prevalence was 0.96/1000, 95% CI (0 to 2.25). The pattern of disease was that of 
amyotrophic lateral sclerosis. .  
 
3.5.3.4 Injury resulting in CNS dysfunction 
3.5.3.4.1 Spinal Cord lesions 
3.5.3.4.1.1 Prevalence and disease subtypes 
There were 5 people in the main study population with spinal cord lesions. The 
consequent prevalence, age adjusted prevalence (based on the WHO standard 
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population) and confidence intervals for cord lesions and the subtype breakdown are 
given in the table below. 
Table 3.42: Spinal Cord Lesion Prevalence and Subtype Breakdown 
Diagnosis Frequency in the 
Main Study 
Population/n=22
32 
Crude Prevalence 
per 1000 (95% CI) 
Age adjusted 
prevalence per 1000 
(95% CI) 
Cord lesions 5 2.24 (0.28 to 4.20) 1.89 (0.09 to 3.69) 
Cervical Cord 
Lesions 3 1.34 (0 to 2.86) 1.10 (0 to 2.47) 
Traumatic Cervical 
Cord lesion 1 0.45 (0 to 1.33) 0.31 (0 to 1.04) 
Non-traumatic 
Cervical Cord Lesion 
(Arthritic 
compression or 
acute lower cervical 
cord lesion) 2 0.90 (0 to 2.14) 0.79 (0 to 1.95) 
Arthritic 
compression 1 0.45 (0 to 1.33) 0.31 (0 to 1.04) 
Acute lower cervical 
cord lesion 1 0.45 (0 to 1.33) 0.48 (0 to 1.39) 
Thoracic Cord 
Lesion 2 0.90 (0 to 2.14) 0.79 (0 to 1.95) 
Traumatic Thoracic 
Cord lesion 0 0 0 
Non-traumatic 
Thoracic Cord Lesion 2 0.90 (0 to 2.14) 0.79 (0 to 1.95) 
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3.5.3.4.1.2 Age and Sex Distribution 
The age and sex distribution of patients with cord lesions are demonstrated in the table below. 20.0% were female and 80.0% 
were male. 
Table 3.43: Spinal Cord Lesion Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-74 2 2.28 (0 to 
5.44)  
0 0 0 2 5.21 (0 to 
12.41)  
85+ 3 7.77 (0 to 
16.53)  
1 4.67 (0 to 
13.81)  
2 11.62 (0 
to 27.65)   
Total 5 2.24 (0.28 
to 4.20) 
1.89 (0.09 to 
3.69) 
1 0.80 (0 to 
2.36) 
0.55 (0 to 
1.85) 
4 4.10 (0.09 
to 8.11)  
3.60 (0 to 
7.36) 
 
342 
 
3.5.4 Peripheral Nervous System Disorders 
3.5.4.1 Polyneuropathy 
3.5.4.1.1 Prevalence and disease subtypes 
There were 42 people in the main study population with peripheral neuropathy. The 
consequent prevalence, age adjusted prevalence (based on the WHO standard 
population) and confidence intervals for peripheral neuropathy and the subtype 
breakdown are given in the table below. 
Table 3.44: Peripheral Neuropathy Prevalence and Subtype Breakdown 
Diagnosis Frequency in the Main 
Study 
Population/n=2232 
Crude Prevalence 
per 1000 (95% CI) 
Age adjusted 
prevalence per 
1000 (95% CI) 
Peripheral 
Neuropathy 42 
18.82 (13.18 to 
24.45) 
18.61 (13.01 to 
24.22) 
Sensory Peripheral 
Neuropathy 39 
17.47 (12.04 to 
22.91) 
17.36 (11.95 to 
22.78) 
Sensorimotor 
Peripheral 
Neuropathy 3 1.34 (0 to 2.86) 1.25 (0 to 2.71) 
Motor Peripheral 
Neuropathy 0 0 0 
 
3.5.4.1.2 Age and Sex Distribution 
The age and sex subdivisions of the patients with peripheral neuropathy are 
demonstrated in the table below. 50.0% were female and 50.0% were male. 
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Table 3.45: Peripheral Neuropathy Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequ
ency 
Male 
Prevalenc
e per 1000 
(95% CI) 
Male Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
70-74 17 19.38 
(10.26 to 
28.51)  
11 22.31 
(9.27 to 
35.35)  
6 15.63 
(3.22 to 
28.03)  
75-79 13 
20.80 (9.61 
to 31.99)  
7 20.59 
(5.49 to 
35.68)  
6 21.05 
(4.39 to 
37.72)  
80-84 4 11.63 (0.30 
to 22.96)  
2 9.57 (0 to 
22.77)  
2 14.81 (0 to 
35.19)   
85+ 8 
20.73 (6.51 
to 34.94)  
1 
4.67 (0 to 
13.81))  
7 40.70 
(11.17 to 
70.23)  
Total 42 18.82 
(13.18 to 
24.45) 
18.61 (13.01 to 
24.22) 
21 16.72 
(9.63 to 
23.81) 
17.42 
(10.18 to 
24.66) 
21 21.52 
(12.41 to 
30.62) 
20.15 
(11.33 to 
28.96) 
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3.5.4.2 Nerve, Nerve Root and Plexus Disorders 
3.5.4.2.1 Cranial Nerve Pathology 
3.5.4.2.1.1 Prevalence and disease subtypes 
There were 14 people in the main study population with cranial nerve lesions. The 
consequent prevalence, age adjusted prevalence (based on the WHO standard 
population) and confidence intervals for cranial nerve pathology and the subtype 
breakdown are shown in the table below. 
Table 3.46: Cranial Nerve Pathology Prevalence and Subtype Breakdown 
Diagnosis Frequency in the 
Main Study 
Population/n=22
32 
Crude Prevalence per 
1000 (95% CI) 
Age adjusted 
prevalence per 
1000 (95% CI) 
Cranial Nerve 
Pathology 14 6.27 (3.00 to 9.55) 
5.71 (2.58 to 
8.83) 
Ptosis 8 3.58 (1.10 to 6.06) 
3.34 (0.95 to 
5.74) 
Ptosis secondary to eye 
pathology - traumatic 4 1.79 (0.04 to 3.55) 1.58 (0 to 3.22) 
Ptosis secondary to eye 
pathology - non 
traumatic 2 0.90 (0 to 2.14) 0.98 (0 to 2.28) 
Ischaemic 3rd CN palsy 2 0.90 (0 to 2.14) 0.79 (0 to 1.95) 
Facial nerve pathology 4 1.79 (0.04 to 3.55) 1.58 (0 to 3.22) 
Bells 2 0.90 (0 to 2.14) 0.79 (0 to 1.95) 
Traumatic  1 0.45 (0 to 1.33) 0.31 (0 to 1.04) 
Hemifacial spasm 2 0.90 (0 to 2.14) 0.79 (0 to 1.95) 
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3.5.4.2.1.2 Age and Sex Distribution 
The Age and Sex distribution of patients with cranial nerve lesions are given in the table below: 50.0% were female and 50.0% 
were male. 
Table 3.47: Cranial Nerve Pathology Prevalence and Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-74 7 
7.98 (2.09 
to 13.87)  
3 
6.09 (0 to 
12.95)  
4 10.42 
(0.26 to 
20.57)  
80-84 1 2.91 (0 to 
8.60)  
1 4.78 (0 to 
14.14)  
0 0 0 
85+ 6 15.54 (3.20 
to 27.88)  
3 14.02 (0 to 
29.77)  
3 17.44 (0 
to 37.01)  
Total 14 6.27 (3.00 
to 9.55) 
5.71 (2.58 to 
8.83) 
7 5.57 (1.46 
to 9.69) 
5.09 (1.16 
to 9.03)  
7 7.17 (1.87 
to 12.47) 
6.50 (1.46 
to 11.54) 
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3.5.4.2.2 Upper Limb Mononeuropathies 
3.5.4.2.2.1 Prevalence and disease subtypes 
There were 15 people in the main study population with upper limb mononeuropathy and 
polyneuropathy. The consequent prevalence, age adjusted prevalence (based on the WHO 
standard population) and confidence intervals for upper limb mononeuropathies and the 
subtype breakdown are shown in the table below. 
Table 3.48: Upper Limb Mononeuropathy Prevalence and Subtype Breakdown 
Diagnosis Frequency in 
the Main Study 
Population 
Crude Prevalence 
per 1000 (95% CI) 
Age adjusted 
prevalence per 
1000 (95% CI) 
Upper Limb Mononeuropathies 15 
6.72 (3.33 to 
10.11)  
6.53 (3.19 to 
9.87) 
Traumatic upper limb multiple 
mononeuropathies  2 0.90 (0 to 2.14) 0.96 (0 to 2.24) 
Traumatic damage to Median 
Nerve 1 0.45 (0 to 1.33) 0.48 (0 to 1.39) 
Non-traumatic damage to 
Median nerve - 
compression/entrapment 4 1.79 (0.04 to 3.55) 1.58 (0 to 3.22) 
Traumatic damage to Radial 
nerve 2 0.90 (0 to 2.14) 0.94 (0 to 2.21) 
Non-traumatic damage to Radial 
nerve 0 0 0 
Traumatic damage to Ulnar 
nerve 2 0.90 (0 to 2.14) 0.98 (0 to 2.28) 
Non-traumatic damage to Ulnar 
nerve 4 1.79 (0.04 to 3.55) 1.60 (0 to 3.26) 
 
347 
 
3.5.4.2.2.2 Age and Sex Distribution 
Age and sex divisions of patients with upper limb mononeuropathies are shown below: 40% were female and 60% were male. 
Table 3.49: Upper Limb Mononeuropathy Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-74 8 
9.12 (2.83 
to 15.41)  
1 
2.03 (0 to 
6.00)  
7 18.23 
(4.85 to 
31.61)  
75-79 1 1.60 (0 to 
4.73)  
0 0  1 3.51 (0 to 
10.37)  
80-84 2 5.81 (0 to 
13.85)  
2 9.57 (0 to 
22.77)  
0 0  
85+ 4 10.36 (0.26 
to 20.47)  
3 14.02 (0 to 
29.77)  
1 5.81 (0 to 
17.18)  
Total 15 6.72 (3.33 
to 10.11) 
6.53 (3.19 to 
9.87) 
6 4.78 (0.96 
to 8.59) 
4.28 (0.67 
to 7.90)  
9 9.22 (3.22 
to 15.22) 
9.42 (3.36 
to 15.48) 
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3.5.4.2.3 Lower Limb Mononeuropathies 
3.5.4.2.3.1 Prevalence and disease subtypes 
There were 5 people in the main study population with lower limb mononeuropathies. 
The consequent prevalence, age adjusted prevalence (based on the WHO standard 
population), confidence intervals and the subtype breakdown are demonstrated in the 
table below. 
Table 3.50: Lower Limb Mononeuropathy Prevalence and Subtype Breakdown 
Diagnosis Frequency in the 
Main Study 
Population/n=22
32 
Crude Prevalence 
per 1000 (95% CI) 
Age adjusted 
prevalence per 
1000 (95% CI) 
Lower Limb 
Mononeuropathies 
5 
2.24 (0.28 to 4.20) 
2.38 (0.36 to 
4.40) 
Traumatic femoral nerve 
injury 
1 
0.45 (0 to 1.33) 0.46 (0 to 1.35) 
Sciatic nerve injury from 
trauma 
1 
0.45 (0 to 1.33) 0.48 (0 to 1.39) 
Sciatic nerve injury from 
injection site 
1 
0.45 (0 to 1.33) 0.48 (0 to 1.39) 
Common peroneal injury 
from operation 
1 
0.45 (0 to 1.33) 0.50 (0 to 1.43) 
Traumatic common peroneal 
nerve injury 
1 
0.45 (0 to 1.33) 0.46 (0 to 1.35) 
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3.5.4.2.3.2 Age Categories 
The age subdivisions of the patients with lower limb mononeuropathies are shown in the 
table below, all patients were male. 
Table 3.51: Lower Limb Mononeuropathy Prevalence with age and sex breakdown 
Age Category Frequency  Crude Prevalence per 1000 
(95% CI) 
Age adjusted prevalence per 
1000 (95% CI) 
70-74 2 2.28 (0 to 5.44)  
75-79 2 3.20 (0 to 7.63)  
80-84 1 2.91 (0 to 8.60)  
Total 5 2.24 (0.28 to 4.20) 2.38 (0.36 to 4.40) 
3.5.4.2.4 Plexus Injury 
3.5.4.2.4.1 Prevalence and disease subtypes 
There were 4 people in the main study population with plexus injury. The consequent 
prevalence, age adjusted prevalence (based on the WHO standard population) and 
confidence intervals for plexus injury and the subtype breakdown are shown in the table 
below. 
Table 3.52: Plexus Injury Prevalence and Subtype Breakdown 
Diagnosis Freque
ncy  
Crude Prevalence per 
1000 (95% CI) 
Age adjusted prevalence 
per 1000 
Plexus Injury 4 
1.79 (0.04 to 3.55) 1.90 
Brachial-traumatic 2 
0.90 (0 to 2.14) 0.94 
Lumbosacral-
traumatic 2 
0.90 (0 to 2.14) 0.96 
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3.5.4.2.4.2 Age and Sex Subdivisions 
The age and sex subdivisions of the patients with plexus injury are shown in the table below: 25.0% were female and 75.0% 
were male. 
Table 3.53: Plexus Injury Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-74 3 3.42 (0 to 
7.29)  
1 2.03 (0 to 
6.00)  
2 5.21 (0 to 
12.41)  
75-79 1 1.60 (0 to 
4.73  
0 
0  
1 3.51 (0 to 
10.37)  
Total 4 1.79 (0.04 
to 3.55) 
1.90 (0.09 to 
3.70) 
1 0.80 (0 to 
2.36) 
0.85 (0 to 
2.46) 
3 3.07 (0 to 
6.55) 
3.95 (0.02 
to 7.89) 
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3.5.4.2.5 Root Lesion 
3.5.4.2.5.1 Prevalence and disease subtypes 
There were 4 people in the main study population with root lesions. The consequent 
prevalence, age adjusted prevalence (based on the WHO standard population) and 
confidence intervals for root lesions and the subtype breakdown are shown in the table 
below. 
Table 3.54: Root Lesion Prevalence and Subtype Breakdown 
Diagnosis Frequency in the Main 
Study 
Population/n=2232 
Crude Prevalence per 
1000 (95% CI) 
Age adjusted 
prevalence per 1000 
(95% CI) 
Root 
Pathology 
4 
1.79 (0.04 to 3.55) 1.69 (0 to 3.40) 
Sciatica 
3 1.34 (0 to 2.86) 1.23 (0 to 2.69) 
C8 root lesion 
1 0.45 (0 to 1.33) 0.46 (0 to 1.35) 
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3.5.4.2.5.2 Age and Sex Distribution 
The age and sex subdivisions of the patients with root lesions are given in the table below: 25% were female and 75% were 
male. 
Table 3.55: Root Lesion Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
75-79 3 1.60 (0 to 
4.73))  
1 2.94 (0 to 
8.70)  
2 7.02 (0 to 
16.71)  
85+ 1 2.59 (0 to 
7.66)  
0 0  1 5.81 (0 to 
17.18)  
Total 4 1.79 (0.04 
to 3.55) 
1.69 (-0.01 to 
3.40) 
1 0.80 (0 to 
2.36) 
0.82 (0 to 
2.40) 
3 3.07 (0 to 
6.55) 
2.81 (0 to 
6.14) 
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3.5.4.3 Inflammatory/infectious diseases of the peripheral nervous system 
3.5.4.3.1 Polio 
3.5.4.3.1.1 Prevalence and disease subtypes 
There were 5 people in the main study population with Polio that had resulted in residual 
neurological deficit. The crude prevalence was 2.24/1000 95% CI (0.28 to 4.20), the age 
adjusted prevalence (based on the WHO standard population) was 2.38/1000 95% CI (0.36 
to 4.40). 
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3.5.4.3.1.2 Age and Sex Distribution 
The age and sex subdivisions of the patients with polio with residual neurological deficit are demonstrated in the table below. 
40.0% were female and 60.0% were male. 
Table 3.56: Polio Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-74 2 2.28 (0 to 
5.44)  
1 2.03 (0 to 
6.00)  
1 2.60 (0 to 
7.70)  
75-79 2 3.20 (0 to 
7.63)  
1 2.94 (0 to 
8.70)  
1 3.51 (0 to 
10.37)  
80-84 1 2.91 (0 to 
8.60)  
0 
0  
1 7.41 (0 to 
21.87)  
Total 5 2.24 (0.28 
to 4.20) 
2.38 (0.36 to 
4.40) 
2 1.59 (0 to 
3.80) 
1.67 (0 to 
3.93) 
3 3.07 (0 to 
6.55) 
3.30 (0 to 
6.89) 
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3.5.4.3.2 Leprosy 
There was 1 person in the main study population with leprosy which was not active but 
was neuropathic, it had resulted in amputation of the right foot to the level of the mid 
foot. The crude prevalence was therefore 0.45/1000, 95% CI (0 to 1.33) and the age 
adjusted prevalence was 0.48/1000, 95% CI (0 to 1.39). The patient was a 73 year old man 
whose Barthel index score was 20.  
 
3.5.4.4 Diseases of the Myoneural Junction and Muscles 
3.5.4.4.1 Myaesthenia Gravis 
There was 1 person in the main study population with Myaesthenia Gravis. The crude 
prevalence was therefore 0.45/1000, 95% CI (0 to 1.33) and the age adjusted prevalence 
was 0.50/1000, 95% CI (0 to 1.43). The pattern of disease was bilateral ptosis. The patient 
was an 80 year old woman whose Barthel index score was 20.  
 
3.5.4.4.2 Muscle Wasting and Atrophy 
3.5.4.4.2.1 Prevalence and disease subtypes 
There were 17 people in the main study population with muscle wasting and atrophy 
resulting in weakness caused by disuse. The cause of the disuse was varied and is 
described below. The consequent prevalence, age adjusted prevalence (based on the 
WHO standard population) confidence intervals and the subtype breakdown is given in 
the table below. 
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Table 3.57: Muscle Wasting and Atrophy Prevalence and Subtype Breakdown 
Diagnosis Frequenc
y in the 
Main 
Study 
Populatio
n 
Crude Prevalence 
per 1000 (95% CI) 
Age adjusted 
prevalence per 
1000 (95% CI) 
Muscle Wasting and Atrophy 
17 7.62 (4.01 to 
11.22) 
7.40 (3.84 to 
10.95) 
Secondary to primary orthopaedic 
problem 
7 
3.14 (0.82 to 5.45) 
3.04 (0.76 to 
5.33) 
Secondary to pain 
5 
2.24 (0.28 to 4.20) 
1.91 (0.10 to 
3.72) 
Secondary to severe cognitive 
impairment and consequent 
immobility 
2 
0.90 (0 to 2.14) 0.96 (0 to 2.25) 
Secondary to soft tissue damage 
secondary to infection 
2 
0.90 (0 to 2.14) 0.98 (02 to 2.28) 
Secondary to period of ill health 
and consequent disability 
1 
0.45 (-0 to 1.33) 0.31 (0 to 1.04) 
 
3.5.4.4.2.2 Age and Sex Distribution 
The Age and sex distribution of the patients with muscle wasting and atrophy are 
demonstrated in the table below. 64.7% were female and 35.3% were male. 
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Table 3.58: Muscle Wasting and Atrophy Prevalence with Age and Sex Breakdown 
Age 
Categor
y 
Total 
Frequen
cy 
Total 
Prevalence 
per 1000 
(95% CI) 
Total Age 
adjusted 
prevalence 
per 1000 (95% 
CI) 
Female 
Frequen
cy 
Female 
Prevalenc
e per 1000 
(95% CI) 
Female 
Age 
adjusted 
prevalence 
per 1000 
(95% CI) 
Male 
Frequenc
y 
Male 
Prevalenc
e per 
1000 
(95% CI) 
Male Age 
adjusted 
prevalenc
e per 
1000 
(95% CI) 
70-74 4 4.56 (0.10 
to 9.02)  
1 2.03 (0 to 
6.00)  
3 7.81 (0 to 
16.62)  
75-79 2 3.20 (0 to 
7.63)  
1 2.94 (0 to 
8.70)  
1 3.51 (0 to 
10.37)  
80-84 6 
17.44 (3.61 
to 31.28)  
5 23.92 
(3.20 to 
44.64)  
1 
7.41 (0 to 
21.87)  
85+ 5 
12.95 (1.67 
to 24.23)  
4 18.69 
(0.55 to 
36.84)  
1 
5.81 (0 to 
17.18)  
Total 17 7.62 (4.01 
to 11.22) 
7.40 (3.84 to 
10.95) 
11 8.76 (3.61 
to 13.91) 
8.33 (3.30 
13.36) 
6 6.15 (1.24 
to 11.05) 
6.19 (1.27 
to 11.11) 
 
358 
 
3.6 The patients Identified using the original question 14  
One patient was thought to have task specific dystonia. This was described on history 
although it was never reproduced on examination. Confirmatory investigations were not 
possible. The condition did not bother the patient and the diagnosis was not certain. The 
potential crude prevalence was 0.45/1000. This is however not something I can definitely 
report as a definitive diagnosis was never made. The prevalence is in keeping with other 
prevalence studies [447, 463]. 
 
Eleven patients described symptoms of paramyotonia – muscle contraction or stiffness 
exacerbated by cold. It was difficult to achieve an accurate account of the symptoms and 
any associated family history. The signs were not reproduced on examination, it was not 
possible to reproduce the exacerbating circumstances. Confirmatory investigations were 
not possible. The condition was “treated” by the patient with simple actions like warming. 
The main differential diagnosis was musculoskeletal – arthritis. The potential crude 
prevalence was 4.93/1000. This is however not something I can report as definitive 
diagnosis was never made. The prevalence is much higher than would be expected from 
the literature which quotes a prevalence of 1/180-350,000 [446]. However it is possible 
that in a small community an autosomal condition such as this one could have a high 
prevalence exacerbated by the lack of population migration. It is worth noting that 5 out 
of the 11 patients (45.5%) were from the same village – a supportive factor. 
 
As I was unable to confirm diagnosis these patients do not form part of the overall 
prevalence figures for Neurological Disorders in the Main Study population. 
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3.7 The Diagnosis and Treatment Gap 
There is a large diagnosis and treatment gap for patients with Neurological conditions in 
the main study population.  
 
The definition of the diagnosis and treatment gap has been fully described and justified in 
the methods section, in summary;  
 
A correct diagnosis was defined as a diagnosis that corresponded to that made by the 
research doctor and the expert consultant expressed as a percentage of all of those 
people with a neurological disorder. 
 
Correct treatment was defined as the treatment that was recommended by the WHO and 
expert review articles for the condition diagnosed [459], this was expressed as a 
percentage of all of those people with a neurological disorder. 
 
I felt that to present the diagnosis and treatment gap in only those that had presented for 
medical care would underestimate the scale of the diagnosis and treatment problem in 
the region [460]. 
 
Of the 349 people with at least one neurological disorders, 64.5% had sought treatment 
for their symptoms.  Of the 384 disorders, only 56 (14.6%) had been diagnosed and only 
38 (9.9%) had received appropriate treatment.  A breakdown of these figures by sex is 
presented in Table 3.59 and by specific neurological disorders in Table 3.60.  Males with a 
neurological condition were significantly more likely to be diagnosed than females (OR 
2.05, 95% CI 1.15 to 3.68).  In cases where treatment was available in Tanzania, males 
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were more likely to be treated, though the difference was not significant (OR 1.68, 95% CI 
0.85 to 3.32).  The lack of significance in the latter result is likely to be due in part to the 
relatively small number of people being treated, representing a Type II error.   
 
Overall, there was no significant difference in levels of disability between those who 
sought treatment and those who did not.  Of 159 who did not seek treatment, 44 (27.7%) 
had moderate or severe disability, whilst of 225 who sought treatment, 67 (29.8%) had 
moderate or severe disability, OR 1.10 (95% CI 0.71 to 1.74).  Rates of treatment sought 
and disability for selected neurological disorders are detailed in Table 3.61.  For each 
specific disorder, level of disability was not significantly associated with whether a person 
sought treatment or not.  However, those disorders which were associated with the 
highest level of disability (epilepsy, stroke and Parkinson’s disease) also had the highest 
levels of treatment sought.   
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Table 3.59: Treatment seeking behaviour and rates of diagnosis and treatment of people with neurological disorders 
 Cases Number who 
previously sought 
treatment (%) 
Number with 
previous 
diagnosis (%) 
Number with 
previous appropriate 
treatment (%) 
Number for 
whom treatment 
exists (%) 
Number for whom 
treatment exists in 
Tanzania (%) 
a. Males 182 in 162 
males 
109 (59.9%) 35 (19.2%) 21 (11.5%) 152 (83.5%) 143 (78.6%) 
b. Females 202 in 187 
females 
116 (57.4%) 21 (10.4%) 17 (8.4%) 188 (93.1%) 183 (90.6%) 
a. Total 384 (in 349 
individuals) 
225 (58.6%) 56 (14.6%) 38 (9.9%) 340 (88.5%) 326 (84.9%) 
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Table 3.60: Treatment seeking behaviour and rates of diagnosis and treatment of people with neurological disorders split into specific 
disorders 
 Cases Number who 
previously sought 
treatment (%) 
Number with 
previous 
diagnosis (%) 
Number with 
previous 
appropriate 
treatment (%) 
Number for 
whom 
treatment exists 
(%) 
Number for whom 
treatment exists in 
Tanzania (%) 
CENTRAL NERVOUS 
SYSTEM DISORDERS 
      
2. 1.  Movement Disorders       
a. Tremor – all causes 
including cerebellar disease 
and Parkinsonism 
110* 36 (32.7%) 6 (5.5%) 4 (3.6%) 103 (93.6%) 96 (87.3%) 
b. Parkinsonism 14 10 (71.4%) 4 (28.6%) 3 (21.4%) 14 (100%) 14 (100%) 
c. Cerebellar disorders 11† 5 (45.5%) 2 (18.2%) 1 (9.1%) 4 (36.4%) 4 (36.4%) 
d. Other dyskinesias 5 0 0 0 5 (100%) 2 (20%) 
2.  Episodic and Paroxysmal 
Disorders 
     
e. Headache disorders 92 62 (67.4%) 4 (4.3%) 12 (13.0%) 92 (100%) 92 (100%) 
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f. Stroke 54 44 (81.5%) 36 (68.7%) 16 (29.6%) 54 (100%) 54 (100%) 
g. Epilepsy 10 9 (90.0%) 2 (20.0%) 2 (20.0%) 10 (100%) 10 (100%) 
3.  Systemic Atrophies/Degenerative Diseases affecting the Central 
Nervous System 
   
h. Motor neuron disease 2 2 (100%) 0 0 2 (100%) 0 
4.  Injury resulting in CNS dysfunction     
i. Spinal cord injury 5 4 (80.0%) 0 0 5 (100%) 0 
3. 5.  Spinal cord dysfunction 
– other 
0 - - - - - 
4. 6.  Infection resulting in 
CNS dysfunction 
0 - - - - - 
PERIPHERAL NERVOUS 
SYSTEM DISORDERS 
      
2. 1.  Polyneuropathies 42 21 (50.0%) 3 (7.1%) 4 (9.5%) 42 (100%) 42 (100%) 
2.  Nerve, nerve root and plexus 
disorders 
     
a. Cranial nerves 14 14 (100%) 1 (7.1%) 0 4 (28.6%) 3 (21.4%) 
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b. Upper limb 
Mononeuropathies 
15 6 (40.0%) 2 (13.3%) 0 8 (53.3%) 8 (53.3%) 
c. Lower limb 
mononeuropathies 
5 4 (80.0%) 0 0 0 0 
d. Plexus pathology 4 4 (100%) 1 (25.0%) 0 0 0 
e. Root pathology 4 3 (75.0%) 0 0 3 (75.0%) 0 
3.  Inflammatory/infectious diseases of the peripheral nervous system    
f. Polio 5 5 (100%) 2 (40.0%) 0 0 0 
g. Leprosy 1 1 (100%) 1 (100%) 0 1 (100%) 1 (100%) 
4.  Diseases of the myoneural junction and muscle     
h. Myaesthenia gravis 1 0 0 0 1 (100%) 0 
i. Muscle wasting and atrophy 17 11 (64.7%) 0 0 15 (88.2%) 13 (76.5%) 
* Including cases of tremor due to parkinsonism/Parkinson’s disease (n= 12) and tremor due to cerebellar disorders (n = 11) but not 
tremor due to stroke affecting the cerebellum (n = 4) 
† Including cases of cerebellar disorders secondary to stroke (n = 4)
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Table 3.61: Treatment seeking behaviour and level of disability for selected neurological 
disorders 
Disorder Total number 
who sought 
treatment 
Number with moderate or severe 
disability (Barthel index < 15) 
Odds 
ratio 
(95% CI) 
Treatment 
sought 
No treatment 
sought 
Epilepsy (n = 10) 9 (90.0%) 8 (88.9%) 1 (100%) 0.52 
(0.01 to 
20.19) 
Stroke (n = 54) 44 (81.5%) 28 (63.6%) 6 (60.0%) 1.17 
(0.29 to 
4.76) 
Parkinson’s disease 
(n = 14) 
10 (71.4%) 6 (60.0%) 3 (75.0%) 0.50 
(0.04 to 
6.68) 
Muscle wasting and 
atrophy (n = 17) 
11 (64.7%) 7 (63.6%) 4 (66.6%) 0.95 
(0.20 to 
4.64) 
Headache (n = 62) 32 (51.6%) 5 (15.6%) 9 (30.0%) 0.21 
(0.06 to 
0.68) 
Peripheral 
polyneuropathy (n = 
42) 
21 (50.0%) 3 (14.3%) 5 (23.8%) 0.53 
(0.11 to 
2.59) 
Tremor (n = 110) 36 (32.7%) 12 (33.3%) 15 (20.2%) 1.97 
(0.80 to 
4.81) 
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3.8 Disability levels 
Of 2232 participants aged 70+ (range 70-115), 4.3% (crude prevalence-95% CI 3.4 to 
5.1)/3.7%(age-adjusted to WHO world population-95% CI 2.9 to 4.5) were severely 
disabled (BI <15), 6.9%(crude prevalence – 95% CI 5.8 to 8.0)/6.2%(age-adjusted to WHO 
world population-95% CI 5.2 to 7.2) were moderately disabled (BI 15-18) and 4.6% of 
women and 3.6% of men were severely disabled. Disability increased with increasing 
age[15]. 
Table 3.62: The relationship of disability and age in the Main Study Population 
 
Males Females 
 Number Mean age (95% CI) Number Mean age (95% CI) 
Barthel Index 0-
14 
n = 37 85.6 (82.0 to 89.2), 
Median 84 
n = 58 87.0 (84.1 to 90.0), 
Median 85.5 
Barthel Index 
15-18 
n = 53 82.1 (79.6 to 84.7), 
Median 80 
n = 101 82.9 (81.3 to 84.5), 
Median 82 
Barthel Index 
19-20 
n = 886 77.3 (76.9 to 77.8), 
Median 76 
n = 
1097 
76.7 (76.3 to 77.0), 
Median 75 
All cases n = 976 77.9 (77.5 to 78.4), 
Median 76 
n = 
1256 
77.6 (77.3 to 78.0), 
Median 76 
 
 Age Bands Total 
70-74 75-79 80-84 85+ 
Barthel Index 0-14 16 12 17 50 95 
15-18 30 30 26 68 154 
19-20 831 583 301 268 1983 
Total 877 625 344 386 2232 
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Across both sexes, those with Barthel index ≤18 are significantly older than those with 
Barthel index of 19-20. 
 
52.6% of all people with a Barthel index of 0-14 are aged 85 years or over.  Only 17.3% of 
all participants were 85 years and over.  For this breakdown χ2 (6) = 194.3, p < 0.001 
demonstrating that the differences between groups is highly significant. 
 
Reducing this table down to dichotomies gives: 
 
Table 3.63: The relationship of disability and age dichotomised 
 Age Dichotomised Total 
70-84 85+ 
Barthel Dichotomised Severe 
and 
Moderate 
Disability 
(BI 0-18) 
131 118 249 
Mild or 
No 
Disability 
(BI 19-20) 
1715 268 1983 
Total 1846 386 2232 
 
47.4% of all people with a Barthel index of 0-18 are aged 85 years or over, whilst only 
13.5% of those with a Barthel of 19 or 20 are aged 85 years or over.  For this breakdown χ2 
(1) = 177.5, p < 0.001, suggesting the differences between groups to be highly significant. 
 
The odds of someone aged 85 years or over having a Barthel index below 19 is 5.76 (95% 
CI = 4.36 to 7.63) that of someone below 85 years.  This odds ratio is highly significant. 
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Table 3.64: The relationship of disability and sex in the Main Study Population 
 Sex Coded Total 
Male Female 
Barthel Index Severe 
Disability (BI 
0-14) 
37 58 95 
Moderate 
Disability (BI 
15-18) 
53 101 154 
Mild or No 
Disability (BI 
19-20) 
886 1097 1983 
Total 976 1256 2232 
 
4.6% of females and 3.8% of males were severely disabled. 12.7% of females and 9.2% of 
males had Barthel index below 19.  For this breakdown χ2 (2) = 7.040, p = 0.030, the 
differences between groups appears significant. 
 
Dichotomising as above:- 
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Table 3.65 The relationship of disability and sex dichotomised 
 Sex Coded Total 
Male Female 
Barthel Dichotomised Moderate 
and 
Severe 
Disability 
(BI 0-18) 
90 159 249 
Mild or 
No 
Disability 
(BI 19-20) 
886 1097 1983 
Total 976 1256 2232 
 
For this breakdown χ2 (1) = 6.549, p = 0.010, the differences between groups is highly 
significant. The odds of a female having a Barthel index of below 19 is 1.43 (95% CI = 1.09 
to 1.88) times that of a male.  This odds ratio is significant and effect is not due to the age 
structure of the population. 
 
A logistic regression model for predictors of moderate or severe disability was constructed 
by Dr Keith Gray, the basis and significance of which I understand, as shown in table 3.66. 
Age, female sex and the presence of a neurological disorder were all identified as 
significant independent predictors of disability in our population. Sex was the weakest 
predictor of disability, whilst age was the strongest predictors. Females were generally 
older than males but even after adjustment, interestingly, female gender was still 
significantly associated with an increased risk for the presence of disability. 
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Table 3.66: Regression model for predictors of moderate or severe disability (BI < 19) 
 β S.E. Wald df Sig. OR/Exp(B) 95% CI for OR 
Lower Upper 
Gender* 0458 0154 10497 1 0001 1645 1217 2223 
Neurological disorder** 1649 0160 106557 1 <0001 5203 3804 7116 
Age (years) 0115 0009 171509 1 <0001 1122 1103 1143 
Constant -1199 0748 256955 1 <0001 0000 - - 
* Coding: Male = 0, Females = 1** Coding: Absent = 0, Present = 1 
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3.8.1 The relationship of disability and Neurological Disorders 
The presence of a neurological disorder is an independent predictor of BI. It is associated 
with a lower BI. The mean BI of those with a Neurological Disorder is 17.7 in comparison 
to 19.5 in those people in the main study population without a neurological disorder. 
14.3% of people with a neurological disorder were severely disabled in comparison to only 
2.39% without a neurological disorder. 14.3% with a neurological disorder were 
moderately disabled in comparison to 5.5% of people without a neurological disorder. 
Neurological diagnoses associated with increased disability were as follows; 
 
Cord lesions (mean BI 9.2, 80.0% severely disabled), Muscle Wasting and Atrophy (mean 
BI 13.6, 52.9% severely disabled), Stroke (mean BI 13.8, 40.7% severely disabled), 
Dyskinesias (mean BI 15.2, 20.0% severely disabled), MND (mean BI 15.5, all patients 
moderately disabled), Cerebellar disorders (mean BI 15.9, 27.3% severely disabled) and 
Parkinsonism (mean BI 16.0, 21.4% severely disabled).  
 
The Neurological disorders least associated with disability were as follows; Leprosy (mean 
BI 20.0, 0.0% severely disabled), Myaesthenia Gravis (mean BI 20.0, 0.0% severely 
disabled), Cranial Nerve pathology (mean BI 19.9, 0.0% severely disabled), Root pathology 
(mean BI 19.8, 0.0% severely disabled), Upper limb mononeuropathies (mean BI 19.3, 
6.7% severely disabled), headaches (mean BI 19.2, 3.3% severely disabled) and peripheral 
neuropathy (mean BI 19.1, 4.8% severely disabled). This is described fully in the following 
table.
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Table 3.67: The relationship of disability and neurological disorders in the Main Study Population 
 Mean 
Barthel 
Index 
Severe 
Disability 
(BI 0-14) 
Frequency 
Severe 
Disability (BI 
0-14) 
Percentage 
(95% CI) 
Moderate 
Disability 
(BI 15-18) 
Frequency 
Moderate 
Disability (BI 
15-18) 
Percentage 
(95% CI) 
No 
Disability 
(BI 19-20) 
Frequency 
No Disability 
(BI 19-20) 
Percentage 
(95% CI) 
Pilot Study Population 18.73 22 7.9%  (4.76 
to 11.13) 
29 10.5% (6.86 
to 14.07) 
226 81.6% (77.02 
to 86.15) 
Main Study 
Population 
19.25 95 4.26% (3.42 
to 5.09) 
154 6.90% (5.85 
to 7.95) 
1983  88.8% (87.85 
to 90.15) 
Main Study 
Population without 
neurological 
Disorders 
19.53 45 2.39 (1.70 to 
3.08) 
104 5.52 (4.49 to 
6.55) 
1734 92.08 (90.87 
to 93.31) 
Neurological 
diagnosis – all 
17.71 55 14.32 (10.82 
to 17.83) 
56 14.58 (11.05 
to 18.11) 
273 71.09 (66.56 
to 75.63) 
People with 
Neurological 
diagnosis 
17.70 50 14.33 (10.65 
to 18.00) 
50 14.33 (10.65 
to 18.00) 
249 71.35 (66.60 
to 76.09) 
Tremor – All 18.43 12 10.9% 12 10.9% 86 78.2% 
Parkinsonism 16.00 3 21.4% 5 35.7% 6 42.9% 
Cerebellar disorders 15.91 3 27.3% 2 18.2% 6 54.5% 
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Dyskinesias 15.20 1 20.0% 2 40.0% 2 40.0% 
Headaches that affect 
ADLs 
19.17 3 3.3% 11 12.0% 78 84.8% 
Stroke – All 13.76 22 40.7% 12 22.2% 20 37.0% 
Epilepsy  18.00 1 10.0% 2 20.0% 7 70.0% 
Motor Neuron 
Disease 
15.50 0 0.0% 2 100.0% 0 0.0% 
Cord Lesions 9.20 4 80.0% 0 0.0% 1 0.0% 
Polyneuropathies 19.10 2 4.8% 6 14.3% 34 81.0% 
Cranial Nerve 
Pathology 
19.93 0 0.0% 0 0.0% 14 100% 
UL 
Mononeuropathies 
19.33 1 6.7% 0 0.0% 14 93.3% 
Lower Limb 
Mononeuropathies 
16.60 1 20.0% 2 40.0% 2 40.0% 
Plexus disorders 18.50 0 0.0% 2 50.0% 2 50.0% 
Root disorders 19.75 0 0.0% 0 0.0% 4 100.0% 
Polio 18.40 0 0.0% 1 20.0% 4 80.0% 
Leprosy 20.00 0 0.0% 0 0.0% 1 100.0% 
Myaesthenia Gravis 20.00 0 0.0% 0 0.0% 1 100.0% 
Muscle Wasting and 
Atrophy 
13.59 9 52.9% 2 11.8% 6 35.3% 
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Table 3.68: The relationship of disability and neurological disorders dichotomised 
 Neurological Disorder Total 
Present Absent 
Barthel Dichotomised Moderate 
and 
Severe 
Disability 
(BI 0-18) 
100 149 249 
Mild or 
No 
Disability 
(BI 19-20) 
249 1734 1983 
Total 349 1883 2232 
The odds of someone being severely disabled if a neurological disorder is present are 4.67 
that of someone who does not have the neurological disorder. This odds ratio was 
significant (95% CI 3.51to 6.22).This effect is real and is not due to the age structure of the 
population. 
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3.9 Walking Aids  
391 (17.5%) people used a walking aid regularly; 352 people used 1 stick, 13 people used 2 
sticks, 9 people used 2 crutches, 5 people had wheelchairs, 3 people used stools, 3 people 
used 1 stick and 1 crutch, 3 people used metal zimmer frames, 2 people used chairs and 1 
person used a wooden zimmer frame. 
 
The majority of these were felt to be appropriate and advice was given to continue 
utilising the walking aid. For those whose walking aid was felt to be inappropriate, 
particularly those using chairs or stools, alternatives were offered. Advice was given to 
many of the patients about acquiring a stick to help their mobility and reduce their falls 
risk. These were readily available and cost very little or could be acquired for free. 21 
people needed wheelchairs, 25 people needed walking frames and 6 people were thought 
to need crutches. These were all provided through charitable donations. 
 
3.10 Visual Problems 
1047 (46.9%) people stated when asked that they had problems with their vision. 907 
(40.6%) denied any problems. 278 people were not asked. 
 
3.11 Diabetes 
111 people (5.0%) stated when asked that they had diabetes, the remainder denied the 
problem. 
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Chapter 4. Discussion 
4.1 Brief Summary of the Main Findings 
This thesis demonstrates a high prevalence of neurological morbidity; in 2232 elderly 
participants, there were 384 neurological diagnoses amongst 349 people. The age-
adjusted prevalence of people with neurological diagnoses was 154.1 per 1000 (95% CI 
139.2–169.1). The age-adjusted prevalence per 1000 of the most common neurological 
disorders were tremor (48.2), headache (41.8), stroke (23.0), peripheral polyneuropathy 
(18.6), upper limb mononeuropathy (6.5) and parkinsonism (5.9). This high prevalence 
demonstrates the large contribution neurological disorders make to the non-
communicable disease epidemic particularly in the elderly population. 
 
This thesis also demonstrates the successful production of a screening instrument for 
measuring the prevalence of neurological disorders in an elderly population of a 
developing country. The questionnaire was practical, acceptable to recipients, and easily 
performed by a NMI. The sensitivity and specificity of the questionnaire were high at 87.8 
and 94.9 %, respectively, in the pilot and 97.0 and 90.4 %, respectively, in the extension 
and supports its feasibility for use in the elderly community population of a developing 
country. 
 
The research reports rates of patient’s: treatment seeking, diagnosis and treatment within 
the prevalent population. Of 349 people who had neurological disorders, 225 (64.5%) had 
sought treatment for their symptoms. Of the 384 disorders identified in these 349 people, 
only 14.6% had been diagnosed and only 9.9% were receiving appropriate treatment. 
Males were significantly more likely to have been diagnosed and were more likely to have 
been treated appropriately. Therefore the levels of diagnosis and treatment were low, 
with some gender inequality. 
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Finally this thesis demonstrates that the age-adjusted prevalence of severe disability 
(BI<15) is 3.7% (95% CI: 2.9-4.5) and the age-adjusted prevalence of moderate disability 
(BI: 15-18) is 6.2% [95% confidence interval (CI): 5.2-7.2] amongst the in 2,232 
participants. Increasing age, female gender, memory problems and the presence of 
neurological disorders were all independent predictors of the presence of disability. In this 
study, the average disability level was lower than seen in high-income countries. 
 
4.2 Study design 
This is one of the most robustly designed epidemiological studies of the prevalence of 
Neurological Disorders in developing countries. It is the only study that focuses on the 
elderly in SSA – an important and expanding group. It is the only up to date prevalence 
study of its kind in SSA.  
 
4.2.1 The Census 
The census was carried out by experienced NMIs who had carried out censuses in previous 
years. All of the households in the district agreed to take part in the census, this increased 
the reliability of the data. The results of the census were handled by experienced data 
analysts in Dar es Salaam who have previously been employed by the AMMP. There were 
no data entry discrepancies. 
 
The census completion date was the 1st of June 2009. The prevalence date of the study 
was the 1st of January 2010. Therefore a proportion of people aged 69 at the time of the 
census had turned 70 by the prevalence date. This was the major reason for additional  
inclusions in the study as well as the original 70 and over population identified by the 
census as detailed previously. A more accurate way of recruiting these patients would 
have been to obtain an additional list of patients aged 70+ on the prevalence date. This 
was not done as inaccuracy of dates of birth meant that many people knew their year of 
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birth but not their exact date of birth so many people had their date of birth recorded as 
the 1st of January. It was therefore felt that including the additional people who felt they 
had turned 70 since the census was a more accurate way of inclusion of all patients aged 
70 and above. Inaccuracy of date of birth and age meant recruiting patients on the basis of 
age, although unavoidable in order to focus on the elderly population was difficult.  
 
4.2.2 The Basic methodology 
I used the previously validated and recommended 2 phased approach to establish the 
prevalence of Neurological Disorders in developing countries [6, 25].  
 
Phase 1: A screening tool designed to pick up neurological disorders administered by 
trained interviewers 
 
Phase 2: A full neurological history and examination for those highlighted by screening   
 
This is recommended by the WHO and other high profile investigators as the best practice 
to accurately establish prevalence in a developing country and its use has been fully 
justified in the introduction [6, 25]. Hospital based studies do not give a reliable measure 
of disease burden in this setting as many patients do not present to hospitals and other 
medical facilities for financial and geographical reasons.   
 
4.2.3 Research Personnel 
The prevalence study involved local Tanzanian staff with previous experience at such 
studies. This was beneficial to the study for the following reasons;  
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1. The majority of the staff were local to the area and in some cases lived in the 
studied villages. They were known to the patients and therefore this increased the 
acceptability and consequent uptake of the project.  
2. The senior staff of the project were local health workers; they were able to inform 
me of the processes of referral and the intricacies of the health care system in 
Tanzania. This was invaluable to ensure best possible care was given to the 
patients. Additionally they facilitated feedback to the District Medical Officer who 
in turn was able to feedback to government officials regarding the level of 
neurological (and other disease) morbidity in the elderly population. Using this 
process I was able to produce and distribute guidelines for diagnosis and 
treatment. 
3. I provided training for the project staff. Consequently they improved their 
knowledge of the diagnosis and treatment of neurological disorders. This ensured 
capacity building in the district and provided a health resource to the community 
after I had left. 
4. Systems were put in place for the maintenance and redistribution of walking aids 
supplied should one become broken or should a recipient die. The local staff were 
happy to take responsibility for this when I left. 
5. Ongoing follow up for the Parkinson’s disease patients will be provided by one of 
the local clinical officers. He will facilitate free supply of medication to these 
patients, the cost will be met by a charitable source. 
 
All these factors ensured that the project was beneficial to the local population. 
 
4.2.4 The age of the population screened 
Determining the exact age of people (particularly the elderly) in developing countries is 
fraught with difficulty. However, we employed validated methods to determine patient’s 
age [449]. This is one of the first robustly designed neurological prevalence study of its 
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kind in SSA that has focussed specifically on the elderly population – a group with different 
and under-recognized needs. Concentration specifically on the elderly has allowed me to 
reflect on the impact of an ageing population.  
 
4.3 The Screening Questionnaire 
The screening instrument was feasible for community screening in SSA, no participant 
refused to answer any of the questions. Previously in this setting, it has been found that 
some people are reluctant to answer personal questions with regard to their health [56]. 
All NMIs found the questionnaire simple and quick to administer and deemed the training 
straightforward and of a suitable length. The use of NMIs is important, as there are often 
few medically trained people available to act as interviewers and NMIs can be relatively 
inexpensive to employ. Furthermore, NMIs often have extensive local knowledge of 
people and geography. This can make them more acceptable to potential interviewees 
and so increase participation rates. While it has been demonstrated that the WHO 
screening instrument can have a higher sensitivity and specificity when neurologists are 
used as screeners, this is generally financially and logistically unfeasible in resource-poor 
countries [60, 61]. Many NMIs felt exclusion of an examination section, present in many 
published instruments[25, 33, 41, 46], ensured the screening instrument was practical, 
increased their confidence in correctly administering the instrument and the acceptability 
of the instrument to the local population. In my experience, the elderly in SSA are often 
unwilling to be examined by an NMI. A published study of a screening instrument 
demonstrated that the examination section was less reliable when performed by an NMI 
[26], and the same authors go on to conclude in their more recent paper that an 
examination section reduces specificity but fails to increase sensitivity [39].  
 
I believe that my instrument is culturally non-specific in content. In designing a screening 
questionnaire for PD, Sarangmath et al[57] noted that if a questionnaire was culturally 
specific, it had lower specificity when administered by NMIs rather than medically trained 
interviewers. The lack of questions that required reading or writing skills ensured it  could 
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be applied to people of all literacy levels. Although the content of the questions is 
culturally non-specific it is important to note that the wording is culturally specific, 
ensured through accurate translation and back-translation, this is very important for 
comprehension within the local population. 
 
4.3.1 The Sensitivity of the Screening Questionnaire 
My screening tool had a high sensitivity, 87.8% in the pilot population and 97.0% in the 
main study population. This is comparable to the sensitivity of other published screening 
tools whose sensitivity vary from 84.0% to 100.0%: Those piloted in SSA 91.0%-100.0% [3, 
6, 26, 40] and Those piloted elsewhere 84.0% to 100.0% [31, 33, 37, 41, 43-48, 53, 58].  
 
4.3.1.1 False Negatives – those patients that reduced the sensitivity 
10 patients with varying neurological diagnoses were not picked up by the screening tool 
within the Pilot study. None of these patients found their symptoms disabling (in some 
cases they were merely incidental findings) and therefore the fact that the screening tool 
failed to bring them to the attention of medical personnel would not have been to their 
detriment. 
 
4.3.2 The Specificity of the Screening Questionnaire 
Our screening questionnaire had a very high specificity, 94.9% in the pilot population and 
90.4% in the main study population. This is substantially better than other tools used in 
SSA whose specificity ranges from 29.2% to 85% [3, 6, 26, 40]. It is better or roughly 
equivalent to screening tools used in non SSA countries whose specificities varied from 
80% to 99.9% [31, 33, 37, 41, 43-48, 53, 58]. This high specificity was achieved despite the 
focus on the elderly, a population group  that often presents with multiple co-morbidities. 
Of previously published screening instruments, only Nicoletti et al[47] have validated their 
screening instrument in the elderly but this was only for identification of essential tremor 
and PD rather than all neurological disorders and so it has not been described in more 
detail in this thesis. In screening populations with high levels of co-morbidity, low 
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specificity can lead to wasted time and resources. Previous investigators have commented 
that poor specificity must often be accepted in order to achieve high sensitivity [59]. 
However, I argue this need not be the case. In my experience, the false-negative cases are 
often not disabled by their symptoms and a low specificity may make screening unwieldy 
and financially impractical. 
 
4.3.2.1 False Positives – those patients that reduced the specificity 
The false positives identified by our questionnaire often required simple clarification by 
the RD (myself) to ascertain that they were not true positives, meaning that although they 
reduced specificity increasing the time required for the second phase of screening, review 
of false positive patients was often very quick and easy for the RD. It was felt that in some 
cases the participants wanted to see the RD for another reason, so answered positively to 
the screening questionnaire to get medical attention, therefore actual specificity is 
underestimated. Some of the false positive patients reported a tremor, but when 
examined no tremor was visible. This may have been due to the tremor only being present 
intermittently, or they may have misinterpreted the tremor for something else. This has 
been reported in a study from the UK [464] where 7/20 patients reporting a tremor had 
none visible at the time of examination, this may be  a common problem and was not a 
result of translation of the questionnaire.  
 
4.3.3 Identification of all cases of neurological disease 
I have ensured that our screening questionnaire picked up all burdensome neurological 
disorders. Some  published screening instruments, including the WHO protocol (and most 
published adaptations), only aim to pick up between two and seven major neurological 
disorders[25, 32, 33, 41, 42, 44, 46, 60]. 
 
4.3.4 Limitations of the screening questionnaire 
There are a number of limitations to our screening tool specifically: I used the ICD-10 
criteria to validate our tool. Although the ICD-10 may have some flaws when used in low 
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and middle-income countries, and some diagnoses may be difficult, it is a recognized 
international standard and allows direct comparison between studies carried out in 
different settings. Thus, I felt it was the most appropriate diagnostic criteria to use.  
 
The size of the pilot study limited the accuracy of validation as some target conditions 
were not present in the population. Therefore, conclusions on sensitivity for these 
conditions were limited. This highlighted the importance of reflecting on the legitimacy of 
the screening questionnaire in the study extension where rarer conditions were 
represented. Questions dedicated to picking up these conditions did so. However, in the 
study extension as every patient did not receive a full neurological history and 
examination, we cannot say with certainty that no patients with these conditions were 
missed. I did not select a random sample of negatives to validate the results. It is possible 
that the sensitivity level in the main study reflects a rather optimistic extrapolation of 
results. The prevalence of the majority of Neurological disorders in the Pilot Study were 
higher than the prevalence in the main study. This might indicate that some cases in the 
main study were missed and could put the accuracy of the sensitivity of the screening 
questionnaire in doubt. 
 
However, further robust sensitivity checks were performed through my unique position of 
having known cases from previous studies namely: stroke (from the TSIP - 1999) [213], 
Parkinson’s disease and Essential Tremor (from the Parkinson’s disease and essential 
tremor prevalence studies -2005) [96, 128] and epilepsy (from the epilepsy prevalence 
study -2009) [333]within the Main study population. The last follow ups of these patients 
were performed in 2008, January 2010 and September 2010 respectively. Clearly incident 
cases have occurred since these studies were performed but the knowledge of cases 
means that the sensitivity of the screening tool can be checked for these conditions. No 
patient identified by any of these studies was missed by the screening questionnaire. Of 
the 12 patients with idiopathic Parkinson’s disease 3 were already known from the 2005 
study and all of these were found by the screening questionnaire. Of the 67 patients with 
essential tremor recorded in the main study 8 were already known from the original study 
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and all 8 were picked up by the screening questionnaire. Of the 10 epilepsy patients, all 
were found by the screening questionnaire. Of the 54 stroke patients recorded in the main 
study 8 were already known from the TSIP, and again 100% of these were found by the 
screening questionnaire. The RD was blinded to all of these diagnoses prior to the study 
and consequently no bias was introduced when the screening questionnaire was 
performed.  
 
Additional sensitivity checks in the form of family history search, informal consultation 
with NMIs, and village elders were also performed; no false-negatives were elucidated., 
which is a further positive reflection on the accuracy of the sensitivity. Finally, all patients 
were observed walking, providing consent and holding a conversation by the RD. In total 
only eight false negatives were identified, all through the brief assessment by the RD.  
 
A further test of sensitivity for rarer neurological conditions would have been to perform 
an additional pilot in a neurology outpatient clinic. However, I felt that piloting the 
instrument in the community would be more informative than in a hospital population as 
this was the proposed area of use. Other tools have only been piloted in hospital settings 
limiting conclusions that can be drawn in view of higher diagnostic yield in this setting [26, 
37, 41, 47].  
 
I could have also performed a medical records search to further check sensitivity however 
I decided against this for the following reasons: time constraints of the RD, previous 
experience from other prevalence studies carried out in Hai when the medical records 
search was not informative because most people in this area do not access hospital based 
care (only 1 additional patient was found in the Parkinson’s Disease prevalence study 
[128]) and informal questioning revealed very few people in the age group studied had 
attended tertiary referral hospitals. Hospitals and health centres other than tertiary 
referral hospitals had “hand held” notes kept by the patient, these were requested and 
reviewed at the time of screening by the NMI to ensure the screen had not missed any 
neurological disorders. 
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I have not yet validated our screening instrument in other countries but due to the 
aforementioned lack of cultural specificity, I do not anticipate any problems with its use. 
The majority of previously published screening instruments have not been validated for 
use in SSA and although this is not a criticism as they were not proposed for use in this 
area it may limit their potential use in future studies in SSA without further validation.  
 
Finally, after the pilot study the PPV fell in the study extension. Nevertheless, sensitivity 
and specificity were relatively high during both phases and our PPVs bear comparison with 
previous tools developed for use in low-and middle-income countries [37]. It is interesting 
that the PPV was higher in the pilot study, when the NMI were supervised. There may be 
many reasons for this, though it is likely that this may be due to NMI taking extra care not 
to miss any diagnoses and so included those where there was doubt. Further training of 
NMI may help to improve the unsupervised PPV.  
 
Neurological diagnosis was based on history and examination alone, while I appreciate 
that this may limit accuracy, I feel it reflects neurological practice in a resource-poor 
setting. 
 
In conclusion no previous screening tools have specifically been tested in a pilot study in 
the community in SSA and purely in an elderly population. This highlights the fact that I 
have designed a unique screening tool with excellent sensitivity and specificity and the 
ability to detect a wide range of neurological conditions even in a population with 
significant co-morbidity. The questionnaire was simple and acceptable to use. I propose 
the use of the validated questionnaire in the community in SSA for dual epidemiological 
and clinical purposes. Epidemiologically, documenting prevalence is fundamental to 
highlight the public health significance of neurological disorders with a background of an 
ageing population, and an NCD epidemic. Clinically, case identification will reduce the 
diagnosis and treatment gap and improve the health of individuals [465]. 
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4.4 The Pilot Study 
The pilot study village was randomly selected and this to its credibility. As previously 
pointed out, the number of patients seen in the pilot study may have been inadequate 
given the low prevalence of some neurological disorders that the screening tool was 
attempting to detect. It was however the biggest pilot study that could be performed in 
the time restraints and is comparable with many that have been performed in the 
literature [26]. 
 
It is of benefit that the pilot study was performed in the same type of community and 
under the same circumstances as the main study was to be performed. As a result, 
conclusions regarding and modifications to, the screening tool were of direct relevance to 
the main study population. Under-diagnosis in the community means that it is important 
not to rely on patients knowing their diagnosis as the sole means of identification. A risk if 
a pilot is performed in a hospital setting. 
 
4.4.1 True Positives - The Prevalence figures of the pilot study 
Of those conditions that were represented in the pilot population prevalence rates of the 
majority were approximately twice as high as those found in the main study. This may 
have been for the following reasons: 
 
This discrepancy could be down to chance: The 95% CIs overlap in some conditions and 
therefore it can be argued that there may be no statistical difference between pilot and 
main study prevalence rates. This is supported by the fact that not all conditions are more 
prevalent in the pilot population and some are actually more prevalent in the main study 
population. 
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Cases were missed in the main study population through systematic bias and false 
negatives and therefore the sensitivity of the screening tool was not as good as the 
results of the pilot suggested. The pilot study results are likely to be more accurate (as 
screening as a source of error has been eliminated) and therefore it may be that 
proportionately more cases (that would have become false negatives in the main study 
population) were identified and it is actually the pilot results that are a better estimate. 
 
There is a true difference between the prevalence rates in the pilot population and the 
main study population. Despite random selection the pilot population may have had an 
unusually high prevalence of some neurological disorders and therefore the larger 
population gives a better representation. Indeed the prevalence rates of the main study 
population seem to be more in keeping with the current literature (this is described in 
detail for each condition below). Conversely this may be because the methods of case 
identification were similar in the other studies and subject therefore to the same source 
of error as outlined above.  
 
I have explored this discrepancy further in the following repeat evaluation and this has 
demonstrated that the observed difference is highly unlikely to be due to chance. By using 
the false negatives (10/277-3.6%) from the pilot study one can recalculate the false 
negative rate for the main study (3.6% of 1955) to be 71. The new prevalence of 
neurological disorders in the population subsequently becomes 259+71=330/1955=16.9%. 
As the samples are independent the differences between the two prevalence rates (16.9% 
versus 29.6%) can be calculated and is  -12.7% (95% CI -7.1% to -18.3%, p<0.0001).  
 
Therefore in conclusion, the difference in prevalence is potentially multi-faceted; the main 
contributors are likely to be: geographical variation, sampling error, statistical treatment 
and missed false negatives. The uncertainty regarding this discrepancy is one of the 
limitations of the study and is described in the limitation section. 
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Table 4.1: The Prevalence figures of the Pilot Study and the Main Study Population allowing direct comparison 
Neurological Condition Number 
in Pilot 
Study 
Populati
on 
Crude 
Prevalenc
e in Pilot 
Study 
Populatio
n per 
1000 
Number in 
Main Study 
Population 
Crude 
Prevalence 
in Main 
Study 
Population 
per 1000 
(95% CI) 
Total neurological diagnosis 89 321.30 384 172.04 
(156.4-
187.7) 
Number of people with a neurological diagnosis 82 296.03 349 156.36 
(141.3-
171.4) 
Tremor – All 23 83.03 110 49.28 
(40.3-58.3) 
Essential Tremor 10 36.10 67 30.02 
Enhanced physiological tremor 7 25.27 14 6.27 
Tremor secondary to Parkinsonism/Parkinson's disease 4 14.44 12 5.38 
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Tremor secondary to cerebellar disease 0 0 11 4.93 
Orthostatic tremor 1 3.61 3 1.34 
Tremor secondary to alcohol withdrawal 1 3.61 2 0.90 
Iatrogenic tremor 0 0 1 0.45 
Parkinsonism 5 18.05 14 6.27 
(3.00-9.55) 
Parkinsonism with tremor 4 14.44 12 5.38 
Parkinsonism without tremor 1 3.61 2 0.90 
Parkinson's Disease 4 14.44 12 5.38 
Vascular Parkinsonism 1 3.61 1 0.45 
Parkinsonism secondary to progressive supranuclear palsy 0 0 1 0.45 
Cerebellar disorders total 0 0 11 4.93 
(2.02-7.83) 
Cerebellar degeneration secondary to alcohol or idiopathic 0 0 7 3.14 
Cerebellar degeneration idiopathic 0 0 5 2.24 
Cerebellar degeneration secondary to alcohol    0 0 2 0.90 
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Cerebellar due to stroke 0 0 4 1.79 
Dyskinesias 0 0 5 2.24 
(0.28-4.20) 
Unspecified chorea 0 0 1 0.45 
Tardive dyskinesias/ iatrogenic 0 0 2 0.90 
Orofacial dyskinesias/ idiopathic/ Meiges syndrome 0 0 2 0.90 
Headaches that affect activities of daily living 22 79.42 92 41.22 
(32.97-
49.47) 
Primary headaches – total 0 0 44 19.71 
Migraine 3 10.83 8 3.58 
Tension Type headaches 9 32.49 36 16.13 
Cluster headaches 0 0 0 0 
Other Primary Headaches 0 0 0 0 
Secondary headaches – total 0 0 48 21.51 
Headaches attributed to head and/or neck trauma 0 0 3 1.34 
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Headaches attributed to infection 0 0 0 0 
Headaches attributed to disorders of homeostasis/headache 
attributed to arterial hypertension 
0 0 3 1.34 
Headache attributed to disorder of homeostasis/headache attributed 
to hypertensive crisis without hypertensive encephalopathy 
0 0 0 0 
Headache attributed to disorder of homeostasis/headache attributed 
to hypertensive encephalopathy 
0 0 0 0 
Headache or facial pain attributed to disorder of the cranium, 
neck/headache attributed to disorders of the neck 
9 32.49 34 15.23 
Headache or facial pain attributed to disorder of the cranium, 
neck/headache attributed to disorders of the eyes 
1 3.61 4 1.79 
Headache or facial pain attributed to disorder of the cranium, 
neck/headache attributed to disorders of the ears 
0 0 1 0.45 
Headache or facial pain attributed to disorder of the cranium, 
neck/headache attributed to disorders of the teeth or jaw 
0 0 2 0.90 
Cranial neuralgias and central causes of facial pain/trigeminal 
neuralgia 
0 0 1 0.45 
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Stroke 12 43.32 54 24.19 
(17.82-
30.57) 
LACS 4 14.44 19 8.51 
PACS 3 10.83 16 7.17 
TACS 4 14.44 12 5.38 
POCS 1 3.61 7 3.14 
POCS cerebellar 0 0 4 1.79 
POCS non cerebellar 1 3.61 3 1.34 
Epilepsy 1 3.61 10 4.48 
(1.71-7.25) 
GTCS 0 0 9 4.03 
Partial with secondary generalization 1 3.61 1 0.45 
Motor Neuron Disease 0 0 2 0.90 
(0.00-2.14) 
Cord Lesions 2 7.22 5 2.24 
(0.28-4.20) 
Cervical Cord Lesions 2 7.22 3 1.34 
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Traumatic Cervical Cord lesion 1 3.61 1 0.45 
Non-traumatic Cervical Cord Lesion 1 3.61 2 0.90 
Arthritic compression 0 0 1 0.45 
Acute lower cervical cord lesion 1 3.61 1 0.45 
Thoracic Cord Lesion 0 0 2 0.90 
Traumatic Thoracic Cord lesion 0 0 0 0 
Non-traumatic Thoracic Cord Lesion 0 0 2 0.90 
Peripheral Neuropathy 16 57.76 42 18.82 
(13.18-
24.45) 
Sensory Peripheral Neuropathy 15 54.15 39 17.47 
Sensorimotor Peripheral Neuropathy 1 3.61 3 1.34 
Motor Peripheral Neuropathy 0 0 0 0 
Cranial Nerve Pathology 2 7.22 14 6.27 
(3.00-9.55) 
Ptosis 1 3.61 8 3.58 
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Ptosis secondary to eye pathology – traumatic 0 0 4 1.79 
Ptosis secondary to eye pathology - non traumatic 0 0 2 0.90 
Ischaemic 3rd CN palsy 1 3.61 2 0.90 
Facial nerve pathology 0 0 4 1.79 
Bells 0 0 2 0.90 
Traumatic  0 0 1 0.45 
Hemifacial spasm 1 3.61 2 0.90 
Upper Limb Mononeuropathies 8 28.88 15 6.72 
(3.33-10.11) 
Traumatic upper limb polyneuropathy  1 3.61 2 0.90 
Traumatic damage to Median Nerve 1 3.61 1 0.45 
Non-traumatic damage to Median nerve - compression/entrapment 1 3.61 4 1.79 
Traumatic damage to Radial nerve 2 7.22 2 0.90 
Non-traumatic damage to Radial nerve 0 0 0 0 
Traumatic damage to Ulnar nerve 0 0 2 0.90 
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Non-traumatic damage to Ulnar nerve 3 10.83 4 1.79 
Lower Limb Mononeuropathy and Polyneuropathy 1 3.61 5 2.24 
(0.28-4.20) 
Traumatic femoral nerve injury 0 0 1 0.45 
Sciatic nerve injury from trauma 0 0 1 0.45 
Sciatic nerve injury from injection site 0 0 1 0.45 
Common peroneal injury from operation 1 3.61 1 0.45 
Traumatic common peroneal nerve injury 0 0 1 0.45 
Plexus Injury 0 0 4 1.79 
(0.04-3.55) 
Brachial-traumatic 0 0 2 0.90 
Lumbosacral-traumatic 0 0 2 0.90 
Root Pathology 1 3.61 4 1.79 
(0.04-3.55) 
Sciatica 1 3.61 3 1.34 
C8 root lesion 0 0 1 0.45 
Polio 0 0 5 2.24 
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(0.28-4.20) 
Leprosy 0 0 1 0.45 
(0.00-1.33) 
Myaesthenia Gravis 0 0 1 0.45 
(0.00-1.33) 
Muscle wasting and atrophy 0 0 17 7.62 
(4.01-11.22) 
secondary to primary orthopaedic problem 0 0 7 3.14 
secondary to pain 0 0 5 2.24 
secondary to severe cognitive impairment and consequent immobility 0 0 2 0.90 
secondary to soft tissue damage secondary to infection 0 0 2 0.90 
secondary to period of ill health and consequent disability 0 0 1 0.45 
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4.5 The workshops 
The NMI attended two workshops one week apart to teach them to use the screening 
questionnaire. This ensured they had time to practice the screening questionnaire on 
friends and family between sessions and could bring up any queries or problems they 
had experienced in the second session. They also received a period of training with 
“real patients” in the field and were observed administering the screening 
questionnaire until they were confident and competent in its use. All of this improved 
the validity of the results.. 
 
4.5.1 The enumerators/NMI 
The NMI were experienced in screening for medical conditions as they had been 
involved in previous prevalence studies in the past. The use of NMI like the 
enumerators has the following main advantages: 
1. They are cost effective to employ and consequently such screening can be used 
in other resource poor settings. 
2. They have optimal geographical knowledge of the area and the households, 
without which a community based prevalence study in similar remote 
geographical locations, could not go ahead, or cases, particularly those that 
need to be seen in their houses, would be missed. 
3. Their standing within the village and the fact that they were well known to the 
villagers and lived in the village ensured that they were acceptable to people 
within the study and this increased the participation in the study.  
 
Disadvantages of using NMI 
1. Their lack of medical knowledge might mean that they produce a higher 
number of false positives and negatives than medically qualified investigators, 
decreasing sensitivity and specificity of the screening questionnaire and 
ultimately underestimating the prevalence of Neurological disorders with an  
increased number of people required to be seen in the second stage. 
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2. The lack of an examination section required to enable NMI to screen may 
reduce the sensitivity of the tool as with a questionnaire alone you rely on the 
patient to report symptoms and signs which they may feel are stigmatising and 
are reluctant to disclose. 
 
4.6 The Main Study 
The selection of villages was random but ensured the proportion of upland and 
lowland villages remained representative of the whole Hai District DSS population. The 
size of the main study was selected due to financial and time constraints. The whole 
population studied was 40,280 (one quarter of the Hai District DSS population 
n=161,119). Of this population I only studied the 70 and over population, n=2232. 
Other community based studies of this nature in SSA have differed in size with no 
universally accepted optimum, the number of subjects studied have varied from 1113 
to 161,071 [3, 5, 34, 96, 99, 128, 131, 187, 191, 204-206, 302, 313, 315, 336, 466, 467].  
 
4.6.1 False Positives 
The number of false positives (n=163) in the main study remained relatively low, 
supporting the high specificity of the screening questionnaire. As in the pilot study, in 
the majority of cases simple questioning revealed that they were false positives and 
consequently the review of these patients was not time consuming. 
 
The false positives were all reviewed and diagnosed by the RD (myself). The most 
common false positive diagnosis was osteoarthritis. Some patients when seen and 
questioned again  immediately became negative. It was felt that in the majority of 
these cases they wanted to see the RD for another reason, so answered positively to 
the screening questionnaire just to get medical attention. Therefore actual specificity 
of the screening questionnaire may be underestimated. 
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4.6.2 False Negatives 
The potential for missed diagnoses of the 8 false negative patients was relatively 
unimportant as their symptoms had very little impact on the individual patient. It is 
possible that some patients may have hidden their symptoms as they believed them to 
be stigmatising for either themselves or their family. I tried to overcome this problem 
by simple observation of all the patients in the main study and by education of the 
enumerators on the nature, causation and potential treatments of neurological 
disorders. They in turn were able to relay this to each individual patient. 
 
4.6.3 Description of cases - True positives – The Prevalence estimates 
To the best of my knowledge, this is the first community-based prevalence study of 
“All-Cause” Neurological Disorders in the Elderly in SSA. Data in this area are sparse 
and most “up-to-date” data is based on observational studies that assessed hospital 
populations. Much of the community based data is old and predictive data from the 
WHO is only speculative. Comparable data on the true prevalence of Neurological 
disorders in the community is limited but is provided by this study and can inform 
healthcare planning in this resource-poor setting. The need for such data has been 
long recognized by the WHO [7]. We can reflect on the prevalence rates that we found 
by comparing them to available community based prevalence studies that investigated 
prevalence from SSA. Due to lack of up-to-date data from SSA I have also utilised 
robust community based epidemiological studies from other developing countries for 
comparison and worldwide review articles. I have done this with reference to "all-
cause" neurological disorders and the most common and public health relevant 
conditions namely, tremor, parkinsonism, cerebellar disorders, headache, stroke and 
epilepsy [13, 384, 385]. The prevalence rates of other neurological disorders identified 
by the study namely; dyskinesias, motor neuron disease, spinal cord dysfunction 
including injury, infection resulting in CNS dysfunction, polyneuropathies, nerve, nerve 
root and plexus disorders and inflammatory/infectious diseases of the PNS e.g. polio 
and leprosy have been briefly discussed. The justification for focussing on literature 
from SSA has been previously explored in the introduction section.  
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The elderly in SSA are an important and expanding group with different (from the 
general adult population) and under-recognised needs and levels of pathology. This 
study allows reflection on the impact of an ageing population and where possible age 
related prevalence rates from the literature have been compared.  
 
4.6.3.1 All Cause Neurological Disorders  
The age adjusted prevalence rate of Neurological disorders in our 70 years and over 
population was 168.9/1000. The age adjusted prevalence rates of a person with one or 
more neurological diagnoses were 154.1/1000. The identification of a complete list of 
neurological disorders as defined by the WHO ICD 10 and the use of standard 
diagnostic criteria  facilitated interpretation of results and increased the quality of the 
study. In addition I used a two-phased approach to achieve accurate prevalence data. I 
used my own feasible, valid and specially developed screening questionnaire, utilising 
findings from previous studies by my research team to help ensure maximal case 
ascertainment [34, 96, 128, 333]. Finally, extensive training of NMIs added to the 
reliability of my figures [24]. 
 
This study and its conclusions have some important limitations which are discussed in 
detail below but briefly include inaccuracies of age and interpretation, its small size 
(consequently the prevalence of rarer conditions are more difficult to interpret), the 
purely clinical diagnosis. Nevertheless, our methodology is robust, and our estimates 
are as accurate as possible given the setting of data collection. 
 
4.6.3.1.1 Comparing our figures to less reliable data sets 
Predictory data from the GBDS has demonstrated neuro-psychiatric disease make up 
14.7% of the total global burden of disease and are one of the leading causes of 
disability[391]. However, these predictions are generally extrapolated from South 
African data with only limited studies from the rest of SSA. 
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Winkler et al[394] recently reviewed hospital-based prevalence studies of neurological 
disorders in rural African settings. They concluded that out of 8676 admissions 740 
patients (8.5%) were given a neurologic diagnosis, the most frequent of which were 
seizures (26.6%) and infectious diseases (18.1%). Other hospital-based studies from 
SSA estimate that neurological disorders (most commonly stroke and neurological 
conditions secondary to infection) make up 3.0– 33.1% of all hospital admissions and 
4.2–7.5% of out-patient reviews [9, 27, 395, 444, 468]. 
 
Mateen et al [396] documented reportable neurologic diseases in refugee camps in 19 
countries (13 from SSA). The data presented is difficult to interpret as it is presented in 
the format of the number of health visits rather than in prevalence format. It does 
however attribute a high morbidity burden to neurological disorders particularly those 
that are non-communicable in nature. 
 
The GBDS hospital based and refugee camp studies do emphasise that neurological 
diseases contribute substantially to morbidity burden. However, their methodology 
and their conclusions are highly biased and therefore they are difficult to generalise or 
compare with our dataset [392].  
 
4.6.3.1.2 Community prevalence studies from SSA 
The only community-based studies from SSA on the prevalence of all cause 
neurological diseases are from over 20 years ago. The studies were significantly larger 
than my own, they used robust methodology with little introduction of bias. 
Osuntokun et al [3] reported a crude prevalence rate of 11.1/1000 or 62.1/1000 if 
inclusive of lifetime prevalence of headache in Nigeria and Tekle-Haimanot et al [5] 
found crude prevalence rate of 14.9/1000 in Ethiopia.  
 
These rates are substantially lower than my own, this can be partially explained by the 
age structure of the population studied. Unfortunately because of rapidly changing 
population demographics these studies are now out of date and of limited use, even 
though they were landmark studies of their time. In the Nigerian study 58% of patients 
402 
 
were aged below 20 years and only 2.82% of the population were aged 70 years and 
over. In the Ethiopian study, 59% of the inhabitants were aged below 20 years, with a 
median age of 14.5 years. This represented the age distribution of SSA at the time, , by 
now the ageing of the population will have impacted significantly on the relative 
contribution of neurological disorders. This population structure, without the means to 
adjust for age means that prevalence rates reported are difficult to compare with 
current worldwide prevalence rates, particularly those from our prevalence study 
which reported on a purely elderly population.  
 
Both studies utilised the WHO neuroepidemiological protocol which was only designed 
to identify 7 major neurological disorders whereas my study (and screening tool) was 
designed to identify a more complete list, this could explain the comparatively high 
prevalence rates in my study.  
 
4.6.3.1.3 Community based prevalence studies from developing countries other 
than SSA 
In 1985 Attia Romdhane et al [4] reported the age adjusted prevalence of "all-cause 
neurological disorders to be 59.5/1000 inclusive of migraine and 25.5/1000 exclusive 
of headache disorders, this is again substantially lower than my results. The study was 
well designed but is dated, the population had a very different age structure and it 
used the WHO neuro-epidemiological protocol which only identified a limited number 
of neurological disorders. 
 
Dated studies from India include those performed by Razdam et al [137] in Kashmir 
and Saha et al [61] in West Bengal. Both studies utilised the WHO protocol in the 
general population. They yielded crude prevalence rates of 9.67/1000 and 29.07/1000 
respectively. 
 
Using similar methodology to that used in our study, Gourie-Devi et al. [52] screened a 
randomly sampled 102,557 urban and rural dwellers from Bangalore, India, and quote 
an age-adjusted prevalence of 33.6 per 1000 in the general population and 50.1 per 
1000 in the >60 years population. Interestingly, they found prevalence rates to be 
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almost twice as high in rural areas (40.7 per 1000) compared to urban (21.9 per 1000) 
dwellers and linked this to lower socioeconomic status.  
 
Das et al. [43, 53] quote a crude prevalence of 60.9/1000 in the 60 and over age group 
in Kolkatar, India and 11.79/1000 in the general population with an age adjusted rate 
of 15.2/1000, but this was performed to the US 2000 population rather than the WHO 
World Standard Population. 
 
In both studies a two-phased approach was used with: random sampling, training of 
interviewers, case verification by neurologists and use of diagnostic criteria to improve 
the reliability of the results.  
 
The higher prevalence rates in the rural population (found by Das et al) and the ten 
year age difference (Das studied those aged over 60) may explain the comparatively 
lower prevalence rates in these two Indian populations.  In addition  the Indian 
screening instrument was not specific for use in the elderly and it is possible that 
neurological disease was mistaken for other co morbidities and therefore was under 
diagnosed. In the case of Das et al the screening questionnaire used was only designed 
to pick up stroke, essential tremor, epilepsy, parkinsonism and dementia and therefore 
the exclusion of other less common neurological disorders may also explain their lower 
prevalence rates. It is also possible that the prevention and treatment of neurological 
disease is more advanced in India in comparison to SSA which has resulted in lower 
levels of disease.  
 
4.6.3.1.4 Community prevalence studies from developed countries 
Broe et al. [155] quoted the prevalence of neurological disorders as 214.1 per 1000 in 
the 65 and over age group in the UK. In the general population of developed countries, 
prevalence rates vary from 68 to 142 per 1000 [398, 399]. 
 
We have demonstrated a high level of neurological morbidity in the elderly population 
of SSA, comparison of this data to other datasets is difficult because of the 
heterogeneity of study design, population age and the number of neurological 
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disorders screened. Elderly populations of SSA do however seem to be at increased 
risk of neurological morbidity than some other populations. They have an equivalent 
level of neurological morbidity to the elderly from developed countries and therefore 
healthcare action is urgently required. 
 
4.6.3.2 Central Nervous System Disorders 
4.6.3.2.1 Movement Disorders 
4.6.3.2.1.1 Tremor Disorders 
The most common neurological disorder was tremor, of which 60.9% of cases were 
essential tremor. My overall prevalence of all cause tremor disorders was 49.3 95% CI 
(40.3 to 58.3), with an age adjusted prevalence of 48.2 95% CI (39.4 to 57.1). 
 
4.6.3.2.1.1.1 Essential Tremor 
The world-wide prevalence of ET (limited to community based studies which use a 
defined and accurate diagnosis of ET) ranges from 4.1–39.2/1000 across whole 
populations, becoming increasingly common with age, prevalence increased to 13.0-
50.5/1000 in persons above 60 years of age [91]. More specifically a recent study from 
the United States reported the substantial impact of ageing with prevalence rates of 55 
per 1000 reported in the over 60 years age group increasing to 217 per 1000 in those 
aged over 95 years [104].  
 
The prevalence of ET appears to be higher in whites than blacks even within the same 
geographic location [92].  
 
In SSA, rates of around 0.1 per 1000 have been reported in the general population [3, 
5].  
 
The crude prevalence of Essential Tremor (ET) in the studied population was 30.0/1000 
95% CI (22.9 to 37.1) and the age adjusted prevalence was 30.1/1000 95% CI (23.0 to 
37.2). Using the combined diagnostic criteria detailed in the introduction[86], my 
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relatively high prevalence rate is likely to reflect the age of our study population. 
However it may also be due to genetic factors, with some clustering of cases within 
specific areas[469]. The following section goes on to discuss this in more detail with 
reference to specific literature. 
 
My ET prevalence figures are reliable because of the robust methodology used, 
specifically a 2 phased epidemiological survey. Hospital prevalence studies are 
generally very poor at documenting accurate prevalence data in developing countries 
and this is particularly the case for the prevalence of ET both in developing countries 
and the rest of the world. A large number of patients are often undiagnosed in the 
community and do not seek medical help despite problematic symptoms that 
substantially effect quality of life. In prevalence studies from Finland [93] and 
Singapore [94], only 2% and 10%, respectively, had been previously diagnosed. Only 10 
cases of ET were identified amongst 2.1 million patients seen in outpatient clinics in a 
teaching hospital in Nigeria over a 25 year period [95].  
 
As described above estimates of the prevalence of ET vary widely. There are few 
existing data, from reliable community based studies, on the prevalence of ET in sub-
Saharan Africa (SSA) [91]. 
 
Early community based studies in SSA investigated all neurological diseases, not just ET 
and were performed in the 1980s, preceding the ongoing substantial population 
change which has increased the elderly portion of the population in SSA. Given this 
and the fact that they focussed on the general population including children, it is not 
surprising that the prevalence rates found (5-10/100,000) were significantly lower than 
those found in my study. Unfortunately it is not possible to extrapolate from the data 
presented in these papers the prevalence rates in older age groups. 
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There have subsequently been two reliable studies of ET conducted in SSA, one in 
Tanzania in the same study site as is the subject of this thesis in 2008 and one more 
recent study from Nigeria, published in 2012. 
 
Dotchin et al's [96] study (also in the Hai district DSS) found similar rates of ET to my 
own when you allow for the different age of the population studied (Dotchin et al 
studied all ages). The crude prevalence rate found by this study was 41/100 000 and 
age standardised prevalence (to the UK population (2001)) was 82/100 000. 61.5% of 
cases were aged 70 years and over. 
 
My more robust methodology is likely to explain slightly higher prevalence rates (when 
the rates in the aged population are directly compared). Dotchin et al did use the gold-
standard 2 phased approach to perform the epidemiological survey and the 
denominator population was accurately recorded as part of a census. However, the 
cases were identified through a questionnaire designed to identify individuals with PD 
and no effort was made to validate this questionnaire for ET. The poor performance of 
the questionnaire was highlighted by the 43 individuals identified by other case finding 
methods which were identical to the ones we used which failed to pick up any 
additional cases. Standard diagnostic criteria from the MDS were used however 
validation by a movement disorder expert was not possible. It is important to 
recognise that Dotchin et al had a much larger sample size than our own 161,071 vs. 
2232 and therefore although we may have been able to ensure more robust 
methodology it may be that our higher figures are a reflection of clustering as 
discussed above. 
 
Subsequent to the work performed by Dotchin and colleagues, Okubadejo et al [98] 
performed a multi phased door-to-door survey investigating the prevalence of 
essential tremor (ET) in an urban Nigerian community. Like our study the sample size 
of 3000 residents was relatively modest (dictated by logistic constraints and 
commitment to robust methodology) although selection bias was avoided through 
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randomisation. Only one of the two screening questionnaires used was validated so 
sensitivity could be an issue and in consequence there could be uncertainty with 
regard to the prevalence figures. Diagnosis of ET was positively based on the 
Movement Disorders Society (MDS) consensus diagnostic criteria for ET. The authors 
found a crude prevalence of 12 per 1000 (95% CI = 8.1- 15.9). Prevalence was age 
adjusted according to the "WHO New World population" and found to be 23.78/1000. 
Gender specific crude prevalence was 10.3 /1000 in males and 14.3/1000 in females. 
Age specific prevalence increased with advancing age in both sexes. The highest rates 
were seen in those aged 75-84 where the crude prevalence rate was found to be 
473.7/1000.  
 
The whole population was screened which could explain the slightly lower overall 
prevalence rates than my own. In contrast the prevalence rates in the older age groups 
were much higher than that found in our study with their peak crude prevalence rate 
of 473.7/1000 in the 75-84 year old age group compared with the 54.7/1000 found in 
our population of 70 and over.  
 
It is worth noting that the rates reported by Okubadejo et al are ten times higher than 
earlier studies based in a rural community in the same ethno-geographical zone [3]. It 
is likely that the latter more robust studies present much more reliable figures, more 
applicable to today's SSA society. In addition direct comparison of these data 
presupposes that the population structures are similar, age adjustment was carried out 
but there is significant variation in the standard population used and so direct 
comparison of the results remains difficult.  
 
The crude and age-standardized prevalence data obtained by ourselves and Okubadejo 
et al [98] fall within the range previously reported from the rest of the world (4.0 – 
39.2/1000) indicating that ET is a problem for developing and developed countries 
alike and likely to become an increasing problem in low-income countries as 
populations age. A recent study in Sile, Turkey demonstrated a crude prevalence rate 
of 30/1000 in persons above 18 years of age [100]. A recent study from Italy reported 
age and sex adjusted prevalence rates of 12/1000 for women and 19/1000 for men 
[101].  
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It is important to note that the methodology used in my study as well as those from 
Dotchin and Okubadejo may underestimate prevalence, as people with mild symptoms 
may not have responded positively to the screening questions. In an American study, 
13 of 46 patients diagnosed with ET had not reported tremor on screening questions 
[92] and further studies by Louis et al [91] reported that patients with mild tremor may 
not screen positively, stressing the importance of examining all subjects if possible. 
However equally it could be argued that those persons with mild tremor may have 
physiological tremor, or tremor induced by the anxiety of seeing a doctor and 
therefore examining patients may increase false positives and reduce the specificity of 
screening. It is also worth noting that in SSA it has been found that patients with 
tremor suffer from stigma [96]. This may make them less likely to answer questions 
positively which would result in underestimation of prevalence in my study. Tremor is 
often thought to be a sign of alcoholism or evil spirits. Social stigma as a result of 
neurological problems is common in Tanzania and awareness of neurological 
conditions is low, as in most of SSA.   
 
With direct reference to our prevalence figures other limiting factors include my 
modest sample size with the potential impact of clustered cases and I used a 
combination of criteria for diagnosis of ET. This was felt to be pragmatic however using 
the MDS criteria alone might have facilitated comparison further. 
 
Reasons for varied worldwide prevalence could be differences in exposure to risk and 
aetiological factors. Different risk factors are explored below with relevance to the 
literature: 
 
Ageing is the most consistent documented risk factor associated with increased 
prevalence of ET [102] a finding also corroborated by Okubadejo et al's and Dotchin et 
al's studies detailed above and obviously specifically relevant to my prevalence rates. 
There have been various studies that specifically report the crude prevalence of 
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essential tremor in the elderly (some where the aged population is the only focus of 
the study, some where the prevalence in this age group is specifically highlighted). Das 
et al [53]performed a study of 5430 people aged 60 years and older in India and found 
the crude prevalence of ET to be 13.76/1000. Benito-Leon et al [103] reported a crude 
prevalence rate of 48/1000 amongst 5278 people aged 65 years and older in a Spanish 
community study. Gilik et al (2003) reported a crude prevalence of 7.8/1000 in those 
aged 65 years and older, in a community door to door survey of 900 individuals.  Louis 
et al [104] assessed the prevalence of essential tremor in 1965 people aged 66-102 in 
Manhattan US, they found that the crude prevalence rate in this whole population was 
55/1000. However the prevalence for those aged over 95 was 217/1000 or 
approximately 1 in 5. Interestingly they found that for each 1 year of advancing age the 
risk of ET increased by 14%. Our prevalence rate of 30.1/1000 is very much in keeping 
with these worldwide prevalence rates from elderly populations and together they 
highlight the impact of ageing on this highly prevalent condition. 
 
Genetics have also been implicated in ET prevalence as demonstrated by clustering of 
the condition within families [105]. It is estimated that one half of cases of essential 
tremor are due to a genetic mutation and the pattern of inheritance is most consistent 
with an autosomal dominant transmission. As yet no genes have been identified but 
genetic linkage has been established with several chromosomal regions [469-471]. 
About a third of the participants with ET reported by Okubadejo et al[98] had a 
positive family history of tremor in a first degree relative and it is possible that 
undiagnosed ET and recall bias would have lowered the reporting of a positive family 
history. Dotchin et al's[96] ET patients also reported a family history in approximately 
one-third of patients (28%). In some cases the first degree relatives had died at a 
young age, making it possible that they may have developed tremor had they lived 
long enough. It is difficult to obtain accurate data on family history on ET, Prakash et al 
[106] report the inaccuracy of family history reporting, with patients tending to under 
report family members with tremor, especially in mild cases, resulting in a sensitivity of 
only 43%. However, the specificity of these reports were high (94%), so if a family 
member is recorded as having a tremor, they probably do have ET. We agree that 
family history was inconsistently reported, in our population 16 patients (23.9%) 
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admitted to having a family history of tremor, with one patient denying a positive 
family history despite the fact that the next patient with ET was her sister, 
 
A gender predilection has previously been reported in some ET studies; several studies 
have suggested ET is more common in men than in women [92-94, 101], but an older 
community based study in Papua New Guinea suggested women were more 
commonly affected than men [108]. Other studies [92, 96, 98], have not found any 
male to female differences. The basis of a gender predisposition is unproven and there 
are no strong biological indications that could explain such findings. However, if such a 
difference does exist it is likely that environmental peculiarities relating to 
occupational and recreational exposures are possible contributors. We found no 
significant different in gender; 55.2% of patients were male and 44.8% were female.  
 
Significant ethnic variation have been reported by Louis et al [109] in the US where 
Caucasians were found to be five times more likely that African Americans to have 
physician diagnosed ET. It was however unclear from this study whether this reflects 
inconsistencies in access to medical care and health seeking behaviour of different 
communities or whether a true difference in prevalence exists. Another study in New 
York showed higher rates in whites compared with African Americans, with Hispanics 
having an intermediate prevalence [92]. Reflecting on the rates reported by Okubadejo 
and ourselves and how comparable they are to worldwide data it seems that under 
presenting in African Americans (eliminated by community based studies) may explain 
ethnic variations in hospital studies.  
 
ET is associated with significant functional disability particularly in persons with an 
upper limb tremor [114]. Work and productivity can be significantly impacted by ET, in 
the UK and the US, up to 25% of patients with ET had to change jobs or retire because 
of their symptoms[105, 115]. The social and emotional burden could be partially 
relieved with treatment. Non-selective beta blockers are available in SSA. Okubadejo 
et al[98] reported that only 1 (2.8%) person had a prior diagnosis of ET, and this was 
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the only individual on treatment. Dotchin et al [96] found that no one they identified 
was receiving medication for tremor and very few had sought any medical help. 
Several factors including differing severity and impact of ET on activities of daily living, 
non-recognition or poor awareness of ET as a neurological or medical disorder 
amenable to treatment and limited access to care may contribute to the treatment 
gap, all highlighting that prevalence of ET derived from hospital-based studies will 
reflect an under estimate of prevalence. Low treatment levels are also seen in 
developed countries; as many as 75-99% of patients with ET detected through 
population-based studies are reported to be previously undiagnosed and untreated 
[92, 117]. No previous studies from SSA have assessed the responsiveness of 
symptoms to simple drug treatments. We found that 85.3% of patients reported that 
they had improved on medication which consisted of varying doses of propranolol. To 
make progress, further consideration of local beliefs behind ET and other neurological 
conditions is necessary, as is education of the population and community health 
workers. 
 
In summary ET is a highly prevalent condition in the elderly and this is supported by my 
data and the more recent studies from SSA and worldwide. It may be that ET is less 
common in black communities but this is not supported by recent community studies 
from SSA including this one. It is likely that differences can be attributed to variations 
in study design and methodology and diagnostic criteria. Improved public awareness 
and physician education is required to ensure that ET is recognized, and treatment 
offered where appropriate. 
 
4.6.3.2.1.2 Cerebellar Disorders 
I found the crude prevalence of all cause cerebellar disorders to be 4.93/1000 95%CI 
(2.02 to 7.83) with the age adjusted prevalence rate being 4.87/1000 95% CI (1.98 to 
7.76). In these patients 45.5% were secondary to idiopathic/unknown cause, 36.4% 
were secondary to stroke and 18.2% were secondary to alcohol. 
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According to the recent BMJ best practice guide there is no exact data on the 
prevalence of cerebellar ataxia of all causes [472]. Epidemiological studies that focus 
on hereditary types of ataxia have shown a prevalence of approximately 10/100,000, 
and idiopathic ataxias probably outnumber hereditary cases [473]. Because there are 
many different types of inherited and degenerative ataxias each individual cause is 
relatively rare. There are clusters of high incidence and prevalence due to genetic 
mutations [472].   
 
Osuntokun et al reported a prevalence of 0.10/1000 for primary cerebellar 
degeneration in Nigeria in 1986 [3]. No other SSA studies comment on the prevalence 
of cerebellar disorders. 
 
Safe et al [474] performed a retrospective study of 624 elderly patients in the UK 
referred for gait and balance problems and found 45 (7.2%) of them to have cerebellar 
ataxia. 37% were secondary to cerebrovascular disease, 20% were due to degenerative 
cerebellar ataxia, 6.7% were secondary to Normal Pressure Hydrocephalus and 4.4% 
were secondary to alcohol. They conclude that a significant proportion of elderly 
people will have cerebellar ataxia due to treatable or reversible causes and therefore it 
is an important diagnosis to screen for. 
 
Nafissi et al [475] also looked at the different causes of cerebellar ataxia in Iran in all 
ages (range 6-73). They concluded that 30.4% were secondary to Multiple Sclerosis 
(MS), 29.6% were secondary to cerebrovascular disease, 3.0% were secondary to a 
tumour or were paraneoplastic, 7.4% were secondary to inflammation or infection, 
11.1% were hereditary ataxias and 14.8% were of unknown origin. This highlights the 
importance of age specification when looking at the subdivisions of neurological 
disorders and the possible causes. 
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4.6.3.2.1.3 Parkinsonism 
This study found the crude prevalence rate of parkinsonism to be 6.3/1000 95% CI (3.0 
to 9.6) and the age adjusted prevalence to be 5.9 95% CI (2.8 to 9.1). The crude 
prevalence of idiopathic Parkinson's disease was 5.4/1000 95% CI (2.3 to 8.4) and age 
adjusted prevalence was 5.1 95% CI (2.2 to 8.1). 
 
The prevalence of PD was originally reported to be much less in SSA than the rest of 
the world. Initial studies from Nigeria [3], Ethiopia [5] and Togo [127] demonstrated 
prevalence rates of 0.07-0.20/1000. Age adjustment was performed in the Nigerian 
study to the black population in Copiah, Mississippi [50] allowing direct comparison of 
the prevalence rates. The age adjusted prevalence rate was 0.67/1000 for those over 
39 in Nigeria five times lower than the 3.41/1000 reported from the US. Positively all 
these African studies were community based. Methodological differences particularly 
inconsistent diagnostic criteria may still have contributed to inaccuracies and 
differences in the prevalence rates. It unclear whether all cases of parkinsonism or just 
idiopathic PD were included. In addition the total number of patients found with 
parkinsonism were small and limited the conclusions that can be drawn.  
 
In 2006 authors from my research group conducted a prevalence study of PD in the 
whole population of the Hai district DSS [128]. Strengths of the study included use of 
an accurate denominator population, standard diagnostic criteria, case verification and 
multiple sources of case ascertainment. Limitations of the study and possible 
underestimation of the burden of PD were lack of validation of the screening tool, 
under reporting due to stigma and use of a surrogate (questioning the head of the 
household). The age standardised prevalence rate found was 0.40/1000. This figure is 
more in keeping with the rate of 0.67/1000 reported in African Americans in 
Manhattan [130] but is still lower than other studies presented in the developed 
world. Dotchin et al [128]report an age adjusted prevalence rate of 2.07/1000 for 
those aged 65 and over. Standardised methodology and more comparable diagnostic 
criteria played a part in detecting more cases of PD in this population than in the 
aforementioned studies. The rates in a similar age group are still less than half that 
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detected in my study, I speculate that this is because of improved detection in our 
study through use of a validated tool and increased awareness of PD brought about 
through repeated prevalence studies. 
 
Winkler et al [131] reported the prevalence of parkinsonism in a population of 
northern Tanzania in 2010, however the methodology was significantly flawed and 
limits the usefulness of the data. A crude prevalence of 1/1000 (n=5) and 0.35/1000 
(n=1) was reported for parkinsonism and Parkinson's disease respectively from a 
hospital population, however this is a highly biased sample and therefore these results 
are difficult to interpret. None of the community based subjects were diagnosed with 
parkinsonism or PD, making the prevalence zero. The authors calculate 95% 
confidence intervals and conclude that prevalence could fall between 0 per 1000 (the 
best estimate based on their observation) and 2.5/1000. 
 
Indian studies conclude the prevalence of PD varies between 0.06-3.28/1000 with 
higher prevalence rates being found in Parsi Indians (with rates similar to those found 
in white Caucasians). The main factor that limits the comparison of my data is the age 
of the population I studied, however on examining age specific prevalence rates from 
the Indian data one can conclude that age-specific rates increase from 0.28/1000 (in 
4th decade) to 5.73/1000 in ninth decade [58, 145] and that my rates of 5.1/1000 in 
the over 70 population are comparable. It is also worth noting that in India PD was 
more prevalent in rural than urban populations [144] potentially another reason why 
the prevalence rates in my population were slightly higher, and could indicate a 
causative factor such as pesticides. 
 
A large (n=29 454) cross-sectional prevalence study of Parkinson’s disease in China was 
undertaken in 1997–98 [133] with robust methodology that included sampling and a 
one stage standardised diagnostic protocol with good inter-rater reliability. The size of 
the study and the fact that 277 people with disease were identified means that 
conclusions drawn are potentially much more accurate than my prevalence figures 
which are limited by the size of the population studied and the small number of cases 
identified. The age standardised prevalence of Parkinson’s disease for those aged 65 
years and over was 21/1000 (19–23) for both sexes. This is easy to compare to studies 
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of the same age group in Rotterdam, the Netherlands (22), and in seven European 
studies (17) and indicates that the prevalence of Parkinson’s disease in China is similar 
to that in developed countries [133] and significantly more than that found in my study 
(5.1). Standardised estimates for both sexes from a previous Chinese study[147] based 
on a different age groups (60 years and over) were lower (1-10/1000) than this study 
from Zhang et al and were more in keeping with my results. The authors attribute this 
to the fact that their methods corrected several limitations of earlier studies, they 
surveyed urban and rural populations in diverse regions and reviewed high numbers of 
participants which yielded statistically precise estimates.  
 
Wickremaratchi et al [134] performed a very large (n=292,637) prevalence study of PD 
amongst residents in Cardiff. Strengths of the study included multiple case finding 
methods that included the use of GP databases, prescriptions and neurology clinic 
notes (robust methods in a developed country).They used standardised diagnostic 
criteria. The age adjusted prevalence rates for the whole population, those aged 70-79 
and those aged 80 and over were 1.42, 7.38 and 12.97/1000 respectively. The authors 
overall prevalence rates were very similar to previous UK studies where the crude 
prevalence reported was 1.13-1.64/1000 [148-152, 154, 476]. The authors 
acknowledge their main limitation is that they only clinically examined one-third of 
cases, and older cases were less likely to be seen. The authors conclude that there are 
no major geographical variations in the prevalence of PD in the UK and that the age 
adjusted prevalence rate has remained relatively stable over the past 40 years. The 
rates found are higher than found in my study in a similar age group; this may 
represent a true difference or may represent problems making accurate conclusions 
on the prevalence of rare conditions in a study with a small sample size such as my 
own. 
 
The EUROPARKINSON collaborative study [135] represents a huge PD prevalence study 
(n=14,636) with an unprecedented level of methodological homogeneity from five 
European populations (France, Italy, The Netherlands and 2 in Spain), it provides 
reliable prevalence data for people aged 65 years or older. The overall age adjusted 
prevalence was 23/1000 for parkinsonism and 16/1000 for Parkinson's disease. 
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In general my study adds to the growing body of evidence that the prevalence is lower 
in blacks than whites but the difference is not as significant as originally thought. 
Studies have shown an association of lack of melanin with PD and this may explain 
racial discrepancies, however more investigation into genetics and the role of melanin 
and environmental causes of PD are required [130].Those studies that reflect the 
prevalence in the whole population as opposed to being more specific to the elderly 
are bound to demonstrate lower prevalence rates, Parkinson’s disease, a disease of 
the ageing brain, becomes more common with increasing age and is one of the many 
neurological conditions that demonstrate the importance of looking specifically at an 
elderly population [118].  
 
4.6.3.2.1.4 Dyskinesias 
The prevalence of chorea in the literature has been reported as 0.05 to 1/1000 of the 
population, with the higher prevalence rate reflecting the prevalence in an age group 
aged 65 and over [5, 155]. I found the prevalence of dyskinesias to be 2.2/1000 95% CI 
(0.3 to 4.2), with an age adjusted prevalence of 2.0/1000 95% CI (0.2 to 3.9). I found 
the prevalence of chorea to be 0.45/1000 95% CI (0 to 1.33), with an age adjusted 
prevalence of 0.31/1000 95% CI (0 to 1.04). 
 
4.6.3.2.2 Episodic and Paroxysmal Disorders 
4.6.3.2.2.1 Headache Disorders 
The worldwide epidemiology of headache disorders is only partly documented. Many 
studies have been performed on migraine, but data on tension type headache (TTH), 
the most frequent, are relatively sparse. In addition, most epidemiological studies have 
been performed in high income countries in Western Europe and North America. The 
studies that have come from SSA have variations in methods and diagnostic criteria 
thus it is difficult to extrapolate meaningful results for comparison.  
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This study found the prevalence of headache to be 41.2/1000 95% CI (33.0 to 49.6), 
age adjusted prevalence 41.8/1000 95% CI (33.5 to 50.1).  These were subdivided as 
follows; Migraine; Prevalence 3.6 95% CI (1.1 to 6.1) Age adjusted prevalence 3.8 95% 
CI (1.2 to 6.3). Tension type headaches; Prevalence 16.1 95% CI (10.9 to 21.4) Age 
adjusted prevalence 16.1 95% CI (10.9 to 21.3). Headache secondary to disorders of 
the neck; Prevalence 15.2 95% CI (10.2 to 20.3) Age adjusted prevalence 15.5 95% CI 
(10.4 to 20.7). Trigeminal Neuralgia; Prevalence 0.45 95% CI (-0.43 to 1.33) Age 
adjusted prevalence 0.46 95% CI (-0.43 to 1.35).  
 
The IHS ICHD-2[178] is the international gold-standard  classification for use in 
epidemiological studies to allow comparison of findings and is the standard for 
defining the different types of headaches found in this study. However in order to 
ensure headaches identified were "disabling neurological disorders" and did not as a 
group make the second stage of the prevalence study unfeasible, I also added the 
caveat that headaches had to be recurrent (present in the last year) and had to affect 
the patient’s ability to do their activities of daily living. I therefore did not use the strict 
definition of when a headache becomes a "headache disorder" as defined by the  WHO 
and IHS;  
 "A current or active headache disorder" is one that has been "symptomatic at 
least once within the last year".  
 "A chronic headache disorder" is headaches occurring in patients on 15+ days 
per month. This is often generally called Chronic Daily Headache (CDH) [174, 
178].  
 
Most headache epidemiological studies provide 1-year prevalence estimates, i.e. 
headache occurring during the last year. In some studies, participants were asked 
about headache during their whole life (life-time prevalence). Our study does provide 
1 year prevalence rates however the additional caveats (although informative about 
disabling headache) may have led to lower estimates of the prevalence of headache in 
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this population and as a result complicate comparison with other studies. Diagnoses 
made were purely clinical and although this is a limitation, it is in keeping with most 
epidemiological studies of headache and the recommended management of the 
majority of headache disorders. 
 
Globally, the percentages of the adult population with a current headache disorder 
are; for general headache 46%-75%, migraine 11% (with male to female ratio 1:3, 
apparently hormonally driven), TTH 42% (on average but >70% in some populations 
[181]) and CDH 3% (range 1.0-4%) [174, 180]. Life-time prevalence, are as expected, 
higher: at 66% for general headache, 14% for migraine, 46% for TTH. There are 
differences in prevalence rates in different continents with general headache 
prevalence rates of 50% in Asia, Australia, Europe and North America, but markedly 
lower (20%) in Africa. Migraine is most prevalent in Europe (15%) and least prevalent 
in Africa (5%). TTH appears to be much more common in Europe (80%) than in Asia or 
the Americas (20–30%). CDH has a global prevalence of 3.4% and is most common in 
Central/South America (5%) and least common in Africa (1.7%). These results 
represent work from many different studies with great variations in size, methodology 
and quality and this has not been accounted for [180]. The relative contribution to 
variations in the results of variations in methodology (compared with variations in age, 
gender distribution, race and continent) has been estimated at around 30% [188]. 
 
4.6.3.2.2.1.1 Comparing the SSA studies with those from the rest of the world: All 
headaches 
The prevalence rates of all headaches in SSA vary from 4.7-75%. However the highest 
values of 75% [192] and 51% [194] represent lifetime prevalence, the former in a 
biased sample of students and the latter using the AHC diagnostic criteria. 1 year 
prevalence of 23.7% is reported by Matuja et al [191] but this is in a biased sample of 
students and workers and used the AHC diagnostic criteria.  The lower values 4.7-
23.1% represent 1 year prevalence rates from community populations and are 
therefore more comparable to worldwide epidemiological studies [187, 195, 196]. The 
prevalence of all headaches in this study was 4.2% (age adjusted), this lower value is 
likely to be as a direct result of my definition of headache and may therefore 
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underestimate the morbidity in this area. In Asian and South-American studies with 
comparable methods gave 1-year prevalence rates of all headaches that  ranged from 
28.5 to 78.8% [180]. In European and North-American studies, 1-year prevalence rates 
of headache varied between 13.4 and 87.3% [180]. Headache in general appears to be 
a highly prevalent disorder worldwide, but seems to be least common in Africa. 
 
4.6.3.2.2.1.2 Comparing the SSA studies with those from the rest of the world: TTH 
In SSA 6 studies have recorded the prevalence of TTH [187, 189-191, 195, 205]. Overall 
the prevalence varied from 0.7-35.8%. However there was great variation in the 
methodology precluding easy comparison. 2 of these studies were from clinic 
populations and recorded that TTH accounted for 19-22% of consultations in headache 
clinics [189, 190]. One of the studies was in a pre-selected population observing that 
TTH has a 1 year prevalence of 35.8% in students and workers aged 20-40 [191]. One 
of the studies used AHC diagnostic criteria and did not include subjects with rare 
episodes reported a 1 year prevalence of 0.7% [195]. It is questionable whether 
reasonable comparison between the two classifications is possible. The most 
universally comparable results came from the studies performed by Tekle-Haimanot et 
al. [187] and Winkler et al [205] they reported a 1 year prevalence of TTH of 1.7% and 
7.0% respectively using the IHS criteria, although Tekle-Haimanot's results only 
represented those with CTTH. This study found the prevalence rates of TTH to be 1.6% 
(age adjusted), it is likely that this also represents CTTH and is therefore directly 
comparable with Tekle-Haimanot et al's study, however, my interpretation of the IHS 
criteria complicates comparison and is one of the limitations of my headache data. 
 
South-American and Asian studies have published lifetime and 1-year prevalence rates 
of TTH using IHS guidelines ranging from 12.9 to 66.2% [180]. In Europe and North 
America the following prevalence rates for TTH were calculated: Finland 35% [477], 
Denmark 74% [181], Croatia 34.8% [478], Germany 38.3% (TTH, IHS 2.3: 0.3%; [198] 
and USA 40.5% (ETTH 38.3%, CTTH 2.2%; [180]. It has to be taken into consideration 
that in Croatia [478] and Germany [198] lifetime prevalence were calculated, whereas 
in all other studies 1 year prevalence rates were calculated and this complicates 
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comparison. The prevalence rates of comparable studies in SSA are lower than those 
found in Europe and the USA and Asia and South America.  
 
4.6.3.2.2.1.3 Comparing the SSA studies with those from the rest of the world: 
Migraine 
Migraine patients are said to make up 34.0-42.4% of clinic patients presenting with 
headache in SSA [189, 190]. Migraine community prevalence data from SSA reports 
rates varying from 3.0%-16.7%. However the higher prevalence rates of 7.3, 11.3 and 
16.7 are in student and young adult populations [191, 192, 207]. Those from unbiased 
community populations range from 3.0-6.9%. Those prevalence surveys of migraine 
headache from African countries applying the IHS criteria reported prevalence rates at 
a low level ranging from 3.0% in Ethiopia [187] up to 4.3% in northern [205] and 5.0% 
in southern Tanzania [196].  
 
It is possible to compare the prevalence rates from SSA with those from the rest of the 
world, however most of the prevalence rates presented from SSA are not age adjusted. 
Winkler et al [205] did however age adjust their figures to the world standard to allow 
ease of comparison, this also demonstrates the difference this calculation makes as 
their rates increased from 4.3% to 6.0% using the WHO world standard [462]. Those 
studies that calculated 1 year prevalence using the IHS criteria for migraine from 
Europe and North America had results ranging from 9.5% in the USA to 17.0% in 
Sweden[199, 479-484]. Even after excluding children and adolescents from the African 
studies and age adjusting where possible the prevalence rates are still lower in SSA 
than in the west.   
 
This study found the age adjusted prevalence of migraine to be 0.4%, this is likely to 
represent the age of the population studied, with the majority of migraineurs possibly 
dying prior to reaching old age, this is discussed in more detail below. In addition the 
definition of headache used may underestimate the morbidity migraine represents to 
our population. However if someone truly suffers from migraine it is likely that it is 
recurrent and will affect the patient's ability to perform their activities of daily living.  
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4.6.3.2.2.1.4 Comparing the SSA studies with those from the rest of the world: 
Causation 
It is mostly speculation that informs us why rates of headaches in Africa do appear to 
be lower than the rest of the world, despite methodological differences in 
epidemiological studies. The following factors appear to play a part; 
 
Stewart et al. [199] performed a meta-analysis of 23 studies and a linear regression 
model. They found that 70.6% of the variation in headache prevalence could be 
explained by sex and age. Since the highest incidence of migraine is observed in the 
third and fourth decades of life a substantially younger population is often represented 
in African studies and a large proportion of ‘future migraineurs’ might not survive past 
childhood. Therefore, where possible population structures should be taken into 
account when comparing migraine prevalence in Africa and western countries, 
however in very few of the African studies are age adjusted prevalence rates 
presented [196].  
 
Headaches may be perceived as less important in rural Africa and recall of headaches 
may be less reliable. This could be the consequence of higher pain thresholds, or the 
fact that headache is less noticed or perceived as a normal occurrence. In the majority 
of African studies it was the head of the household who was the main informant of the 
presence of headaches and to report what might be perceived to be minor ailments to 
the household head may be deemed unacceptable in this culture. In short it may be in 
SSA that the socio-economical weight of other diseases makes it culturally 
unacceptable to mention headaches. 
 
Genetic differences may explain variations, especially with regard to migraine. In 
western studies racial differences are found in prevalence with higher rates found in 
Whites compared with African Americans [199, 484, 485]. Stewart et al (1996) 
compared the prevalence of migraine among Caucasians, African Americans, and Asian 
Americans in the United States in attempt to determine if differences among races 
reported in international prevalence studies are as a result of cultural, environmental, 
or methodological factors or if also present in one standard multi-race population, are 
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actually due to genetic factors. The authors conducted a large study of 12,328 
randomly selected individuals in Baltimore County, Maryland aged 18-65 they used 
telephone interview only. Migraine diagnoses were assigned using International 
Headache Society criteria. In women, migraine prevalence was significantly higher in 
Caucasians (20.4%) than in African (16.2%) or Asian (9.2%) Americans. A similar pattern 
was observed among men (8.6%, 7.2%, and 4.2%). African Americans were less likely to 
report nausea or vomiting with their attacks, but more likely to report higher levels of 
headache pain but less disability. While differences in socioeconomic status, diet, and 
symptom reporting were not taken into account and may contribute to differences in 
estimated prevalence (especially if those of African descent are less likely to see their 
migraine as disabling and are less likely to report classic features to aid diagnosis), the 
authors suggest that race-related differences in genetic vulnerability to migraine are 
more likely to predominate as an explanatory factor. It is thought that inherited factors 
may influence susceptibility to migraine such as variation in neurotransmitter 
metabolism and receptors [485]. Stewart et al[199] suggested that the higher platelet 
level of the tyramine conjugating enzyme phenolsulfotransferase in African-Americans 
compared with Whites may protect against migraine by metabolizing suspected 
dietary triggers.  
 
Environmental factors may also have a role, the exposure to environmental triggers for 
migraine, particularly dietary factors may be less in SSA.  
 
It is likely that lifestyle factors have a particular role in the type of headaches found in 
my study population. There were a significant number of people with headaches 
secondary to disorders of the neck 1.6% (age adjusted) and this is likely to represent 
the impact of years of manual labour and carrying heavy objects on their heads. 
Unfortunately there is no similar data published for comparison. 
 
In summary environmental factors, genetic differences or cultural diversity in the 
reporting of pain may explain the apparent difference in headache susceptibility in 
African and Western countries, and should be the topic of future research [205] 
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Outside these factors prevalence differences could be explained by varying sampling 
methods and diagnostic criteria.  
 
4.6.3.2.2.1.5 Gender Specific Prevalence rates 
All headaches and more specifically migraine and TTH have found to be more common 
in women than men in SSA [191, 195, 196, 205] and the rest of the world[481, 486-
492].  The male to female ratio of the prevalence of migraine is 1:3 in studies from 
both SSA and the rest of the world [196, 205]. Reasons for this are unclear but the 
influence of hormones has been suggested [181]. 
 
4.6.3.2.2.1.6 Age Specific Prevalence rates 
The age-specific peak prevalence rate of all types of headache was found in the fifth 
decade of life in 2 studies from Tanzania [196, 205] and one study from Puerto Rico 
[488]. Other studies have shown peak prevalence rates at younger ages [186, 194, 195, 
481, 490, 492].  
 
Looking more specifically at TTH, Rasmussen et al[181], reports a decrease of 
prevalence rates of TTH with increasing age. A peak of TTH between 20 and 55 years 
has been reported in other studies [186, 205, 477, 487, 493-496]. I found the 
prevalence rate of overall TTH increased with increasing age in both genders this is in 
agreement with studies from Saudi Arabia and Singapore where more TTH was found 
in elderly people [486, 497]. However, results of these studies refer to lifetime 
prevalence and could be explained as cumulative effect with increasing age. Winkler et 
al [205] conclude that in Tanzanian rural communities TTH is a disease of elderly 
people. This indicates that the prevalence of TTH is potentially underestimated in our 
study, which is likely due to the diagnostic criteria used. 
 
When considering migraine headache prevalence, rates increase rapidly after puberty 
with a peak between 30 and 60 years in women and 25 and 40 years in men. 
Subsequently, migraine prevalence decreases with age. A minimum of migraine 
sufferers has been reported in children and in the elderly [206]. This is in agreement 
with the low prevalence rates found in our study. 
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4.6.3.2.2.1.7 Difficulty in comparing African studies with the rest of the world's data 
As already discussed it is very difficult to compare prevalence results from the SSA 
studies with the rest of the world's data. Problems include differences in classification 
and case definition, variations in time periods for prevalence study methodology and 
population samples as well as the influence of socio-demographic and psycho-social 
factors [205]. 
 
4.6.3.2.2.1.8 Limitations of African work in general 
The information recorded above has demonstrated how limited data from SSA is on 
the prevalence of headaches and how difficult it is to compare prevalence rates with 
the rest of the world. Firstly there is a very small number of studies carried out in only 
6 countries. A major problem inherent to these studies is the use of different headache 
classifications. Very few series used the Diagnostic Criteria and Classification of the IHS, 
the established gold-standard [187, 196, 204-206]. Often they have been limited to 
small and narrowly defined samples, such as students or clinical cases [189-192]. More 
studies are needed that focus on the general population and use the IHS criteria. My 
study may have added to the data on headaches from SSA in the elderly, however 
extension of the diagnostic criteria used does limit easy comparison and potentially 
underestimates the impact of headache on the elderly population when interpreted at 
face value. 
 
4.6.3.2.2.1.9 Headaches in the elderly  
Stovner et al's recent review article highlight's the five prevalence studies that have 
been performed to describe headaches specifically in the elderly. Two were performed 
in low income countries in Asia, whereas the remaining 3 were performed in high 
income countries in Europe and North America. They focussed on the age range of 65 
years and over, with the exception of the Thai study which examined the over 60 
population [498]. These studies represent the studies performed in the elderly 
community population worldwide, they contain potentially comparable data to my 
own. The features of these studies are presented below;
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Table 4.2: The Prevalence of headaches in the elderly worldwide 
Country  
1st author 
year ref 
Population Diagnost
ic 
criteria 
used 
Method 
 
N Age 
year
s 
Prevalen
ce period 
Headache 
prevalenc
e 
% 
Migrain
e total 
% 
Classic
al 
(with 
aura) 
% 
Commo
n 
(withou
t 
aura)% 
TT
H 
% 
Chronic 
headach
e % 
China 
Wang  
1997 
[499] 
Community 
rural 
his Persona
l 
Intervie
w 
153
3 
65+ 1 year 38.0 3.0    3.9 
Thailand  
Srikiatkhac
ho 
1991 
[498] 
Instituationalis
ed elderly 
? Persona
l 
Intervie
w 
241 61+ 1 year 54.8      
Italy  
Prencipe  
2001 
[500] 
Community 
rural 
his Persona
l 
Intervie
w 
833 65+ 1 year 51.0 
(some 
participan
ts had 
migraine 
and TTH) 
11.0   44.
5 
4.4 
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Italy 
Camarda 
2003 
[501] 
Community 
rural 
IHS Persona
l 
Intervie
w 
103
1 
65+ 1 year 21.8 4.6   16.
0 
 
USA 
Cook 
1989 
[502] 
Community 
rural 
? Persona
l 
Intervie
w 
381
1 
65+ 1 year 45.0      
IHS: International Headache Society, All prevalence rates are crude unless otherwise stated  
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These studies support my conclusions that TTH was more problematic in the elderly 
population than migraine. 
 
4.6.3.2.2.1.10 Discussion of the Headache literature in Summary 
At least half of the world’s population lives in countries where headache burden is 
partially or completely unknown. Headache burden is thought to vary considerably 
worldwide due to genetics, climate, socioeconomics, lifestyle and co morbidities. This is 
suggested by current studies but methodological problems and variation in cultural 
attitudes to headaches complicate interpretation. The WHO state it is a priority to 
document prevalence worldwide accurately using gold-standard methods and the IHS 
diagnostic criteria. I hope that my study does add to the available data on the prevalence 
of headache in the elderly population but recognise its limitations particularly with 
relation to the exact definition of headache used. It does however reinforce that TTH is 
more problematic than migraine in this age group and that headaches secondary to 
musculoskeletal pathology need to be considered and managed in populations where 
manual labour is the predominant occupation. 
 
Headache disorders are prevalent, disabling and largely treatable, but under-recognized, 
under-diagnosed and under-treated. Headache burdens, both individual and societal, 
persist with financial costs to society through lost productivity far outweighing any health-
care expenditure required to be spent in any country. Health care for headache must be 
improved, to include supply of medications, improvement of services and very importantly 
education at multiple levels to achieve this.  
 
4.6.3.2.2.2 Stroke 
The prevalence of stroke worldwide is said to range from 0.5% to >1% in those aged over 
65 years in developed countries. Generally the prevalence in SSA is reported to be half 
that of developed countries, however with demographic transition this is thought to 
change [56, 503]. 
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My crude prevalence rate of stroke was 24.2/1000 95% CI (17.8 to 30.6) and the age 
adjusted prevalence was 23.0 95% CI (16.8 to 29.2). They are lower than in equivalent age 
groups in developed countries, we can speculate that this is due to an increased mortality 
rate; the recently updated Global burden of disease study estimated that over 80% of 
stroke deaths  occur in low-income and middle-income countries [215, 216, 389].  
 
My prevalence rates are relatively high for SSA, and I feel to a certain extent this reflects 
the robust methodology used and the good case ascertainment that resulted. Worthy of 
note is that I identified all cases previously identified from stroke incidence and 
prevalence studies in the Hai District DSS [34, 213]. Improved case ascertainment may 
have also have resulted from the education of the community with regard to stroke this 
could have resulted from these two previous epidemiological surveys. As a result of these 
factors it may be that our estimate offers a more accurate reflection of the prevalence of 
stroke in this setting than some previous studies. It is important to recognise however that 
the main reason for our higher prevalence rates is likely to be due to the elderly nature of 
the population studied. 
 
It is worth reflecting that many reported stroke prevalence rates represent previous 
stroke with or without residual deficit. Our study specifically looked for previous stroke 
with residual deficit given the notorious inaccuracy of a patient’s history in this setting. 
This does however have the potential to complicate comparison with other studies by 
underestimating stroke prevalence and the potential short term burden of stroke in those 
that subsequently recover from their symptoms and signs. It does however reflect the 
true burden of long term disabling stroke in this community. 
 
My prevalence rates are compared with the current literature in more detail below, 
specifically population-based studies from SSA that investigated the prevalence of all 
types of stroke, recent publications specific to stroke in the elderly population and 
worldwide review articles. Stroke prevalence studies, particularly in demographic 
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surveillance sites with a known denominator population, have arguably provided the most 
accurate and up-to-date measures of stroke burden in SSA. It is however important to 
recognise their limitations which include problematic retrospective diagnosis, 
underestimation of burden because of case fatalities and confusion with co morbidities 
such as arthritis and dementia, and methodological differences complicating worldwide 
comparison. The methodology used in this study is the gold standard for documenting the 
prevalence of stroke in low income countries and therefore the data is reliable, this is not 
the case for many studies performed.  
 
Many studies from high income countries now report incidence (methodology that is 
difficult to perform in SSA) and this further complicates data comparison.  
 
The surveillance of stroke prevalence in SSA began in the 1980s, with landmark studies in 
Nigeria and Ethiopia. In Nigeria and Ethiopia the prevalence was found to be between 15-
68.4/100,000[3, 5, 25, 99]. There were two main limitations of these studies. Firstly their 
size, which at initial review appear more than adequate, but when one considers that 
typically 44% of the population in SSA was less than 15 years old [216] then the 
representation of the older age groups (those predominately affected by stroke) is limited, 
this particularly complicates any comparison to my data. Secondly the diagnostic criteria 
or even the types of stroke sought was not detailed, therefore conclusions on the 
accuracy of diagnoses are difficult to make. The low prevalence rates are likely to reflect, 
low stroke incidence that results from a young population that died before they were 
affected by stroke disease and high case fatality from stroke and therefore failure to 
detect cases.  
 
Walker et al [34] performed the largest study (n=148 135) to date of the prevalence of 
stroke in SSA in the Hai district DSS (the study population that is the focus of this thesis). 
The authors limited their study to only detect disabling hemiplegic stroke, which although 
practical, limits the comparability of the data with the rest of the world and with my data. 
The crude prevalence of stroke in the whole population was 73/100,000. Age 
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standardisation was performed to the Segi world population, it gave  prevalence of 
disability resulting from stroke of 154/100 000 in men and 114/100 000 in women over 15 
years of age. The crude prevalence rates for those aged 65 and over were 876/100,000 
(975/100,000 for men and 786/100,000 for women). My prevalence rates 2300/100,000 
were significantly higher, probably because our population were slightly older (aged 70 
years and over), Walker et al found the median age of patients was 70 years old and the 
median age at first stroke was 65, which suggests that studying even a slightly older 
population would have a significant impact. The difference could also be explained by my 
methodology that detected all types of stroke. Walker et al concluded that prevalence of 
disabling hemiplegic stroke was low in comparison to high income countries (age 
standardised rates for stroke with residual disability was approximately half found by 
previous studies in high income countries), they felt this was mainly explained by the age 
structure of the population with <6% of participants being aged 65 and over. Mortality 
rates may have also been higher. 
 
The Southern Africa Stroke Prevention Initiative (SASPI) team [219]performed a very 
similar study to Walker et al in rural South Africa. The age adjusted prevalence of 
hemiplegic stroke was 290/100 000 in people over the age of 15 years. The crude 
prevalence of those aged 65 years and older was 1490/100,000, more in keeping with my 
prevalence rates. 
 
Gradual health transition might explain difference in the prevalence of stroke in these 
most recent robust prevalence studies from SSA, in comparison to each other and in 
comparison to older studies. Firstly the lifestyle risk factors of South Africans may be 
higher than Tanzanians, stroke risk factors have recently been shown to be common in all 
population groups in South Africa [220]. Secondly Tanzanians may have a higher case 
fatality than South Africans in rural areas.  
 
The age-standardized prevalence of stroke in high-income countries was reported in a 
recent review to range from 461 to 733/100,000. The largest of these came from 
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Auckland, New Zealand, where age adjusted prevalence of stroke was found to be 
833/100,000 [221]. 
 
The prevalence of stroke in Tanzania is half that of South Africa which is in turn a third of 
that found in Auckland. Methodological differences cannot be excluded as an explanation 
of the differences.  The Auckland Stroke Study followed on from incidence studies and 
therefore probably recorded mild strokes which would not have been picked up by either 
of the SSA studies. However both sub-Saharan African countries may have a lower 
prevalence of stroke when compared with New Zealand, because of a lower incidence of 
stroke and higher mortality and case mortality [216].  
 
Cossi et al's[223] study from Benin is the most up-to-date well designed stroke prevalence 
study from SSA. The authors demonstrated age adjusted prevalence rates of 870/100,000, 
higher than ever previously recorded in SSA which highlighted the increased burden that 
stroke represents. The mean age of the patients at onset was 56 +/- 13 years. 
 
The prevalence of disabling stroke in sub-Saharan Africa has also been reported by the 
studies described above and this has been found to be at least as high as in high-income 
areas. This potentially indicates that the low overall prevalence of stroke (just under half 
that found in high income regions) may reflect that non-disabling strokes are not 
identified easily by epidemiological surveys in SSA. 
 
Community based incidence studies with follow-up are required to determine whether 
the low overall prevalence of stroke results from low incidence or high case fatality or a 
combination of the two. As risk factors for vascular disease increase, and the populations 
age, so the burden of vascular disease will certainly increase in SSA. Indeed, without 
intervention, stroke and heart-disease-related deaths in developing countries are 
expected to increase from 3 million in 1998 to 5 million in 2020 [216]. The burden of 
stroke is likely to become epidemic unless interventions are put in place. 
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4.6.3.2.2.3 Epilepsy 
This study found the crude prevalence of epilepsy to be 4.5/1000 95% CI (1.7 to 7.3) and 
the age adjusted prevalence to be 4.4/1000 95% CI (1.7 to 7.2). These rates are lower than 
the majority of reports from the whole population in low income countries and more in 
keeping with reports from high income countries. It is likely that this reflects  the burden 
of epilepsy in low income countries which still remains in childhood and early adulthood 
rather than in the elderly as a result of high mortality. However  as the population in 
developing countries continues to age this part of the community will contribute more to 
the epilepsy morbidity burden, especially with the increased survival from conditions that 
predispose to epilepsy, such as stroke disease. 
 
The prevalence of active epilepsy in people of all ages from Europe and North America is 
5–8 per 1000 [318]. Higher rates have been reported in studies from Asia, South and 
Central America and particularly from SSA. The median prevalence of epilepsy in SSA has 
been reported as 14-15/1000 with an inter-quartile range of 10-21 [294, 295].That is not 
to say that the rates were consistent, rates were highly varied from 2.9 to 75 per 1000, 
higher rates were seen in children and young adults, rural areas, and studies with small 
population sizes and older studies. Therefore, the prevalence of epilepsy in the whole 
population of sub-Saharan Africa cannot be generalised [294]. Relative contributions of 
causes of epilepsy are difficult to determine given the limited case-control data, however 
it is suggested that infections particularly cysticercosis, cause the majority of cases. As 
populations age non-infective causes such as stroke disease will start to make an impact 
[294, 295]. 
 
Prevalence estimates vary widely from country to country in SSA. This may be false and 
due to methodological problems or it could be true. I have had to consider these "false 
factors" when interpreting my results and comparing them with other studies and so the 
strengths and limitations of my study design are highlighted. 
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4.6.3.2.2.3.1 False Factors 
 
4.6.3.2.2.3.1.1 Generalised Methodology 
There are many estimates of the burden of epilepsy using hospital based studies, including 
2 recently published in northern Tanzania by the same group of authors. They conclude 
that epileptic seizures account for 3% of all hospital admissions, 27% of neurological 
diagnoses [299] and febrile seizures and epileptic seizures account for 20.6% and 13.9% of 
admissions with impairment of consciousness respectively[300]. These cannot however 
represent true prevalence given the majority of the population in low income countries do 
not present to hospital for reasons related to geography, finance and health beliefs. 
Comparison to my prevalence figures is impossible. 
 
Preux and Druet-Cabanac's 2005 review[294], only looked at door-to-door surveys, 
acknowledging any methodology, other than this gold-standard, will lead to misleading 
results, the authors observed that studies with data from only medical registries or 
passive ascertainment systems gave lower estimates and a falsely reassuring picture of 
the true burden of disease.  
 
My study used mostly the 2 phased epidemiological approach and to add to the robust 
nature of the prevalence data, multiple other case finding methods were used as 
suggested by Preux and Druet-Cabanac [294] and Debrock et al [302] when performing 
epilepsy surveys. Unfortunately it was not possible to perform the capture-recapture 
method which may have ensured the data was even more complete.  
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4.6.3.2.2.3.1.2 Under-reporting due to stigma 
The Stigma related to epilepsy adds an extra complexity to the derivation of accurate 
prevalence data as this prevents patients coming forwards even when directly questioned.  
This is particularly true when surrogates are questioned such as the head of the household 
and therefore this was avoided in my study [295, 319, 320]. 
 
4.6.3.2.2.3.1.3 Screening tools used 
Most studies that have been performed have focussed on convulsive epilepsies[295], 
given the ease to which surveys can reliably detect them and the increased morbidity that 
they represent to the patient. Unfortunately as a result there are limited accurate 
estimates of non-convulsive epilepsies (difficult to accurately detect through simple 
questioning and clinical examination alone) and reported prevalence rates should be 
accepted to underestimate the true burden of disease. This exclusion of non-convulsive 
seizures (along with under-reporting levels secondary to stigma) is said to underestimate 
the prevalence of epilepsy by two to four times [295, 319, 320].This is true of my study 
and the majority of studies reported from SSA. 
 
There are standardised questionnaires (the Limoges questionnaire) for the accurate 
collection of epilepsy prevalence data. However unfortunately given their time consuming 
nature and that my study focussed on all neurological disorders rather than just epilepsy, 
it was not possible to use this questionnaire for my study. Unfortunately this limits the 
comparability of my results with some of the robust studies from SSA, namely those from 
Benin [302, 308], Burkina-Faso [303], Burundi [304], Cameroon [305],  Mali [504],  Central 
African Republic [307].  
 
4.6.3.2.2.3.1.4 Classifications used 
The use of different terminologies to classify seizures and epilepsy also hinders study 
comparison and with this in mind my study utilised the standard ILAE classification [294, 
295]. 
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4.6.3.2.2.3.2 True Factors 
 
4.6.3.2.2.3.2.1 Different samples of populations studied and risk factors 
Consistent findings from epidemiologic studies of epilepsy in developing countries 
including SSA indicate that the prevalence is higher in rural than urban areas of the same 
country [323, 324]. The higher prevalence of epilepsy in rural areas might be caused by an 
increase in the incidence of risk factors. However, many people who develop epilepsy do 
not migrate to urban areas for work, or if they do develop epilepsy whilst in urban areas, 
individuals might lose their jobs and return to their rural homes [351]. 
 
In some sub-Saharan Africa areas, the consanguinity is reported to be very high e.g. some 
areas in Mali, 96% [504]. The stigmatization of PWE potentially forces them to intermarry 
thereby increasing the genetic transmission of epilepsy and prevalence rates in pockets of 
the community. 
 
Ngugi et al[331] quantify that over 50% of the variation in the global estimates of the 
lifetime prevalence of epilepsy can be attributed to the differences between studies in 
rural and urban areas, between children and adults, and in the size of the denominator in 
the study  
 
The prevalence of epilepsy has been observed to be variable in the same country and 
ethnic community, even when the same methodology has been utilised. Two Nigerian 
studies, used the same protocol to investigate two population groups from the same 
community living 20 km apart. They observed very different results 5.3/1000 in Igbo-Ora 
[25] and 37/1000 in Aiyété [327]. The researchers felt this highlighted the impact of risk 
factors on prevalence particularly sanitary conditions, neonatal infections and birth 
trauma. In contrast the prevalence may be very similar, as observed in Togo [314, 328-
330] 
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The true prevalence of epilepsy in SSA is still hotly debated. A few large-scale studies 
showed prevalence nearer that found in industrialised countries and this is in line with my 
own findings. The question is: have these studies underestimated the prevalence because 
of non-ascertainment of cases or are the smaller scale studies misleading and represent 
genetic influences of inbreeding and consanguinity, consequences of specific aetiological 
factors or over inclusion of provoked seizures. There is also the possibility that the 
discrepancy lies in factors specific to different geographic zones in sub-Saharan Africa. In 
the case of my study the discrepancy is likely to be purely related to the age of the 
population studied [294]. 
 
The section below discusses the recent prevalence studies in SSA in more detail and  
demonstrates what meaningful conclusions can be drawn from their data compared to my 
own: 
 
Edwards et al [319] performed a very robust and large scale study of the prevalence of 
epilepsy in a poor rural area on the coast of Kenya. They assessed those people aged 6 
years and older of which only 3% of the population were aged 65 or older. Thus  their 
population is not directly comparable with the population I studied. Limitations of the 
data presented include use of a surrogate (the head of the household was questioned) 
and the lack of validation of the screening questions in adults. Strengths include the 
robust study design, verification of diagnosis by neurologists and use of the ILAE 
classification, all which allow direct comparison to my data.  
 
The authors reported the prevalence of active convulsive epilepsy and therefore non-
convulsive seizures were excluded from the prevalence figures. Although this is generally a 
limitation it allows comparison to my prevalence rates which were very similar. The 
overall crude prevalence of active convulsive epilepsy was 2·9 per 1000 (95% CI 2·6–3·2); 
after adjustment for non-response and sensitivity of the questionnaire, prevalence was 
4·5 per 1000 (4·1–4·9). The prevalence of those aged 50 and over was 2.1 (95% CI 1.7-2.7). 
Age adjusted prevalence rates were not presented.  
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Hunter et al [333] present the findings from their very large 2009 community based 
prevalence study performed in the same demographic surveillance site as is the subject of 
this thesis. Robust methodology supports their conclusions, although there were a 
number of limitations that the authors acknowledge; strengths and weaknesses of the 
study are described below: 
 
The authors utilised a previously validated questionnaire and validated it further in a small 
Tanzanian hospital population, it achieved  a sensitivity of 100% and specificity of 54.5%. 
A large and unbiased adult population of 103,026 were assessed with the gold standard 2 
phased methodology. Additional case finding methodology was also used to pick up cases 
which adds to the validity of the prevalence rates but calls into question the sensitivity of 
the questionnaire as a further 82 cases were found in this way. 
 
ILAE classification was used,  directly comparable with my data and use of CT, MRI, and 
verification by neurologists added to the robust nature of each diagnosis.  
 
The age-standardised prevalence (to the WHO standard population allows ease of 
comparison) of convulsive epilepsy was 2.91/1000 adults (95% CI 2.58–3.24); the crude 
prevalence adjusted for non-response was 3.84/1000 adults (95% CI 3.45–4.20). 
The crude prevalence of those aged 60 years and older was found to be 1.17/1000 (95% CI 
0.66-1.68) Unfortunately the authors were not able to assess nearly one third of those 
who responded positively to the screening questionnaire, an inability to trace these 
individuals may be related to stigma and may indicate why the prevalence rate presented 
is lower than the majority of studies from SSA and specifically in the older age groups 
lower than I found in my study. 
 
Prevalence rates of epilepsy were reported recently from 3 villages in Burkina Faso from a 
study conducted in 2007 of 888 individuals aged 7 years and over [335]. However due to 
the rather flawed methodology the results need to be interpreted with caution. The 
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selection of villages was based on pig rearing practices and hearsay that the villages had a 
high prevalence of epilepsy and therefore the authors admit that the prevalence rates 
may not represent that from the rest of the country. 
 
The authors used a previously validated questionnaire (however it was not adapted for or 
validated in this community) and the ILAE criteria for diagnosis. However diagnoses were 
not verified by a neurologist. 14/70 people who screened positive were not examined by 
the physician for various reasons, thus cases may have been missed. The prevalence of 
epilepsy was 4.5% (95% CI 3.3%-6.0%). The prevalence of active epilepsy was 3.9% (95% CI 
= 2.8%; 5.4%). The authors acknowledge that their estimates are higher than those 
reported in Burkina Faso study in 1993 (1.1%; 95% CI 0.9%-1.2%). The methodology of this 
study was more robust, it involved random selection of 18 villages in 2 provinces and 
therefore it may be that the former study's prevalence figures are more representative of 
the entire country. However it may also be that there is a true difference in prevalence of 
epilepsy between the investigated areas and over the nearly 20-year difference between 
the studies. 
 
As described above the key limitations of the studies by myself, Edwards et al[319], 
Hunter et al[333]and Nitiema et al[335] that hamper comparison with other findings are 
the exclusion of people with non-convulsive epilepsy (non intentionally in the case of 
Hunter et al). In high income countries partial epilepsies (with focal onset) are more 
common than generalised onset epileptic disorders or account for at least 50% of all 
epileptic disorders [320, 334]. If this pattern also applies in Africa an estimated total 
prevalence would be 6-10 per 1000 population.  
 
Winkler et al [315] performed a study of 7,399 people reporting the prevalence of 
epilepsy in rural Tanzania, they used unbiased methodology. Strengths included use of a 
validated questionnaire with high sensitivity and specificity, the use of ILAE criteria and 
verification of diagnoses by a neurologist. The prevalence rate was age standardised to 
the WHO standard population and was 13.2/1,000. The prevalence rate of active epilepsy 
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was 9.1/1,000. The crude prevalence rate of active epilepsy for those aged 55+ was 
6.0/1000. 
 
Crepin et al [308] performed a well executed community prevalence study in amongst 
11,668 individuals in a rural area of Benin. A questionnaire (the Limoges) validated for 
epilepsy in tropical countries was used but it was not validated further in this specific 
population. The entirety of a population was screened with a 94% ascertainment so no 
bias was produced through sampling errors. The initial screen was performed by trained 
local physicians and confirmation of cases in the second phase was performed by a 
neurologist. Final diagnosis was purely clinical but took into account a collateral history 
and internationally recognised criteria. All types of seizures were included adding to the 
comparability of their results. The prevalence of epilepsy was found to be 12.7/1000; 95% 
CI: 10.8 – 14.8. The median number of seizures per year was 12. Both the high number of 
seizures per year and the fact that the majority of the cases were convulsive indicates that 
the prevalence of epilepsy may have been underestimated.  
 
4.6.3.2.2.3.2.2 Age and epilepsy 
There is a marked difference in the age of onset of epilepsy in low income countries in 
comparison to high. The latter has a bimodal distribution [316] with peaks of incidence in 
childhood and those aged over 65. In the former it is generally understood that incidence 
is increased in children and young adults. Age at seizure onset is reported in a few studies 
but is usually susceptible to recall bias. When available, seizure onset was before age 20 
years in more than 60% of cases. This young incidence results from infection and trauma. 
However it is worth noting especially for this thesis with its focus on the older population, 
that studies in the older age groups from SSA are limited. As the population of developing 
countries continues to age and the prevalence of NCDs such as stroke increases as will the 
burden of epilepsy in these age groups, again demonstrating the impact that the "double 
burden" of disease will have on SSA [25, 295, 311, 327, 341]. This data explains why my 
prevalence figures are difficult to compare with other prevalence figures available.  
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4.6.3.2.2.3.2.3 Prevalence potentially underestimates burden due to high mortality from 
epilepsy 
The mortality associated with epilepsy in low-income countries is substantially higher than 
in high-income countries. Mostly this is felt to be a consequence of untreated epilepsy 
resulting in falls or status epileptics. However this is another under-researched area [295]. 
This could explain the relatively low prevalence rates found in my study as the majority of 
those with epilepsy may have died before reaching old age.  
 
4.6.3.2.2.3.3 Discussion of the epilepsy literature in summary 
In conclusion my prevalence rates are similar to those found by other authors in SSA who 
have performed similar robust studies. The main limiting factor for direct comparison is 
the age of the individuals I studied along with the identification of only convulsive 
epilepsies and the small numbers of cases identified in association with the modest 
sample screened. In general reports of the prevalence of epilepsy are highly varied and 
need to be interpreted in the context of the methodology used.  
 
4.6.3.2.3 Systemic Atrophies/Degenerative Diseases affecting the Central Nervous 
System 
4.6.3.2.3.1 Motor Neurone Disease 
Studies in developed countries reveal a prevalence of 0.6 to 1.0/1000 [46, 155]. Studies in 
SSA have demonstrated a prevalence of 0.05 to 0.15/1000 but they are dated and their 
methodology is questionable [3, 5]. My crude prevalence was 0.90/1000 95% CI (0 to 2.14) 
and the age adjusted prevalence was 0.96/1000 95% CI (0 to 2.25). This is in keeping with 
this limited number of studies but the conclusions that can be drawn are limited by the 
size of the main study population and the fact that there were only 2 patients found. 
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4.6.3.2.4 Injury resulting in CNS dysfunction 
4.6.3.2.4.1 Spinal Cord Pathology 
There are very few community data regarding the prevalence of spinal cord pathology in 
SSA. Tekle-Haimanot et al report that post traumatic spinal cord pathology has a 
prevalence of 0.03/1000 but this was published in 1988 [5]. All other studies are hospital 
based and therefore it is difficult to extrapolate meaningful results that reflect the disease 
burden in the community. My crude prevalence rate was 2.2/1000 95% CI (0.3 to 4.2) and 
our age adjusted prevalence rate was 1.9/1000 95% CI (0.1 to 3.7). 
 
4.6.3.3 Peripheral Nervous System Disorders 
4.6.3.3.1 Polyneuropathies 
Early prevalence studies from developed countries report rates anywhere between 5.5 to 
16.4/1000 [399, 505]. A more up to date review article by Hughes et al in 2001 reports 
prevalence rates between 24 and 80/1000 and states that prevalence increases with age 
[506]. Mold et al performed a prevalence study in the US community with general practice 
records in 2000. They looked specifically at the older age groups stating that the 
prevalence was 310/1000 in those aged 65 and over. The prevalence did increase with 
age, with 260/1000 affected between the ages of 65 and 74, 360/1000 between the ages 
of 75 and 84 and 540/1000 for those aged 85 years and older [507].  
 
The data from developing countries is not as comprehensive. Community studies from 
Ethiopia and Nigeria are dated but reveal rates of 1.5 and 2.1/1000 respectively [3, 5]. A 
community based study from India in the 1990s reported a prevalence of 23.84/1000 
[508]. Variation may be due to methodological and diagnostic criteria. 
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Evidently the prevalence rates vary widely. My crude prevalence rate of 18.8/1000 95% CI 
(13.2 to 24.5) and age adjusted rate of 18.6/1000 95% CI (13.0 to 24.2) is in the middle of 
these figures. Methodology, diagnostic criteria and causative factors may all explain the 
wide differences. We did not include patients with “tingling” or paraesthesia alone and 
stated that they needed to have a loss of at least one modality of sensation for diagnosis. 
This allowed simple clinical confirmation of the diagnosis using examination techniques. 
To Include patients with paraesthesia alone relied on histories and was open to error due 
to translation difficulty. In Swahili there are limited words for symptoms and paraesthesia 
or tingling can often be reported when the patient actually means pain. 
 
4.6.3.3.2 Nerve, Nerve root and plexus disorders 
The prevalence of Bells palsy in the literature is reported as between 0.13 and 1.2/1000 
[5, 46]. The prevalence of peripheral nerve lesions is reported as anywhere between 0.62 
to 144/1000 depending on the diagnostic criteria with the higher figure reflecting even 
mild symptoms of carpal tunnel syndrome in a community population [3, 46, 155, 509, 
510].  
 
The prevalence figures I found are as follows and are in keeping with the current 
literature. Cranial nerve pathology had a crude prevalence of 6.3/1000 95% CI (3.0 to 9.6) 
and an age adjusted prevalence of 5.7/1000 95% CI (2.6 to 8.8). Upper limb 
mononeuropathies and polyneuropathies had a crude prevalence of 6.3/1000 95% CI (3.0 
to 9.6) and an age adjusted prevalence of 5.7/1000 95% CI (2.6 to 8.8). Lower limb 
mononeuropathies and polyneuropathies had a crude prevalence of 2.2/1000 95% CI (0.3 
to 4.2) and an age adjusted prevalence of 2.4 95% CI (0.4 to 4.4). Plexus pathology was 
seen in 1.8/1000 95% CI (0.04 to 3.6) with an age adjusted prevalence of 1.9 95% CI (0.09 
to 3.7). Root pathology had a crude prevalence of 1.8/1000 95% CI (0.04 to 3.6) and an 
age adjusted prevalence of 1.7 95% CI (0.00 to 3.4).  
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4.6.3.3.3 Inflammatory/infectious diseases of the peripheral nervous system 
4.6.3.3.3.1 Polio 
The prevalence of poliomyelitis resulting in disability obviously depends on geographical 
location and age of the population screened (there is a significant impact from vaccination 
programmes) but is quoted as between 0.15 to 3.1/1000 [3, 5, 46, 511]. 
 
In my population LMN developmental disorders, including polio, had a crude prevalence 
of 2.2/1000 95% CI (0.3 to 4.2) and an age adjusted prevalence of 2.4 95% CI (0.4 to 4.4). 
 
4.6.3.3.3.2 Leprosy 
I saw one case of residual neurological deficit as a result of leprosy. The crude prevalence 
was therefore 0.45/1000 95% CI (0.00 to 1.33) and the age adjusted prevalence was 
0.48/1000 95% CI (0.00 to 1.38). Prevalence varies greatly worldwide as a result of 
eradication programmes that are continuing to be successful.  The latest figures from the 
WHO 2009 global registry quote rates of 0 to 0.2/1000 for Tanzania. These are however 
for active cases and not residual deficit from cases that have been cured which was the 
case for my patient [512-514].  
 
4.6.3.3.4 Diseases of the myoneural junction and muscle 
4.6.3.3.4.1 Myaesthenia Gravis 
There was 1 person in the main study population with Myaesthenia Gravis. The crude 
prevalence was therefore 0.45/1000 95% CI (0.00 to 1.33) and the age adjusted 
prevalence was 0.50/1000 95% CI (0.00 to 1.43). The pattern of disease was bilateral 
ptosis. Review articles from developed countries quote prevalence rates that vary 
between 0.015 and 0.18/1000 [515, 516]. 
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4.6.3.3.4.2 Muscle wasting and atrophy 
It is notoriously difficult to differentiate actual neurological pathology from neurological 
pathology post fracture and resultant disuse or disuse for another reason, especially when 
reviewing the patient many years after the primary event. Therefore accurate diagnosis of 
these patients was difficult and prevalence figures should be interpreted as such. Data 
from the literature on such patients are lacking. 
 
4.6.4 Reasons for Variations in prevalence 
4.6.4.1 Age 
Most published prevalence studies are not specific for the elderly however many 
neurological conditions are more prevalent in the elderly and an ageing population will 
further increase their prevalence. This is most notable in Stroke, Parkinson’s disease, 
Essential Tremor and Peripheral Neuropathy. Some conditions, however, are not 
represented in this age group in developing countries as the mortality rate in this 
environment preclude sufferers of these conditions from living to old age. Further, if 
incident cases occur in this age group (in the case of traumatic injury) then subsequent 
lifespan is short. These include; traumatic spinal injuries, cerebral palsy and hereditary 
disorders. 
 
4.6.4.2 Geography-world perspective 
Geographical location does alter the prevalence of Neurological disorders. Some 
conditions are more prevalent in SSA, e.g. consequences of infectious disease, and some 
are less prevalent, e.g. Multiple sclerosis. There are limited data on the prevalence of MS 
in SSA. Data has been reported from the following countries in Africa - South Africa 
32/100,000, Egypt 30/100,000, Morocco 20/100,000, Tunisia 15/100,000, Algeria 
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10/100,000, Nigeria 5/100,000, Cameroon 0.2/100,000, Guinea 0.13/100,000, Senegal 
0.05/100,000 and Benin 0/100,000. All the remaining countries in Africa have not reported 
their prevalence of MS or the data is unknown. This is in comparison to 10 to 150/100,000 
in Europe [517]. We found no cases of MS in the Main Study population, this was as 
expected and we can speculate that this was due to the following reasons; 
1. The 70 and over population was studied – if MS had presented in middle age in 
Africa it is unlikely that a patient will survive to this age 
2. MS prevalence is said to be very low in the tropics 
3. Diagnostic criteria for MS would make diagnosis in this prevalence study very 
difficult, histories are often inconsistent and investigation was not available. 
 
4.6.4.3 Sex 
Headache was found to be more common in women. This is in keeping with the literature 
[191]. Tremor was less prevalent in women, we can speculate that this is a real difference 
or is because women are less likely to come forward in the case of tremor as there is a 
widespread belief that tremor is associated with alcohol excess, a personal attribute 
looked down upon with respect to women but more readily accepted in men. Additionally 
any condition that may be thought of as inherited is less likely to be admitted to by 
women. The mother’s and the grandmother’s health is judged in this society to be a good 
predictor of the child’s health and ill health will affect affects female offspring’s ability to 
find a husband.  
 
4.6.5. Cases we may have missed 
148 people refused to take part in the study. No one had the questionnaire performed 
and then refused to be seen by the RD so no positive responders refused to be seen by the 
RD. 1 person responded positively then moved out of the area so we were unable to see 
them; they were consequently recorded as a false positive to ensure that the results of 
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the screening questionnaire specificity reflected the “worst case scenario” and the 
prevalence data did not include any cases that could not be accurately confirmed. People 
with early stage disease may not have answered the screening questionnaire positively. 
Trying to increase specificity meant asking patients to distinguish pain from weakness this 
is very difficult and cases may have been missed as a result. 
 
4.6.6. Accuracy of diagnosis 
The accuracy of our neurological diagnosis was limited due to the fact that there were no 
available investigations. This does however accurately reflect the majority of clinical 
encounters in SSA. Validation was performed as much as possible through the use of 
internationally recognised diagnostic criteria and through discussion of all cases with a 
consultant neurologist, movement disorder expert or geriatrician, blinding the expert to 
the provisional diagnosis and where appropriate using scripted video recordings. I do 
however have to recognise the limitations of purely clinical diagnosis even with 
recognised diagnostic criteria that are routinely used to make diagnoses without 
investigation in the UK. This is demonstrated using PD as an example; clinical diagnosis 
remains the gold standard using the UK PD Society Brain Bank Criteria. However, it still 
does not confer 100% sensitivity and specificity.  Post-mortem remains the conclusive 
diagnostic test. Previous studies suggest that the best clinical (pre-morbid) diagnostic 
accuracy of the UK PD Society BBC is around 90% [122].  
 
Further inaccuracies may have resulted from the fact that I did not attempt to undertake 
either inter or intra-observer reliability studies use of the screening instrument. Each 
village had one or two NMIs who were based there so that any village differences, if not 
due to chance, could reflect systematic bias from the use of the tool by the NMI.  
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Complete blinding of the research doctors was not possible and therefore has the 
potential to introduce bias. Whilst the RD who assessed patients in the pilot was 
completely blinded to the results of the tool it was not possible to completely blind the RD 
in the main study as only those patients that responded positively to the screening tool 
were seen, however the RD was blinded to which question the participant had responded 
positively to. In addition it was not possible to blind the consultants who assessed the 
cases as they were selected on the basis of the presumptive diagnosis. 
 
I therefore acknowledge that there could be some diagnostic inaccuracy and this could in 
turn result in misdiagnosis in some cases. However I believe that I have taken as many 
steps as possible to accurately diagnose as many neurological disorders as possible in this 
population. 
 
4.7 Health seeking behaviour - Level of under diagnosis and the treatment gap in the 
community 
To the best of my knowledge, this is the first published study of rates of diagnosis and 
treatment for neurological disorders in SSA from within a prevalent population.  It reveals 
that although almost two-thirds of people with neurological disorders had sought 
treatment for their condition, less than one-tenth were on appropriate treatment.   
 
4.7.1 Treatment seeking behaviour 
Of the more common disorders, rates of treatment seeking for stroke, epilepsy and 
Parkinson’s disease were high whilst rates for tremor and headache were low.  Although 
the reason why treatment is sought for some conditions but not others are likely to be 
complex, surprisingly the extent to which a condition is disabling appears not to be a 
significant factor.  Previous researchers who have investigated treatment seeking 
behaviours in SSA have found that whether people seek medical treatment for their 
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symptoms depends on a number of factors, such as access to services, financial issues, 
education level, social networks, intra-household power and health beliefs [5-8].  In the 
current study, rates of treatment seeking were similar for males and females.  There is a 
growing need for effective interventions for many medical conditions in SSA.  Further 
investigation of the factors which influence treatment seeking will help to inform 
strategies for the development of healthcare services in SSA. 
 
4.7.2 Diagnosis and treatment 
The majority of neurological disorders had not been diagnosed prior to the study.  This 
was despite relatively high levels of treatment seeking.  When patients sought treatment, 
it was often not in health centres and hospitals, but via un-registered private pharmacies 
and traditional healers.  In these cases, an appropriate formal diagnosis was rarely made.  
Of the most prevalent disorders, stroke was the most likely to be diagnosed.  Those who 
had been diagnosed were not necessarily treated, with just over two-thirds of those 
diagnosed being on appropriate treatment.  Those least likely to be on treatment when it 
was routinely available were patients with tremor disorders, and those most likely to be 
on treatment (secondary prevention) were those patients with a previous stroke.  These 
generally low rates of diagnosis and treatment may partly reflect patterns of treatment 
seeking behaviour and health beliefs.  However, in this resource poor setting, it may also 
be due to a lack of access to formal good quality healthcare. 
 
Despite the fact that health seeking behaviour was similar between sexes, the results of 
this study suggests that men had higher rates of diagnosis and treatment than women.  
There might be for a number of reasons for this. Firstly, in a society where healthcare is 
not free at the point of delivery, men are more likely to be the head of the household and 
have the final decision on financial matters [518, 519].  When the male is the main 
provider of income, he must keep healthy and the health of a husband and the children is 
often prioritised over that of the mother. Women have different priorities in the home 
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with the health of the husband and children coming above their own health [520].  
Likewise, money for schooling and food for other family members often comes before the 
health of the mother[518].  Finally, women often hide symptoms if it reflects badly on 
their children or grandchildren and their suitability for marriage [521, 522].  Such 
disparities are likely to be deep rooted in society and are present from early childhood in 
many cultures [523].  A study published in 2012 of 4822 people aged 18 years and over in 
Burkina Faso found a significantly higher prevalence of asthma, angina pectoris, back pain 
and joint disease in women compared to men [524]. Therefore even though women and 
men were equally likely to seek help for their symptoms in this study, for the reasons 
explored above men were more likley to recieve a diagnosis and recieve treatment. 
 
Work from this thesis has shown that people with neurological disorders in this population 
are significantly more likely to be disabled than people without neurological disorders 
[15].  Low diagnosis and treatment rates are likely to exacerbate the burden of non-
communicable disease in SSA, a burden which is predicted to increase substantially as 
populations age and the infection rates for communicable diseases, such as HIV/AIDS, 
tuberculosis and malaria, decline [216, 460, 525]. 
 
4.8 Disability 
Current data estimate 10% of the world’s population are disabled [18].  Disability is 
associated with increasing age and poverty, yet there are few data regarding disability 
amongst the elderly in developing countries [62].  
 
This study provides a comprehensive picture of the prevalence of disability and its 
contributory factors, namely increasing age and NCD. We have demonstrated that 3.7% of 
elderly adults in a developing country are severely disabled and 6.2% are moderately 
disabled (age adjusted) and that disability is more likely with increasing age, female sex 
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and the presence of NCD. More specifically it was significantly associated with the 
presence of neurological disorders, the most detrimental to a person’s independence 
being motor neurone disease, cord lesions, dyskinesias, cerebellar disorders, 
parkinsonism, disuse weakness and muscle atrophy and stroke. 
 
4.8.1 Comparison to disability levels in the developed world 
Reported disability prevalence rates around the world vary significantly because of 
different definitions, study designs, and lack of a universal assessment tool, leading to 
difficulty making comparisons. I selected the Barthel Index for use because it is widely 
used and recommended by the RCP and the BGS for routine use in the assessment of 
older people [426] it is quick and easy to do and it is possible for a wide range of surveyors 
to perform it consistently. It is culturally and disease non-specific and simple modification 
allows easy use in Africa. Because it does not need to be highly modified there are fewer 
requirements for validation in this setting. On saying that it is important to note that 
actual validation has not been carried out in SSA and therefore caution is required in 
interpretation of the results. For this study we translated the BI into Swahili and back 
translated it to ensure accuracy. The use of a simple and commonly used screening tool 
ensures easy comparison between disability levels in developed and developing countries. 
The focussed population group allowed direct comparison of our population to a 
European population studied by Heslin et a l[435] in 2001. They measured BI on 4004 
elderly aged 70+. Of the total sample, 9% (10% of women and 7% of men) and 26% were 
severely and moderately disabled respectively [435]. This is substantially higher than that 
seen in our population. This may reflect increased mortality from disease that results in 
disability in developing countries. It also may highlight risk factors for disability within the 
developed world. Disability levels are likely to increase as the population ages and disease 
survival increases, thus impacting more on quality of life and requiring urgent attention 
from healthcare policy makers.  
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Overall, as generally defined, disabled people represent a significant proportion of the 
world's population. Data from developed countries and some recent studies in developing 
countries (Brazil, Ecuador, India, Nicaragua, Vietnam, and Zambia) suggest that an 
estimate of 10-12%. This estimate is in line with the United Nations’ often cited figure of 
10%, an informed guess based on data from developed countries [18]. 
 
Reported disability prevalence rates around the world do however vary dramatically but in 
general are lower in developing countries. Rates reported in Kenya [437] and Bangladesh 
are <1% [438]. Allain et al’s Zimbabwean study who found less than 4% of people aged 60 
and over experienced difficulty with self maintenance of ADLs [20]. Fitaw et al looked at 
the prevalence of disability in Ethiopia, they reported the crude disability rate of 3.8% 
using the WHO international classification functioning disability and health (ICF) when all 
age groups were studied [21]. Rates in developed countries are substantially higher, 20% 
in New Zealand [22] and with the Townsend disability scale, The Medical Research Council 
Cognitive Function and Ageing Study and Resource Implications Study found 11% of men 
and 19% of women aged 65 and over were disabled in the UK [23]. This variation may be 
caused by several factors: differing definitions of disability, different methodologies of 
data collection, and variation in the quality of study design and population group studied 
[438],[437],[22]. However, my directly comparable study indicates a real difference 
between disability rates in developed and developing countries in the elderly population 
at least, comparable data from younger age groups is required to extrapolate this 
conclusion to the general population. 
 
4.8.2 Disability levels in the elderly 
I have demonstrated that functional dependence increases with age. The Cognitive 
Function and Ageing Study supports this conclusion, it reports that 38% of disabled people 
were aged 85 or over. They concluded that very elderly people make up a large proportion 
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of those in need of long term care, demonstrating the economic and social burden that an 
ageing population represents [23]. 
 
4.8.3 Disability levels in NCD 
We have demonstrated the association between NCD, specifically neurological disorders, 
and disability, this is in agreement with work from the 10/66 dementia research group 
who concluded that dementia, stroke, limb impairment, arthritis, depression and eyesight 
problems were in decreasing order associated with disability [62].[62] 
 
4.8.4 Limitations of the BI 
As a result of its ease of use the BI has one main limitation - it is a measure of physical 
restriction on daily activities and doesn’t look into the social and psychological aspect of 
disability and should therefore be interpreted as such. 
 
4.9 Ethical issues surrounding the study 
Ethical approval was granted by local and regional ethics committees. I felt strongly that 
this should not just be a prevalence study but it should be of benefit to both the local 
community under study and more generally the elderly within Tanzania and SSA. We 
believe this was achieved in the following ways; 
 
4.9.1 Benefit Afforded to the Local Population 
1. The population studied had neurological disorders diagnosed and fully explained. 
2. Those conditions that could be treated were provided with at least 1 month supply 
of medication and means, financial, logistical and geographical, to get  more. 
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3. One follow up consultation was provided for all tremor patients who wanted, and 
were amenable to, treatment. If first line treatment was not successful a second 
line option was suggested and supplied. 
4. One follow up consultation was provided for all epilepsy patients to check their 
level of control and requirement for an increased dose. 
5. Parkinson’s disease patients were offered and are to receive lifelong follow up and 
treatment. 
6. All patients were made aware of systems for follow up and for financial support for 
healthcare in their local community. 
7. Disabled patients who needed them were all provided with walking aids 
independent of the underlying cause of their disability. Follow up for these 
patients, including repairs and redistribution is to be provided as part of this 
arrangement. 
8. Guidelines for treatment were provided for the region. 
9. Information on the prevalence of disorders in this age group was fed back to the 
District Medical Officer and in turn to government officials. 
 
4.9.2 Benefit Afforded to the elderly Population in Tanzania and SSA 
1. Through feedback to the District Medical Officer it is hoped that the issues raised 
by this study will be brought to the attention of government officials. 
2. It is hoped this study will increase knowledge of the plight of elderly patients in 
SSA and the substantial contribution that Neurological disorders make to 
morbidity, mortality and disability in this age group. It is hoped the results will be 
published in peer review journals, and presented at national and international 
conferences. 
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4.9.3 Public health Implications of the study 
The WHO document "Neurological disorders: public health challenges" highlights the fact 
that "unless immediate action is taken globally, the neurological burden is expected to 
become an even more serious and unmanageable threat to public health" 
 
I have provided evidence on which to base a public health framework for neurological 
diseases; I believe that the results obtained from this study will facilitate the evidence-
based healthcare planning that is needed for neurological disorders and other non 
communicable diseases in this and other resource-poor settings. 
 
I have demonstrated that the burden is high and increasing further 
This study reveals a high prevalence of neurological disorders in the elderly. Neurological 
morbidity will make a substantial contribution to the non communicable disease 
epidemic. This, along with the ageing population, constitutes a public health dilemma.  
 
I have demonstrated that neurological disorders can be screened for easily and cheaply 
Identification of those with neurological disorders is clearly an important component in 
reducing the morbidity burden in SSA. I propose the use of the validated questionnaire in 
the community in low-income countries for dual epidemiological and clinical purposes. 
Epidemiologically, documenting prevalence is fundamental to highlight the public health 
significance of neurological disorders on a background of an ageing population, and an 
NCD epidemic. Clinically, case identification will reduce the diagnosis and treatment gap 
and improve the health of individuals. Due to the use of NMIs costs will be contained and I 
believe the screening will then be cost effective.  
 
We know that; 
Cost effective interventions are available 
Many neurological disorders can be treated readily and inexpensively, the importance of 
screening for these conditions and their precursors is therefore obvious, these include: 
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Stroke for secondary prevention (aspirin and antihypertensives) and rehabilitation, 
Epilepsy with phenobarbitone, Essential Tremor with propranolol, Parkinson's disease 
with levodopa [161]. Screening for other neurological disorders may be less intuitive but 
many are amenable to rehabilitation and disability management.  
 
Resources are inadequate and unequally distributed and need addressing 
It has recently been reported that African nations have very few neurologists [11], so 
training of primary caregivers would be important. 
 
4.9.3.1 Recommendations for Action  
My study not only demonstrates the burden that neurological disorders represent in a 
specific area in SSA it also offers health professionals and planners the opportunity to 
assess the burden caused by neurological disorders in their country and to take 
appropriate action to reduce the mortality, morbidity and disability caused by neurological 
disorders. One must appreciate that low income countries have limited resources (and 
multiple problems to tackle), it therefore may be difficult for governments to act alone. I 
have demonstrated that neurological disorders do need to be prioritised but appreciate 
that assistance may be required from non government organisations and international 
agencies 
 
4.9.3.1.1 Gain commitment from decision-makers 
Political commitment is required to ensure proper funding policies and publicity to 
subsequently raise awareness and reduce stigma. I have provided solid information on the 
prevalence, consequences, burden, treatment and prevention of neurological disorders 
and have fed this back to the district medical officer for Hai who in turn has discussed the 
problem with government officials.  
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4.9.3.1.2 Increase public and professional awareness 
I have also presented and published my work, nationally and internationally, to increase 
public and professional awareness of public health aspects of neurological disorders. 
Further actions that need to be taken are global and local campaigns.  
 
4.10.3.1.3 Minimize stigma and eradicate discrimination 
Stigma and discrimination against people with neurological disorders exist and need to be 
eradicated with education and global campaigns. If this issue is not addressed disclosure 
of symptoms will remain low and the poverty of care will remain. 
 
4.9.3.1.4 Strengthen neurological care within the existing health systems 
I have already stated that African nations have very few neurologists [11], so training of 
primary caregivers and medical students in neurological disorder recognition and 
treatment would be fundamental, a recent book "Neurology in Africa" has been written by 
Dr William Howlett and aims to provide relevant teaching material for this goal [503]. 
 
4.9.3.1.5 Incorporate rehabilitation into the key strategies 
Rehabilitation complements the other key strategies but in addition it may be the only 
management option for some conditions therefore effective rehabilitation and provision 
of function aids is fundamental to promote the quality of life of many and their ability to 
contribute financially to the community. Since community-based rehabilitation 
programmes are low-cost they need to be encouraged, linked to and supported by 
institutional and hospital-based rehabilitation services. 
 
4.9.3.1.6 Develop national capacity and international collaboration 
Many of the problems faced by low income countries with regard to neurological 
disorders are similar so collaboration with each other, high income countries and non 
government organisations may be an effective way to address them. The awareness of 
neurological disorders needs to be increased amongst NGOs and other organisations, to 
prioritise them on their agenda lists.  
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4.9.3.1.7 Establish links to other sectors 
Prevention of neurological disorders needs to involve other sectors for example, road 
traffic safety, healthy lifestyle campaigns, education and social welfare.  
 
4.9.3.1.8 Define priorities for research 
The burden of the problem needs to be documented in other communities and that is 
where our screening tool with its duel epidemiological and clinical purpose needs to be 
used.  
 
In summary there should be a screening programme resourced by associations and 
collaboration with government and non government organisations, this would be cost 
effective because of its cheap nature and the impact of identification and treatment for 
individuals and societies. Treatment and rehabilitation needs to be available through  
influencing education and policy. Follow up needs to be provided to ensure benefit is 
assured to the patients.  
 
4.10 Comparison with previous prevalence studies in SSA 
This is the first community-based prevalence study of neurological disorders specifically in 
the elderly population in SSA. The other community-based studies in Nigeria and Ethiopia 
looked at the whole population (a heterogeneous group with very different neurological 
disorders and treatment requirements). In addition they are outdated and use criticized 
screening tools. I have used well recognized diagnostic criteria which have been used in 
prevalence studies in other areas of the world to increase comparability, and I have 
calculated age-standardised rates, again to increase comparability. The diagnosis of the 
patients has been independently reviewed by specialists in Neurology, Movement 
Disorders and Geriatrics. Standardised video scripts have been used when appropriate.  
Diagnosis has been purely clinical which leaves it open to criticism but this accurately 
reflects the conditions of Neurological practice in the developing world. 
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Participation rates in the census and the door to door study were 100% and 93.8% 
respectively, higher than reported from other studies. The screening questionnaire for 
neurological disorders proved to have an excellent sensitivity and specificity, a challenge 
in the geriatric age group. It is the only screening tool that focuses on identification of all 
cause Neurological disorders in the elderly populations. A group that differs from the adult 
population to such an extent that they warrant an alternative screening tool, in the same 
way alternative methods of screening are utilized in children.  
 
Detailed information about the nature and prevalence of diseases and their subtypes has 
been reported, much of which is similar to previous world-wide studies but accurate 
current data has been lacking in SSA and my data highlights the high level of neurological 
morbidity in this age group. High rates of previously undiagnosed and untreated cases 
were detected, re-enforcing the need for a community rather than hospital based search 
in such areas and the unmet needs of the community in SSA with regard to the treatment 
and diagnosis of Neurological disorders. 
 
Lower levels of disability have been seen when compared directly to the developed world. 
This may be falsely reassuring and explained by a higher level of mortality from disabling 
disease in developing countries. As the population ages and survival from disabling 
disease increases a public health issue of disability in developing countries may present 
itself. The disabled adults that are present are not catered for demonstrated by the 
limited availability of walking aids despite an obvious requirement.  
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4.11 Study Limitations 
My study was limited by a number of factors; 
 The use of historical events to determine participants’ year of birth gives some 
uncertainty over ages [443].  However, this is a well recognised problem of 
research in SSA and the techniques we used are standard practice [449].  
 Whilst we had excellent interpreters who were medically trained, it was difficult at 
times to ascertain the finer points of a patient’s symptom burden, given the lack of 
medically descriptive words in Swahili, and other local tribal languages spoken by 
village elders. 
 The screening questionnaire and the Barthel Index were translated into Swahili 
and back translated to ensure accuracy, however some of the elderly population 
only speak tribal languages and therefore translation was performed at the point 
of interview by the NMI. This may not have been an accurate translation but it was 
felt to be impractical to formally translate the screening questionnaire into all 
tribal languages and all dialects. 
 There was no attempt to undertake either inter or intra-observer reliability studies 
using the screening instrument, which constrains reliability estimates.  
 Each village had one or two NMIs who were based there so that any village 
differences, if not due to chance, could reflect systematic bias from the use of the 
tool by the NMI.  
 The size of the main study was selected due to financial and time constraints. The 
whole population studied was 40,280 (one quarter of the Hai District DSS 
population n=161,119). Of this population we only looked at the 70 and over 
population, n=2232. Other community based studies of this nature in SSA have 
differed in size with no universally accepted optimum, the number of subjects 
studied have varied from 1113 to 161,071 [3, 5, 34, 96, 99, 128, 131, 187, 191, 204-
206, 302, 313, 315, 336, 466, 467].  We must appreciate that our sample 
population is quite small and that the prevalence of rarer conditions is more 
difficult to interpret. This is a weakness of our study but is a direct consequence of 
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the time consuming nature of a robust door to door community study. It was felt 
robust methodology should be the priority.  
 The accuracy of our neurological diagnoses was limited due to the purely clinical 
nature of our assessments and the lack of investigations available. Although this 
reflects the majority of medical encounters in SSA some diagnostic inaccuracy is 
inevitable. Validation was performed as much as possible through the use of 
internationally recognised diagnostic criteria and through discussion of all cases 
with a consultant neurologist, or movement disorder expert, where appropriate 
using video recordings. Unfortunately the consultants who assessed the cases 
could not be fully blinded to the diagnosis made by the research doctor as they 
were selected on the basis of the presumptive diagnosis. 
 The prevalence rates in the pilot population were approximately twice as high as 
those in the main study population indicating that prevalence in the main study 
population may have been underestimated as a result of false negatives. 
 The main limitation regarding health seeking, diagnosis and treatment level 
conclusions relates to the presence of a number of previous epidemiological 
studies that have been carried out in the Hai district over the last ten years[34, 96, 
128, 213, 333].  Consequently, rates of diagnosis and treatment may be higher 
than would be found otherwise.  Specifically, those who had had a stroke were 
most likely to be on treatment to prevent recurrence.  This may be partly a 
reflection of the educational work done by the Tanzanian Stroke Incidence Project, 
which ran from 2003-2006[213].  Rates of secondary preventative treatment for 
stroke in other areas of SSA have been reported to be substantially lower 
[526][26]. 
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Chapter 5. Conclusions 
5.1 Study review 
This is the first community based prevalence study of “all cause” Neurological Disorders 
focussing on the elderly population in SSA. A 2009 census provided demographic 
information on 161,119 people inhabiting the Hai District DSS which allowed me to focus 
on those of the population aged 70 and over (n=8869). An innovative screening tool, 
sensitive and specific for picking up a wide range of Neurological Disorders in the Elderly 
was produced. The Pilot study provided evidence of its excellent sensitivity and specificity 
in this age group. A two phased approach was utilised. Screening of a quarter of the 
elderly patients (n=2232) with the screening tool was combined with multiple other case 
finding strategies to perform a sensitivity check. Positive responders then underwent 
detailed assessment by the RD (myself). The diagnostic categories used were the widely 
applicable WHO ICD 10 criteria, which facilitates worldwide comparison of the prevalence 
figures. For each condition detailed internationally recognised criteria were used for 
diagnosis. Scripted video recording (where appropriate) and case descriptions of patients 
confirmed diagnosis which were validated with a Neurologist, Movement disorder expert 
or geriatrician depending on the nature of the case. 
 
5.1.1 Study design 
The methodology used in this study, of a community two stage epidemiological survey has 
been recommended by the WHO as the “gold-standard” way to detect neurological 
disease in a developing country.  The sensitivity of the screening tool used was 87.8-97.0% 
and it was able to detect previously diagnosed and undiagnosed cases, of all neurological 
diseases.  Multiple case finding methods confirmed the excellent sensitivity as no 
additional cases were picked up. I am confident therefore that the prevalence estimate is 
as accurate as could possibly be achieved. 
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5.1.2 Main conclusions -Addressing the Main Aim and the Subsidiary Aims of the Study 
5.1.2.1 The Main Aim –  Prevalence estimates 
The main aim of this study was to calculate the age-standardised prevalence of Neurological Disorders in the 70 and over 
population in the Hai district of northern Tanzania.  I report the age standardised figures as summarised in the table below. 
Table 5.1: The Prevalence of Neurological Disorders in the 70 and over population of the Hai District of Northern Tanzania 
Diagnosis 
Group 
Diagnosis Sub-diagnosis Cases Crude 
Prevalence/1000 
(95% CI) 
Age Adjusted 
Prevalence*/1000 (95% 
CI) 
All 
Neurological 
Disorders 
  384 172.04/1000 (156.39 
to 187.70).  
168.94/1000 (153.39 to 
184.48)  
 
People with 
Neurological 
Disorders 
  349 156.36/1000 (141.29 
to 171.43)  
154.14/1000 (139.16 to 
169.12) 
Central 
Nervous 
System 
Disorders 
     
Movement 
Disorders 
Tremor – total - 110 49.28 ( 40.30 to 
58.26) 48.22 (39.34 to 57.11) 
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  Essential Tremor 67 30.02 (22.94 to 37.10) 30.10 (23.01 to 37.18) 
  Enhanced physiological tremor 16 7.17 (3.67 to 10.67) 6.40 (3.10 to 9.71) 
  Tremor secondary to 
Parkinsonism/Parkinson's disease 
12 
5.38 (2.34 to 8.41) 5.13 (2.16 to 8.09) 
  Tremor secondary to cerebellar 
disease 
11 
4.93 (2.02 to 7.83) 4.87 (1.98 to 7.76) 
  Orthostatic tremor 3 1.34 (0.00 to 2.86) 1.27 (0.00 to 2.74) 
  Iatrogenic tremor 1 0.45 (0.00 to 1.33) 0.46 (0.00 to 1.35) 
 Parkinsonism - 14 6.27 (3.00 to 9.55) 5.94 (2.75 to 9.12) 
  Parkinsonism with tremor 12 5.38 (2.34 to 8.41) 5.13 (2.16 to 8.09) 
  Parkinsonism without tremor 2 0.90 (0.00 to 2.14) 0.81 (0.00 to 1.99) 
  Parkinson's Disease 12 5.38 (2.34 to 8.41) 5.13 (2.16 to 8.09) 
  Vascular Parkinsonism 1 0.45 (0.00 to 1.33) 0.31 (0.00 to 1.04) 
  Progressive Supra-nuclear palsy 1 0.45 (0.00 to 1.33) 0.50 (0.00 to 1.43) 
 Cerebellar 
disorders total - 11 4.93 (2.02 to 7.83) 4.87 (1.98 to 7.76) 
  Secondary to alcohol or idiopathic 7 3.14 (0.82 to 5.46) 3.14 (0.82 to 5.46) 
  Idiopathic 5 2.24 (0.28 to 4.20) 2.20 (0.25 to 4.14) 
  Secondary to alcohol    2 0.90 (0.00 to 2.14) 0.94 (0.00 to 2.21) 
  Secondary to stroke 4 1.79 (0.04 to 3.55) 1.73 (0.01 to 3.46) 
 Dyskinesias - 5 2.24 (0.28 to 4.20) 2.02 (0.16 to 3.88) 
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  Unspecified chorea 1 0.45 (0.00 to 1.33) 0.31 (0.00 to 1.04) 
  Tardive dyskinesias/ iatrogenic 2 0.90 (0.00 to 2.14) 0.77 (0.00 to 1.92) 
  Orofacial dyskinesias – idiopathic 2 0.90 (0.00 to 2.14) 0.94 (0.00 to 2.21) 
Episodic and 
Paroxysmal 
Disorders 
Headaches – 
total 
- 92 41.22 (32.97 to 49.47) 41.79 (33.49 to 50.09) 
  Primary headaches – total 44 19.71 (13.95 to 25.48) 19.86 (14.07 to 25.64) 
  Migraine 8 3.58 (1.10 to 6.06) 3.77 (1.22 to 6.31) 
  Tension Type headaches 36 16.13 (10.90 to 21.36) 16.09 (10.87 to 21.31) 
  Cluster headaches 0 0 0 
  Other Primary Headaches 0 0 0 
  Secondary headaches – total 48 21.50 (15.49 to 27.52) 21.93 (15.86 to 28.01) 
  Headaches attributed to head 
and/or neck trauma 3 1.34 (0.00 to 2.86) 1.40 (0.00 to 2.95) 
  Headaches attributed to infection 0 0 0 
  Headache attributed to arterial 
hypertension 3 1.34 (0.00 to 2.86) 1.10 (0.00 to 2.47) 
  Headache attributed to 
hypertensive crisis without 
hypertensive encephalopathy 0 0 0 
  Headache attributed to 
hypertensive encephalopathy 0 0 0 
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  Headache attributed to disorders 
of the neck 34 15.23 (10.15 to 20.31) 15.53 (10.40 to 20.66) 
  Headache attributed to disorders 
of the eyes 4 1.79 (0.04 to 3.55) 1.98 (0.14 to 3.83) 
  Headache attributed to disorders 
of the ears 1 0.45 (0.00 to 1.33) 0.48 (0.00 to 1.39) 
  Headache attributed to disorders 
of the teeth or jaw 2 0.90 (0.00 to 2.14) 0.98 (0.00 to 2.28) 
  Trigeminal neuralgia 1 0.45 (0.00 to 1.33) 0.46 (0.00 to 1.35) 
 Stroke - 54 24.19 (17.82 to 30.57) 22.95 (16.74 to 29.17) 
  LACS 19 8.51 (4.70 to 12.32) 8.10 (4.38 to 11.82) 
  PACS 16 7.17 (3.67 to 10.67) 6.62 (3.26 to 9.99) 
  TACS 12 5.38 (2.34 to 8.41) 5.40 (2.36 to 8.44) 
  POCS 7 3.14 (0.82 to 5.46) 2.83 (0.63 to 5.04) 
  POCS cerebellar 4 1.79 (0.037 to 3.55) 1.73 (0.01 to 3.46) 
  POCS non cerebellar 3 1.34 (0.00 to 2.86) 1.10 (0.00 to 2.47) 
 Epilepsy - 10 4.48 (1.71 to 7.25) 4.44 (1.69 to 7.20) 
  GTCS 9 4.03 (1.40 to 6.66) 3.97 (1.36 to 6.57) 
  Partial with secondary 
generalization 1 0.45 (0.00 to 1.33) 0.48 (0.00 to 1.39) 
Degenerative 
Diseases  
Motor neuron 
Disease 
- 2 0.90 (0.00 to 2.14) 0.96 (0.00 to 2.25) 
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Spinal Cord 
Dysfunction 
Cord lesions 
- 5 2.24 (0.28 to 4.20) 1.89 (0.09 to 3.69) 
  Cervical Cord Lesions 3 1.34 (0.00 to 2.86) 1.10 (0.00 to 2.47) 
  Traumatic Cervical Cord lesion 1 0.45 (0.00 to 1.33) 0.31 (0.00 to 1.04) 
  Non-traumatic Cervical Cord Lesion 
(Arthritic compression or acute 
lower cervical cord lesion) 2 0.90 (0.00 to 2.14) 0.79 (0.00 to 1.95) 
  Arthritic compression 1 0.45 (0.00 to 1.33) 0.31 (0.00 to 1.04) 
  Acute lower cervical cord lesion 1 0.45 (0.00 to 1.33) 0.48 (0.00 to 1.39) 
  Thoracic Cord Lesion 2 0.90 (0.00 to 2.14) 0.79 (0.00 to 1.95) 
  Traumatic Thoracic Cord lesion 0 0 0 
  Non-traumatic Thoracic Cord 
Lesion 2 0.90 (0.00 to 2.14) 0.79 (0.00 to 1.95) 
Peripheral  
Nervous 
System 
Disorders 
 
    
 Polyneuropathi
es Peripheral Neuropathy 42 18.82 (13.18 to 24.45) 18.61 (13.01 to 24.22) 
  Sensory Peripheral Neuropathy 39 17.47 (12.04 to 22.91) 17.36 (11.95 to 22.78) 
  Sensorimotor Peripheral 
Neuropathy 3 1.34 (0.00 to 2.86) 1.25 (0.00 to 2.71) 
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  Motor Peripheral Neuropathy 0 0 0 
Nerve, nerve 
root and 
plexus 
disorders 
Cranial Nerve 
Pathology 
- 14 6.27 (3.00 to 9.55) 5.71 (2.58 to 8.83) 
  Ptosis 8 3.58 (1.10 to 6.06) 3.34 (0.95 to 5.74) 
  Ptosis secondary to eye pathology 
– traumatic 4 1.79 (0.04 to 3.55) 1.58 (0.00 to 3.22) 
  Ptosis secondary to eye pathology - 
non traumatic 2 0.90 (0.00 to 2.14) 0.98 (0.00 to 2.28) 
  Ischaemic 3rd CN palsy 2 0.90 (0.00 to 2.14) 0.79 (0.00 to 1.95) 
  Facial nerve pathology 4 1.79 (0.04 to 3.55) 1.58 (0.00 to 3.22) 
  Bells 2 0.90 (0.00 to 2.14) 0.79 (0.00 to 1.95) 
  Traumatic  1 0.45 (0.00 to 1.33) 0.31 (0.00 to 1.04) 
  Hemifacial spasm 2 0.90 (0.00 to 2.14) 0.79 (0.00 to 1.95) 
 Upper Limb 
Mononeuropat
hies - 15 6.72 (3.33 to 10.11)  6.53 (3.19 to 9.87) 
  Traumatic upper limb multiple 
mononeuropathies  2 0.90 (0.00 to 2.14) 0.96 (0.00 to 2.24) 
  Traumatic damage to Median 
Nerve 1 0.45 (0.00 to 1.33) 0.48 (0.00 to 1.39) 
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  Non-traumatic damage to Median 
nerve - compression/entrapment 4 1.79 (0.04 to 3.55) 1.58 (0.00 to 3.22) 
  Traumatic damage to Radial nerve 2 0.90 (0.00 to 2.14) 0.94 (0.00 to 2.21) 
  Non-traumatic damage to Radial 
nerve 0 0 0 
  Traumatic damage to Ulnar nerve 2 0.90 (0.00 to 2.14) 0.98 (0.00 to 2.28) 
  Non-traumatic damage to Ulnar 
nerve 4 1.79 (0.04 to 3.55) 1.60 (0.00 to 3.26) 
 Lower Limb 
Mononeuropat
hies - 
5 
2.24 (0.28 to 4.20) 2.38 (0.36 to 4.40) 
  Traumatic femoral nerve injury 1 0.45 (0.00 to 1.33) 0.46 (0.00 to 1.35) 
  Sciatic nerve injury from trauma 1 0.45 (0.00 to 1.33) 0.48 (0.00 to 1.39) 
  Sciatic nerve injury from injection 
site 
1 
0.45 (0.00 to 1.33) 0.48 (0.00 to 1.39) 
  Common peroneal injury from 
operation 
1 
0.45 (0.00 to 1.33) 0.50 (0.00 to 1.43) 
  Traumatic common peroneal nerve 
injury 
1 
0.45 (0.00 to 1.33) 0.46 (0.00 to 1.35) 
 Plexus Injury - 4 1.79 (0.04 to 3.55) 1.89599 
  Brachial-traumatic 2 0.90 (0.00 to 2.14) 0.93965 
  Lumbosacral-traumatic 2 0.90 (0.00 to 2.14) 0.95634 
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 Root Pathology - 4 1.79 (0.04 to 3.55) 1.69 (0.00 to 3.40) 
  Sciatica 3 1.34 (0.00 to 2.86) 1.23 (0.00 to 2.69) 
  C8 root lesion 1 0.45 (0.00 to 1.33) 0.46 (0.00 to 1.35) 
Inflammatory
/infectious 
diseases of 
the peripheral 
nervous 
system 
Polio - 5 2.24 (0.28 to 4.20) 2.38 (0.36 to 4.40) 
 
 Leprosy - 1 0.45 (0.00 to 1.33 0.48 (0.00 to 1.39) 
Diseases of 
the 
myoneural 
junction and 
muscle 
Myaesthenia 
Gravis 
- 1 0.45 (0.00 to 1.33) 0.50 (0.00 to 1.43) 
 Muscle wasting 
and atrophy - 
17 
7.62 (4.01 to 11.22) 7.40 (3.84 to 10.95) 
  Secondary to primary orthopaedic 
problem 
7 
3.14 (0.82 to 5.45) 3.04 (0.76 to 5.33) 
  Secondary to pain 5 2.24 (0.28 to 4.20) 1.91 (0.10 to 3.72) 
  Secondary to severe cognitive 
impairment and consequent 
2 
0.90 (0.00 to 2.14) 0.96 (0.00 to 2.25) 
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immobility 
  Secondary to soft tissue damage 
secondary to infection 
2 
0.90 (0.00 to 2.14) 0.98 (0.00 to 2.28) 
  Secondary to period of ill health 
and consequent disability 
1 
0.45 (0.00 to 1.33) 0.31 (0.00 to 1.04) 
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I report an age-standardised figure of 168.94/1000 for “all cause” neurological disorders in 
the 70 years and older population, using the WHO population as standard. 
 
This is comparable to the limited number of published studies in developing countries 
(often hospital based and therefore not a reflection of true prevalence) and more robust 
studies in developed countries. Specific prevalence data in the elderly in SSA is very 
limited and differing diagnostic criteria and methodology make results difficult to 
interpret.  
 
Whilst age standardisation takes into account the difference in the age structure of the 
population in Hai compared to the UK, I cannot allow for the increased mortality that is 
likely for those with neurological disease in Hai in comparison to the developed world. The 
only way to take account of this would be through analysis of an accurate death 
certification system and more data based on verbal autopsies, both of which are not 
currently available in this setting.  
 
Given my experience and the data I have presented I feel this community is likely to 
change over time. The aged population will continue to increase in size and those 
conditions that are more prevalent in old age such as PD and ET will become more 
prevalent as a result. Those conditions associated with other NCDs such as stroke 
(associated with hypertension) and peripheral neuropathy (associated with diabetes) will 
also become increasingly problematic. Conditions resulting from infections are likely to 
become less prevalent as treatments and vaccination programmes become widespread 
however it is likely to be many years before the long term consequences of these 
conditions are eradicated from the elderly population. 
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5.1.2.2  The Subsidiary Aims 
5.1.2.2.1 The Screening Tool 
The initial subsidiary aim of the study was to produce a screening tool for the detection 
Neurological Disorders in the 70 and over population of the Hai District DSS. I successfully 
produced a screening tool with a sensitivity of 87.8-97.0% and specificity of 90.4-94.9%. I 
demonstrated that it can be effectively and accurately used by NMI with minimal training, 
this was facilitated by removal of an examination section which complicates many 
currently available screening tools. Because of the nature of this screening tool (its ease of 
use and its lack of cultural specificity) I can recommend it for use in other countries 
throughout the world, particularly developing countries where hospital based prevalence 
studies are inadequate and there is a limited budget for such screening. The screening 
questionnaire can also be used to identify cases of neurological disorders for diagnosis 
and treatment in an attempt to address the large amount of under treatment in the 
community and the plight of those who remain undiagnosed. 
 
5.1.2.2.2 Subtypes of Neurological Disease 
A further subsidiary aim was to describe the subtypes of Neurological disease in the 
prevalent population in Hai.  Diagnosis was purely clinical and based on international 
guidelines and was enhanced through consultation with Neurologists, Geriatricians and 
Movement disorders experts. Although this was the only practical option in this setting 
and reflects the practice in SSA it is not (in the case of the majority of the diseases studied) 
the gold standard. Accuracy of diagnosis may therefore be limited but the training of the 
RD (myself) and the confirmation of diagnoses by experts helped to validate the 
conclusions drawn. The prevalence of the subtypes of neurological disorders are described 
in table 5.1 above. The prevalence rates highlight a high level of neurological morbidity in 
this age group. 
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5.1.2.2.3 The diagnosis gap and treatment Gap 
I have demonstrated low levels of diagnosis and treatment of neurological disorders in the 
community.  Many neurological disorders can be treated readily and inexpensively. 
However, the reasons for these low rates are likely to be multi-factorial and relate not 
only to availability and affordability in the broadest sense, but also to accessibility and 
cultural acceptability [374, 440].  Identification and diagnosis of those with neurological 
disorders is clearly an important component to reduce the morbidity burden in SSA.  It has 
recently been reported that African nations have very limited numbers of neurologists and 
geriatricians, with some countries having none [11, 527].  As this situation is unlikely to 
change in the immediate future, other strategies to manage this burden should be sought.  
Since diagnosis must precede treatment, screening for neurological disorders by NMI and 
lay healthcare workers is an important first step to improve treatment rates.  Programmes 
to raise awareness of medical conditions at a community level should be considered.  In 
addition, the training of primary caregivers in the use of non-pharmacological 
interventions to manage such conditions should be considered.  In the absence of 
initiatives to improve rates of diagnosis and treatment, neurological morbidity will 
continue to make a substantial, and increasing, contribution to the non-communicable 
disease epidemic in SSA [524]. 
 
5.1.2.2.4 The level of disability 
The final aim of the study was to record the level of disability in this 70 and over 
population and see the impact neurological disorders had on this problem. The average 
level of disability was lower than in a comparable European population. This may reflect 
increased mortality from disease that would result in disability in developing countries but 
it may also highlight risk factors for disability within the developed world. Disability levels 
are likely to increase as the population ages and survival of people with disabling 
conditions increases, this will impact more on quality of life in older people and requires 
urgent attention from healthcare policy makers. I have demonstrated the relative ease 
with which it is possible to identify those that are disabled and to record the level of 
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disability in an area. This is easily transferrable to many populations worldwide and is a 
relatively low budget way to identify those in need. I have also demonstrated that 
disability is associated with the presence of neurological disorders and increased age. 
 
5.2 Recommendations for future 
5.2.1 Future epidemiological studies 
5.2.1.1 Neurological Disorders 
The two stage approach with a screening tool followed by medical examination is the 
most accurate approach to identify the true prevalence of neurological disorders in 
developing countries. Due to health seeking behaviours and the diagnosis and treatment 
gap other methods will substantially underestimate the prevalence. These methods are 
recommended to anyone wishing to undertake such a study to allow comparability. The 
calculation of age-standardised rates, again allows comparability with other studies.  The 
use of well recognised diagnostic criteria further adds to this. I can recommend my 
screening questionnaire for use in such studies.  
 
Neurological Disorders can significantly impair the quality and span of life. Neurological 
disorders and other NCD will become increasingly problematic in developing countries as 
the population ages and therefore the management of these conditions needs to be 
addressed.  
 
5.2.1.2 Disability 
This study reports a lower age adjusted prevalence of disability than seen in other parts of 
the world.  This probably reflects a survival bias, where those with disease that results in 
disability died at a younger age/survived for less time with the disease. If this is the case 
the impact of improvement in survival rate will substantially increase the burden of 
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disability.  Further community based studies in other developing regions are required to 
answer this question.   
 
5.2.2 Training for medical staff 
Healthcare professionals within developing countries have a lack of knowledge of and 
training on Neurological Disorders as  this study demonstrates. This needs to change in 
order to afford optimal care to elderly patients with neurological disorders. Given the 
ageing population this training should extend to other NCDs that affect the elderly to 
improve the quality of life of the aged in developing countries. 
 
5.2.3 Treatment 
For patients affected by Neurological Disorders, the treatment gap is significant and is the 
cause of unnecessary morbidity and mortality, it has a substantial effect on the quality and 
quantity of life of individuals and societies. This needs to be addressed, cost effective 
medication, rehabilitative techniques and aids to assist function are available and supply 
of these is fundamental, not just in this highlighted study population but in the elderly in 
other developing countries who suffer in the same way. 
 
5.3 In Summary 
This is the first community-based Neurological Disorder prevalence study specifically in 
the elderly in SSA. It reveals a high prevalence of Neurological Morbidity and associated 
disability. I have demonstrated low levels of diagnosis and treatment in the community 
despite the availability of inexpensive treatments for some conditions. Neurological 
Morbidity will make a substantial contribution to the non-communicable disease 
epidemic. This, along with the ageing population constitutes a public health dilemma. I 
believe that the results obtained will facilitate the evidence based healthcare planning 
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that is needed for neurological disorders and other NCDs in this resource poor setting, to 
relieve the aged population of their significant medical and social implications.  
 
I designed a unique screening questionnaire for the detection of Neurological Disorders in 
the elderly of low income countries. It had a high sensitivity only reduced by incidental 
findings or non-disabling conditions. It had a very high specificity; a challenging task given 
the target population. It was designed to be inclusive of all neurological conditions of 
public health significance in this population and age group. The questionnaire was simple 
and acceptable to use. 
 
In the future I propose the validated questionnaires use in the community of low income 
countries for dual epidemiological and clinical purpose. Epidemiologically, documenting 
prevalence is fundamental to highlight the public health significance of neurological 
disorders on a background of an Ageing population and a non communicable disease 
epidemic to allow appropriate allocation of resources in low income settings. Clinically, 
case identification will reduce the diagnosis and treatment gap and improve the health of 
individuals. Benefits from a public health perspective are therefore two fold. 
 
This is also the first study demonstrating a directly comparable disability rate to a 
European population. I have illustrated a lower prevalence of disability in the elderly of 
low income countries in comparison to high, this is supported by published literature. This 
may reflect increased mortality from disease that results in disability in developing 
countries. It also may highlight risk factors for disability within the developed world. 
Disability levels are likely to increase as the population of developing countries ages and 
disease survival increases; this is supported by the positive relationship between disability 
and increasing age and NCD. As studies from developed countries demonstrate, the 
societal costs of increasing disability are enormous, urgent attention is required from 
healthcare policy makers of developing countries.  
477 
 
References 
1. The World Health Organization, https://www.who.int/features/factfiles/aging/en/index. 
2007. 
2. Heligman, L., N. Chen, and O. Babakol, Shifts in the structure of population and deaths in 
less developed regions. Epidemiologic Transitions: Policy and Planning Implications for 
Developing Countries. Washington, D.C.: National Academy Press., 1993: p. 9-41. 
3. Osuntokun, B.O., et al., Neurological disorders in Nigerian Africans: a community-based 
study. Acta Neurologica Scandinavia, 1987. 75(1): p. 13-21. 
4. Attia Romdhane, N., et al., Prevalence study of neurologic disorders in Kelibia (Tunisia). 
Neuroepidemiology, 1993. 12(5): p. 285-99. 
5. Tekle-Haimanot, R., et al., Community-based study of neurological disorders in rural 
central ethiopia. Neuroepidemiology, 1990. 9: p. 263-277. 
6. The World Health Organization, World Health Organization Research protocol for 
measuring the prevalence of neurological disorders in developing countries. 1981. 
7. Murray, C.J.L. and A.D. Lopez, The global burden of disease: a comprehensive assessment 
of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 
2020. Cambridge, MA, Harvard School of Public Health on behalf of the World Health 
Organisation and the World Bank, 1996 1996. Global Burden of Disease and Injury Series, 
Volume 1. 
8. Ojini, F.I. and M. Danesi, The Pattern of Neurological Admissions At The Lagos University 
Teaching Hospital Nigerian. Jrnl of Clin Prac, 2003. 6: p. 38-44. 
9. Emmanuel, C.J., Neurologic Admissions in the Niger Delta Area of Nigeria - A Ten Year 
Review. Afr J of Neuro Sci, 2004. 23(1): p. 14-20. 
10. World Health Organisation. https://apps.who.int/infobase/mortality.aspx. 2011. 
11. Bower, J.H. and G. Zenebe, Neurologic services in the nations of africa. Neurology, 2005. 
64: p. 412-415. 
12. World Health Organisation and World Federation of Neurology, Atlas: Country resources 
for Neurological Disorders. Geneva, World Health Organisation and World Federation of 
Neurology, 2004: p. 1-59. 
13. World Health Organisation, Neurological Disorders: Public Health Challenges. World Health 
Organisation Website, 2006. 
14. Gupta, M., N. Singh, and S. Verma, South Asians and Cardiovascular Risk. What Clinicians 
should know, . Circulation, 2006. 113: p. e924-e929. 
15. Dewhurst, F., et al., The prevalence of disability in older people in Hai Tanzania. Age and 
Ageing, 2012. 41(4): p. 517-523. 
16. National Bureau of Statistics, National Bureau of Statistics. Tanzanian Disability Survey 
Report. Dar es Salaam, Tanzania. 2010. 
17. World Health Organisation, The International Classification of Functioning Disability and 
Health. World Health Organisation Website, 2001. 
18. Mont, D., Measuring Disability Prevalence. Disability and Development Team, The World 
bank, 2007. 
19. Crepaidl, G., et al., Reducing disability among the elderly in europe. The Lancet, 1998. 351: 
p. 375. 
20. Allain, T.J., et al., Morbidity and disability in elderly Zimbabweans. Age and Ageing, 1997. 
26: p. 115-121. 
21. Fitaw, Y. and J.M.F. Boersma, Prevalence and impact of disability in north-western 
Ethiopia. Disability and Rehabilitation, 2006. 28(15): p. 949-953. 
22. Statistics New Zealand, Disability Counts. 1998. 
478 
 
23. Medical Research Council Cognitive Function and Aging Study (MRC CFAS) and Resource 
Implications Study (RIS MRC CFAS), et al., Profile of disability in elderly people: estimates 
from a longitudinal population study. British Medical Journal, 1999. 318: p. 1108-11. 
24. Schoenberg, B.S., Clinical neuroepidemiology in developing countries: neurology with few 
neurologists. Neuroepidemiology, 1982. 1: p. 137-142. 
25. Osuntokun, B.O., et al., Research Protocol for Measuring the Prevalence of Neurologic 
Disorders in Developing Countries: Results of a Pilot Study in Nigeria. Neuroepidemiology, 
1982. 1: p. 143-153. 
26. Bower, J.H., et al., A Screening Instrument to Measure the Prevalence of Neurological 
Disability in Resource-Poor Settings. Neuroepidemiology, 2009. 32: p. 313-320. 
27. Siddiqi, O.K., et al., The spectrum of neurological disorders in a Zambian tertiary care 
hospital. Journal of the Neurological Sciences, 2010. 290(1): p. 1-5. 
28. Bower, J.H., et al., The burden of inpatient neurologic disease in two Ethiopian hospitals. 
Neurology, 2007. 68(5): p. 338-334. 
29. Casanova-Sotolongo, P., P. Casanova-Carrillo, and J. Rodríguez-Costa, A 
neuroepidemiological study in Beira, Mozambigue. Rev Neurol., 2000. 30(12): p. 1135-
1140. 
30. Mathers, C.D. and D. Loncar, Updated projections of global mortality and burden of 
disease, 2002-2030: data sources, methods and results. . Geneva, World Health 
Organisation (Evidence and Information for Policy Working Paper, 2005. 
31. Gutierrez-del-Olmo, A.M.C., B.S. Schoenberg, and A. Portera-Sanchez, Prevalence of 
neurological diseases in Madrid, Spain. Neuroepidemiology, 1989. 8: p. 43-47. 
32. Kapoor, S.K., Pilot study of the prevalence of major neurologic disorders in a rural 
population of India. Neuroepidemiology, 1990(9): p. 287-295. 
33. Nicoletti, A., A neuroepidemiological survey in rural Bolivia: Background and Methods. 
Neuroepidemiology, 1998. 17: p. 273-280. 
34. Walker, R.W., et al., Age specific prevalence of impairment and disability relating to 
hemiplegic stroke in the Hai district of northern Tanzania. Journal of Neurology, 
Neurosurgery and Psychiatry, 2000. 68: p. 744-749. 
35. Anderson, D.W., W.A. Rocca, and J.A. Rosario, Pitfalls in neuroepidemiologic research. 
Neuroepidemiology, 1998. 17: p. 55-62. 
36. Meneghini, F., Door-to-door prevalence survey of neurological diseases in a Sicilian 
population. Neuroepidemiology, 1991. 10: p. 70-85. 
37. Gourie-Devi, M., V.N. Rao, and R. Prakashi, A protocol to detect neurological disorders in 
the community. Indian Journal of Medical Research, 1988: p. 443-449. 
38. Morgante, L., et al., Neuroepidemiological Survey on Sicilian Population. A feasibility study. 
Neuroepidemiology, 1989. 8: p. 214-220. 
39. Bower, J., et al., Validity of a screening instrument for neurologic disability in resource-poor 
African communities. Journal of the Neurological Sciences, 2012. 320: p. 52-55. 
40. Tekle-Haimanot, R., M. Abebe, and A. Gebre-Mariam, Community based study of 
neurological disorders in Ethiopia: The development of a screening instrument. Ethiopian 
Medical Journal, 1990. 3: p. 123-37. 
41. Meneghini, F., et al., Validating screening instruments for neuroepidemiologic surveys: 
experience in Sicily. Sicilian Neuro-Epidemiologic Study (SNES) Group. Journal of clinical 
epidemiology, 1992. 45(4): p. 319-31. 
42. Meneghini, F., et al., Screening Instrument for a neuroepidemiological survey in Sicily, Italy 
(the SNES study): Validation in a hospital population. Neuroepidemiology, 1990. 9: p. 169. 
43. Das, S.K., et al., A random sample survey for prevalence of major neurological disorders in 
Kolkata. Indian Journal of Medical Research, 2006: p. 163-172. 
479 
 
44. Gourie-Devi, M., et al., Neuroepidemiological pilot survey of an urban population in a 
developing country. A study in Bangalore, South India. Neuroepidemiology, 1996. 15: p. 
313-320. 
45. Anderson, D.W., M.O. Melcon, and R.H. Vergara, Methods for a Prevalence Survey of 
neurological Disorders in Junin, Buenos Aires, Argentina. Neuroepidemiology, 1995. 14: p. 
110-122. 
46. Vita, G., L. Mortagne, and F. Grigoletto, Prevalence survey of major neurological disorders 
in Siciliy. Journal of Neurology   1989. 236: p. 315-318. 
47. Nicoletti, A., A screening instrument for a Sicilian neuroepidemiological survey in the 
elderly. Archives of Gerontology and Geriatrics, 2004. 38: p. 37-44. 
48. Bharucha, N.E., et al., Pilot survey of the prevalence of neurologic disorders in the Parsi 
Community of Bombay. Am J Prev Med, 1987. 3: p. 293-299. 
49. Meneghini, F., et al., Door-to-Door Prevalence Survey of Neurological Diseases in a Sicilian 
Population. Neuroepidemiology, 1991. 10: p. 70-85. 
50. Haerer, A.F., D.W. Anderson, and B.S. Schoenberg, Survey of Major Neurologic Disorders in 
a Biracial United States Population: The Copiah County Study. Southern Medical Journal, 
1987. 80(3): p. 339-343. 
51. Gourie-Devi, M., V.N. Rao, and R. Prakashi, Neuroepidemiological Study in Semiurban and 
Rural Areas in South India: Pattern of Neurological Disorders Including Motor Neurone 
Disease. Motor Neurone Disease, 1987: p. 11-21. 
52. Gourie-Devi, M., et al., Prevalence of Neurological Disorders in Banglaore, India: A 
community-based study with a comparison between urban and rural areas. 
Neuroepidemiology, 2004. 23: p. 261-268. 
53. Das, S.K., et al., Prevalence of major neurological disorders among geriatric population in 
the metropolitan city of kolkata. Journal of the association of physicians of india, 2008. 56: 
p. 175-181. 
54. Quet, F., et al., Determining the burden of neurological disorders in populations living in 
tropical areas: who would be questioned? Lessons from a Mexican rural community. 
Neuroepidemiology, 2011. 36(3): p. 194-203. 
55. Stuck, A.E., Comprehensive geriatric assessment for older adults. British Medical Journal, 
2011. 343: p. d6799. 
56. Howitt, S.C., et al., A cross-sectional study of quality of life in incident stroke survivors in 
rural northern Tanzania. J Neurol., 2011. Published online, doi 10.1007/s00415-011-5948-
6: p. accessed online 16th March 2011. 
57. Sarangmath, N., Validity of a modified Parkinson's disease screening questionnaire in India: 
effects of literacy of participants and medical training of screeners and implications for 
screening efforts in developing countries. Movement Disorders, 2005. 20(12): p. 1550-56. 
58. Das, S.K. and K. Sanyal, Neuroepidemiology of major neurological disorders in rural Bengal. 
Neurol India, 1996. 44: p. 47-58. 
59. Twelves, D., K. Perkins, and C. Counsell, Systematic review of incidence studies of 
Parkinson's disease. Movement Disorders, 2003. 18(1): p. 19-31. 
60. Das, S., K. Sanyal, and A. Mitra, A pilot study of neurepidemiology in urban bengal. Indian 
Journal of Public Health, 1998. 42: p. 34-41. 
61. Saha, S.P., et al., Epidemiological Study of Neurological Disorders in a Rural Population of 
Eastern India. Journal of Indian Medical Assocation, 2003. 101: p. 299-304. 
62. Sousa, R.M., et al., Contribution of chronic diseases to disability in elderly people in 
countries with low and middle incomes: a 10/66 Dementia Research Group population-
based survey. The Lancet, 2009. 374: p. 1823-30. 
480 
 
63. Royal College of Physicians, Physical Disability in 1986 and beyond. A report of the Royal 
College of Physicians Journal of the Royal College of Physicians of London, 1986. 20(3): p. 
160-94. 
64. Martin, J., H. Metzer, and D. Elliot, The prevalence of disability in adults, OPCS surveys of 
disability in Great Britain. Report 1. HMSO, 1988. 
65. Jette, A.M. and L.G. Branch, The Framlington Disability Study: II. Physical disability among 
the aging. American Journal of Public Health, 1981. 71(11): p. 1211-6. 
66. Pomeranz, B., et al., Prosthetics and orthotics for the older adult with a physical disability. 
Clinical Geriatric Medicine, 2006. 22(2): p. 377-94. 
67. Colin, C., et al., The Barthel Index: a standard measure of physical disability? International 
Disability Study, 1988. 10(2): p. 64-7. 
68. Gosman-Hedstrom, G. and E. Svensson, Parallel reliability of the Functional Independence 
Measure and the Barthel ADL index. 2000. 22(16): p. 702-715. 
69. World Health Organisation, What are Neurological Disorders. website: 
www.who.int/features/qa/55/en/index.html, 2007. 
70. World Health Organisation, International Classification of Disease (ICD). Website: 
www.who.int/classifications/icd/en/, 1994. 
71. World Health Organisation, ICD Version 2007 Diseases of the Nervous System. website: 
www.who.int/classifications/apps/icd/icd10online/, 2007. 
72. National Institute of Neurological Disorders and Stroke, National Institute of Neurological 
Disorders and Stroke Disorders A - Z. Website: 
www.ninds.nih.gov/disorders/disorder_index.htm. 
73. Brucki, S.M. and R. Nitrini, Subjective memory impairment in a 574 rural population with 
low education in the Amazon rainforest: an 575 exploratory study. Int Psychogeriatr, 2009. 
21: p. 164-171. 
74. O'Brien, M.D., Taking a neurological history. Medicine 2004. 32(9): p. 1-6. 
75. Parry, E., et al., eds. Principles of Medicine in Africa. 2004, Cambridge university press: 
Cambridge. 
76. Manji, H., et al., Oxford Handbook of Neurology, ed. O.M. Publications. 2007: Oxford 
Medical Publications. 
77. Movement Disorder Society. www.movementdisorders.org/disorders. 2012. 
78. Medical Research Council, Aids to the examination of the peripheral nervous system. 
Memorandum no. 45, Her Majesty's Stationery Office, London 1981. 
79. Kennedy, A. and R. Zakariaa, Taking a Neurological History. Medicine, 2008. 36(10): p. 509-
514. 
80. www.guardian.co.uk. 
81. Cohen, A.B., J.P. Klein, and S. Mukundan, A guide to imaging for common neurological 
problems. British Medical Journal, 2010. 341: p. 4113. 
82. Mallick, A. and A. Weir, Nerve Conduction Studies: Essentials and Pitfalls in Practice. 
Neurology Neurosurgery and Psychiatry, 2005. 76: p. ii23-ii31. 
83. Tripepi, G., et al., An overview of standard statistical methods for assessing exposure-
outcome link in survival analysis (Part I): basic concepts. Aging-Clinical & Experimental 
Research, 2012. 2012(24): p. 109-12. 
84. Porta, M., S. Greenland, and J.M. Last, A Dictionary of Epidemiology. Vol. 5th Edition. 
2008: New York Oxford University Press. 
85. Chan, D., Pilot study of prevalence of Parkinson's disease in Australia. Neuroepidemiology, 
2001. 20(2): p. 112-117. 
86. Deuschl, G., et al., Consensus Statement of the Movement Disorder Society on Tremor. 
Movement Disorders, 1998. 13(Supplement 3): p. 2-23. 
87. National Institute of Health, NIH Collaborative Genetic Criteria for essential tremor. 1996. 
481 
 
88. Fahn, S., E. Tolosa, and C. Martin, Clinical rating scale for tremor Parkinson's Disease and 
Movement Disorders, 1993: p. 271-280. 
89. Deuschl, G., et al., Physiologic classification of essential tremor Handbook of Tremor 
Disorders. New York, 1995: p. 195-208. 
90. Louis, E.D., et al., Diagnostic Criteria for Essential Tremor. Archives of Neurology, 1998. 55: 
p. 823-828. 
91. Louis, E.D., R. Ottman, and W.A. Hauser, How common is the most common adult 
movement disorder? estimates of the prevalence of essential tremor throughout the world. 
Movement Disorders, 1998. 13(1): p. 5-10. 
92. Louis, E., K. Marder, and L. Cote, Differences in the prevalence of essential tremor among 
elderly African Americans, whites and Hispanics in Northern Manhattan, NY. Arch Neurol, 
1995. 52: p. 1201-1205. 
93. Rautakorpi, I., J. Takala, and R. Marttila, Essential tremor in a Finnish population. . Acta 
Neurol Scand, 1982. 66: p. 58-67. 
94. Tan, L., N. Venketasubramanian, and V. Ramasamy, Prevalence of essential tremor in 
Singapore: a study of three races in an Asian country. Parkinsonism Relat Disorders, 2005: 
p. 233-239. 
95. Aiyesimoju, A., B. Osuntokun, and O. Bademosi, Hereditary neurodegenerative disorders in 
Nigerian Africans. Neurology 1984. 34: p. 361-362. 
96. Dotchin, C.L. and R.W. Walker, The prevalence of essential tremor in rural northern 
Tanzania. Journal of Neurology Neurosurgery Psychiatry 2008. 79: p. 1107-1109. 
97. Louis, E.D., B. Ford, and H. Lee, Does a screening questionnaire for essential tremor agree 
with the physician’s examination? Neurology, 1998. 50: p. 1351-1357. 
98. Okubadejo, N., et al., Prevalence of essential tremor in urban Lagos, Nigeria: a door-to-
door community-based study. BMC Neurology, 2012. 12: p. 110. 
99. Longe, A.C. and B.O. Osuntokun, Prevalence of neurological disorders in Udo, a rural 
community in southern Nigeria. Tropical and Geographical Medicine, 1989. 41(1): p. 36-40. 
100. Sur, H., et al., Prevalence of essential tremor: a door-to-door survey in Sile, Istanbul, 
Turkey. Parkinsonism Relat Disord 2009. 15: p. 101-104. 
101. Mancini, M., F. Stracci, and N. Tambasco, Prevelance of essential tremor in the territory of 
Lake Trasimeno, Italy: results of a population-based study. Mov Disord, 2007. 22: p. 540-
545. 
102. Dogu, O., et al., Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol 
Neurosurg Psychiatry, 1984. 47: p. 466-470. 
103. Benito-León, J., et al., Prevalence of essential tremor in three elderly populations of central 
Spain. Movement Disorders, 2003. 18(4): p. 389-394. 
104. Louis, E.D., S.P. Thawani, and H.F. Andrews, Prevalence of Essential Tremor in a 
Multiethnic, Community-Based Study in Northern Manhattan, New York, N.Y. 
Neuroepidemiology, 2009. 32: p. 208-214. 
105. Louis, E.D., et al., Risk of tremor and impairment from tremor in relatives of patients with 
essential tremor: a community- based family study. Ann Neurol 2001. 49(6). 
106. Prakash, K. and E. Tan, Validity of family history in essential tremor. Parkinsonism Relat 
Disorders, 2008. 14: p. 151-153. 
107. Tan, E., et al., Non-motor manifestations in essential tremor: use of a validated instrument 
to evaluate a wide spectrum of symptoms. . Parkinsonism Relat Disorders, 2005. 11(6): p. 
375-380. 
108. Hornabrook, R. and J. Nagurney, Essential tremor in Papua New Guinea. . Brain, 1976. 99: 
p. 659-672. 
482 
 
109. Louis, E.D., L. Fried, and A. Fitzpatrick, Regional and racial differences in the prevalence of 
physician-diagnosed essential tremor in the United States. Mov Disord 2003. 18: p. 1035-
1040. 
110. Hubble, J., K. Busenbark, and R. Pahwa, Clinical expression of essential tremor: effects of 
gender and age. Mov Disord, 1997. 12: p. 969-972. 
111. Hardesty, D., D. Maraganore, and J. Matsumoto, Increased risk of head tremor in women 
with essential tremor: longitudinal data from the Rochester epidemiology project. Mov 
Disord, 2004. 19: p. 529-533. 
112. Cohen, O., S. Pullman, and E. Jurewicz, Rest tremor in patients with essential tremor: 
prevalence, clinical correlates and electrophysiologic characteristics. Arch Neurol, 2003. 
60: p. 405-410. 
113. Louis, E., K. Wendt, and S. Pullman, Is essential tremor symmetric? Arch Neurol, 1998. 55: 
p. 1553-1559. 
114. Rajput, A., C. Robinson, and A. Rajput, Essential tremor course and disability: a 
clinicopathologic study of 20 cases. Neurology, 2004. 62: p. 932-936. 
115. Bain, P.G., L. Findley, and P. Thompson, A study of hereditary essential tremor. Brain 1994. 
117: p. 805-824. 
116. Bain, P.G., The Management of Tremor. Journal of Neurology Neurosurgery and 
Psychiatry, 2002. 72: p. Suppl i3-i9. 
117. Benito-Leon, J., F. Bermejo-Pareja, and E.D. Louis, Neurological disorders in central Spain 
(NEDICES) study group. Incidence of essential tremor in three elderly populations of central 
Spain. Neurology, 2005. 64: p. 1721-1725. 
118. National Institute of Clinical Excellence, Parkinson's Disease diagnosis and management in 
primary and secondary care. www.nice.org.uk, 2006. 
119. Rajput, A.H., B. Rozdilsky, and A. Rajput, Accuracy of clinical diagnosis in Parkinsonism - A 
prospective study. Canadian Journal of Neurological Sciences., 1991. 18(3): p. 275-278. 
120. Hughes, A.J., S.E. Daniel, and L. Kilford, Accuracy of clinical diagnosis of idiopathic 
Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, 
Neurosurgery & Psychiatry., 1992. 55(3): p. 181-184. 
121. Hughes, A.J., S.E. Daniel, and Y. Ben Shlomo, The accuracy of diagnosis of parkinsonian 
syndromes in a specialist movement disorder service. Brain, 2002. 125: p. 4-70. 
122. Hughes, A.J., S.E. Daniel, and A.J. Lees, Improved accuracy of clinical diagnosis of Lewy 
body Parkinson's disease. Neurology, 2001. 57(8): p. 1479-9. 
123. Schrag, A., Y. Ben-Shlomo, and N. Quinn, How valid is the clinical diagnosis of Parkinson’s 
disease in the community? J Neurol Neurosurg Psychiatry, 2002. 73: p. 529-534. 
124. Marras, C. and C. Tanner, The Epidemiology of Parkinson’s Disease.” In Movement 
Disorders Neurologic Principles and Practice, ed. K.W.C. Watts R.L. 2002, New York: 
McGraw-Hill. 
125. Tanner, C. and S. Goldman, Epidemiology of Parkinson’s Disease. Neurology Clinics, 1996. 
14: p. 317-35. 
126. Ascherio, A., et al., Prospective Study of Caffeine Consumption and Risk of Parkinson’s 
Disease in Men and Women. Annals of Neurology, 2001. 50(1): p. 56-63. 
127. Balogou, A.A.K., A. Doh, and K.E. Grunitzky, Affectations neurologiques et endemie 
goitreuse: analyse comparative de deux provinces du Togo. Bull Bull Soc Pathol Exot, , 
2001. 94(5): p. 406-410. 
128. Dotchin, C.L., The Prevalence of Parkinson's disease in rural Tanzania. 2008. 23(11): p. 
1567-1572. 
129. Anderson, D.W., et al., Case ascertainment uncertainties in prevalence surveys in 
Parkinson's disease. . Movement disorders 1998. 46: p. 1052-1060. 
483 
 
130. Mayeux, R., The frequency of idiopathic Parkinson's disease by age, ethnic group and sex in 
Northern Manhatten, 1988-1993. American Journal of Epidemiology, , 1995. 142(8): p. 
820-827. 
131. Winkler, A.S., et al., Parkinsonism in a population of northern Tanzania: a community-
based door-to-door study in combination with a prospective hospital-based evaluation. 
Neurology, 2010. 257(5): p. 799-805. 
132. Bharucha, N.E., et al., Prevalence of Parkinson’s disease in the Parsi community of Bombay, 
India. . Arch Neurol, 1988. 45: p. 1321-1323. 
133. Zhang, Z., et al., Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. 
Lancet, 2005. 365: p. 595-597. 
134. Wickremaratchi, M., et al., Prevalence and age of onset of Parkinson’s disease in Cardiff: a 
community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry, 
2009. 80: p. 805-807. 
135. de Rijk, C.M., et al., Prevalence of parkinsonism and Parkinson's disease in Europe: the 
EUROPARKINSON collaborative study. Journal of Neurology, Neurosurgery, and Psychiatry, 
1997. 62: p. 10-15. 
136. Leonardi, M., Neurology and Public Health in Developing Countries. Recent Advances in 
Tropical Neurology, 1995: p. 1-6. 
137. Razdan, S., et al., Epidemiology of Neurological disorders in Kashmir. Neuroepidemiology, 
1994. 13: p. 113-119. 
138. Gourie-Devi, M., G. Gururaj, and P. Satishchandra, Neuroepidemiology in developing 
countries. A manual for descriptive studies. . Prism Books Pvt. Ltd.,Bangalore, 1997. 
139. Gourie-Devi, M., G. Gururaj, and P. Satishchandra, Bangalore Urban and Rural 
Neurological Survey. Report to Indian Council of Medical Research,. 1995. 
140. Anand, K.S. and M.M. Singh, Pattern of neurological disorders above the middle aged 
population in JIPMER, Pondicherry. Neurology India, 1993. 41: p. 165-168. 
141. Ragothaman, M., et al., High occurrence and low recognition of Parkinson’s disease in 
Elderly Homes in Bangalore, India: Implications for healthcare of elderly. Movement 
Disorders., 2006. 
142. Wadia, N.H. and R.K. Swami, A new form of heredo-familial spinocerebellar degeneration 
with slow eye movements (nine families). Brain, 1971. 94: p. 359-374. 
143. Wadia, N.H. and K. Bhatia, Multiple Sclerosis is prevalent in the Zoroastrians (Parsis) of 
India. Ann Neurol, 1990. 28: p. 177-179. 
144. Muthane, U.B., M. Ragothaman, and G. Gururaj, Epidemiology of Parkinson’s Disease and 
Movement Disorders in India: Problems and Possibilities JAPI, 2007. 55: p. 719-724. 
145. Gourie-Devi, M., et al., Prevalence of Parkinson’s disease in Bangalore. A door to door 
survey of urban and rural population. Neurology India, 1999. 47: p. 73. 
146. Calne, D.B., B.J. Snow, and C. Lee, Criteria for diagnosing Parkinson’s disease. Ann Neurol, 
1992. 32: p. S125-S127. 
147. Zhang, Z.X., D.W. Anderson, and J.B. Huang, Prevalence of Parkinson’s disease and related 
disorders in the elderly population of greater Beijing, China. Mov Disord 2003. 18: p. 764-
772. 
148. Porter, B., et al., The Prevalence of Parkinson’s Disease in an Area of North Tyneside in the 
North-East of England. Neuroepidemiology, 2006. 26(3): p. 156-161. 
149. Hobson, P., J. Gallacher, and J. Meara, Cross-sectional survey of Parkinson’s disease and 
parkinsonism in a rural area of the United Kingdom. Mov Disord, 2005. 20: p. 995-998. 
150. Schrag, A., Y. Ben-Shlomo, and N.P. Quinn, Cross sectional prevalence survey of idiopathic 
Parkinson’s disease and Parkinsonism in London. . BMJ, 2000. 321: p. 21-2. 
151. MacDonald, B.K., et al., The incidence and lifetime prevalence of neurological disorders in a 
prospective community-based study in the UK. Brain, 2000. 123: p. 665-676. 
484 
 
152. Mutch, W.J., I. Dingwall-Fordyce, and A.W. Downie, Parkinson’s disease in a Scottish city. 
BMJ, 1986. 292: p. 534-536. 
153. Sutcliffe, R.L., R. Prior, and B. Mawby, Parkinson’s disease in the district of the 
Northampton Health Authority, United Kingdom. A study of prevalence and disability. Acta 
Neurol Scand, 1985. 72: p. 363-379. 
154. Brewis, M., D.C. Poskanzer, and C. Rolland, Neurological disease in an English city. Acta 
Neurol Scand, 1966. 42 (Suppl 24): p. 1-89. 
155. Broe, G.A., A.J. Akhtar, and G.R. Andrews, Neurological disorders in the elderly at home. 
Journal of Neurology Neurosurgery and Psychiatry, 1976 39: p. 362-366. 
156. Schoenberg, B.S., D.W. Anderson, and A.F. Haerer, Prevalence of Parkinson's disease in the 
biracial population of Copiah county, Mississippi. Neurology, 1985. 35: p. 841-845. 
157. Van Den Eeden, S.K., et al., Incidence of Parkinson’s Disease: Variation by Age, Gender, and 
Race/Ethnicity. American Journal of Epidemiology, 2003. 157(11): p. 1015-22. 
158. Berger, K.M., et al., Prognosis with Parkinson’s Disease in Europe: A Collaborative Study of 
Population-Based Cohorts: Neurologic Diseases in the Elderly Research Group. Neurology, 
2000. 54(11 Suppl 5): p. S24-27. 
159. Mathers, C.D., Global burden of disease in 2002:data sources, methods and results. GPE 
Discussion Paper, 2004. 54. 
160. Dotchin, C.L., O. Msuya, and R.W. Walker, The challenge of Parkinson's disease 
management in Africa. Age Ageing, 2007. 36(2): p. 122-127. 
161. Dotchin, C.L., J. A., and W. R.W., Three year follow up of Levodopa plus Carbidopa 
treatment in a prevalent cohort of patients with Parkinson’s disease in Hai, Tanzania. J 
Neurol., 2011: p. (in press). 
162. Cilia, R., et al., Parkinson’s disease in sub-Saharan Africa: step-by-step into the challenge. 
Neurodegenerative Disease Management, 2011. 1(3): p. 193-202. 
163. Litvan, I., et al., Movement Disorders Society Scientific Issues Committee Report SIC Task 
Force Appraisal of Clinical Diagnostic Criteria for Parkinsonian Disorders. Movement 
Disorders, 2003. 18(5): p. 467-486. 
164. Grosset, D., Differential Diagnosis ofParkinsonism and Tremor, in Birmingham Movement 
Disorders Course. 2010: Birmingham. p. 39-54. 
165. Nath, U., et al., Clinical features and natural history of progressive supranuclear palsy: a 
clinical cohort study. Neurology, 2003. 2003(60): p. 910-6. 
166. Osaki, Y., Y. Ben-Shlomo, and A.J. Lees, Accuracy of clinical diagnosis of progressive 
supranuclear palsy. Movement Disorders, 2003. 19: p. 181-9. 
167. Litvan, I., G. Campbell, and C.A. Mangone, Clinical research criteria for the diagnosis of 
progressive supranuclear palsy (Steel-Richardson-Olszewski syndrome): report of the 
NINDS-SPS international workshop. Neurology, 1996. 1996(47): p. 1-9. 
168. Gilman, S., G.K. Wenning, and P.A. Low, Second consensus statement on the diagnosis of 
multiple system atrophy. Neurology, 2008. 26(71): p. 9. 
169. Mahapatra, R.K., et al., Corticobasal degeneration. Lancet Neurology 2004. 3: p. 736-43. 
170. Thanvi, B., N. Lo, and T. Robinson, Vascular parkinsonism—an important cause of 
parkinsonism in older people. Age and Ageing, 2005. 34: p. 114-119. 
171. Winikates, J. and J. Jankovic, Clinical correlates of vascular parkinsonism. Arch Neurol, 
1999. 56: p. 98-102. 
172. Hirose, G., Drug Induced Parkinsonism. A Review. . Journal of Neurology 2006. 
253(Supplement 3): p. 3004-8. 
173. Hebb, A.O. and M.D. Cusimano, Idiopathic normal pressure hydrocephalus: a systematic 
review of diagnosis and outcome. Neurosurgery, 2001. 49(5): p. 1166-1186. 
485 
 
174. World Health Organisation, Atlas of headache disorders and resources in the world 2011. A 
collaborative project of the World Health Organisation and Lifting The Burden. . 
http://www.who.int/mental_health/management/who_atlas_headache_disorders.pdf. 
175. Steiner, T.J., Lifting the burden: the global campaign against headache. Lancet Neurol, 
2004. 3: p. 204-5. 
176. Headache Classification Committee of the International Headache Society, Classification 
and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. 
Cephalalgia, 1988. 8(Suppl. 7): p. 1-96. 
177. International Headache Society, ICD-10 Guide for Headaches. Cephalalgia, 1997. 17: p. 1-
91. 
178. Headache Classification Subcommittee of the International Headache Society, The 
International Classification of Headache Disorders, 2nd Edition. Cephalalgia, 2004. 24: p. 1-
160. 
179. International Headache Society, International classification of headache disorders - Second 
edition. International headache society website www.ihs-classification.org, 2003. 
180. Stovner, L.J., et al., The global burden of headache: a documentation of headache 
prevalence and disability worldwide Cephalalgia, 2007. 27: p. 193-210. 
181. Rasmussen, B.K., Epidemiology of headache. Cephalalgia, 1995. 15: p. 45-68. 
182. World Health Organisation, Factsheet 277 
http://www.who.int/mediacentre/factsheets/fs277/en/index.html  
http://www.who.int/mental_health/neurology/headache/en/index.html. 2012. 
183. Castillo, J., Epidemiology of chronic daily headache in the general population. Headache, 
1999. 39: p. 190-196. 
184. Srikiatkhachorn, A. and K. Phanthumchinda, Prevalence and clinical features of chronic 
daily headache in a headache clinic. . Headache 1997. 37: p. 277-280. 
185. Fischera, M., et al., The incidence and prevalence of cluster headache: a meta-analysis of 
population based studies. 
186. Alders, E.E., A. Hentzen, and C.T. Tan, A community-based prevalence study on headache 
in Malaysia. Headache 1996. 36: p. 379-384. 
187. Tekle-Haimanot, R., B. Seraw, and L. Forsgren, Migraine, chronic tension-type headache, 
and cluster headache in an ethiopian rural community. Cephalalgia, 1995. 15: p. 482-488. 
188. Scher, A.I., W.F. Stewart, and R.B. Lipton, Migraine and headache: a meta-analytic 
approach. Epidemiology of pain., 1999: p. 159-170. 
189. Lisk, D.R., Severe headache in the African. report on 250 cases from Sierra Leone, West 
Africa. Headache, 1987. 27: p. 477-483. 
190. Matuja, W.B., Headache: pattern and features as experienced in a neurology clinic in 
Tanzania. East Afr Med J 1991. 68: p. 935-943. 
191. Matuja, W.B., I.B. Meteza, and H.T. Rwiza, Headache in a nonclinical population in Dar es 
Salam, Tanzania. Headache, 1995. 35: p. 273-276. 
192. Adoukonou, T., et al., Migraine Among University Students in Cotonou (Benin)  Headache, 
2009. 49: p. 887-893. 
193. Osuntokun, B.O., et al., Migraine Headache in a Rural Community in Nigeria: Results of a 
Pilot Study. Neuroepidemiology, 1982. 1: p. 31-39. 
194. Osuntokun, B.O., et al., Prevalence of headache and migrainous headache in Nigerian 
Africans: a community based study. East Afr Med J, 1992. 69: p. 196-199. 
195. Levy, L.M., An epidemiological study of headache in an urban population in Zimbabwe. 
Headache, 1983. 23: p. 2-9. 
196. Dent, W., et al., Prevalence of migraine in a rural area of South Tanzania: a door to door 
survey. Cephalgia, 2004. 24: p. 960-966. 
197. Ba´nk, J. and S. Ma´ rton, Hungarian migraine epidemiology. Headache, 2000. 40: p. 164-9. 
486 
 
198. Göbel, H., M. Petersen-Braun, and D. Soyka, The epidemiology of headache in Germany: a 
nationwide survey of a representative sample on the basis of the headache classification of 
the International Headache Society. Cephalalgia, 1994. 14: p. 97-106. 
199. Stewart, W.F., et al., Prevalence of migraine headache in the United States. Relation to 
age, income, race, and other sociodemographic factors. JAMA 1992. 267: p. 64-9. 
200. O'Brien, B., R. Goeree, and D. Steiner, Prevalence of migraine headache in Canada: a 
population-based survey. Int J Epidemiology, 1994. 23: p. 1020-6. 
201. Wong, T.W., et al., Prevalence of migraine and other headaches in Hong Kong. 
Neuroepidemiology 1995. 14: p. 82-91. 
202. Zaho, F., et al., Epidemiology of migraine: a survey in 21 provinces of the People’s Republic 
of China,. Headache, 1988. 28: p. 558-65. 
203. Cheng, X.M., et al., An epidemiologic survey of migraine in six cities in China. . Chin J 
Neurol 1990. 23: p. 44-6. 
204. Houinato, D., et al., Prevalence of Migraine in a Rural Community in South Benin 
Cephalalgia, 2010. 30(1): p. 62-67. 
205. Winkler, A.S., et al., The Prevalence of Headache With Emphasis on Tension-Type 
Headache in Rural Tanzania: A Community-Based Study Cephalalgia, 2009 29(12): p. 1317-
1325. 
206. Winkler, A.S., et al., Prevalence of migraine headache in a rural area of northern Tanzania: 
a community-based door-to-door survey. Cephalalgia, 2010. 30(5): p. 582-592. 
207. Ogunyemi, A.O., Prevalence of headache among Nigeria University students. . Headache, 
1984. 24: p. 127-30. 
208. Friedman, A.P., et al., Classification of headache (Ad Hoc committee on classification of 
headache). JAMA, 1962. 179: p. 717-8. 
209. The World Health Organization, WHO MONICA project (monitoring trends and 
determinanats in cardiovascualr disease) a major international collaberation Journal of 
clinical epidemiology, 1988. 41: p. 105-114. 
210. Poungvarin, N., A. Viriyavejakul, and C. Komontri, Siriraj Stroke Score and Validation Study 
to Distinguish Supratentorial Intracerebral Haemorrhage from infarction. British Medical 
Journal, 1991. 302: p. 1565-1567. 
211. Celani, M.G., E. Righetti, and R. Migliacci, Comparibility and validity of two clinical scores in 
the early differential diagnosis of acute stroke British Medical Journal, 1994 308: p. 1674-
1676. 
212. Bamford, J., et al., Classification and natural history of clinically identifiable subtypes of 
cerebral infarction. Lancet, 1991. 337(8756): p. 1521-1526. 
213. Walker, R., et al., Stroke incidence in rural and urban Tanzania: a prospective, community-
based study. Lancet Neurology, 2010. 9(8): p. 786-792. 
214. Lopez, A.D., et al., Global and regional burden of disease and risk factors, 2001: systematic 
analysis of population health data. Lancet, 2006. 367: p. 1747-57. 
215. Mathers, C.D., et al., The burden of disease and mortality by condition: data, methods and 
results for 2001. Global burden of disease and risk factors.New York Oxford University 
Press, 2006: p. 45-240. 
216. Connor, M.D., et al., Burden of stroke in black populations in sub-Saharan Africa. Lancet 
Neurology, 2007. 6(3): p. 269-278. 
217. Mahony, P.G., et al., Validation of a population screening questionnaire to assess 
prevalence of stroke. Stroke, 1995. 26: p. 1334-37. 
218. Geddes, J.M., et al., Prevalence of self reported stroke in a population in northern England. 
J Epidemiol Community Health 1996. 50: p. 140-43. 
487 
 
219. Connor, M.D., et al., Prevalence of stroke survivors in rural South Africa: results from the 
Southern Africa Stroke Prevention Initiative (SASPI) Agincourt field site. Stroke, 2004. 35: p. 
627-32. 
220. Connor, M.D., et al., The South African Stroke Risk in General Practice Study. SAMJ, 2005. 
95: p. 334-338. 
221. Bonita, R., N. Solomon, and J.B. Broad, Prevalence of Stroke and Stroke-Related Disability  
Estimates From the Auckland Stroke Studies Stroke, 1997. 28: p. 1898-1902. 
222. Danesi, M., N. Okubadejo, and F. Ojini, Prevalence of stroke in an urban, mixed-income 
community in Lagos, Nigeria. Neuroepidemiology, 2007. 28(4): p. 216-223. 
223. Cossi, M.J., et al., Stroke: prevalence and disability in Cotonou, Benin. Cerebrovascular 
Diseases., 2012. 33(2): p. 166-72. 
224. Sudlow, C.L.M. and C.P. Warlow, Comparing stroke incidence worldwide. Stroke, 1996. 27: 
p. 550-558. 
225. Feigin, V.L., et al., Worldwide stroke incidence and early case fatality reported  in 56 
population-based studies: a systematic review. Lancet Neurol, 2009. 8: p. 355-69. 
226. Lavados, P.M., C. Sacks, and L. Prina, Incidence, 30-day case-fatality  rate, and prognosis of 
stroke in Iquique, Chile: a 2-year  community-based prospective study (PISCIS project). 
Lancet, 2005. 365: p. 2206-15. 
227. Corbin, D.O.C., V. Poddar, and A. Hennis, Incidence and case fatality  rates of fi rst-ever 
stroke in a black Caribbean population: the Barbados register of strokes. . Stroke, 2004. 35: 
p. 1254-58. 
228. Minelli, C., L.F. Fen, and D.P.C. Minelli, Stroke incidence, prognosis,  30-day, and 1-year 
case fatality rates in Matao, Brazil: a population-based prospective study. Stroke, 2007. 38: 
p. 2906-11. 
229. Dalal, P.M., S. Malik, and M. Bhattacharjee, Population-based stroke  survey in Mumbai, 
India: incidence and 28-day case fatality. Neuroepidemiology, 2008. 31: p. 254-61. 
230. Wang, W.Z., B. Jiang, and S.P. Wu, Change in stroke incidence from  a population-based 
intervention trial in three urban communities in China. Neuroepidemiology, 2007. 28: p. 
155-61. 
231. Edwards, R., N. Unwin, and F. Mugusi, Hypertension prevalence and care in an urban and 
rural area of Tanzania. J Hypertens, 2000. 18: p. 145-52. 
232. Aspray, T.J., F. Mugusi, and S. Rashid, Rural and urban differences in diabetes prevalence in 
Tanzania: the role of obesity, physical inactivity and urban living. . Trans R Soc Trop Med 
Hyg, 2000. 94: p. 637-44. 
233. Osuntokun, B.O., et al., Incidence of stroke in an African city: results from the stroke 
registry at Ibadan, Nigeria, 1973–1975. . Stroke 1979. 10: p. 205-07. 
234. Matenga, J., Stroke incidence rates among black residents of Harare: a prospective 
community-based study. . S Afr Med J 1997. 87: p. 606-09. 
235. Rosman, K.D., The epidemiology of stroke in an urban black population. Stroke, 1986. 17: 
p. 667-69. 
236. Walker, R.W., et al., Stroke Mortality in Urban and Rural Tanzania: Adult Morbidity and 
Mortality Project. The Lancet, 2000. 335(9216): p. 1684-1687. 
237. Sacco, R.L., B. Boden-Albala, and R. Gan, Stroke incidence among white, black, and 
Hispanic residents of an urban community: the Northern Manhattan Stroke Study. . Am J 
Epidemiol 1998. 147: p. 259-68. 
238. Feigin, V.L., et al., Stroke epidemiology: a review of population-based studies of incidence, 
prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003. 2: p. 43-53. 
239. Razum, O., Monitoring cardiovascular disease in Zimbabwe: a review of needs and options. 
. Cent Afr J Med 1996. 42: p. 120-24. 
488 
 
240. Bradshaw, D., et al., South African cause-of-death profi le in transition—1996 and future 
trends. S Afr Med J, 2002. 92: p. 618-23. 
241. Dennis, M.S., et al., Rapid resolution of signs of primary intracerebral haemorrhage in 
computed tomograms of the brain. BMJ, 1987. 295: p. 379-81. 
242. Dennis, M.S., J.M. Bamford, and C.P. Warlow, Strokes among black people in Harare, 
Zimbabwe [letter]. . BMJ ClinRes, 1994: p. 134. 
243. Warlow, C.P., Epidemiology of stroke. Lancet 1998. 352: p. 1-4. 
244. Murray, C.J.L. and A.D. Lopez, Mortality by cause for eight regions of the world: global 
burden of disease study. Lancet 1997. 249: p. 1269-76. 
245. Lisk, D.R. and E.K. McEwen, The significance and trend of hypertension related deaths in 
urban Sierra Leonean Africans. J Hum Hypertens, 1996. 10: p. 215-18. 
246. INDEPTH network, Population and health in developing countries. Ottawa: International 
Development Research Centre,. 2002. 
247. Kahn, K. and S.M. Tollman, Stroke in rural South Africa-contributing to the little known 
about a big problem. South African Medical Journal,, 1999. 77: p. 248-251. 
248. Office for National Statistics, Mortality statistics—cause: review of the Registrar General 
on deaths by cause, sex, and age, in England and Wales, 1993 (revised) and 1994. Office of 
National Statistics: United Kingdom,, 1996. 
249. Kahn, K., et al., Validation and application of verbal autopsies in a rural area of South 
Africa. Trop Med Int Health, 2000. 5: p. 824-31. 
250. Chukwumeka, A.C., J.O.M. Pobee, and E. Larbi, Are cardiovascular diseases important 
causes of mortality in Africa? Results of a WHO/UGMS cardiovascular disease follow-up 
study over a five year period in a suburb of Accra. . Trop Cardiol, 1982. 8: p. 105-09. 
251. Walker, A.R. and H. Grusin, Coronary heart disease and cerebral vascular disease in the 
South African Bantu: examination and discussion of crude and age-specific death rates. . 
Am J Clin Nutr, 1959. 7: p. 264-70. 
252. Walker, A.R., Mortality from coronary heart disease and from cerebral vascular disease in 
the different racial populations in South Africa. S Afr Med J, 1963. 37: p. 1155-59. 
253. Wyndham, C.H., Mortality from cardiovascular diseases in the various population groups in 
the Republic of South Africa. . S Afr Med J, 1979. 56: p. 1023-30. 
254. Wyndham, C.H., Trends with time of cardiovascular mortality rates in the populations of 
the RSA for the period 1968–1977. . S Afr Med J 1982. 61: p. 987-93. 
255. Botha, J.L. and D. Bradshaw, African vital statistics—a black hole? S Afr Med J, 1985. 67: p. 
977-81. 
256. Unwin, N., Non-communicable disease and priorities for health policy in sub-Saharan 
Africa. Health Policy Plan, 2001. 16: p. 351-52. 
257. Caldwell, J.C., Population health in transition. Bull World Health Organ, 2001. 79: p. 159-
60. 
258. Walker, R.W., N. Unwin, and K.G. Alberti, Hypertension treatment and control in Sub-
saharan Africa. Burden of cerebrovascular disease will increase as more people survive to 
old age. . BMJ, 1998. 317: p. 76-77. 
259. Obiako, O.R., S.K. Oparah, and A. Ogunniyi, Prognosis and outcome of acute stroke in the 
University College Hospital Ibadan, Nigeria. Nigerian Journal of Clinical Practice, 2011. 
14(3). 
260. Joubert, J., The MEDUNSA stroke data bank: an analysis of 304 patients seen between 
1986 and 1987. S Afr Med J, 1991. 80: p. 567-70. 
261. Walker, R.W., et al., Mortality and recovery after stroke in the Gambia. Stroke, 2003. 34: p. 
1604-09. 
262. Sene Diouf, F., A.M. Basse, and K. Toure, Prognosis of stroke in department of neurology of 
Dakar. Dakar Medical, 2006. 51: p. 17-21. 
489 
 
263. Sene Diouf, F., A.M. Basse, and A.K. Ndao, Pronostic fonctionnel des accidents vasculaires 
cerebraux dans les pays en voie de developpement : Senegal. Ann Readapt Med Phys, 
2006. 49: p. 100-04. 
264. Keir, S.L., J.M. Wardlaw, and C.P. Warlow, Stroke epidemiology studies have 
underestimated the frequency of intracerebral haemorrhage: a systematic review of 
imaging in epidemiological studies. J Neurol, 2002. 249: p. 1226-31. 
265. Wardlaw, J.M., S.L. Keir, and J. Seymour, What is the best imaging strategy for acute 
stroke? . Health Technol Assess 2004. 8: p. 1-180. 
266. Wiredu, E.K. and P.K. Nyame, Stroke-related mortality at Korle Bu Teaching Hospital, 
Accra, Ghana. East Afr Med J., 2001. 78(4): p. 180-4. 
267. Mensah, G.A., Global burden of cardiovascular disease, Epidemiology of stroke and high 
blood pressure in Africa. Heart 2008. 94. 
268. Mating, J., I. Kitai, and L. Levy, Strokes among black people in Harare, Zimbabwe: results of 
computed tomography and associated risk factors. BMJ (Clin Res Ed), 1986. 292: p. 1649-
51. 
269. Connor, M.D. and C. Warlow, Stroke in Sub-Saharan Africa: a systematic review (abstract). 
. Stroke, 2000. 31: p. 2793. 
270. Marmot, M.G. and N.R. Poulter, Primary prevention of stroke. Lancet, 1992. 339: p. 344-7. 
271. Connor, M.D., G. Modi, and C.P. Warlow, Accuracy of the Siriraj and Guy’s Hospital Stroke 
Scores in urban South Africans. Stroke, 2007. 38: p. 62-68. 
272. Nyame, P.K., K.B. Jumah, and S. Adjei, Computerised tomographic scan of the head in 
evaluation of stroke in Ghanaians. East Afr Med J, 1998. 75: p. 637-39. 
273. Kolapo, K.O., et al., Validation study of the Siriraj Stroke score in African Nigerians and 
evaluation of the discriminant values of its parameters: a preliminary prospective CT scan 
study. Stroke, 2006. 37: p. 1997-2000. 
274. Sandercock, P., A. Molyneux, and C. Warlow, Value of computerised tomography in 
patients with stroke: the Oxfordshire Community Stroke Project. BMJ 1985. 290: p. 193-
207. 
275. National Stroke Association, Recovery and Rehabilitation National Stroke Association, 
Englewood www.stroke.org/homepage, 2002. 
276. Chandra, V., et al., eds. Disease control priorities in developing countries. second ed., ed. 
e.a. Jamison D.T. 2006. 
277. Thorvaldsen, P.K., et al., Stroke Incidence, Case Fatality, and Mortality in the WHO 
MONICA Project: World Health Organization Monitoring Trends and Determinants in 
Cardiovascular Disease. Stroke, 1995. 26(3): p. 361-367. 
278. Smaha, L.A., The American Heart Association Get with the Guidelines Program. American 
Heart Journal, 2004. 148(suppl 5): p. S46-48. 
279. Chinese Acute Stroke Trial Collaborative Group, CAST: Randomised Placebo-Controlled 
Trial of Early Aspirin Use in 20,000 Patients with Acute Ischaemic Stroke: CAST (Chinese 
Acute Stroke Trial) Collaborative Group. The Lancet, 1997. 349(9066): p. 1641-49. 
280. International Stroke Trial Collaborative Group, The International Stroke Trial (IST): A 
Randomised Trial of Aspirin, Subcutaneous Heparin, Both, or Neither among 19,435 
Patients with Acute Ischaemic Stroke: International Stroke Trial Collaborative Group. The 
Lancet, 1997. 349(9065): p. 1569-81. 
281. Antithrombotic Trialists’ Collaboration, Collaborative Meta-Analysis of Randomised Trials 
of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High 
Risk Patients. British Medical Journal, 2002. 324(7329): p. 71-86. 
282. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, Tissue 
Plasminogen Activator for Acute Ischemic Stroke:The National Institute of Neurological 
490 
 
Disorders and Stroke rt-PA Stroke Study Group. New England Journal of Medicine, 1995. 
333(24): p. 1581-87. 
283. Sacco, R., J. Sivenius, and H.C. Diener, Efficacy of Aspirin Plus Extended-Release 
Dipyridamole in Preventing Recurrent Stroke in High-Risk Populations. Archives of 
Neurology, 2005. 62: p. 403-8. 
284. Diener, H.C., et al., Aspirin and Clopidogrel Compared with Clopidogrel Alone after Recent 
Ischaemic Stroke or Transient Ischaemic Attack in High-Risk Patients (MATCH): 
Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 2004. 364(9431): p. 301-
7. 
285. European Atrial Fibrillation Trial Study Group, Secondary Prevention in Non-Rheumatic 
Atrial Fibrillation after Transient Ischaemic Attack or Minor Stroke. The Lancet, 1993. 
342(8882): p. 1255-62. 
286. Mohr, J.P., et al., A Comparison of Warfarin and Aspirin for the Prevention of Recurrent 
Ischemic Stroke. New England Journal of Medicine, 2001. 345(20): p. 1444-51. 
287. Asymptomatic Carotid Surgery Trial Collaborative Group, Prevention of Disabling and Fatal 
Strokes by Successful Carotid Endarterectomy in Patients without Recent Neurological 
Symptoms: Randomised Controlled Trial. The Lancet, 2004. 363: p. 1491-502. 
288. Asymptomatic Carotid Atherosclerosis Study, Endarterectomy for Asymptomatic Carotid 
Artery Stenosis. Journal of the American Medical Association, 1995. 273(18): p. 1421-28. 
289. North American Symptomatic Carotid Endarterectomy Trial Collaborators, Beneficial Effect 
of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis: 
North American Symptomatic Carotid Endarterectomy Trial Collaborators. New England 
Journal of Medicine, 1991. 325(7): p. 445-53. 
290. Outpatient Service Trialists, Therapy-Based Rehabilitation Services for Stroke Patients at 
Home. Cochrane Database of Systematic Reviews (2) CD002925., 2002. 
291. Commission on epidemiology and prognosis International league against epilepsy (ILAE), 
Guidelines for epidemiological studies on epilepsy. Epilepsia, 1993. 34: p. 592-596. 
292. Commision on classification and terminology of the international league against epilepsy, 
Proposal for the revised clinical and electroencephalographic classification of epileptic 
seizures. Epilepsia, 1981. 22: p. 489-501. 
293. Berg, A.T., et al., Revised terminology and concepts for organization of seizures and 
epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009. 
Epilepsia, 2010. 51(4): p. 676–685. 
294. Preux, P.M. and M. Druet Cabanac, Epidemiology and aetiology of epilepsy in sub-Saharan 
Africa. Lancet Neurol 2005. 4: p. 21-31. 
295. Newton, C.R. and H.H. Garcia, Epilepsy in poor regions of the world. Lancet, 2012. 
380(9848): p. 1193 - 1201. 
296. World Health Organisation, Epilepsy: an historical overview. Fact Sheet 168. Geneva: WHO, 
2001. 
297. World Health Organisation and E.H. Reynolds, The ILAE/IBE/WHO Global Campaign 
against Epilepsy: Bringing Epilepsy “Out of the Shadows”. . Epilepsy Behav, 2000. 1: p. S3-
S8. 
298. World Health Organisation, WHO Epigraph: The newsletter of the International League 
against Epilepsy. Geneva 1999. 1: p. 5-6. 
299. Mosser, P., E. Schmutzhard, and A.S. Winkler, The pattern of epileptic seizures in rural 
Tanzania. . J Neurol Sci, 2007. 258: p. 33-8. 
300. Winkler, A.S., A. Tluway, and E. Schmutzhard, Aetiologies of altered states of 
consciousness: A prospective hospital-based study in a series of 464 patients of northern 
Tanzania,. Journal of the Neurological Sciences, 2011. 300: p. 47-51. 
491 
 
301. Quet, F., et al., Investigating epilepsy in Africa: 10 years of data collection using a 
standardized questionnaire in 2,269 peoples with epilepsy. Epilepsia,, 2011. 52(10): p. 
1868-1876. 
302. Debrock, C., et al., Estimation of the prevalence of epilepsy in the Benin region of Zinvie 
using the capture-recapture method. International Journal of Epidemiology, 2000. 29: p. 
330-335. 
303. Kabre, D., Epidemiologie de l’epilepsie dans le foyer d’Onchocercose du bassin de la 
Bougouriba (Burkina Faso). These de Doctorat en Medecine Ouagadougou, 1998. 
304. Nsengiyumva, G., M. Druet-Cabanac, and B. Ramanankandrasana, Cysticercosis as a major 
risk factor towards epilepsy in Burundi, East Africa. Epilepsia, 2003. 44: p. 950-55. 
305. Dongmo, L., et al., Cysticercosis and epilepsy: a case–control study in Mbam Valley, 
Cameroon. Bull Soc Pathol Exot, 2004. 97: p. 105-108. 
306. Farnarier, G., et al., Onchocerciasis and epilepsy. Epidemiological survey in Mali. Med Trop, 
2000. 60: p. 151-155. 
307. Druet-Cabanac, M., P.M. Preux, and B. Bouteille, Onchocerciasis and epilepsy: a matched 
case-control study in Central African Republic. Am J Epidemiol 1999. 149: p. 565-70. 
308. Crepin, S., et al., Link between Epilepsy and Malnutrition in a Rural Area of Benin. 
Epilepsia,, 2007. 48(10): p. 1926-1933. 
309. Ngugi, A.K., et al., Incidence of epilepsy: a systematic review and meta-analysis. Neurology 
2011. 77: p. 1005-12. 
310. Kaiser, C., G. Asaba, and M. Leichsenring, High incidence of epilepsy related to 
onchocerciasis in West Uganda. Epilepsy Res, 1998. 30: p. 247-51. 
311. Tekle-Haimanot, R., L. Forsgren, and J. Ekstedt, Incidence of epilepsy in rural central 
Ethiopia. . Epilepsia, 1997. 38: p. 541-46. 
312. Debouverie, M., et al., Epidémiologie de l’épilepsie au Burkina-Faso  Neurologie Tropicale, 
Paris: John Libbey Eurotext, 1993: p. 57-61. 
313. Rwiza, H.T., et al., Prevalence and incidence of epilepsy in Ulanga, a rural Tanzanian 
district: a community-based study. Epilepsia, 1992. 33(6): p. 1051-1056. 
314. Grunitzky, E.K., M. Dumas, and E.M. Mbella, Les épilepsies au Togo. Epilepsies, 1991. 3: p. 
295-303. 
315. Winkler, A.S., et al., Prevalence, incidence, and clinical characteristics of epilepsy--a 
community-based door-to-door study in northern Tanzania. Epilepsia, 2009. 50(10): p. 
2310-2313. 
316. Sander, J.W.A.S. and S.D. Shorvon, Epidemiology of the epilepsies. J Neurol Neurosurg 
Psychiatry, 1996. 61: p. 433-43. 
317. Forsgren, L., E.O. Beghi, and A. Sillanpa, The epidemiology of epilepsy in Europe – a 
systematic review. European Journal of Neurology, 2005. 12: p. 245-253. 
318. Forsgren, L., et al., Epidemiology and prognosis of epilepsy and its treatment. The 
treatment of epilepsy. Oxford: Blackwell Science, , 2004: p. 21-42. 
319. Edwards, T., A.G. Scott, and G. Munyoki, Active convulsive epilepsy in a rural district of 
Kenya: a study of prevalence and possible risk factors. . Lancet Neurol, 2008. 7: p. 50-56. 
320. Cockerell, O.C., et al., Epilepsy in a population of 6000 re-examined: secular trends in first 
attendance rates, prevalence, and prognosis. J Neurol Neurosurg Psychiatry 1995. 58: p. 
570-76. 
321. Mac, T.L., et al., Epidemiology, aetiology, and clinical management of epilepsy in Asia: a 
systematic review. . Lancet Neurol, 2007. 6: p. 533-43. 
322. World Health Organisation, Atlas: epilepsy care in the world. Geneva: World Health 
Organization,, 2005. 
323. Jallon, P., Geographical distribution of epilepsy in the world. Presse Med, 1996: p. 1876-
1880. 
492 
 
324. Jallon, P., Epilepsy in developing countries. . Epilepsia 1997. 38. 
325. Mielke, J., M. Sebit, and B. Adamolekun, The impact of epilepsy on the quality of life of 
people with epilepsy in Zimbabwe: A pilot study. . Seizure, 2000. 9: p. 259-264. 
326. Birbeck, G.L., Epilepsy Curr Epilepsy care in developing countries: part I of II. , 2010. 10: p. 
75-79. 
327. Osuntokun, B.O., A.O. Adeuja, and V.A. Nottidge, Prevalence of the epilepsies in Nigerian 
Africans: a community-based study. Epilepsia, 1987. 28: p. 272-79. 
328. Grunitzky, E.K., A.K. Balogou, and K. Agboli, Cartographie des épilepsies au Togo. 
Communication presented to the 12th Congress of the Pan-African Association of 
Neurological Sciences, Durban (South Africa), , 1996: p. 19-23. 
329. Dumas, M., K. Grunitzky, and M. Deniau, Epidemiological study of neurocysticercosis in 
Northern Togo (West Africa). Acta Leidensia, 1989. 57: p. 191-96. 
330. Balogou, A.A.K., K.E. Grunitzky, and K.A. Beketi, Cysticercose et épilepsie au nord du Togo 
dans le Tone. . Rev Neurol 2000. 156: p. 270-73. 
331. Ngugi, A.K., et al., Estimation of the burden of active and life-time epilepsy: a meta-analytic 
approach. Epilepsia 2010. 51: p. 883-90. 
332. Munyoki, G., et al., Clinical and neurophysiologic features of active convulsive epilepsy in 
rural Kenya: A population-based study. Epilepsia, 2010. 51(12): p. 2370-2376. 
333. Hunter, E., et al., Prevalence of active epilepsy in rural Tanzania: A large community-based 
survey in an adult population. Seizure, 2012. 21: p. 691-698. 
334. Banerjeea, P.N., D. Filippi, and W.A. Hauser, The descriptive epidemiology of epilepsy –a 
review. . Epilepsy Research, 2009. 85: p. 31-45. 
335. Nitiéma, P., et al., Prevalence case-control study of epilepsy in three Burkina Faso villages. . 
Acta Neurol Scand, 2012. 126: p. 270-278. 
336. Simms, V., et al., Prevalence of epilepsy in Rwanda: a national cross-sectional survey. 
Tropical Medicine and International Health, 2008. 13(8): p. 1047-1053. 
337. Gbenou, H.D., Contribution à l’étude de l’association onchocercoseépilepsie: résultats 
préliminaires d’une enquête neuroépidémiologique à Agbogbomé—commune de 
Paouignan, Sous-Préfecture de Dassa, Zoumé, au Bénin. Medical Thesis, Cotonou, Benin,. 
1995. 
338. Avodé, D.G., O.B. Capo-Chichi, and P. Gandaho, Epilepsie provoquée par la cysticercose: a 
propos d’une enquête sociologique et culturelle réalisée à Savalou au Bénin. Bull Soc Pathol 
Exot 1996. 89: p. 45–47. 
339. Nkwi, P.N. and F.T. Ndonko, The epileptic among the bamilékés of Maham in the Nde 
division, West Province of Cameroon. . Cult Med Psychiatry, 1989. 13: p. 437-48. 
340. Dongmo, L., D. Ndo, and G. Atchou, Epilepsie au Sud-Cameroun: enquête préliminaire dans 
le village de Bilomo. Bull Soc Pathol Exot, 2000. 93: p. 266-67. 
341. Tekle-Haimanot, R., L. Forsgren, and M. Abebe, Clinical and electroencephalographic 
characteristics of epilepsy in rural Ethiopia: a community-based study. . Epilepsy Res, 1990. 
7: p. 230-39. 
342. Kouassi B, K.J., Diarra JA, et al. .1988; 89: 25–30., Prévalence de l’épilepsie en milieu rural 
ivoirien: étude pilote. Pub Méd Afr 1988. 89: p. 25-30. 
343. Kouadjo, Y., Génétique et épilepsie : à propos d’un foyer d’épilepsie observé dans un village 
ivoirien. Medical Thesis, Abidjan, Cote d’Ivoire, 1990. 
344. Kaudjhis, P.J.R., Les agrégats de l’épilepsie de M’brou : approche électro-clinique et 
étiologique. Medical Thesis, Abidjan, Cote d’Ivoire, 1995. 
345. Kaamugisha, J. and A.T. Feksi, Determining the prevalence of epilepsy in the semi-urban 
population of Nakuru, Kenya, comparing two independent methods not apparently used 
before in epilepsy studies. Neuroepidemiology., 1988. 7(3): p. 115-21. 
493 
 
346. Goudsmit, J., F.W. Van Der Waals, and D.C. Gajdusek, Epilepsy in the Gbawein and 
Wroughbarh clan of Grand Bassa County, Liberia: the endemic occurrence of “See-ee” in 
the native population. Neuroepidemiology, 1983. 2: p. 24-34. 
347. Andriantseheno, L.M. and D. Dalaizandriny, Prévalence communautaire de l’épilepsie chez 
les malgaches. Epilepsies, 2004. 16: p. 83-86. 
348. Ndiaye, I.P., J.B. Mauferon, and M. Diagne, Epidémiologie de l’épilepsie au Sénégal. 
Communication presented to the 7th Congress of the Pan-African Association of 
Neurological Sciences, Abidjan, (Cote d’Ivoire),, 1986. 
349. Diop, A.G., O.L. Agbohous, and M. Ndiaye, Prévalence de l’épilepsie en milieu scolaire 
sénégalais. Communication presented to the 12th Congress of the Pan-African Association 
of Neurological Sciences, Durban (South Africa), 1996. 
350. Kaiser, C., W. Kipp, and G. Asaba, The prevalence of epilepsy follows the distribution of 
onchocerciasis in a West Ugandan focus. Bull WHO, 1996. 74: p. 361-67. 
351. Birbeck, G.L. and E.M.N. Kalichi, Epilepsy prevalence in rural Zambia: a door-to-door 
survey. Trop Med Intern Health, 2004. 9: p. 92-95. 
352. Forsgren, L., et al., Mortality of epilepsy in developed countries: a review. Epilepsia 2005. 
46(suppl 11): p. 18-27. 
353. Kaiser, C., et al., Mortality from epilepsy in an onchocerciasis-endemic area in west 
Uganda. . Trans R Soc Trop Med Hyg 2007(101): p. 48-55. 
354. Jilek-Aall, L. and H.T. Rwiza, Prognosis of epilepsy in a rural African community: a 30-year 
follow-up of 164 patients in an outpatient clinic in rural Tanzania. Epilepsia, 1992. 33: p. 
645-50. 
355. Kamgno, J., S.D.S. Pion, and M. Boussinesq, Demographic impact of epilepsy in Africa: 
results of a 10-year cohort study in a rural area of Cameroon. Epilepsia, 2003. 44: p. 956-
63. 
356. Herman, S.T., Where in the World Are We? Generalizing the Results of Status Epilepticus 
Trials. Epilepsy Curr, 2009. 9(2): p. 38-40. 
357. Ogunniyi, A., B.O. Osuntokun, and O. Bademosi, Risk factors for epilepsy: case control 
study in Nigeria. Epilepsia, 1987. 28: p. 280-85. 
358. Bademosi, O., A. Ogunniyi, and B.O. Osuntokun, Febrile convulsion as a risk factor for 
epilepsy in Nigerians: a case control study. Afr J Neurol Sci 1989. 8: p. 20-23. 
359. Matuja, W.B., G. Kilonzo, and P. Mbena, Risk factors for epilepsy in a rural area in 
Tanzania. A community-based case-control study. . Neuroepidemiology 2001. 20: p. 242-
47. 
360. Newell, E.D., F. Vyungimana, and J.E. Bradley, Epilepsy, retarded growth and 
onchocerciasis, in two areas of different endemicity of onchocerciasis in Burundi. . Trans R 
Soc Trop Med Hyg 1997. 91: p. 525-27. 
361. Winkler, A.S., et al., Epilepsy and neurocysticercosis in sub-Saharan Africa, . Wien Klin 
Wochenschr 2009. 121(suppl 3): p. 3-12. 
362. Pal, D.K., A. Carpio, and J.W.A.S. Sander, Neurocystercerscosis in  developing countries, . J 
Neurol Neurosurg Psychiatry, 2000. 68: p. 137-143. 
363. Singhi, P., et al., Clinical spectrum of 500 children with neurocysticercosis and response to 
albendazole therapy. J Child Neurol 2000. 15: p. 207-213. 
364. Mbuba, C.K., et al., The epilepsy treatment gap in developing countries: a systematic 
review of the magnitude, causes, and intervention strategies. Epilepsia 2008. 49: p. 1491-
503. 
365. Scott, R.A., S.D. Lhatoo, and J.W.A.S. Sander, The treatment of epilepsy in developing 
countries: where do we go from here? Bulletin of the World Health Organization 2001. 
79(344-51). 
494 
 
366. Meyer, A.C., T. Dua, and J. Ma, Global disparities in the epilepsy treatment gap: a 
systematic review. Bull World Health Organ 2010. 88: p. 260-66. 
367. Kale, R., Global campaign against epilepsy: the treatment gap. . Epilepsia, 2002. 43(Suppl. 
6): p. 31-3. 
368. Meinardi, H.R., et al., The Treatment Gap in Epilepsy: The Current Situation and Ways 
Forward. Epilepsia, 2001. 42(1): p. 136-49. 
369. Coleman, R., L. Loppy, and G. Walgraven, The treatment gap and primary health care for 
people with epilepsy in rural Gambia. Bull World Health Organ, 2002. 80: p. 378-83. 
370. Mbuba, C.K., A.K. Ngugi, and G. Fegan, Risk factors associated with the epilepsy treatment 
gap in Kilfi , Kenya: a cross-sectional study. Lancet Neurology, 2012. 11(8): p. 688-696. 
371. Ndoye, N.F., A.D. Sow, and A.G. Diop, Prevalence of epilepsy, its treatment gap and 
knowledge, attitude and practice of its population in sub-urban Senegal, an ILAE/IBE/WHO 
study. Seizure, 2005. 14: p. 106-11. 
372. Ogunniyi, A., O.S.A. Oluwole, and B.O. Osuntokun, Two-year remission in Nigerian 
epileptics. . East Afr Med J, 1998. 75: p. 392-95. 
373. Bruckner, T.A., R.M. Scheffler, and G. Shen, The mental health workforce gap in low- and 
middle-income countries: a needs-based approach. Bull World Health Organ 2011. 89: p. 
184-94. 
374. Mushi, D., et al., Social-cultural aspects of epilepsy in Kilimanjaro Region, Tanzania: 
Knowledge and experience among patients and carers. Epilepsy & Behavior 2011: p. 338-
343. 
375. Sander, J.W., The use of antiepileptic drugs—principles and practice. . Epilepsia, 2004. 
45(suppl 6): p. 28-34. 
376. Zaccara, G., Neurological comorbidity and epilepsy: implications for treatment. Acta Neurol 
Scand, 2009. 120: p. 1-15. 
377. International League Against Epilepsy, Evidence based guideline: Antiepileptic drug 
selection for people with HIV/AIDS: Report of the Quality Standards Subcommittee of the 
American Academy of Neurology and the AdHoc Task Force of the Comission on 
Therapeutic Strategies of the International League Against Epilepsy, . Neurology, 2012. 
78(2): p. 139-145. 
378. Chisholm, D. and S. Saxena, Cost effectiveness of strategies to combat neuropsychiatric 
conditions in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ 
2012. 344: p. 609. 
379. Janca, A., L. Prilipko, and J.A. Costa e Silva, The World Health Organisation's global 
iniitiative on neurology and public health. Journal of the Neurological Sciences, 1997. 145: 
p. 1-2. 
380. Gwatkin, D.R., M. Guillot, and P. Heuveline, The burden of disease among the global poor. 
Lancet, 1999. 354: p. 586-589. 
381. Janca, A., L. Prilipko, and J.A. Costa e Silva, The World Health Organisation's work on public 
health aspects of neurology. Journal of Neurology, Neurosurgery and Psychiatry, 1997. 
63(Suppl 1): p. S6-7. 
382. Janca, A., L. Prilipko, and B. Saraceno, A World health Organisation perspective on 
neurology and neuroscience. . Archives of Neurology, 2000. 57: p. 1786-1788. 
383. Owolabi, M.O., J.H. Bower, and A. Ogunniyi, Mapping Africa's way into prominence in the 
field of neurology. Arch Neurol, 2007. 64(12): p. 1696-1700. 
384. Janca, A., WHO/WFN survey on neurological services: a world-wide perspective. Journal of 
the Neurological Sciences, 2006. 247: p. 29-34. 
385. World Health Organisation, Atlas: Country resources for neurological disorders Geneva: 
World Health Organisation, 2004. 
495 
 
386. Murray, C.J.L., A.D. Lopez, ., and D.T. Jamison, The global burden of disease in 1990: 
summary results, sensitivity analyses, and future directions. Bulletin of the World Health 
Organisation, 1994. 72: p. 495-508. 
387. Lopez, A.D. and C.J.L. Murray, The global burden of disease, 1990-2020. Nature Medicine, 
1998. 4: p. 1241-1243. 
388. Barendregt, l.J.J., A generic model for the assessment of disease epidemiology: the 
computational basis of DisMod II. Population Health Metrics, 2003. 1: p. e4. 
389. Lopez, A.D., et al., Global and regional burden of disease and risk factors, 2001: systematic 
analysis of population data. Lancet, 2006. 367(9524): p. 1747-1757. 
390. Bergen, D.C., The world-wide burden of neurologic disease. Neurology, 1996. 47(1): p. 21-
25. 
391. Bergen, D.C. and D. Silberberg, Nervous system disorders: a global epidemic. Arch Neurol, 
2002. 59(7). 
392. Coleman, R., Disease Burden in sub-Saharan Africa. Lancet, 1998. 351: p. 1208-1209. 
393. Mathers, C.D., Sensitivity and uncertainty analyses for burden of disease and risk factor 
estimates In Lopez AD et al., eds. Global burden of disease and risk factors. The World 
Bank and Oxford University Press, 2006. 
394. Winkler, A.S., P. Mosser, and E. Schmutzhard, Neurological disorders in rural Africa: a 
systematic approach. Tropical doctor, 2009. 39(2): p. 102-104. 
395. Kwasa, T., The pattern of neurological disease at Kenyatta National Hospital. East Africa 
Medical journal, 1992. 69: p. 236-239. 
396. Mateen, F.J., et al., Reportable neurologic diseases in refugee camps in 19 countries. 
Neurology, 2012. 79(9): p. 937-40. 
397. Attia Romdhane, N., Prevalence study of neurologic disorders in Kelibia (Tunisia). 
Neuroepidemiology, 1993. 12: p. 285-299. 
398. Munoz, M., et al., Prevalence of Neurological Disorders in Haute-Vienne Department 
(Limousin Region – France) Neuroepidemiology, 1995. 14: p. 193-198. 
399. Nakashimaa, K., et al., Prevalence of Neurological Disorders in a Japanese Town. 
Neuroepidemiology, 1996. 15: p. 208-213. 
400. Perkin, D.G., The impact of neurological illness and disability. The likely impact of 
demographic changes on the incidence and prevalence of neurological disease: 
demography in the United Kingdom. J Neurol Neurosurg Psychiatry 1997. 63: p. S8-S10. 
401. Aarli, J.A., A. Gallo Diop, and H. Lochmuller, Neurology in sub-Saharan Africa. A challenge 
for World Federation of Neurology. . Neurology 2007. 69: p. 1715-1718. 
402. Association of British Neurologists, Neurology in the United Kingdom towards 2000 and 
beyond. London: ABN, 1997. 
403. Larner, A.J. and S.F. Farmer, Clinical Review. Recent Advances. Neurology. British Medical 
Journal, 1999. 319: p. 362-366. 
404. Zarocostas, J., WHO launches programme to extend treatment of mental and neurological 
disorders. British Medical Journal, 2008. 337: p. 2090. 
405. Al-Shahi, R., R.G. Will, and C.P. Warlow, Amount of research interest in rare and common 
neurological conditions: bibliometric study. British Medical Journal, 2001. 323: p. 1461-2. 
406. Gross, C.P., G.F. Anderson, and N.R. Powe, The relation between funding by the national 
institutes of health and the burden of disease. New England Journal of Medicine, 1999. 
340: p. 1881-7. 
407. Global Forum for Health Research, The 10/90 report on health research. Geneva: Global 
forum for health research, 2000. 
408. 2010, W.P.d.s. World Population data sheet. 2010. 2010; 
www.prb.org/pdf10/10WorldDataSheet.pdf.]. 
409. www.geology.com. 
496 
 
410. Nordberg, E. and African Medical and Research Foundation, Health and the elderly in 
developing countries with special reference to sub-Saharan Africa. East African Medical 
Journal, 1997. 74(10): p. 629-33. 
411. The Royal College of Nursing, Report. Ensuring equity and quality for care of elderly people. 
London: RCN 1994. 
412. Hacker, C., Health care for an aging population. . New York: State University of New York 
Press, 1976. 
413. Kinsella, K., Aging in the Third World.. Washington, DC: Bureau of the Census, US 
Department of Commerce, 1988. 
414. Fuchs, V.R., New Priorities for Future Biomedical Innovations. New England Journal of 
Medicine, 2010. 363: p. 706. 
415. Dworkin, R., Life's dominion, an argument about abortion and euthanasia. Harper Collins, 
1993: p. 219-20. 
416. Rivlin, M., Protecting elderly people: flaws in ageist arguments. British Medical Journal, 
1995. 310: p. 1179. 
417. Africa's population and development bulletin, A Note on Aging Africa's population and 
development bulletin, 1999. 
418. Social Administration Unit, University of Ghana, and Legon., International models. Health 
care of the elderly in Africa: focus on Ghana. Caring, 1995. 14(1): p. 42-45 47-49. 
419. Stuck, A.E., J.C. Beck, and M. Egger, Preventing disability in elderly people. The Lancet, 
2004. 364: p. 1641-1642. 
420. Awofeso, N. and A. Rammohan, Elderly Africans have AIDS too. British Medical Journal, 
2010. 341: p. 4169. 
421. Centers for disease control and prevention, HIV/AIDS surveillance report: cases of HIV 
infection and AIDS in the United States and dependent areas. 2007. 
422. Kassu, A., et al., HIV and syphilis infection among elderly people in Northwest Ethiopia. 
Journal of Infectious Diseases, 2004. 57: p. 264-7. 
423. Mmbaga, E.J., et al., Trends in HIV-1 prevalence and risk behaivours over 15 years in a rural 
populaiton in kilimanjaro region of Tanzania. AIDS research and therapy, 2007. 4: p. 23. 
424. Altschuler, J., A.P. Katz, and M. Tynan, Developing and implementing an HIV/AIDS 
educational curriculum for older adults. Gerontologist, 2004. 44: p. 121-6. 
425. Kautz, T., et al., AIDS and the declining support for dependent elderly people in Africa: 
retrospective analysis using demographic and health surveys. British Medical Journal, 
2010. 340: p. 2841. 
426. British Geriatric Society, Rehabilitation of Older People. BGS Best Practice Guide, 2009. 
427. Mahoney, F. and D. Barthel, Functional Evaluation: The Barthel Index. Maryland State 
Medical Journal, 1965. 14: p. 56-61. 
428. Colin, C., et al., The Barthel ADL Index: a reliability study. International Disability Study, 
1988. 10(2): p. 61-3. 
429. Research Unit of the Royal College of Physicians and British Geriatric Society, Standardised 
assessment scales for elderly people SAFE. Royal College of Physicians 1992. 
430. Royal College of Physicians, Report of joint workshops of the Royal College of Physicians 
and the British Geriatrics Society. Standardised assessment scales for elderly people. Royal 
College of Physicians, 1992. 
431. Sainsbury, A., et al., Reliability of the Barthel Index when used with older people. Age and 
Aging, 2005. 34: p. 228-232. 
432. Uyttenboogaart, M., et al., Optimizing Cutoff Scores for the Barthel Index and the Modified 
Rankin Scale for Defining Outcome in Acute Stroke Trials. Stroke, 2005. 36: p. 1984-1987. 
433. Celani, M., et al., Different measures for assessing stroke outcome: an analysis from the 
international stroke trial in Italy. Stroke, 2002. 33(218-223). 
497 
 
434. Kay, R., et al., Dichotomizing stroke outcomes based on self-reported dependency. 
Neurology, 1997. 49: p. 1694-1696. 
435. Heslin, J.M., et al., Health status and service utilisation of older people in different 
European countries. Scandanavian Journal of Primary Health Care 2001. 19: p. 218-22. 
436. The World Health Organization, Developing the World Health Organisation Disability 
Assessment Schedule 2.0 The World Health Organisation Bulletin, 2010. 
437. Central Bureau of Statistics, Kenya population census. 1989. 
438. Bangladesh Bureau of Statistics, Disabled population of Bangladesh, evidence from a 
demographic sample survey. 1987. 
439. Jacoby, A., D. Snape, and G.A. Baker, Epilepsy and social identity: the stigma of a chronic 
neurological disorder. Lancet Neurology, 2005. 4: p. 171-178. 
440. Mshana, G., et al., Urban-rural contrasts in explanatory models and treatment-seeking 
behaivours for stroke in Tanzania. Journal of Biosocial Science, 2008. 40(1): p. 35-52. 
441. Jilek-Aall, L., Psychological study of epilepsy in Africa. Social Science and Medicine, 1997. 
45: p. 783-795. 
442. Butler, R.N., Why Survive? Being old in America. New York: Harper and Row, 1975: p. 11-
12. 
443. Adult Morbidity and Mortality Project (AMMP), Policy Implications of Adult Morbidity and 
Mortality; final report. Dar-es-Salaam:. Tanzanian Ministry of Health 2004. 
http://research.ncl.ac.uk/ammp/finrep/  
444. Talabi, O.A., A 3-year review of neurologic admissions in University College Hospital 
Ibadan, Nigeria. West African Journal of Medicine, 2003. 22: p. 150-1. 
445. Marsden, C.D. and N.P. Quinn, The dystonias. British Medical Journal, 1990. 300: p. 139-
144. 
446. Jarman, P.R. and T.T. Warner, The Dystonias. Journal of Medical Genetics, 1998. 35: p. 
314-318. 
447. Torres-Russottoa, D. and J.S. Perlmuttera, Task-specific dystonia. Ann N Y Acad Sci. , 2008. 
1142: p. 179-199. 
448. National Institutes of Health (NIH) Office of Rare Diseases Research (ORDR), 
www.rarediseases.info.nih.gov. 2011. 
449. Paraïso, M.N., et al., Validation of the Use of Historical Events to Estimate the Age of 
Subjects Aged 65 Years and Over in Cotonou (Benin). Neuroepidemiology, 2010. 35: p. 12-
16. 
450. Findley, L.J. and W.C. Koller, Handbook of Tremor Disorders. New York, 1995. 
451. American Psychiatric Association Task Force on Tardive Dyskinesia, “Tardive Dyskinesia” 
summary of a task force report of the American Psychiatric Association by the Task Force 
on Late Neurological Effects of Antipsychotic drugs. American Journal of Psychiatry, 1980. 
137: p. 1163-1172. 
452. National Institute of Neurological Disorders and Stroke. Motor Neuron Disease Fact Sheet. 
2011. 
453. American Spinal Injury Association, International Standards for Neurological Classifications 
of Spinal Cord Injury. revised ed. Chicago, Ill: American Spinal Injury Association; , 2000: p. 
1-23. 
454. Ditunno, J.F.J., et al., The international standards booklet for neurological and functional 
classification of spinal cord injury. . Paraplegia. , 1994. 32(2): p. 70-80. 
455. Jaretzki, A., et al., Myasthenia gravis: recommendations for clinical research standards. 
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of 
America. Annals of Thoracic Surgery, 2000. 70(1): p. 327-34. 
456. Kjeldsen, S.E., et al., Hypertension Optimal Treatment (HOT) Study: Home Blood Pressure in 
Treated Hypertensive Subjects. Hypertension., 1998. 31: p. 1014-1020. 
498 
 
457. Sherwin, R., et al., The Multiple Risk Factor Intervention Trial (MRFIT): II. The development 
of the protocol. Prey Med, 1981. 10: p. 402-25. 
458. Bassey, E., Demi-span as a measure of skeletal size. Annals of Human Biology 1986. 13(5): 
p. 499-502. 
459. World Health Organisation, WHO Model List of Essential Medicines. 
http://www.who.int/medicines/publications/essentialmedicines/en/index.html, 2011. 
460. Dewhurst, F., et al., Rates of diagnosis and treatment of neurological disorders within a 
prevalent population of community-dwelling elderly people in sub-Saharan Africa. Journal 
of Epidemiology and Global Health, 2012. 2(4): p. 207-214. 
461. Walker, R., et al., Aetiology of stroke in an incident stroke population in Tanzania: first two 
year data for the Tanzania Stroke Incidence Project in the Hai district Age and Ageing, 
2006. 35(Suppl 3): p. 59. 
462. Ahmad, O.B., et al., Age standardisation of rates. A new WHO standard (GPE discussion 
paper series: No 31). Geneva: World Health Organisation, 2001. 
463. Dystonia in Europe Collaborative Group, A prevalence study of primary dystonia in eight 
European countries. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative 
Group. J Neurol. , 2000. 247(10): p. 787-92. 
464. Racette, B.A., A rapid method for mass screening for parkinsonsim. . Movement Disorders, 
2004. 19 (Suppl 9): p. S186. 
465. Dewhurst, F., et al., Neurological disorder screening in the elderly in low-income countries. 
J Neurol., 2012. 259(10): p. 2189-97. 
466. Kaamungisha, J. and A.T. Feksi, Determining the prevalence of epilepsy in the semi-urban 
population of Nakuru, Kenya, comparing two independent methods not apparently used 
before in epilepsy studies. Neuroepidemiology, 1998. 7: p. 115-121. 
467. Patel, V., et al., Prevalence of severe mental and neurological disorders in Mozambique: a 
population-based survey. The Lancet, 2007. 370: p. 1055-1060. 
468. Matuja, W.B.P. and W.J. Makene, Neurological disease pattern in adults admitted to the 
medical wards at Muhimbili Medical Centre. Tanzanian Medical Journal, 1989. 4: p. 18-21. 
469. Deng, H., W. Le, and J. Jankovic, Genetics of essential tremor. Brain, 2007. 130: p. 1456-
1464. 
470. Higgins, J.J., L.T. Pho, and L.E. Nee, A gene (ETM) for essential tremor maps to chromosome 
2p22-p25. Movement Disorders, 1997. 12: p. 859-864. 
471. Gulcher, J.R., P. Jonsson, and A. Kong, Mapping of a familial essential tremor gene, FET1, 
to chromosome 3q13. Nature Genetics, 1997. 17: p. 84-87. 
472. British Medical Journal, Assessment of Ataxia. http://bestpractice.bmj.com/best-
practice/monograph/1097.html. 
473. Muzaimi, M.B., J. Thomas, and S. Palmer-Smith, Population based study of late onset 
cerebellar ataxia in south east Wales. Journal of Neurology Neurosurgery and Psychiatry, 
2004. 75: p. 1129-1134. 
474. Safe, A.F., S. Cooper, and A.C. Windsor, Cerebellar ataxia in the elderly. Journal of the 
Royal Society of Medicine, 1992. 85(8): p. 449-51. 
475. Nafissi, S., et al., Epidemiology of Cerebellar Ataxia on the Etiological Basis: A Cross 
Sectional Study. Acta Medica Iranica, 2009. 47(6): p. 465-468. 
476. Sutcliffe, R.L. and J.R. Meara, Parkinson’s disease epidemiology in the Northampton 
District, England, 1992. Acta Neurol Scand, 1995. 92: p. 443-450. 
477. Nikiforow, T., Headache in a random sample of 200 persons: a clinical study of a 
population in northern Finland. . Cephalalgia, 1981. 1: p. 99-107. 
478. Zivadinov, R., et al., Migraine and tension type headache in Croatia: a population-based 
survey of precipitating factors. Cephalalgia, 2003. 23: p. 336-343. 
499 
 
479. Lipton, R.B., et al., Migraine in the United States: epidemiology and patterns of health care 
use. Neurology, 2002. 58: p. 885-894. 
480. Henry, P., et al., A nationwide survey of migraine in France: prevalence and clinical 
features in adults. GRIM. . Cephalalgia, 1992. 12: p. 229186–37. 
481. Hagen, K., et al., Prevalence of migraine and non-migrainous headache—head-HUNT, a 
large population-based study. Cephalalgia, 2000. 20: p. 900-6. 
482. Rozen, T.D., et al., Incidence of medically recognized migraine: a 1989–1990 study in 
Olmsted County, Minnesota. Headache, 2000. 40: p. 216-223. 
483. Dahlo, F.C. and M. Linde, One-year prevalence of migraine in Sweden: a population-based 
study in adults. Cephalalgia, 2001. 21: p. 664-71. 
484. Steiner, T.J., et al., The prevalence and disability burden of adult migraine in England and 
their relationships to age, gender and ethnicity. Cephalalgia, 2003. 23: p. 519-27. 
485. Stewart, W.F., R.B. Lipton, and J. Liberman, Variation in migraine prevalence by race. 
Neurology, 1996. 47: p. 52-59. 
486. Abduljabbar, M., et al., Prevalence of primary headache syndrome in adults in the Qassim 
Region of Saudi Arabia. Headache, 1996. 36: p. 385-388. 
487. Deleu, D., M.A. Khan, and T.A. Al Shehab, Prevalence and clinical characteristics of 
headache in a rural community in Oman. Headache 2002. 42: p. 963-973. 
488. Miranda, H., et al., Prevalence of headache in Puerto Rico. . Headache 2003. 43: p. 774778. 
489. Garcia-Pedroza, F., et al., Prevalence survey of headache in a rural Mexican village. 
Neuroepidemiology, 1991(10). 
490. Boardman, H.F., et al., Epidemiology of headache in an English district. Cephalalgia, 2003. 
23: p. 129-137. 
491. Waters, W.E., The Pontypridd headache survey. Headache, 1974: p. 81-90. 
492. Queiroz, L.P., L.M. Barea, and N. Blank, An epidemiological study of headache in 
Florianopoli, Brazil. . Cephalalgia 2006. 26: p. 122-7. 
493. Cheung, R., Prevalence of migraine, tension-type headache, and other headaches in Hong 
Kong. . Headache 2000. 40: p. 473-9. 
494. Takeshima, T., et al., Population-based door-to-door survey of migraine in Japan: the 
Daisen Study. Headache, 2004. 44: p. 8-19. 
495. Lavados, P.M. and E. Tenhamm, Epidemiology of tension-type headache in Santiago, Chile: 
a prevalence study. Cephalalgia, 1998. 18: p. 552-558. 
496. Roh, J.K., J.S. Kim, and Y.O. Ahn, Epidemiologic and clinical characteristics of migraine and 
tension-type headache in Korea. Headache 1998. 38: p. 356-365. 
497. Ho, K.H. and B.K.C. Ong, A community-based study of headache diagnosis and prevalence 
in Singapore. . Cephalalgia, 2003. 23: p. 6-13. 
498. Srikiatkhachorn, A., Epidemiology of headache in the Thai elderly: a study in the Bangkae 
Home for the Aged. Headache, 1991. 31: p. 677-81. 
499. Wang, S.J., et al., Prevalence of headaches in a Chinese elderly population in Kinmen: age 
and gender effect and cross cultural comparisons. Neurology, 1997. 49: p. 195-200. 
500. Prencipe, M., et al., Prevalence of headache in an elderly population: attack frequency, 
disability, and use of medication. J Neurol Neurosurg Psychiatry, 2001. 70: p. 377-381. 
501. Camarda, R. and R. Monastero, Prevalence of primary headaches in Italian elderly: 
preliminary data from the Zabut Aging Project. Neurolog Sci, 2003. 24((Suppl. 2)): p. S122-
S124. 
502. Cook, N.R., et al., Correlates of headache in a population-based cohort of elderly. . Arch 
Neurol, 1989. 46: p. 1338-44. 
503. Howlett, W., Neurology in Africa. 2012, Bergen, Norway: BRIC. 
504. Farnarier, G., S. Diop, and B. Coulibaly, Onchocercose et épilepsie. Enquête 
épidémiologique au Mali. Méd Trop, 2000. 60: p. 151-55. 
500 
 
505. Munoz, M., et al., Prevalence of Neurological Disorders in Haute-Vienne Department 
(Limousin Region-France). Neuroepidemiology, 1995. 14: p. 193-198. 
506. Hughes, R., Peripheral Neuropathy Review. British Medical Journal, 2002. 324: p. 466-469. 
507. Mold, J.W., et al., The Prevalence, Predictors, and Consequences of Peripheral Sensory 
Neuropathy in Older Patients. Journal of the American Board of Family Practice, 2004. 17: 
p. 309-318. 
508. Bharucha, N.E., A.E. Bharucha, and E.P. Bharucha, Prevalence of peripheral neuropathy in 
the Parsi community of Bombay. Neurology, 1991. 41(8): p. 1315-1317. 
509. Atroshi, I., et al., Prevalence of carpal tunnel syndrome in a general population. JAMA, 
1999. 282: p. 153-158. 
510. Fuller, G., Diagnosing and managing mononeuropathies. CME Neurology, 2004. 4(2): p. 
113-117. 
511. Lambert, M.L., et al., Household survey of locomotor disability caused by poliomyelitis and 
landmines in Afghanistan. British Medical Journal, 1997. 315: p. 1424. 
512. Wallace, R.B., ed. Public health and Preventative Medicine. 2008. 
513. World Health Organisation. Prevalence of Leprosy. 
http://www.who.int/lep/situation/prevalence/en/index.html 2009. 
514. World health Organisation, Leprosy-Global situation. Wkly Epidemiol Rec, 2000. 28: p. 226-
231. 
515. Carr, A.S., et al., A systematic review of population based epidemiological studies of 
myaesthenia gravis. BMC Neurology 2010, 2010. 10(46): p. 10-46. 
516. Awwad, S., R. Ma'luf, and N. Hamush, Myaethenia Gravis. 
http://emedicine.medscape.com/article/1216417-overview, 2010. 
517. MS Society, www.atlasofms.org. 2008. 
518. Vlassoff, C., Gender inequalities in health in the third world: uncharted ground. Soc Sci Med 
1994. 39: p. 1249-59. 
519. Ojanuga, D.N. and C. Gilbert, Womens access to health care in developing countries. Soc 
Sci Med, 1992. 35: p. 613-7. 
520. Vlassoff, C. and C. Garcia Moreno, Placing gender at the centre of health programming: 
challenges and limitations. Soc Sci Med, 2002. 54: p. 1713-23. 
521. Sen, G. and P. Ostlin, Gender inequity in health: why it exists and how we can change it. . 
Glob Public Health, 2008. 3: p. Suppl 1-12. 
522. Bates, L.M., O. Hankivsky, and K.W. Springer, Gender and health inequities: a comment on 
the Final Report of the WHO Commission on the Social Determinants of Health. Soc Sci 
Med 2009. 69: p. 1002-4. 
523. United Nations Childrens Fund, Boys and girls in the life cycle: sex-disaggregated data on a 
selection of well-being indicators, from early childhood to young adulthood. 2011. 
524. Miszkurka, M., et al., Heavy burden of non-communicable diseases at early age and gender 
disparities in an adult population of Burkina Faso: World Health Survey. BMC Public Health, 
2012. 12: p. 24. 
525. Elbaz, A., Validity of family history data on PD: evidence for a family information bias. 
Neurology, 2003. 61(1): p. 11-17. 
526. Thorogood, M., et al., Secondary prevention of stroke-results from the Southern Africa 
Stroke Prevention Initiative (SASPI) study. Bull World Health Organ, 2004. 82: p. 503-8. 
527. Dotchin, C.L., et al., Geriatric medicine: services and training in Africa. . Age Ageing, 2012. 
471: p. 119. 
 
 
